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Abstract 
Genome wide association studies (GWAS) have identified multiple loci which are 
associated with increased risk of atrial fibrillation (AF). The mechanisms underlying 
these associations are not understood. None of the variants identified result in 
alteration of coding sequences; they are therefore likely to act by altering gene 
expression. Identification of intermediate gene expression phenotypes which are 
associated with the risk variants could provide important insights into disease 
pathogenesis which could in turn lead to development of therapeutic targets.  
One of the genetic variants identified by GWAS is situated within an intron of the gene 
HCN4, which encodes the major component of the If pacemaker current. This raised 
the question whether lower activity of HCN4 could be a risk factor for AF. By 
performing meta-analysis of randomised controlled trials of ivabradine, an If inhibitor, I 
demonstrated an increase in relative risk of incident AF of 15% in patients treated with 
ivabradine vs. controls, supporting the role of HCN4 in AF susceptibility. 
Analysis of total expression and allelic expression ratios of candidate genes in the 
GWAS hit regions in whole blood identified associations between AF risk variants and 
increased expression of KCNN3 and SYNE2 and decreased expression of CAV1.   
Analysis of total expression and allelic expression ratio in right atrial appendage tissue 
identified further associations between AF risk variants and increased expression of 
PITX2a/b and decreased expression of MYOZ1, CAV1, C9orf3 and FANCC in right atrial 
tissue. Furthermore, although the experiments were not designed to detect difference 
between AF cases and controls, I have shown that AF is associated with reduced 
expression of SYNE2, HCN4 and CAV1. 
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1 Introduction 
1.1 Introduction 
AF is the most common sustained cardiac arrhythmia, with a prevalence of 0.5% in the 
fifth decade of life, rising to 5-15% over the subsequent 20 years1. AF is a rhythm 
which is characterised by apparently chaotic electrical activity in the atria. A number of 
potential underlying electrophysiological mechanisms have been proposed and it is 
likely that all of them play some role in the initiation and maintenance of AF. All of the 
proposed mechanisms have a common appearance on the electrocardiogram (ECG). In 
AF the electrical activity of the atrium can be detected as fine, rapid deflections of a 
variable rate and morphology at a rate of between 300 and 600 beats per minute 
(bpm), called f waves. The ventricular response is irregularly irregular and, in the 
context of normal atrioventricular (AV) nodal conduction, is usually between 100 and 
160 bpm2. 
The three most commonly proposed mechanisms which underlie AF are focal ectopic 
firing, a single localised re-entry circuit or multiple variable functional re-entry circuits3. 
It is likely that the importance of each of these mechanisms varies with the time point 
in the natural history of the disease. Usually AF presents as the paroxysmal form, 
where episodes of AF are short lived and resolve spontaneously. There is often 
progression to persistent AF, defined as an episode which lasts longer than seven days, 
and usually requires chemical or electrical cardioversion to restore normal sinus 
rhythm. The final stage, permanent AF, is defined as the situation where restoration of 
sinus rhythm is no longer possible or considered advisable by the treating physician. 
Paroxysmal AF is largely driven by focal ectopic activity, often from the pulmonary vein 
myocardium4. Permanent AF, on the other hand is characterised by multiple re-entrant 
circuits involving the entire atrial myocardium, whereas the intermediate persistent 
stage may be characterised by one or more relatively stable rotors of re-entry5. AF 
results in electrical and structural remodelling of the atria, which in turn provides a 
substrate for further AF, leading to the natural progression of the disease from 
paroxysmal to persistent and finally to permanent AF3.  
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AF is not a benign arrhythmia: it is associated with a significant reduction in quality of 
life and exercise capacity. More importantly; AF is associated with a 5-fold increase in 
the risk of thromboembolic stroke and a 2-fold increase in all-cause mortality6.  
There are many well recognised environmental factors and disease states which 
contribute to AF risk; including hypertension, heart failure, valvular heart disease, 
obesity, diabetes mellitus, chronic obstructive pulmonary disease, sleep apnoea, 
thyroid disease and renal failure6. A significant number of individuals, however, 
develop AF in the absence of these factors, so-called ‘lone AF’7. The first case of 
familial AF was identified in 1943, in three brothers who developed AF in childhood8. 
However it was not until the late 1990s that the importance of genetic risk in AF 
became increasingly appreciated following the first published report of AF segregating 
as a Mendelian trait9.   
Management strategies for AF can be broadly divided into two: rate control strategies, 
where the AF is presumed to be permanent and the focus is on controlling the 
ventricular rate; and rhythm control strategies where attempts are made to restore 
sinus rhythm. Where a rate control strategy is adopted, the ventricular rate is limited 
by pharmacological inhibition of conduction through the AV node with Beta 
adrenoceptor antagonists, rate-limiting calcium channel antagonists or digoxin, or 
occasionally by radiofrequency ablation of the AV node (which would necessitate 
implantation of a permanent pacemaker). The most commonly used pharmacological 
agents used for rhythm control are Vaughn Williams class Ic agents, which block 
sodium channels, such as flecainide or propafenone or class III agents which block 
potassium channels, such as amiodarone or dronedarone10. A more effective approach 
to rhythm control is to prevent focal atrial activity arising in the pulmonary vein 
myocardium form initiating AF by electrically isolating the pulmonary veins using 
radiofrequency energy, cryotherapy or laser energy11.  
 Current pharmacological strategies have a very low success rate in maintaining sinus 
rhythm in patients with paroxysmal or persistent AF, and while pulmonary vein 
isolation is more effective, 25% of patients have recurrent symptomatic AF despite 
multiple ablation procedures12. No rhythm control strategy has been shown to reduce 
mortality or stroke risk, probably due to the relatively high incidence of asymptomatic 
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AF. It is therefore important to improve our understanding of the mechanisms which 
underlie AF at a molecular level in order to develop new therapies which can improve 
our ability to maintain sinus rhythm. 
 
1.1.1 Evidence for genetic susceptibility to AF 
AF has been shown to exhibit a significant degree of heritability. A Danish twin study of 
1137 single-sex twin pairs identified increased concordance in monozygotic vs. 
dizygotic twins (22.0% versus 11.6%, P<0.0001) and estimated the heritability of AF to 
be 62% (95% CI 55-68%)13. By comparison the heritability of coronary artery disease is 
estimated to be around 40%14, and that of breast cancer to be 30%15. Although this 
study provides strong evidence for a genetic component to atrial fibrillation, twin and 
family studies in selected populations with lone AF may overestimate the genetic 
contribution to risk in a population with multiple risk factors for AF. Analysis of 
participants in the Framingham study, however, identified a significantly increased rate 
of AF in the children of patients with AF with an odds ratio (OR) 1.85 [95% confidence 
interval (CI) 1.12–3.06, P=0.02]16; demonstrating that AF displays a significant degree 
of heritability even in a more general population. In keeping with there being a 
stronger heritable component in lone AF, the association was stronger when the 
analysis was limited to parents and offspring developing AF under the age of 75 (OR 
3.23, 95% CI 1.87–5.58, P<0.001). These odds ratios were calculated after adjustment 
for multiple variables, including hypertension, diabetes mellitus, clinically overt heart 
disease, age and sex. The unadjusted odds ratios were somewhat higher, highlighting 
the importance of these risk factors. It is noteworthy that some of the recognised risk 
factors for AF, including diabetes and hypertension, exhibit significant heritability17,18, 
and this will indirectly contribute to the overall heritability of AF. 
 
1.1.2 The genetic architecture of AF susceptibility 
Although there is good evidence that there is an important genetic contribution to AF 
susceptibility, establishing the genetic elements that are responsible for the heritable 
component is not straightforward. AF is the result of complex electrical and structural 
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changes within the atria19. Multiple genetic loci have been identified as conferring AF 
risk. Some of these were identified in linkage studies of families with early-onset AF. 
This type of study has identified AF-causing mutations in multiple genes, including 
those coding for sodium channels (SCN5A)20, Potassium channels (KCNQ1)21, atrial 
natriuretic peptide (NPPA)22 and atrial gap junction connexins (GJA5)23. These 
mutations have a large effect size with a high incidence of early onset AF in carriers. 
These mutations give insight into genes that may be involved in atrial electrical 
signalling; but they are rare and they are unlikely to explain the overall heritability of 
AF susceptibility in the general population; candidate gene studies, including some of 
those described in Table 1.1, typically find mutations which are likely to be causative of 
AF in less than 5% of lone AF patients screened13,24-27. Conversely, genome-wide 
association studies (GWAS) have identified nine genetic regions that are associated 
with AF and several further regions associated with alterations in heart rate28,29 and PR 
interval, which is considered a marker for AF susceptibility30. Typical effect sizes for loci 
identified by GWAS are, unsurprisingly, smaller than those seen in families with 
inherited lone AF (median OR 1.33, inter-quartile range (IQR) 1.20– 1.61)31.  
 
1.1.3   Common variation in human populations 
The Human Genome Project was a major collaborative publicly-funded project to 
sequence the whole human genome using the then state-of-the-art Sanger sequencing 
technology. It reported the human genome as a single haploid sequence in 200132. The 
human sequence, of course, is diploid and contains a significant amount of genetic 
variation, both within and between human populations. Genetic variation can be 
divided into two major groups, single nucleotide variants and structural variants 
(Figure 1.1)33. Common single nucleotide variants can also be referred to as single 
nucleotide polymorphisms (SNPs), a polymorphism being an occurrence in a 
population of more than one allele where the variant allele has a frequency of greater 
than 1%.  
Before the invention of sequencing technology, microscopic, i.e. large enough to see 
with a microscope, structural abnormalities had been observed in chromosomes. 
These included rearrangements, aneuploidies (an abnormal number of chromosomes), 
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heteromorphisms (visible changes in the size, morphology or staining of a 
chromosome) and fragile sites (small breaks or constriction of a chromosome, visible 
under special cell culture conditions)34. The advent of sequencing technologies has 
allowed the identification of sub-microscopic variation, relatively short repetitive DNA 
sequences such as mini- and microsatellites and the sub-microscopic structural 
variants described below35. 
Structural variations involve more significant sequence alterations than single 
nucleotide variants. Insertion/deletion (indel) mutations are segments of DNA that are 
present in some chromosomes but not others; they are mostly a few bases in length 
but can be up to 1 kb long36. Longer segments of DNA (i.e. > 1000bp), that are present 
in some chromosomes but not others, are called copy number variants (CNVs). CNVs 
can be surprisingly large without being harmful, for example, the largest CNV in the 
Venter genome (the genome of Craig Venter, who was one of the first individuals to be 
sequenced) was almost 2 megabases long36. Block substitutions are similar to SNPs but 
several consecutive base pairs vary between genomes. Inversions occur where 
segments of DNA are present in the reverse order in some chromosomes; for example 
there is a 900kb segment of chromosome 17 that is inverted in 20% of Europeans37.  
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Figure 1.1  Common forms of genetic variation 
 
Variants are highlighted in red. Figure adapted from Frazer et al33. 
 
1.1.4  Single nucleotide polymorphisms 
Of the variants above, the easiest to determine and analyse are SNPs. For this reason, 
SNPs have been more widely studied than other variants. Each individual has 
approximately 3.5 million single nucleotide variants with respect to the reference 
genome38, over 62 million are reported in build 138 of the single nucleotide database 
(dbSNP)39, and there are estimated to be around 11 million with a minor allele 
frequency (MAF) of >1%40, i.e. more than 1:100 chromosomes carry the variant allele.  
Interestingly, a large proportion of the single nucleotide variants carried by any given 
individual are common, suggesting that most variation between two individuals is the 
result of common, rather than rare variants.  
 
1.1.5  Linkage disequilibrium and haplotypes 
The diploid human genome consists of 46 chromosomes, 22 pairs of autosomes and 
two sex chromosomes. During gametogenesis, the formation of egg and sperm cells, 
the genome is reduced from diploid to haploid (22 autosomes and a single sex 
chromosome) through meiosis, consisting of two cell divisions, meiosis I and II. Prior to 
division the chromosomes divide to form two chromatids, joined at the centromere. 
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The maternally and paternally derived chromatids align to form a four strand structure 
called a tetrad. When the chromatids are aligned they can exchange material via 
breakage and recombination of the DNA strand at points called chiasmata. The 
chromatids are then separated and the cell divides to form the gametes. The 
consequence of this recombination is that the chromosomes within each gamete 
contain genetic material from both the maternally and paternally derived 
chromosomes41. Alleles of marker polymorphisms on the same chromosome are 
therefore not always inherited together. The chance of markers being separated at 
meiosis is increased with increasing distance and when the regions between the two 
markers are particularly prone to chiasm formation, so called ‘recombination 
hotspots’42. After many mitotic generations markers are shuffled many times so that 
only those that happen to be in regions where recombination has not occurred 
between the variants remain associated. If two markers are preferentially associated 
with one another, due to infrequent recombination between them, they can be 
referred to a being in linkage disequilibrium (LD). Markers which are more strongly 
associated are described as having higher linkage disequilibrium. One measure of LD, 
D’, is calculated as the deviation of the observed frequency of the markers from the 
expected value, divided by the theoretical maximum deviation. Regions of the genome 
that are inherited together are known as haplotype blocks. These can be defined as 
sets of consecutive markers where there is little or no evidence for historical 
recombination. One approach to this relies on constructing a confidence interval based 
on the population value of D’ 43.  Haplotype blocks allow the use of marker 
polymorphisms to ‘tag’ variants on the genome, as the genotype of variants near the 
tagging variant can be inferred from the genotype of the tag. Mapping of these 
patterns of inheritance is the aim of the International HapMap Project44  (Figure 1.2).  
The size of haplotype blocks is in part due to the distribution of recombination 
hotspots but is also a consequence of the number of generations which have elapsed, 
as a greater number of meioses would be expected to result in recombination at a 
greater number of loci. If a new population is established from a small number of 
individuals, then a loss of genetic variation occurs, the founder effect, and the 
haplotype structure will be relatively coarse45. Therefore, one of the major 
determinants of the coarseness of haplotype structure is demographic history. This is 
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important as large haplotype blocks allow for tagging of the genome with fewer 
markers. A finer haplotype structure will require a greater number of tag SNPs but has 
the advantage that the disease associated polymorphism is in linkage disequilibrium 
with a smaller region of the genome, allowing finer mapping of the locus (Figure 1.3). 
 
Figure 1.2 The haplotype map 
 
The construction of a haplotype map occurs in three steps. (a) SNPs are identified in DNA 
samples from multiple individuals. (b)Adjacent SNPs that are inherited together are compiled 
into haplotypes. (c)Tag SNPs identify each haplotype. By genotyping the three tag SNPs shown 
in this figure, researchers can identify which of the four haplotypes shown here are present in 
each individual. Figure reproduced from the International HapMap project44. 
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Figure 1.3 Decay of association with time 
 
The hypothetical ancestral chromosome contains all markers in association with the disease 
locus. Over time recombination events ensure that each chromosome is a mosaic. After a 
relatively small number of generations the mosaic is quite coarse and both markers M1 and 
M2 are associated with the disease locus. After many generations the mosaic is fine and only 
marker M2, which is closer to the disease locus, remains in association. Figure adapted from 
Cunnington and Keavney46. 
 
In human populations the haplotype mosaic is relatively coarse, allowing tagging of the 
genome with a relatively small number of SNPs. The coarseness of the mosaic does 
vary to some degree between ethnic groups, however. Those populations that have 
been through a population bottleneck and therefore have a relatively small founder 
population in the not-too-distant past have had much less time for shuffling of the 
haplotypes and so will have a coarser mosaic. For this reason European populations 
need fewer SNPs (ca. 300,000) to tag the majority of common polymorphisms than 
African populations (ca. 1,000,000)43, as Africa has been populated by humans for 
considerably longer than Europe and the European founder population will have only 
contained a small number of the haplotypes present in the original African gene pool. 
The International HapMap Project, by providing a map of human haplotypes in several 
reference populations, allows selection of appropriate marker polymorphisms for the 
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tagging of common polymorphisms. Of note, the HapMap project focused on 
describing the patterns of association between common single nucleotide 
polymorphisms, that is those with a MAF of >5%. Due to the sample size in the 
HapMap cohorts, the ability to define haplotypes for variants with a MAF <5% was 
limited by the small number of carriers of rarer alleles. As mentioned above a 
significant proportion of the variation between individuals is a consequence of 
structural variants. It appears however that common short indels and the commoner 
structural variants are in LD with and behave in a similar fashion to common SNPs, 
suggesting that they are both ancestral, i.e. each variant has arisen once in human 
history rather than being the consequence of multiple similar mutation events47. 
Structural variations in segmental duplications, however are less well captured by 
tagging SNPs48.  
Despite these cautions a large number of genome wide association studies (GWAS), 
using SNPs selected with the aid of the HapMap, have demonstrated important 
associations between diseases and genetic loci and identified new genes associated 
with these diseases30. 
 
1.2 Mendelian AF  
Some genetic variants can be considered to be causative of AF, i.e. a single gene defect 
results in AF in all or most carriers: these are monogenic or Mendelian defects. In most 
families the inheritance is autosomal dominant with penetrance; almost all family 
members with a single defective copy of the gene will develop AF. The genes 
responsible for AF in these families can be identified by traditional genetic linkage 
studies or, more recently, by directly sequencing a large portion of the genome, either 
the coding regions (exome sequencing) or a large number of candidate genes, or more 
recently the whole genome, in affected members.  
Linkage studies (Figure 1.4) are performed by genotyping multiple genetic markers 
throughout the genome in both affected and unaffected family members in order to 
identify a haplotype, a region of a chromosome that is inherited as a complete block, 
which co-segregates with the disease. Once the disease-associated haplotype is 
identified known genes within the region can be sequenced.  
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The first published study of Mendelian AF used this approach to identify a region in 
chromosome 10 that was common to the affected members of three families with AF 
and left ventricular systolic dysfunction9. Further studies have identified regions on 
chromosomes 5 and 6 and a second region on chromosome 1049-51 (Table 1). 
Unfortunately the regions identified are large and identification of the responsible 
variant in each of these cases has not, as yet, proven possible. 
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Figure 1.4 Linkage analysis.  
 
Filled shapes represent affected individuals, squares are male and circles are female. 
Panel A. An affected male carries a disease causing gene (orange) located on a chromosome 
(red). During meiosis there is recombination between the disease carrying chromosome and its 
normal partner (blue) so that his affected son inherits only part of the disease carrying 
chromosome. 
Panel B. In a large family, many recombination events occur. Only those family members who 
have inherited that part of the chromosome in which the gene is located will be affected. The 
region of the chromosome which carries the gene can therefore be narrowed down to the 
region which is present in all of the affected family members and none of the unaffected 
(vertical black line). This allows sequencing of genes in the shared haplotype region. 
 
Some families are not large enough to perform linkage analysis, as a minimum number 
of family members are required to produce a statistically significant result. Under 
these circumstances it is possible to adopt a candidate gene sequencing approach. 
Genes are identified which are thought to be involved in AF (candidate genes) and 
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these are sequenced in affected and unaffected family members. This allows 
identification of variants which segregate with disease, i.e. they are present in affected 
family members but not in unaffected members. Some investigators have extended 
this approach further, by sequencing candidate genes in cohorts of unrelated 
individuals with lone AF of early onset; followed up with genotyping of any variant in 
affected and unaffected family members, if possible.   The candidate gene approach 
can introduce significant bias, as variants will only be found in those genes that the 
investigators have selected for analysis. It is possible, if not likely, that there will be 
disease causing variants located outside the sequenced regions which will be missed. 
The sequencing of a large proportion of any individual’s DNA will identify rare and 
unreported variants. As described above there are a great number of variants in every 
genome. Many of these variants cause significant changes to the amino acid sequence 
of the encoded proteins and it is estimated that each of us typically carries around 100 
genuine loss-of-function mutations with around 20 genes totally inactivated52. It is 
difficult, therefore, to be certain that any new variant identified will be causative of 
disease. In spite of these difficulties it has been possible to identify a number of 
mutations which have some evidence supporting their role in AF. These include 
mutations causing gain or loss of function in sodium20,53-58, potassium21,24,26,59-67 and 
calcium channels68, gap junctions23,69-71, endocrine peptides22, developmentally 
important transcription factors72-77 and even nucleoporins78, which regulate transport 
of large molecules between the nucleus and cytoplasm (see Figure 1.5 and Table 1.1). 
AF is characterised by a disturbance in the normal electrical activity in the atrium and 
therefore the ion currents which are responsible for the normal action potential in 
sino-atrial cells and atrial myocytes are of particular interest. The five phases of the 
action potential (numbered 0-4) are the result of complex interaction between several 
membrane currents, each of which is generated by one or more ion channels. The ion 
channels are often heteromultimers of several subunits, which are encoded by 
individual genes. There are also other ion currents which have tonic effects on the 
membrane potential and do not vary in their activity over the time course of a single 
action potential. In the case of sodium and calcium channels the pore-forming α-
subunit consists of 4 covalently bound domains encoded by a single gene, with 
regulatory β-subunits. In the case of potassium channels the pore forming domains are 
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not covalently linked and therefore different α-subunits combine to form 
heteromultimers. The main genes responsible are listed by each current in Figure 1.5. 
Several of these genes have been identified as being associated with AF, either 
through gain- or loss-of-function mutations or through GWAS hits, see Tables 1.1 and 
1.2.  
In the atria, the non-voltage-gated IK,Ca Ca
2+-gated, IKACh acetylcholine-gated and IKATP 
ATP-gated currents serve to hyperpolarise the cell throughout the action potential and 
therefore shorten action potential duration and reduce automaticity. IK,Ca and IKACh are 
not present in ventricular myocytes. Gap junctions, formed by connexins 40 and 43, 
allow the transmission of electrical impulses between cells79.   
In the atrial myocyte, the resting potential in phase 4 is maintained by the IK1 inward 
rectifying current. Depolarisation (phase 0) is usually triggered by depolarisation of an 
adjoining cell and is transmitted through the connexin channels that link adjoining 
myocytes. Phase 0 is very rapid due to the INa sodium current. There is a brief 
repolarisation (phase 1) as a result of the Ito1 transient outward current, followed by a 
plateau (phase 2), which is a result of the balance of the ICa,L, IKs and IKur delayed ultra-
rapid current. The IKur is unique to atrial myocytes. Repolarisation (phase 3) is 
mediated by the IKr current. 
In the sino-atrial cell,  there is a gradual depolarisation throughout phase 4 as a result 
of the If funny current and the ICa,T transient calcium current, which at threshold 
triggers the ICa,L long-lasting calcium current and depolarisation (phase 0). 
Repolarisation, (phase 3), is mediated by the IKs slow rectifying current and the IKr 
delayed rapid rectifying current. Phases 1 and 2 are absent. 
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Figure 1.5 The main currents contributing to the action potential in sino-atrial 
and atrial myocytes.  
 
 
 
 
 
17 
 
Figure legend overleaf 
The sino atrial cell and the atrial myocyte are represented with a curve representing the 
normal action potential (the change in membrane potential over time). Depolarising currents 
are (red) and repolarising currents (blue) are indicated with their periods of maximum 
activation. The main genes responsible for each current are listed with colour coding to 
indicate Mendelian inheritance of gain of function (red) or loss of function (blue) mutations or 
nearby GWAS hits (yellow). 
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Table 1.1 Loci identified as causing Mendelian AF 
Gene Chromosomal 
region 
Inheritance Variant Functional effect and phenotypic details Other associated diseases 
Unknown 10q22-q24  AD Unknown Molecular effect unknown. 19 affected 
subjects in 3 families, diagnosed with 
permanent (18) or paroxysmal (1) AF at age 2-
46. Two subjects in one family had left 
ventricular systolic dysfunction9. 
 
Unknown 6q14-q16 AD Unknown Molecular effect unknown. 8 of 34 family 
members diagnosed with paroxysmal AF at 
age 21-72, progressing to permanent AF in 4 
older subjects. Two family members without 
AF had peripartum cardiomyopathy49. 
 
Unknown 10p11-q21 AD Unknown Molecular effect unknown. Haplotype present 
in 9 of 34 samples. AF present in all except 3 
youngest. Age at onset 40-5850. 
 
Unknown 5p15 AD Unknown Molecular effect unknown. 8 of 27 family 
members affected diagnosed at age 18-42. 
Increase in signal-averaged P-wave duration 
(203±21ms vs. 116±12ms) in cases and 
carriers. Two affected members had mild 
LVH51. 
 
KCNQ1 11p15.5 AD R14C,  S140G, V141M, 
S209P, R231H, R231C 
 
 
Gain of function in KCNQ1-KCNE1 and KCNQ1-
KCNE2 IKs channels. R231H and R231C found in 
multiple families, V141M found in a single 
proband with in utero AF21,59,80-83. 
Long QT, Jervell and Lange-Nielsen 
Syndrome, Short QT syndrome 
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Gene Chromosomal 
region 
Inheritance Variant Functional effect and phenotypic details Other associated diseases 
   
KCNE1 21q22.12 ?AD G25V, G60D Gain-of-function in KCNQ1-KCNE1 IKs channels. 
Two families identified by candidate gene 
sequencing of 209 Danish probands with AF 
onset at <40 years old24. 
Jervell and Lange-Nielsen Syndrome, 
Long QT 
KCNE2 21q22 AD R27C Gain on function in KCNQ1-KCNE2 IKs channels. 
Symptomatic premature atrial complexes in 5 
and paroxysmal AF in 3 affected members of 
two families60. 
Long QT 
 
KCNE3 11q13-q14 AD R53H, V17M Reduced KCNE3 inhibition of IKs channels. 
R53H effect unknown. R53H in one family, 
V17M in one individual61,84. 
Brugada Syndrome 6 
KCNE4 2q36 n/a E141A Molecular effect unknown. Identified in a 
single individual in a cohort of 80 European AF 
probands25. 
 
KCNE1L Xq23 n/a L65F Failure of KCNE1L to suppress KCNQ1-KCNE1 
IKs current. Single mutation found in candidate 
gene study of 158 patients with AF26. 
 
KCND3 1p13 n/a A2E, K214R, A545P A545P leads to gain of function in ITO channels. 
Identified in a single individual in a cohort of 
209 Danish probands85. No channel 
dysfunction effect detected for other 
mutations, which were identified in a single 
individual in a cohort of 80 European AF 
probands25. 
Spinocerebellar ataxia-19 
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Gene Chromosomal 
region 
Inheritance Variant Functional effect and phenotypic details Other associated diseases 
KCNH2 7q36 n/a E444K Loss of function in IKr. Identified in a single 
individual in a cohort of 80 European AF 
probands25. 
Long QT 
KCNJ2 17q24.3 AD V93I Gain of function of IK1. Mutation found in 6 
members of one family. 4 had AF at age 50-57; 
two had ‘uncertain phenotypes’67. 
Andersen cardiodysrhythmic periodic 
paralysis, 
Short QT 
KCNJ8 12p12.1 n/a S422L Gain of function of KATP current. Two 
individuals identified in a candidate gene study 
of a cohort of 325 probands. 
?Prinzmetal angina 
KCNA5 12p13.32 Some AD Y155C, E375X, D469E, 
P488S, T527M, A576V, 
E610K,  
71-81del 
Loss of function of IKur. Different mutations 
identified in different individuals and families. 
71-81del results in loss of function and 
interferes with tyrosine kinase modulation of 
IKur
62,64,65,86.  
 
  n/a E48G, A305T, D322H, 
G586V 
Gain of function in IKur. Each identified in a 
single individual in two cohorts25,86. 
 
ABCC9 12p12.1 n/a T1547I Loss of ADP-induced potassium channel 
opening. Single mutation identified in an 
individual with paroxysmal AF from age 43.66 
Dilated cardiomyopathy, 
Hypertrichotic osteochondrodysplasia 
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Gene Chromosomal 
region 
Inheritance Variant Functional effect and phenotypic details Other associated diseases 
SCN5A 
 
3p22.2 
 
AD M138I, T220I, R222Q, 
R340Q, R367H, E428K, 
H445D, N470K, A572D, 
L618F, E655K, fs851, 
E446K, R814W, E1053K, 
T1131I, D1275N, V1279I, 
F1520L, F1596I, D1595H, 
R1826C, I1835T, N1986K, 
V1951M 
Loss (or presumed loss) of function of INa. Only 
D1275N and R222Q reported in more than one 
family. Incomplete penetrance of DCM and AF 
with phenotypes often, but not always, 
overlapping. Reduction in INa may be 
dependent on presence of common H558R 
polymorphism of SCN5A20,53-56,87-89. 
Brugada, 
Long QT, 
DCM, 
Heart block 
 
AD S216L, A997S, R1193Q, 
K1493R, R1626H, 
M1785T, D1819N, F2004L 
Gain of function of INa. Some reported in 
multiple individuals with lone AF. Many 
reported in families with sudden infant death 
syndrome or long QT syndrome57,87,89-92. 
SCN1B 19q13.11 n/a R85H, D153N  Reduction in INa. Two individuals, one with lone 
paroxysmal AF, one with AF and moderate 
aortic stenosis; neither had LVSD58. 
Brugada, 
Epilepsy 
   R214Q Molecular function not known. Three 
individuals in a cohort of 214 Danish probands 
with lone AF.  
 
SCN2B 11q23.3 n/a R28W, R28Q Reduction in INa. Two individuals, one with lone 
paroxysmal AF one with hypertension and 
paroxysmal AF; neither had LVSD58. 
 
SCN3B 11q24.1 n/a R6K, L10P, A130V, M161T Reduction in INa. Each variant identified in a 
single individual with lone AF93,94. 
Brugada 
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Gene Chromosomal 
region 
Inheritance Variant Functional effect and phenotypic details Other associated diseases 
RYR2 1q42-q43 AD Deletion in exon 3 Presumed reduction in Ca2+ efflux from SR. 16 
members of 2 unrelated families. Phenotype 
of dilated cardiomyopathy with ventricular 
tachycardia, atrial standstill and AF68. 
Arrhythmogenic right ventricular 
dysplasia, 
Catecholaminergic polymorphic VT 
JPH2 20q13.12 n/a E169K Increased Ca2+ efflux due to loss of JPH2-
mediated stabilisation of RyR2. Observed in 
two individuals with hypertrophic 
cardiomyopathy and early onset AF95. 
Hypertrophic cardiomyopathy 
GJA5 1q21.1 Somatic G38D, P88S, A96S, 
M163V 
 
 
 
 
Reduced connexin 40-mediated cell-cell 
coupling and/or transport of connexin protein 
to the cell surface. All but A96S were somatic 
mutations, detected by sequencing tissue from 
15 individuals with lone AF23. 
 
 
AD Q49X, I75F, V85I, L221I, 
L229M 
I75F results in loss of connexin 40 gap junction 
function. The molecular effects of the other 
mutations are unknown. Missense mutations 
segregate with AF in 5 unrelated Chinese 
families70,71,96. 
GJA1 6q22.31 Somatic c.932delC Reduced connexin 43-mediated cell-cell 
coupling and transport of connexin protein to 
the cell surface. Somatic mutation in a single 
individual with lone AF69. 
Atrioventricular septal defect, 
Hallermann-Strieff syndrome, 
Hypoplastic left heart, Oculodentaldigital 
dysplasia, Syndactyly 
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Gene Chromosomal 
region 
Inheritance Variant Functional effect and phenotypic details Other associated diseases 
GATA4 8p23.1-p22 AD G16C, H28D, Y38D, S70T, 
P103A, S160T 
All shown to result in reduced transcription of 
reporter gene vs. wild type in cell culture. 
Other GATA4 mutations associated with 
congenital heart disease. Mutations identified 
in single families in three cohorts of 130, 150 
and 160 Han Chinese probands with lone 
AF73,74,97 
ASD, Atrioventricular septal defect, VSD 
   M247T, A411V,  Molecular function not known. Each identified 
in a single patient, one with lone AF and one 
with ASD and VSD98. 
 
GATA6 18q11.2 AD Q206P, Y265X, Y235S, 
G469V 
Y235S and G469V decreases expression of 
downstream reporter gene, the molecular 
effect of Q206P and Y265X is unknown. 
Mutations found in multiple members of single 
families identified by candidate gene 
sequencing of three cohorts of 110, 138 and 
140 Han Chinese probands with lone AF. One 
family member carrying Q206P had an atrial 
septal defect (ASD), two family members 
carrying Y265X had ventricular septal defects 
(VSD) and one family member carrying Y235S 
had an ASD and one had a VSD75-77. 
ASD, Atrioventricular septal defect, 
Tetralogy of Fallot, Persistent truncus 
arteriosus, Pancreatic agenesis 
NPPA 1p36-p35 AD c.456-457delAA Increased ANP levels with shortened APD and 
ERP. Seen in 11 of 15 members in a single 
family22. 
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Gene Chromosomal 
region 
Inheritance Variant Functional effect and phenotypic details Other associated diseases 
TBX5 12q24.21 AD G373A Gain of function in TBX5 presumed to increase 
NPPA, GJA5, KCNJ2 and TBX3 expression. 12 
affected members in a single family with 
atypical Holt-Oram syndrome72. 
 
LMNA 1q22 AD A278T, T488P Molecular function unknown. A278T 
segregated in a single family with lone AF of 
onset at 21-72 years old and mild muscle 
weakness99. T488P was identified in a single 
individual in cohort of 268 probands27. 
Dilated cardiomyopathy, Malouf 
Syndrome, Emery-Dreifuss muscular 
dystrophy, Limb girdle muscular 
dystrophy, Charcot-Marie-Tooth disease, 
Lipodystrophy, Restrictive dermopathy, 
Hutchinson-Gilford Progeria, 
Manibuloacral Dysplasia 
NUP155 5p13 AR R391H Loss of function of nuclear pore complex. 
Segregated in an autosomal recessive fashion 
with AF in single family78. 
 
NKX2-5 5q35.1 AD F145S, N19D, F186S Reduced transcriptional activity. Each present 
in a single family100,101. 
ASD, Tetralogy of Fallot, Hypoplastic left 
heart syndrome, VSD, Conotruncal heart 
malformation. 
ASD – atrial septal defect, APD – action potential duration, ERP – effective refractory period, LVH – left ventricular hypertrophy, LVSD – left ventricular systolic 
dysfunction, VSD – ventricular septal defect. Genetic variants are given as amino acid substitutions, except where preceded by “c.” to indicate cDNA changes. For 
some of the loci, such as for the S140G mutation in KCNQ1, there is very good evidence, with statistically significant LOD scores on linkage analysis and functional 
data from cellular models. For other loci there is significantly less evidence and must be treated with a degree of circumspection. Also listed are those non-AF 
disease associations for each gene reported in the Online Mendelian Inheritance in Man database102
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1.3 AF inherited as a complex trait 
Few of the variants listed in Table 1.1 have been identified in more than one family; 
partly because deleterious mutations will tend to be removed from the population by 
negative selection, but also because rare mutation will be lost over time by the process 
of genetic drift. Therefore highly penetrant variants of this type are unlikely to be 
important causes of the total burden of AF in the population. This does not, however, 
rule out the possibility that lower penetrance common variants in the same genes 
could be responsible for a significant proportion of AF risk. In common with many 
other complex diseases, it has been hypothesised that the heritability of AF in the 
general population results from the interaction of many individual risk variants: that is, 
it is inherited as a complex trait. One method of identifying the variants that contribute 
to this overall risk is to look for associations between common genetic variants, usually 
SNPs, and AF in case-control studies. The initial studies of this type focussed on 
variants which lay in or near candidate genes for AF. Unfortunately many of these 
studies were underpowered and therefore were at significant risk of type-II errors; 
that is they were likely to miss significant associations. Conversely, the large number of 
small studies and subgroup analyses performed means that the associations found are 
likely to reflect type-I errors, since they are underpowered to detect real associations, 
and the statistical significance threshold was set too low in the context of millions of 
common SNPs throughout the genome. Indeed, an attempt to replicate in two large 
European cohorts the findings of all the candidate gene association studies of AF 
published before 2007 failed to replicate a single association103 and none of the 
associations identified in candidate gene studies have subsequently reached 
significance in genome wide studies. 
The systematic identification of SNPs by the SNP consortium, the mapping of common 
variation by the HapMap project and the availability of microarray genotyping 
platforms have allowed extension of association studies to the whole genome. Such 
GWAS typically look for associations between a disease state and 300,000 to 2.5M 
SNPs and reliably capture 80-90% of variants in the genome that have a minor allele 
frequency (MAF) greater than 1%104. High-throughput techniques allow the inclusion 
of large numbers of cases and controls, and therefore stringent statistical significance 
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levels with replication in a similar sized cohort to the discovery cohort (typically ~2000 
cases in each cohort), thus avoiding the pitfalls of the earlier candidate gene studies. 
A number of GWAS have performed in order to identify regions associated with AF. 
The first study, performed in an Icelandic population, identified a signal at 
chromosome 4q25, which has been identified as the strongest signal in all subsequent 
GWAS to date105. Further studies in populations of European descent have identified 
associations at 16q22 and 1q21106-108. In 2012 a large meta-analysis of all of the 
previously published AF GWAS data in individuals of European ancestry was published, 
including 6,707 cases and 52,426 controls (Figure 3, Table 1.2)109. The results were 
further replicated in 5,381 cases and 10,030 controls of European ancestry and 843 
cases and 3,350 controls of Japanese descent. This analysis confirmed the three 
previously described associations at 4q25, 16q22 and 1q21, and identified a further six 
loci which were replicated in the European cohort: 1q24, 7q31, 9q22, 10q22, 14q23 
and 15q24. These genetic regions are discussed below. 
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Table 1.2 AF loci identified by GWAS studies 
Study 
 
Phenotype Cases/controls 
in discovery 
sample 
Cases/controls 
in replication 
sample 
Region SNP risk allele Nearest 
gene 
Odds ratio [95% 
CI] 
P value Number of 
SNPs  
Gudbjartsson, 
2007105 
AF and atrial 
flutter 
550/4,476 3,336/17616 4q25 rs2200733-T PITX2 1.72 [1.59-1.86] 3x10-41  316,515 
4q25 rs10033464-T PITX2 1.39 [1.26-1.53] 7x10-11 
Gudbjartsson, 
2009106 
AF 2,385/33,752 2,427/3,379 4q25 rs2200733-T PITX2 1.42 [NR] 1x10-14  303,136 
16q22 rs7193343-T ZFHX3 1.21 [1.14-1.29] 1x10-10 
Benjamin, 
2009107 
AF 3,413/37,105 2,145/4,073 4q25 rs17042171-A PITX2 1.65 [NR] 4x10-63  2.5 million 
(imputed) 
16q22 rs2106261-T ZFHX3 1.25 [NR] 2x10-15 
Ellinor, 
2010108 
 
 
 
 
 
Lone AF 1,335/12,844 1,164/3,607 4q25 rs6843082-G PITX2 2.03 [1.79-2.30] 3x10-28 2.5 million 
(imputed) 
1q21 13376333-T KCNN3 1.52 [1.40-1.64] 2x10-21 
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Study 
 
Phenotype Cases/controls 
in discovery 
sample 
Cases/controls 
in replication 
sample 
Region SNP risk allele Nearest 
gene 
Odds ratio [95% 
CI] 
P value Number of 
SNPs  
Ellinor 2012109 AF 6,707/52,426 5,381/10,030 4q25 rs6817105-C PITX2 1.64 [1.55-1.73] 2x10-74 2.5 million 
(imputed) 
15q24 rs7164883-G HCN4 1.19 [1.14-1.24] 3x10-17 
16q22 rs2106261-T ZFHX3 1.24 [1.17-1.30] 3x10-16 
1q21 rs6666258-C KCNN3 1.18 [1.13-1.23] 2x10-14 
1q24 rs3903239-G PRRX1 1.14 [1.10-1.17] 8x10-14 
14q23 rs1152591-A SYNE2 1.13 [1.09-1.17] 6x10-13 
7q31 rs3807989-G CAV1 1.11 [1.09-1.15] 4x10-12 
9q22 rs10821415-A C9orf3 1.11 [1.08-1.15] 4x10-11 
10q22 rs10824026-A SYNPO2L 1.15 [1.10-1.20] 4x10-9 
NR – not reported
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Figure 1.6 Manhattan plot from Ellinor et al. 2012109.  
 
Each point plotted represents an individual SNP with AF. Position on the x-axis indicates 
position of the SNP in the genome and SNPs are colour-coded alternately light and dark grey to 
indicate on which chromosome they lie. Height on the y-axis represents the strength of the 
evidence for the association expressed as the negative log of the p-value of the association 
test. The horizontal dashed line indicates the p-value cut-off threshold for GWAS of 5x10-8, 
which corrects for multiple testing. The three associations identified previously are marked in 
blue with other significant associations in orange. The association with SNPs near WNT8A in 
chromosome 5 was not replicated.  
 
1.3.1 The 1q21 region 
One of three loci independently identified in a lone AF population lies in 1q21108, 6 
megabases downstream of the locus of the 1q21.1 microdeletion syndrome, which is 
associated with cardiac developmental abnormalities110. The associated SNPs are 
within intron 1 of KCNN3, the gene which codes for the small conductance calcium-
activated potassium channel SK3. The calcium-activated potassium current, IK,Ca, 
mediated by SK channels, is a key effector in atrial repolarisation111.  Activation of SK 
channels produces membrane hyperpolarisation suppresses  membrane excitability112. 
SK channels are expressed at different levels in different cardiac tissues, being 
predominantly found in atrial myocytes.  As described in Table 1.1 and Figure 1.5, 
highly penetrant mutations in other potassium channel genes (KCNQ1, KCNE2, KCNJ2, 
KCNA5)21,62,65,67 have been found in familial forms of AF. Members of the SK channel 
family form heteromultimers; thus relatively small effects on expression of one family 
member such as KCNN3 might, through disturbing interactions between channel 
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subunits, have marked effects on atrial electrophysiology. SK channel trafficking to the 
cell membrane is a requirement for the shortening of the action potential duration 
during burst pacing in a rabbit model113. Action potential shortening decreases the 
refractory period of the myocyte114, which is thought to have an important role in the 
initiation and maintenance of AF. Endothelial derived hyperpolarising factor (EDHF) 
signalling in blood vessels requires SK3 activity, which initiates gap junction-conducted 
arteriolar dilatation115. This observation links SK3 to the gap junction protein Connexin-
40, which has been shown to be implicated in monogenic AF23. 
 
1.3.2 The 1q24 region 
Of the associations identified by meta-analysis but not in an individual GWAS, the 
strongest was seen with the genotype of the SNP rs3903239 in chromosome 1q24, 
near the gene PRRX1. PRRX1 is a transcription factor which is widely expressed in 
mesenchymal tissue during embryogenesis and especially in the endocardial cushions 
and atrio-ventricular valves. Prx1 null mouse models have significant great vessel 
abnormalities116 and deficiencies in pulmonary vascularisation117. 
 
1.3.3 The 4q25 region 
The locus with the strongest associations in all of the published GWAS of AF is in 4q25.  
The lead AF risk SNPs on 4q25 are approximately 120 kilobases 5’ from the nearest 
gene, PITX2. The PITX2 gene encodes the PITX2 protein which has three major 
isoforms in humans, PITX2a, PITX2b and PITX2c, and which plays a roles in the 
development of the heart, as well as the eye, gut, spleen, lungs and in limb 
myogenesis118-121. PITX2a and PITX2b share a promoter region and are differentially 
spliced. PITX2a consists of exons 1, 2, 5 and 6; PITX2b also includes exon 3122. PITX2c 
has a different promoter region and consists of exons 4, 5 and 6. Proteins often consist 
of several domains, which are conserved parts of the protein sequence which can 
function independently of the rest of the protein chain. All three isoforms of PITX2 
share the same C-terminus and homeobox domain but have differing N-terminus 
regions.  In humans a fourth isoform, PITX2d, has been identified which consists of the 
c-terminal and part of the homeobox domain only, and has a dominant-negative action 
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on the effect of the other isoforms123. PITX2c is the only isoform to be asymmetrically 
expressed in the left lateral plate mesoderm, indicating its role in the development of 
the left-right axis.122 PITX2c is the only isoform to be identified in RNAseq studies of 
human atrium thus far124, however a recent qPCR study indicated that other isoforms 
of PITX2 are expressed, predominantly PITX2a, at similar levels in left atrial appendage 
(LAA) and right atrial appendage (RAA)125.  
PITX2c regulates expression of downstream genes to suppress development of the left-
sided sino-atrial node126,127, control cardiac left-right asymmetry and left atrial 
development128, and control development of the pulmonary vein myocardium, which 
is an important source of triggered activity that initiates paroxysmal AF4. The 
importance of PITX2a and PITX2b in cardiac development is less well established. PITX2 
isoforms form heterodimers, potentiating their transcriptional effects123, and providing 
a potential mechanism whereby genetic variation influencing transcription of non-c 
isoforms of PITX2 could indirectly affect the biological activity of the c isoform. 
PITX2 isoforms are not expressed in easily accessible tissues other than skeletal 
muscle, which has made large cohort studies of eQTLs regulating PITX2 expression 
difficult. A recent analysis of PITX2c expression did not find any association with AF risk 
variants in a cohort of 239 LAA samples, but did identify elevated PITX2c expression in 
patients in AF at the time of tissue collection compared to those in sinus rhythm129. A 
genome-wide eQTL mapping study in left and right atrial samples from 64 European 
individuals found no association between PITX2 expression and AF risk variants130.  So 
far no study has examined the relationship between PITX2a and PITX2b expression and 
AF-associated SNPs. 
 
1.3.4 The 7q31 region 
Another SNP identified by meta-analysis, rs3807989, is in CAV1 in chromosome band 
7q31, which encodes caveolin-1, a signal transduction protein. The same SNP was 
found to be significantly associated with P-R interval on the ECG, itself an indicator of 
AF risk, and also with insulin resistance in hypertensive individuals in previous GWA 
studies131,132.  CAV1 is expressed in atrial myocytes.  CAV1 knockout mice, in which the 
gene has been inactivated, develop a dilated cardiomyopathy with pulmonary 
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hypertension and demonstrate a hypertensive, insulin resistant phenotype; suggesting 
multiple pathways through which AF risk could be mediated.  
 
1.3.5  The 9q22 region 
Another SNP identified by meta-analysis, rs10821415, in chromosome band 9q22, is 
situated in an intron of C9orf3, also known as APO, which codes for aminopeptidase O. 
Aminopeptidase O is a protease which cleaves angiotensin III to angiotensin IV. It is 
mainly expressed in the pancreas, placenta, liver, testis, and heart133. Angiotensin II is 
the main effector in the renin-angiotensin system, and regulates blood pressure and 
fluid and electrolyte homeostasis by its action on the AT1 and AT2 receptors
134. It is 
cleaved to angiotensin III which retains 38% of its affinity to AT1 and 81% of its affinity 
to AT2. By contrast angiotensin IV has no affinity for AT1 and only 1% of angiotensin II’s 
affinity for AT2, making the degradation of angiotensin III a key ‘off-switch’ in the 
renin-angiotensin system.  
 
1.3.6 The 10q22 region 
Another SNP identified by meta-analysis, rs10824026, is located between the genes 
SYNPO2L and MYOZ1 in chromosome 10q22, within the region identified in the first 
published report of Mendelian AF9. Both SYNPO2L and MYOZ1 encode Z-disc proteins 
of unknown function in cardiac and skeletal muscle135,136.  A mouse knockout of Myoz1 
did not demonstrate a significant cardiac phenotype 137, but there is some uncertainty 
whether Myoz1 is expressed in the mouse heart136.  
 
1.3.7 The 14q23 region 
Another SNP identified by meta-analysis, rs1152591, is in an intron of SYNE2 in 
chromosome band 14q23. SYNE2 codes for multiple tissue specific isoforms of the 
protein nesprin-2, which forms complexes linking the nucleoskeleton to various 
structures including the actin cytoskeleton138. SYNE2 mutations can cause Emery 
Dreifuss muscular dystrophy (EDMD) by interrupting nucleoskeleton-cytoskeleton 
bonds. The phenotype of EDMD in individuals with SYNE2 mutations includes early-
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onset AF139.  Atrial tissue is subject to physical stresses and an alteration in the 
patterns of cytoskeletal links caused by altered SYNE2 expression may play a role in AF 
susceptibility. 
 
1.3.8 The 15q24 region 
The last SNP identified by meta-analysis, rs7164883 in chromosome band 15q24, lies in 
the first intron of HCN4, which codes for an isoform of the hyperpolarisation-activated 
cyclic nucleotide-gated channel, also known as the pacemaker channel. This generates 
the If current in the sino-atrial node. HCN4 mutations have been associated with 
conduction defects140-142 and Hcn4 knockout mice demonstrate bradycardia and heart 
block143. Interestingly HCN4 channels have been shown to interact with caveolin-1 and 
HCN4 channels with a disrupted caveolin binding domain have more positive activation 
potentials and slowed deactivation144, providing a further possible explanation of 
mechanism of action of the CAV1 variants. 
 
1.3.9 The 16q22 region 
An association to be identified in individual GWAS in two European populations is in 
chromosome band 16q22106,107. One of the SNPs, rs7193343, is also associated with 
cardioembolic ischaemic stroke106, which is likely to be mediated by AF. The SNPs lie in 
intron 1 of ZFHX3 (previously known as ATFB1). ZFHX3 is the only protein-coding gene 
within 500kb of the GWAS hit SNPs in chromosome 16q22. ZFHX3 codes for a 
transcription factor (TF) which is widely expressed and is reported in all 16 tissues 
covered by the Body Map 2.0 project145. ZFHX3 induces the expression of platelet-
derived growth factor receptor beta (PDGFRB)146. The PDGF signalling pathway has 
been suggested to be particularly important in atrial fibrosis, and thus potentially in 
arrhythmogenic atrial structural remodelling. Normal atrial fibroblasts express higher 
levels of PDGF pathway genes, including PDGF receptors, than ventricular fibroblasts, 
and atrial fibroblasts from congestive heart failure patients show enhanced expression 
of PDGF receptors compared with ventricular fibroblasts from such patients147. The 
mouse equivalent, Zfhx3, is expressed in mouse hearts and, in mice where Pitx2 
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expression in the heart is suppressed, expression levels of Zfhx3 have been shown to 
be reduced.  
There are two known splice variants, ZFHX3 A and ZFHX3 B. The two transcripts have 
different promoter regions148. The ZFHX3 A transcript differs from the B isoform by the 
addition of 420 amino acids at the N-terminus (see Figure 1). The amino acid sequence 
which is common to both isoforms contains an ATP-binding domain, four 
homeodomains and multiple zinc-finger motifs, which bind to DNA and RNA. The N-
terminal portion of the sequence specific to ZFHX3 A contains a DEAD box-like motif 
and a DEAH box-like motif, these motifs are associated with RNA helicase activity and 
transcriptional regulation, suggesting that ZFHX3 A and B have different affinities for 
RNA and may interact with different downstream targets148. Absence of ZFHX3 
expression and mutations near the ATP binding domain are associated with an 
increase in malignant activity in hepatocellular, gastric, breast and prostate carcinoma 
149-152 and ZFHX3 interacts with p53 at the p21(Waf1/Cip1)promoter 153. This suggests 
an important role in the regulation of the cell cycle and of cellular proliferation.  
In cultured mouse HL1 cardiomyocytes, overexpression and underexpression of Pitx2 
regulates Zfhx3 expression but overexpression of Zfhx3 does not affect Pitx2 levels, 
suggesting that Pitx2 is an upstream regulator of Zfhx3 expression154.  
Of the associations above, only those in 4q25, 16q22, 1q24 and 7q31 were replicated 
in a Japanese cohort. Alternate SNPs with stronger associations were identified in 
1q21, 1q24 and 9q22. In the case of the 1q21 association the alternate Japanese SNP 
lies 375 kilobases from the lead European SNP109. No GWA study has been performed 
to date in African or African-American populations, where the overall incidence of AF is 
lower. A small study of the 4q25, 16q22 and 1q21 loci in African-Americans found that 
the SNPs with the strongest association differed from those found in Europeans in all 
three regions, suggesting that the AF association is mediated by different mechanisms 
in different populations155. 
 
1.4 Clinical implications of the genetic determinants of AF 
The primary motivation behind attempts to identify genetic variation which is 
associated with AF and the mechanisms by which these variants operate is to improve 
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our ability to manage patients with AF. In this context there are two major benefits 
that can be derived from an increased understanding of the genetic basis of AF. One 
possible implication of identifying genetic determinants of AF lies in the possibility of 
using an individual's genotype to inform decision-making in AF management, thus 
improving the ability to tailor the treatment of specific individuals (personalised 
medicine). The other, probably more important, benefit is an increased understanding 
of the pathophysiological mechanisms underpinning AF. The involvement of a gene in 
AF development indicates that the protein product and, by extension, other proteins 
with which it interacts may be involved in the maintenance of normal sinus rhythm. 
This gives insight into how other factors, genetic and environmental, which affect 
these protein networks modify disease risk, and raises the possibility of deliberately 
altering activity in these networks, by pharmacological and other means, to aid in AF 
management. Insights derived from genetic studies, therefore, may result in 
developments which improve the diagnosis, monitoring and treatment of AF of any 
aetiology. 
 
1.4.1 Personalised medicine 
As has been previously stated the common variants associated with AF have modest 
effect sizes, with odds ratios of between 1.11 and 1.64 in the largest study109. An 
important question therefore arises; do these variants provide useful information to 
the clinician treating the individual patient? A large prospective study of 26 946 middle 
aged Swedish individuals found that genotype of the 4q25 and 16q22 SNPs predicted 
incidence and prevalence of AF with a risk magnitude that was similar to clinical risk 
factors. However, the addition of the genotyping information to the clinical risk did not 
result in a significant improvement in risk prediction156. A fine mapping study identified 
two further SNPs (rs17570669 and rs3853445) in 4q25 which appear to be 
independently associated with AF, suggesting multiple independent regulatory 
elements within the region. Individuals who were homozygous for the risk allele at all 
three SNPs were six times as likely to develop AF as those with the most common 
genotype. Only 1.2% of the subjects in the study had this particular combination, 
limiting the usefulness of the markers for disease prediction for most individuals157.  
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Genotyping of common variants may be useful in specific circumstances. Genotype of 
the 4q25 risk SNPs predicts risk of new AF after coronary artery bypass grafting and the 
addition of genotype to clinical risk factors provides a small but significant 
improvement in risk prediction158. 4q25 variant rs10033464 has also been associated 
with an increase in both early and late AF recurrence after catheter ablation (OR 1.994, 
95% CI 1.036 to 3.837, p= 0.039 and OR 4.182, 95% CI: 1.318 to 12.664 respectively)159, 
and an increase in risk of AF recurrence on antiarrhythmic drug therapy (OR 3.27, 95% 
CI 1.77 to 6.04)160. These findings have been demonstrated in small studies but they 
have, as yet, not been replicated. 
 
1.4.2 Biomarker development 
The identification of the mechanisms by which variants affect disease risk may also 
allow the identification of downstream biomarkers which indicate disease risk. A 
biomarker is a "characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes or pharmacological 
responses to a therapeutic intervention”161. Biomarkers have been useful in aiding the 
diagnosis and monitoring of many diseases including myocardial infarction162 and heart 
failure where, for example, measurement of serum brain natriuretic peptide (BNP) 
provides a simple blood test which can indicate left ventricular dysfunction163.  
 
1.4.3 Drug development 
One of the primary benefits of identifying genetic variants associated with AF is that 
they provide significant insights into the mechanisms underlying the pathophysiology 
of AF. The strength of the association and the relative effect of the variant do not 
indicate the potential usefulness of the drug target. For example, in the case of plasma 
cholesterol level, common variants at the HMGCR locus in 5q13 are associated with 
only modest changes in LDL cholesterol but statins, which inhibit the HMGCR’s 
product, HMG-CoA reductase, are a cornerstone of lipid lowering therapy164. By 
identifying loss- or gain-of function mutations in key ion channels, we are provided 
with a valuable model of the effects of pharmacological blockade or enhancement of 
that current. One of the most promising targets is the IKur current. It is unique to atrial 
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myocytes and so blocking agents are unlikely to cause ventricular arrhythmia. 
Vernakalant is a novel class III antiarryhthmic with a short half life with IKur blocking 
action. It has been approved in Europe for iv administration for cardioversion of acute 
AF.  It is not a specific blocker of IKur, however, and concerns have been raised that 
there is an increased risk of ventricular arrhythmia6.  
Blockade or activation of the other currents implicated in Mendelian AF may prove to 
be more problematic. Loss of function in INa channels has been identified in familial AF 
and Brugada syndrome165 whereas gain of function has been identified in AF and long 
QT syndrome type 3166. Clearly the maintenance of sinus rhythm requires the activity 
of the Na+ channel to be finely regulated and antiarrhythmic agents would be expected 
to have a significant proarrhythmic potential, as is seen in the case of the commonly 
used class I agents167. Similarly, gain of function in IKs channels has been associated 
with AF but loss of function mutations have been identified in Long QT syndrome168. IKs 
blockade is one of the mechanisms of action of amiodarone and dronedarone, both of 
which prolong the Q-T interval169,170; more specific agents, such as HMR1556 and L-
768673 have been trialled in animal models but are not yet sufficiently developed for 
human studies171.  
GWAS can provide insights into the potential effects of currently licensed drug 
treatments. HCN4 encodes the major subunit of the ion channel responsible for the 
pacemaker current If. The association of AF with SNPs near HCN4 may indicate the 
importance of If in AF risk. Treatment with the If-blocker ivabradine in the SHIFT trial 
was associated with a modest but significant increase in the incidence of AF, compared 
with controls172. AF is reported as a rare (<1:10 000) complication of ivabradine 
treatment, but AF incidence is not widely reported in the major trials of ivabradine to 
date173-177.  In Chapter 3, I present a meta-analysis of the available studies which have 
assessed the effects of ivabradine treatment, in order to quantify any excess risk of AF. 
GWAS hits also suggest possible targets for novel drug treatments. Inhibition of SK 
channels in isolated guinea pig and rat hearts protects against and terminates AF178.  
The IK,Ca current in which ZFHX3 plays an important role is more prominent in atrial 
myocytes, suggesting that blocking agents would be atrium-specific. The association 
with SNPs near the gene which codes for aminopeptidase O is also interesting. 
Inhibition of the renin-angiotensin-aldosterone system, either by angiotensin 
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converting enzyme (ACE) inhibitors or angiotensin receptor blockers, is effective as 
secondary prevention of AF as well as primary prevention in heart failure179. Further 
investigation of the role of APO and Angiotensin III and IV may produce further targets 
for drug therapy. 
A less conventional target for future pharmacological agents might lie in the control of 
transcription in the adult atrium. PITX2, ZFHX3, GATA4, GATA6 and TBX5 are important 
transcription factors in regulation of cardiac development. A mouse model, in which 
Pitx2c expression was suppressed after embryonic day nine, had normal left-right atrial 
morphology but abnormal adult cardiac function180, suggesting an ongoing role for 
PITX2c beyond early cardiac development. This may be true of other transcription 
factors; treatments which favourably affect these molecular pathways might prove to 
be useful in the management of AF.   
 
1.5 Assessing the effects of risk loci on expression 
1.5.1 Variation and regulation of gene expression 
Phenotypic variation between individuals arises from a combination of genetic and 
non-genetic factors. Both genetic and non-genetic factors can operate, however, via 
common mechanisms. Insights derived from a greater understanding of genetic 
influences on disease can therefore inform our understanding of the disease in a wider 
sense. Alterations in the DNA sequence may result in changes to the amino acid 
sequence of a protein and thereby its structure (‘quality’) or by affecting the amount of 
protein produced (‘quantity’).  
Prior to the advent of the GWAS, the majority of variants definitively associated with 
disease were coding variants which were either missense, and altered the structure of 
the protein produced, or nonsense, and resulted in haploinsufficiency. Nonsense 
variants result in protein only being produced from one allele, haploinsufficiency, and 
therefore cause a significant decrease in expression. This is the case, for example, for 
fibrillin-1 in Marfan syndrome181. This was largely due to the greater certainty with 
which one can ascribe pathological effects to variants which alter a protein’s function, 
and thereby have a large phenotypic effect. Candidate gene studies, as described in 
Table 1.1, have identified many variants. The yield of this approach in identifying AF 
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risk variants has been low, however, with no pathological variant identified in the 
majority of subjects examined. A recent study identified that just 7.6% of alleles of  
candidate genes (identified by their role in cardiac physiology, rather than by GWAS or 
linkage analysis) in AF subjects contained a novel or very rare variant (minor allele 
frequency < 0.1% in the Exome Variant Server182), compared with 4.1% of alleles in 
subjects in a reference database183. Of course, not all individuals with apparently 
unprovoked AF will have a genetic substrate, but it is likely, given the low yield of the 
candidate gene approach and the high degree of heritability of lone AF, that a 
significant proportion of the genetic determinants of AF are not in the coding regions 
examined by this approach. The importance of non-coding regions in AF heritability 
has been highlighted by the results of GWAS, in which none of the most significantly 
associated SNPs are in protein-coding regions (Table 1.2).  
Disease-causing mutations in non-coding regions have been well described for a 
number of disorders, including complex diseases184-186. The non-coding regions of the 
genome are coming under increasing scrutiny in order to identify functional elements. 
One of the largest projects to date has been the ENCODE project, which has mapped a 
large number of regulatory elements including transcription factor motifs, chromatin 
patterns, histone modifications, non-coding RNAs and DNA methylation, in order to 
annotate some of the functions of the 99% of the genome which is does not code for 
protein187-191. Another recent large project, the FANTOM project has created an atlas 
of 40 000 enhancer candidates across 800 human cell and tissue types192.  Systematic 
attempts have also been made to map associations between gene expression and 
genotype genome-wide193-196. These approaches have yielded significant results in 
identifying the effects of variants identified by GWAS on gene expression. Not all 
genotype-gene expression associations are stable across all tissue types. Unsurprisingly 
therefore, the greatest success in identifying effects on gene expression of GWAS-
identified SNPs has been achieved when the tissue in which expression is measured is 
relevant to the disease of interest193. This tissue specificity may well explain the lack of 
associations seen so far between AF risk SNPs and gene expression, as the most 
relevant tissue, namely atrium, is not easily accessible, making the collection of large 
cohorts of samples difficult. Additionally, the true target tissue, in which regulation of 
expression mediates AF risk, may not be easily identified. For example, angiotensin 
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conversion by aminopeptidase O, encoded by the gene C9orf3 could operate in any of 
a wide range of tissues to affect circulating angiotensin levels, and not necessarily in 
atrial tissue. Furthermore, the effects of any of the identified variants may be 
restricted to a subpopulation of cells within the atrium; cardiomyocytes, fibroblasts, 
endothelial cells, pacemaker cells, smooth muscle cells and epicardial cells are all 
present within the atria and have different gene expression profiles197. An alteration in 
the functional properties of just one cell type may result in an increase in the risk of 
AF. 
 
1.5.2 Cis- versus trans-acting effects on expression 
Gene expression varies considerably between individuals and variation in the 
expression levels of many genes has a heritable component193,198-200. Genetic 
influences on gene expression may act in cis or in trans. Cis-acting elements act on 
expression of the allele of the gene which lies on the same chromosome; i.e. they act 
in an allele-specific manner. These include regulatory elements such as promoters and 
enhancers and are usually close to the transcription start site of the gene which they 
regulate, but may lie several hundred kilobases distant201. Trans-acting factors, on the 
other hand, are diffusible molecules, which act on both alleles of a gene and are not 
necessarily transcribed near the gene which they regulate and are often located on a 
different chromosome altogether (Figure 1.8).  
The MuTHER study investigators estimated that cis-acting variants are responsible for 
30-36% of the heritability of gene expression, of which 60% was explained by common 
genetic variants (MAF>1%)193. This estimate may not be accurate as it is based on the 
assumption that all effects within 1Mb of the transcription start site operate in cis and 
all other effects operate in trans. This assumption does not necessarily hold. To give an 
extreme example; the inactivation of the X chromosome in female cells is dependent 
on the non-coding RNA JPX activating the non-coding RNA XIST, which lies just 92kb 
away, in trans202. XIST, in turn, inactivates the entire 153 million bp X chromosome in 
cis203.  
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Figure 1.8 Cis and trans effects on gene expression 
 
  
Depicted is the situation in which an individual is heterozygous for a cis-acting polymorphism 
with alleles T and C and also heterozygous for a transcribed polymorphism with alleles A and 
G. In A) the cis-acting T/C polymorphism affects expression of the allele on the same 
chromosome, resulting in an imbalance in the expression of RNA with A and G alleles. In B) 
trans-acting influences act on both chromosomes and so do not result in an imbalance in the 
relative amount of RNA from each allele. Adapted from Teare DM et al. 2011204 
 
The discovery of trans-acting associations with gene expression is made difficult by the 
ability of such influences to operate independently of the location of the target.  A 
genome-wide approach is therefore required for association studies, which 
necessitates large sample sizes in order to overcome the problem of correction for 
multiple testing. As the AF risk SNPs identified by GWAS do not lie in known 
transcripts, it is unlikely that they alter production of a diffusible trans-acting factor: 
they are likely, therefore, to operate in cis on nearby genes. 
SNPs may influence gene transcript levels in cis via a number of mechanisms. The 
commonest mechanism of action is that the SNP lies within a promoter region close to 
the transcription start site and act to alter levels of transcription by affecting the 
binding of transcription factors which initiate transcription205. Indeed, genome-wide 
studies of SNP effects demonstrate that expression-associated SNPs are clustered 
symmetrically around the transcription start site193,196. Not all regulatory SNPs lie in the 
promoter region, however, and many exert their effect by altering distant regulatory 
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regions206-208. SNPs have also been shown to influence transcript levels by altering 
mRNA stability209,210, mRNA processing efficiency211-213, DNA methylation214,215, and  
RNA splicing216. As described above, genetic variants in close proximity to one another 
may also be in LD. Associations between a variant and gene expression may, therefore, 
either operate directly, via one or more of the mechanisms above, or simply be 
associated, via LD, with another variant nearby. It is likely therefore, depending on the 
local LD structure, that multiple variants will be associated with gene expression, 
making the identification of the true functional variant within a haplotype block 
difficult.  
 
1.5.3 Mapping cis-acting effects on expression 
Traditionally, studies investigating the influence of polymorphisms upon gene 
expression have used in vitro methods, relying on synthetic reporter constructs 
transfected into cell lines. These techniques are limited by the difficulties in capturing 
the entire regulatory region for a gene, by the differences between the cell culture and 
in vivo environments and by the low power of in vitro assays to detect in vivo 
effects217. The most common approach to investigating expression in-vivo has been to 
compare total expression levels between individuals with different genotypes of the 
polymorphism under investigation. This approach treats total expression levels as a 
quantitative trait that is modified by the putatively active SNP (expression quantitative 
trait locus, or eQTL analysis)218.  Expression can also respond to environmental, 
hormonal or other influences acting in trans. This increases inter-individual variability 
and may obscure the effect of cis acting polymorphisms185.  
An alternative approach to mapping cis-acting genetic influences on expression is to 
make use of the allele-specific nature of cis-acting effects and to measure the 
difference in expression between the two alleles of a gene, or more precisely, the 
allelic expression ratio (AER). The main benefit of using the AER to map eQTLs (aerQTL 
mapping) is that trans-acting influences would be expected to act on both copies of 
the gene and therefore not affect the AER.  
Therefore, if there is substantial contribution to the variability in gene expression from 
trans-acting factors the traditional eQTL approach may have lower power to detect cis 
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acting effects than methods such as aerQTL analysis, which are more are specific for 
cis-acting effects. (Figure 1.9). The curves in the figure show the rapid drop-off in 
statistical power as the variance of the trans acting influences increases for the eQTL 
approach. This demonstrates, therefore, that when the trans acting influences are very 
similar between samples, eQTL is the more powerful approach but when there are 
significant differences in trans-acting influences between samples, aerQTL is more 
powerful. 
 
Figure 1.9 The effect of trans-acting variation on power to detect cis-acting 
effects 
 
The power has been simulated for 100 samples with a cis-acting polymorphism (minor allele 
frequency 0.2) that causes a 2.7 fold increase in expression and a transcribed marker with a 
minor allele frequency of 0.1. The mean effect of the trans-acting influence is 0 (i.e. there is no 
change in expression).  
 
Allelic expression analysis relies on the ability to differentiate between both alleles in 
an individual, i.e. individuals that are not heterozygous for a transcribed polymorphism 
do not contribute to the analysis. Nevertheless, work on the CDKN2A/CDKN2B/ANRIL 
locus on chromosome 9p21 and genome wide approaches to eQTL and aerQTL analysis 
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have clearly illustrated that allelic expression analysis can achieve substantially more 
power than classical eQTL approach185,219. Since gene expression is often regulated in a 
tissue specific manner, the effects of polymorphisms can vary in different tissues: 
however, to a significant extent, the effects are consistent across a wide range of 
tissues, with 50-83% of effects being shared between tissue types193,220. It is therefore 
possible to gain some insight into the effects in the target tissue by studying cis-acting 
effects in readily accessible tissues, for example whole blood, provided the gene of 
interest is expressed.  To take account of possibly significant tissue specific effects on 
expression, it is also important to replicate findings in the tissue of interest, namely 
atrial tissue, where this is available. Not all the genes of interest in the AF associated 
regions are expressed in blood, including the strongest candidate gene identified by 
GWAS, PITX2105, and therefore alternative tissues are required to investigate gene 
expression.  Atrial tissue is the ideal tissue to study, and right atrial appendage (RAA) 
and left atrial appendage (LAA) samples can be collected at the time of cardiac surgery 
with no additional risk to the tissue donor. Insights may also be gained from studying 
other available tissue types, where the candidate genes are expressed. One such 
possibility is to use arterial tissue, harvested from the internal mammary artery (IMA) 
at the time of cardiac bypass surgery. This also has the additional benefit that tissue 
samples from the IMA and RAA will often be available from the same patient. 
 
1.5.4 Measurement of total expression and allelic expression ratio 
Total expression can be measured by a number of technologies, all of which have been 
used for eQTL mapping. The commonest approaches involve measurement of mRNA 
levels using quantitative polymerase chain reaction (qPCR)129,185, microarrays193,221,222 
or next-generation RNA sequencing (RNAseq)195. Microarray and RNAseq approaches 
are genome-wide, which means that the detection of effects is not restricted to a small 
number of transcripts. qPCR, however, has some key advantages. First, it is much 
cheaper, if only a few genes are of interest, to measure expression by qPCR than to 
perform either an array or RNAseq experiment. In addition, qPCR has a lower error 
rate than either RNAseq or microarray studies when determining differences in 
expression of transcripts which are expressed at low levels223. In order to minimise the 
bias in qPCR experiments, a set of guidelines has been drawn up for the design and 
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conduct of qPCR experiments, the Minimum Information for Publication of 
Quantitative Real-Time PCR Experiments (MIQE guidelines)224, which have become the 
standard for the performance of qPCR. According to the recommendations set out in 
the MIQE guidelines, total expression is measured and normalised to the geometric 
mean of the total expression levels of at least three reference genes, which have been 
selected as having stable expression across the samples studied. What is used for 
comparison between groups, therefore, is the normalised total expression, which I will 
henceforth refer to as total expression. 
Allelic expression imbalance can also be measured using a number of different 
approaches, including microarray analysis219,225, qPCR226,227, and PCR with MALDI-TOF 
mass spectrometry on the Sequenom platform228,229. The Sequenom platform allows 
reliable measurements of allelic expression ratio from small amounts of starting 
material with the additional option of performing multiple assays in a multiplex 
reaction 
  
1.5.5 Statistical approaches to mapping of cis-acting variants 
A standard approach to mapping eQTLs is to measure total expression and then 
perform a linear regression of the logarithm of the expression versus genotype of the 
study subjects, who will have two, one or no copies of the variant allele. This 
regression provides an estimate of the effect size of the allele, β, and a p value, the 
estimated probability of falsely rejecting the hypothesis that genotype does not affect 
expression.  
Mapping aerQTLs requires a more complex approach. The most important difference 
from eQTL mapping is that the two alleles within each individual are being compared, 
rather than total expression levels between individuals. In the simplest case the 
putative cis-acting SNP is also the transcribed marker which is used to identify each 
allele of the gene. Under these circumstances it is easy to determine whether the 
putative cis-acting SNP results in allelic expression imbalance (AEI), by measuring 
whether the AER deviates significantly from 1:1, when measured using the transcribed 
SNP.  
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The situation is more complex when determining the effect of a SNP which is not the 
transcribed marker. In this case it is necessary to perform phasing of the genotypes of 
each individual across the studied region in order to recreate the haplotype of each of 
their chromosomes. It is then possible to know whether a putatively cis-acting variant 
is in phase (the minor alleles are on the same chromosome) or out of phase (the minor 
alleles are on opposite chromosomes) with the transcribed marker. Once phase is 
accounted for, the same analysis can be performed as before by measuring whether 
the phase-corrected AER deviates significantly from 1:1. The power of the analysis is 
dependent on the number of subjects who are heterozygous at both the transcribed 
SNP and at the cis-acting SNP and so the power to detect associations will always be 
greatest when the effect of transcribed SNP itself is assesed.  
The phasing of the transcribed and cis-acting SNPs can be performed at the same time 
as the analysis or can be done in advance. However it is not always possible to 
determine the phase without ambiguity. Therefore rather than a single phase, the 
probability that each of the possible phases occurs can be computed. Often, however, 
only the most likely phase is used. Simulation data suggest that the power of the 
aerQTL mapping is diminished to a modest degree by pre-phasing and by using the 
only the ‘best estimate’ phase, but this loss of power is minimal where the two SNPs 
are in some degree of linkage disequilibrium (i.e. D’>0) and use of ‘best estimate’ 
phase significantly reduces computational requirements when many SNPs are 
considered204.  
 
1.6 Summary and overall project aims 
Atrial fibrillation displays a significant degree of heritability. A large number of high-
penetrance variants have been identified which can cause AF in a Mendelian fashion, 
but these are rare and are unlikely to contribute significantly to AF risk at a population 
level. GWAS have identified 9 chromosomal regions where variants are associated with 
AF risk. These variants do contribute to some, if not all, of the heritability of AF in the 
general population and knowledge of the mechanism of these associations would 
provide insights into the pathophysiology of AF. 
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It is therefore essential to investigate the AF risk variants identified by GWAS to 
establish their mechanisms of action. As none of the variants lie in transcribed regions, 
it is likely that they operate by regulating expression of nearby genes in cis. Genes 
which are regulated by AF risk SNPs provide insights into the biological processes 
which underlie the initiation and maintenance of AF and may identify therapeutic 
targets. 
One particularly interesting candidate gene is HCN4, which encodes the major subunit 
responsible for the If current, as the If current blocking agent, ivabradine, is licensed for 
use and may influence AF risk. In Chapter 3 I present a study which aimed to identify 
whether inhibition of the If current by ivabradine was associated with an increase in AF 
risk and to quantify any risk identified. 
The identification of effects of AF-associated SNPs on expression of candidate genes 
can be performed in easily accessible tissues.  More than half of cis-acting eQTLs 
operate across tissue types and so effects identified in easily accessible tissue can 
indicate effects in disease relevant tissue. In Chapter 4 I present a study which aimed 
to identify associations between genotype and expression of candidate genes in 
peripheral blood.  
Candidate genes in AF risk regions may not be expressed in peripheral blood. 
Additionally, the site of action of variants which are associated with AF risk is likely to 
be the atrium. It is therefore of interest to identify the effects of AF risk variants on 
gene expression in atrial and other tissues. In Chapter 5 I present a study which aimed 
to identify associations between expression of candidate genes in atrial and internal 
mammary artery tissue and AF risk SNPs. 
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Chapter 2 
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2  Methods 
2.1 Materials and Samples  
2.1.1 South African (SA) cohort 
DNA and peripheral blood RNA samples were collected from 310 healthy adult 
volunteers at a blood donor clinic at the University of the Western Cape, Cape Town, 
South Africa. Samples were anonymised, but limited demographic data including age, 
gender, and self-reported ethnicity were collected. Informed consent was obtained 
from all participants and the study was approved by the University of Cape Town 
Faculty of Health Sciences Research Ethics Committee.  
The self-reported ethnicity of the SA cohort was: 200 Cape mixed-ancestry; 67 African 
black; 19 Indian; 10 white; 4 other/unknown. 42% were male, with median age 20 
years (range 17-60, lower quartile 19, upper quartile 23). These samples had been 
collected and largely extracted before the beginning of the project185. 
 
2.1.2 North East (NE) cohort 
DNA and peripheral blood RNA samples were collected from 405 participants recruited 
on attendance for cardiac catheterisation at the Freeman Hospital, Newcastle and the 
James Cook University Hospital, Middlesbrough. DNA, peripheral blood and cardiac 
tissue RNA samples were collected from 159 participants recruited on attendance for 
cardiac surgery at the Freeman Hospital, Newcastle; the James Cook University 
Hospital, Middlesbrough; the Northern General Hospital, Sheffield; the Wythenshawe 
Hospital, Manchester; or Manchester Royal Infirmary. Samples were anonymised but 
information on previous AF status was recorded. Written informed consent was 
obtained from all participants and the study was approved by the NRES Committee, 
North East – Sunderland. Study No: 12/NE/0072.  
 
2.1.3 Labware 
All experiments were performed using standard sterile nuclease-free plasticware from 
the following laboratory suppliers: Thermo Fisher Scientific (USA) and Eppendorf 
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(Germany) and Sigma-Aldrich (USA). Barrier pipette tips (Starlab, Belgium) were used 
for all pre-PCR preparation steps, which were performed in designated laminar-flow 
hoods. 
2.2 Nucleic Acid Preparation 
2.2.1 DNA extraction and quantification. 
For the SA cohort, peripheral blood samples for DNA analysis were collected in 5mL 
EDTA tubes using standard venesection from veins in the antecubital fossa. Samples 
were stored at -80°C until extraction and were extracted within two months. DNA was 
extracted using a standard phenol/chloroform methods by technicians at the 
Department of Molecular Biology and Human Genetics, University of Stellenbosch, 
Cape Town. 
For the NE cohort, peripheral blood samples were collected in two 4ml EDTA tubes 
from the arterial sheath at the time of cardiac catheterisation or from the central 
venous catheter at the time of cardiac surgery. Samples were stored at -20°C until 
extraction and were extracted within 4 months. DNA was extracted from 150 samples 
using a standard phenol/chloroform method by a technician at Newcastle University 
(see acknowledgements). The remainder were extracted using a QIAamp DNA Blood 
Maxi Kit (Qiagen, Germany), according to the manufacturer’s instructions by me and a 
technician at Newcastle University. 
DNA concentrations and purity were measured by A260/A280 absorbance using a 
NanoDrop ND-8000 Spectrophotometer (NanoDrop Technologies, USA). Nucleic acids 
and proteins have absorbance maxima at 260 and 280 nm, respectively. The 
absorbance at 260nm can therefore be used to quantify nucleic acid concentrations 
and a high ratio of absorbance at 260nm vs. 280nm indicates low levels of protein 
contamination. Samples were vortexed prior to measurement and 1µl of solution was 
used in at least 2 replicates. 
DNA was diluted to a stock concentration of 200ng/µl with TE. Further dilutions were 
prepared for downstream applications, as necessary. 
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2.2.2 DNA visualisation 
After each PCR reaction carried out in Newcastle University, PCR products were 
visualised by gel electrophoresis to determine product size and to exclude the 
presence of alternative PCR products or PCR products in no-template controls. 2% w/v 
Agarose gel was made using 2g of SeaKem LE Agarose powder (Cambrex, USA) per 
100mL of 1xTAE, containing 1ml of 1000x GelRed per ml of gel. 
PCR products were mixed in a ratio of 5:1 with 6x Orange G loading dye (Sigma 
Aldritch, UK) and 3-5µl of mixture was loaded alongside 3-5µl 100bp DNA ladder. 
Electrophoresis was carried out in 1x TAE buffer for 30-60 minutes at ~100V on a 10cm 
gel. Gel images were then recorded using a GelDoc-It Gel imaging system (UVP, USA). 
 
2.2.3 RNA extraction 
Peripheral blood RNA samples were collected in two or four 2.5ml PAXgene blood RNA 
tubes in the same way as the DNA samples. After incubation at room temperature for 
24 hours, they were stored at 4°C for up to 48 hours, then at -80°C until extraction. 
RNA was extracted from the blood using the Qiagen Paxgene blood RNA extraction kit 
(Qiagen, Germany) according to the manufacturer’s specifications. I performed 300 
extractions and the remainder were performed by a technician at Newcastle University 
(see acknowledgements). The DNase treatment step was omitted from the protocol. 
Tissue RNA samples were stored in RNAlater (Invitrogen, USA) at 4°C from the time of 
collection for up to 48 hours, then at -80°C until extraction. Right atrial appendage 
(RAA) and left atrial appendage (LAA) samples did not require dissection prior to 
analysis. Internal mammary artery tissue was, for the most part, supplied as dissected 
for use in grafting, i.e. attached to a 5-10mm strip of thoracic wall, including parietal 
pleura and intercostal muscle. These samples required careful dissection to ensure 
that only arterial tissue was included in the sample used for extraction. RNA was 
extracted from up to 30mg of tissue using a Qiagen fibrous tissue mini kit and a 
TissueRupter tissue homogeniser (Qiagen, Germany) according to the manufacturer’s 
protocol for manual extraction without the use of a QiaCUBE. 
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2.2.4 DNA removal 
For the peripheral blood samples, contaminating DNA was removed from the eluted 
RNA using a DNAfree DNase kit (Ambion, USA) with a modified protocol as described 
below. Up to 44µl RNA was incubated with 5µl DNAfree 10x buffer, 1µl recombinant 
DNase I solution (2 Units/µl) and water to a total volume of 50µl for 30 minutes. A 
further 1µl of DNase I solution was added and incubated for 30 minutes and then a 
further 1µl of DNase I was added and incubated for 30 minutes. 10µl of DNase 
inactivation reagent were added and the mixture kept at room temperature for 2 
minutes, mixing occasionally. The sample was then centrifuged at 13000g for 90 
seconds before the supernatant was pipetted into a clean storage tube. For tissue 
samples DNase treatment was performed during extraction, as per the manufacturer’s 
protocol. Effective DNase treatment of the RNA extracted from tissue is important to 
minimise the risk of bias in the aerQTL experiments. The PCR amplicons used for the 
determination of allelic expression were wholly contained within a single exon. This is 
to allow the use of genomic DNA from heterozygous individuals for normalization, but 
carries the risk that the results could be biased by contamination with genomic DNA. 
For the eQTL experiment, DNA contamination is less problematic as qPCR probe-
primer sets were chosen to overlap exon boundaries and therefore not to produce PCR 
products from a genomic DNA template. 
 
2.2.5 RNA quantification 
RNA was quantified by A260/A280 absorbance using a NanoDrop ND-8000 
Spectrophotometer (NanoDrop Technologies, USA). Samples were vortexed prior to 
measurement and 1µl of solution was used in at least 2 replicates. For the peripheral 
blood RNA samples, the elution buffer BR5 from the blood extraction kit was used as a 
no DNA sample for calibration. Previous testing in our laboratory has yielded reliable 
quantification but not purity assessment using the NanoDrop spectrophotometer, due 
to absorption of light of wavelength 260nm by the buffer.  
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2.2.6 RNA quality assessment 
A selection of RNA samples were assessed by capillary electrophoresis using the 
Agilent 2100 bioanalyser and the RNA pico LabChip (Agilent, USA), according to the 
manufacturer’s protocol. RNA integrity numbers (RIN) are calculated by the Agilent 
software on the basis of the electropherogram, RIN of greater than 7.5 were 
considered acceptable230(REF, PMID 16448564). Contamination230 with genomic DNA 
was assessed by performing PCR without the reverse transcription step and analysing 
the products on an agarose gel. Fleige and Pfaffl231 measured the effect of RNA 
integrity on the results of qPCR and found that for amplicon sizes of greater than 
400bp, a RIN of greater than 5 was desirable, but that performance of relative 
quantification assays where the PCR amplicon was small (<250bp) was independent of 
RNA quality. Therefore RIN greater than 5 and the use of short (<150bp) amplicons for 
PCR minimises the risk of bias due to RNA degradation, and so the results of the 
experiments performed in this study are unlikely to be biased by poor RNA quality.  
 
2.2.7 Reverse transcription 
Up to 2.5µg of RNA were reverse transcribed using a SuperScript VILO cDNA synthesis 
kit (Invitrogen, USA) in 20µl, according to the manufacturer’s instructions. cDNA was 
diluted to a concentration of 25ng/µl of RNA template. cDNA was checked by PCR 
amplification using primers specific to the gene GUSB, designed to straddle an intron, 
and to amplify fragments of different sizes for cDNA and contaminating genomic DNA. 
 
2.3 Assays 
2.3.1 Polymerase chain reaction 
PCR setup was performed in a designated pre-PCR area in a laminar flow hood using 
barrier pipette tips. PCR reactions were performed in 96-well plates (Thermo Fisher 
Scientific, UK) sealed with adhesive lids and a thermal cycler (BioRad DNA engine 
Tetrad 2, BioRad, USA). Except where specified, PCR was performed using Qiagen 
HotStar Taq DNA polymerase kit (Qiagen, Germany). The following were combined in a 
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PCR tube: 1µl cDNA or DNA template, 1.5µl 10x buffer, 0.9µl 25nM MgCl2, 1.2µl 10nM 
dNTPs, 1.5µl of a 5µM solution of forward and reverse primer, 0.075µl 5U/µl HotStar 
Taq and water to a total volume of 15µl. Optimal annealing temperatures for each 
primer pair were established by performing a temperature gradient PCR with 
annealing temperatures of 50-70°C. Agarose gel electrophoresis of PCR products was 
performed for all plates to confirm successful PCR in sample wells and exclude PCR 
product in the no-template controls. 
 
2.3.2 TaqMan genotyping 
TaqMan genotyping was carried out in 5µl reactions according to the standard 
manufacturer’s protocol on a 7900HT Real-Time PCR instrument (Applied Biosystems), 
using custom TaqMan SNP Genotyping assays (Life Technologies). The assays are listed 
in Appendix 1.  
 
2.3.3 Sequenom genotyping 
Sequenom experiments were carried out on my behalf by the High-Throughput 
Genomics Group, Wellcome Trust Centre for Human Genetics, Oxford. Multiplex SNP 
genotyping was performed by primer extension and MALDI-TOF mass spectrometry 
using iPLEX Gold SNP technology (Sequenom). SNP assays were designed using 
Sequenom’s MassARRAY Assay Design v3.0 Software (multiplex details and primer 
sequences are available in Table A1.2). PCR was performed using 25ng in a 7μl reaction 
volume for 35 cycles using standard iPLEX methodology. Spectra were analysed using 
MassARRAY Typer v4.0 Software (Sequenom). Spectra and plots were manually 
reviewed and auto-calls were manually adjusted if required. Assay quality control was 
performed using 92 CEPH samples to assess genotype concordance with HapMap 
genotypes. Individual samples with low genotype call rates (<95%) and SNP assays with 
poor quality spectra/cluster plots were excluded. Correspondence to Hardy-Weinberg 
proportions was checked for each SNP and SNPs were excluded from analysis where 
the H-W p value was less than 0.001.  
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2.3.4 Quantification of total gene expression using real-time PCR 
Quantification of total gene expression was performed by real time PCR, according to 
the MIQE guidelines224. Assays were performed using TaqMan gene expression probes 
and reagents (Life Technologies, USA) and run on a 7900HT Real Time PCR System 
(Applied Biosystems). Commercially available validated VIC- and FAM-labelled assays 
were used to measure expression of the primary candidate gene in each region and 
reference genes, (Life Technologies). Primer details are given in Table A1.1. PCR was 
performed in four replicates according to the manufacturer’s protocol.  
Relative total expression was analysed using the comparative cycle threshold (Ct) 
method. Ct values for the target gene were normalised to the mean Ct value of three 
reference genes232. Delta Ct values were excluded where the standard error of the 
technical replicates was high. Outliers were excluded using Grubb’s test. 
In order to be able to compare gene expression between different samples it is 
important that the reference genes used to normalise expression are expressed stably 
between samples (i.e. that levels of expression are similar between samples and are 
not influenced by outside factors); this is also true where expression is to be compared 
between tissues, where expression levels of reference genes may vary 233.  One 
measure of reference gene variability is the M value, defined as the average pairwise 
variation of a particular gene with all other control genes, which provides an indication 
of the degree to which expression of a reference gene differs from that of the other 
reference genes measured232. Values of M greater than 1.5 are considered an 
indication of low stability of expression. M values were calculated using the geNorm 
algorithm in the Excel software package (Microsoft, USA)234. 
 
2.3.5 Allelic expression analysis 
Allelic expression analysis was performed following the method published by Ding and 
Cantor (Figure 2.1). This method can be described as follows235. RNA is reverse 
transcribed, using random hexamer primers, to cDNA. The cDNA then undergoes PCR 
amplification using primers designed to generate a small (~100bp) amplicon which 
contains the transcribed SNP. As the sequence of the two alleles of the transcribed SNP 
differs by only one base, amplification efficiency should be very similar for both alleles 
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and therefore the relative amount of each amplicon will remain the same throughout 
amplification. After removal of any excess dNTPs, the PCR products are then used as 
the basis of an extension reaction where a single mass-modified nucleotide is added to 
an extension primer, which binds to the PCR product immediately adjacent to the 
transcribed SNP. The mass modified nucleotides differ from ordinary nucleotides such 
that they have sufficiently different molecular weights to allow differentiation by mass 
spectroscopy. The relative amounts of the extended extension primers are then 
measured by mass spectrometry. Any method which compares the relative abundance 
of two alleles is vulnerable to bias due to systematic differences in amplification 
efficiency. In order to account for this, the results are normalised to the results from a 
genomic DNA template of one or more heterozygous individuals, where the starting 
proportion of the two alleles is known to be 1:1.  
As above, Sequenom experiments were carried out on my behalf by the High-
Throughput Genomics Group, Wellcome Trust Centre for Human Genetics, Oxford. 
Quantification of the allelic expression ratio was performed by primer extension and 
MALDI-TOF spectrometry using iPLEX Gold with identical parameters to the genotyping 
assay. Spectra were analysed using MassARRAY Typer v4.0 Software (Sequenom) and 
allelic expression ratios were estimated as the ratios of the area under the peak 
representing allele 1 to that representing allele 2. Measurements were performed in 
four replicates using 25ng cDNA template. Results from the amplification of genomic 
DNA were used as an equimolar reference to normalise the cDNA values. The allelic 
expression assay is prone to bias from experimental factors, such as small differences 
in PCR efficiency between two alleles being assayed or small differences in the 
efficiency of the extension reaction. Normalisation of the assay is therefore required 
using a mixture of both alleles in known concentrations. Genomic DNA provides a 
perfect template for this normalisation, as in DNA from heterozygous individuals there 
will be the same amount of starting material from each allele (i.e. one copy of each 
from every cell in the source material). The allelic expression assays we used therefore 
are not able to distinguish between cDNA and contaminating genomic DNA. 
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Figure 2.1 Sequenom analysis of AER 
 
Figure adapted from Ding and Cantor235. A transcribed SNP with alleles A and G is amplified by 
PCR using primers which generate a small PCR amplicon (black arrows). The PCR products are 
then used as a template for the addition of a single mass modified nucleotide to an extension 
primer (green arrow). The extension primers are then detected by mass spectroscopy.  
 
A variety of different methods of normalisation of allelic expression assays have been 
reported, including normalisation of each individual using their own genomic DNA236, 
normalisation of a cohort using the mean allelic ratio from the genomic DNA assays of 
the entire cohort237,238 and normalisation using a subset of the allelic ratios from 
genomic DNA239. Normalisation of each individual to their own genomic control is not 
superior than normalisation using the mean allelic ratio from multiple genomic 
controls185, which was the method used here.  Mass spectra were examined for 
evidence of salt peaks which could interfere with measurement of area under the 
peak. The extension primers undergo a Clean Resin desalting step to remove K+ and 
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Na+ ions before MALDI-TOF analysis. 6mg of Clean Resin (Sequenom), which binds salt 
ions, is added to each reaction well with 16μl of water and then centrifuged to bring 
the resins and salts to the bottom of the well. This is required because inadequate 
desalting can result in K+ and Na+ ions remaining bound to the extension primer. The 
subsequent mass of these ions, 39 and 23 Da, respectively, is very close to the 
difference in mass between extension products from different alleles and can result in 
errors in measurement of area under the peak and therefore of AER (Figure 2.2). AER 
values were excluded where the standard error of the log AER of the technical 
replicates was high (>0.5). Outliers were excluded using Grubb’s test. 
Figure 2.2 Salt peaks 
 
 
Top: Mass spectrum with clear salt peaks. Additional peaks are clearly visible (arrows) with 
masses of 23Da and 39Da greater than the G allele peak. These represent the G allele of the 
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extension primer with bound Na+ and K+ respectively Bottom: small salt peaks are visible which 
do not interfere with assay measurements. 
 
2.4 Statistical Analysis 
This was conducted using established methods185. Briefly, total expression was treated 
as a quantitative trait and its association with each SNP assessed using linear 
regression of the log-transformed normalised expression values on the genotype 
assuming no dominance or interactions between the effects of different SNPs.  These 
methods allow the assessment of the effects of single SNPs or groups of SNPs and to 
adjust for the effects of other sites.  Multiple testing was taken into account by 
calculating the familywise error rate (FWER); associations with a FWER below a 
threshold of 0.05 were called significant.  The FWER is the probability of making one or 
more false discovery, or type I error, among all the associations tested. Total and allelic 
expression data was used to estimate the proportion of total expression variance that 
is due to cis and trans-acting effects185. 
 
2.4.1 Power calculations 
Using traditional eQTL analysis, a sample size of 200 would lead to over 90% power to 
detect a polymorphism with a minor allele frequency of 0.1 that accounts for 20% of 
the total variation in expression. As outlined in Teare et al (2011)204, study power for 
the AER approach depends upon effect size, minor allele frequency of the studied 
SNPs, degree of linkage disequilibrium between the transcribed marker and putative 
functional SNP, and also ability to infer the phase of the SNPs in question. We have 
calculated that a sample size of 200 individuals and a minor allele frequency of 0.10 for 
the transcribed marker will have in excess of 80% power to detect the effect of a 
biallelic cis acting polymorphism with a minor allele frequency of 0.1 where there is a 
20% difference in expression between the two alleles. Thus, even if there are 
substantial trans-acting effects on the variance of gene expression, limiting the power 
of eQTL analysis, aerQTL analysis will retain high power to detect small effects on 
expression in the number of subjects to be studied. In these calculations other 
parameters such as the variance were estimated from the results of previous studies 
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185,240,241 and the power of the allelic expression study was determined using previously 
described methods204. The most common transcribed markers in KCNN3 and ZFHX3 
that we propose to use in the AER analyses have minor allele frequencies of 0.47 and 
0.41 respectively. There are two transcribed markers in PITX2c with minor allele 
frequencies of 0.03 and 0.1. Therefore, for all the three strongest candidate genes in 
the GWAS-associated regions, transcribed markers exist which will give high power to 
detect even small cis acting effects on gene expression in the number of subjects we 
propose to study.  
 
2.4.2 Phasing and linkage disequilibrium assessment 
Genotype phase was estimated for each cohort separately using the BEAGLE v3.3.2 
Genetic Analysis Software Package 242. LD was calculated using phased genotypes in 
HaploView v4.2 and haplotype blocks were identified using the confidence interval 
algorithm43,243.  
 
2.4.3 aerQTL analysis 
We analysed allelic expression ratios using a previously published approach185. We 
restricted ourselves to biallelic markers and code one arbitrarily chosen allele as 0 and 
the other as 1. We designate with   the phase-known and with   the phase-unknown 
genotype of an individual. The latter can be ascertained through genotyping. We 
assume that the amount of mRNA originating from a single allele follows a lognormal 
distribution where the variance does not vary between the two alleles. The log of the 
ratio of the expression levels of both alleles,   can therefore be assumed to be 
normally distributed.  
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For an individual that is heterozygous for  transcribed polymorphisms,  ratios can 
be determined. We designate the vector of the logarithms of these ratios as 
           . 
Under the assumptions above, the components of   are normally distributed with 
               where the means       depend on the genotype   but the 
variance    is genotype independent but may depend on the site used to measure the 
allelic expression ratio. We model the expected value as a linear combination of the 
influences of the typed polymorphisms: 
         
 
   
       
where    represents the effect of the  
   cis-acting marker; and     characterises the 
phase between transcribed and putative cis-acting markers: 
        
 
  
 
 
 
 
 
 
 
 
                                          
              
         
 
In order to assess the association between a specific SNP and allelic expression, let us 
consider a set of   individuals. For an individual            we can measure the 
unphased genotype    and a vector representing the log of the allelic expression ratios 
  . Up to a multiplicative constant the likelihood of observing certain pattern of 
imbalance in this set of individuals given their genotyping results is: 
           
 
 
with 
                 
 
 
where    describes the most likely phased genotype given the genotyping results    
and         describes the density of the distribution of    given the genotype  .   was 
estimated using the BEAGLE Genetic Analysis Software Package  
We assume the allelic expression ratios measured at different sites are conditionally 
independent given the genotype. Therefore: 
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where     
         
            and     
            denotes the density of a 
normal distribution with the individual expression ratio   
  as variate, a genotype 
dependent mean       and a variance   
 . Therefore   depends on             
and            , and maximisation of this likelihood allows assessment of the 
effects of single SNPs or groups of SNPs and to adjust for the effects of other markers 
by comparing nested models using likelihood ratio tests.  
The effect sizes are presented as   in all figures (i.e. the log effect size). The fold-
change can therefore be determined by    
 
2.4.4 eQTL analysis 
The association between total expression and SNP genotype was assessed using linear 
regression of the log transformed normalised expression values on the genotype, 
assuming no dominance or interactions between the effects of different SNPs. PCR 
plate was included as a categorical variable. 
In order to allow comparison with the results of aerQTL analysis, the effect sizes are 
presented as   in all figures (i.e. the log effect size). The fold-change can therefore be 
determined by    
 
2.4.5 Correction for multiple testing 
For both total and allelic expression multiple testing was taken into account by 
calculating a significance threshold as 0.05 divided by the number of tests 
performed244. 
 
2.4.6 Estimation of proportion of variation due to cis acting effects 
From our allelic and total expression data we also estimated the proportion of the 
total expression variance that is due to cis-acting effects. This assumes that cis- and 
trans-acting factors act in an additive manner, do not interact, are independent, and 
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that there is random mating, no segregation distortion and the locus is not subject to 
imprinting. Given these assumptions, we estimate the variance due to cis-acting 
effects     , as  
      
 
      
    
  
    
    
 
  
   
 
where    is the allelic expression ratio for individual  , and the proportion of the total 
variation due to cis-acting effects can be estimated as 
     
     
 , where       is the 
estimated total variance, i.e. 
       
 
   
         
 
 
   
 
with  
   
 
 
    
 
   
 
and     represents the total expression level for individual     . 
Statistical analyses were performed in the R software package version 2.15.1 “roasted 
marshmallows”245 using custom scripts. 
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3 Atrial fibrillation associated with ivabradine 
treatment:  meta-analysis of randomised 
controlled trials 
3.1 Abstract 
A recent meta-analysis of genome-wide association studies (GWAS) of atrial fibrillation 
(AF) identified associations near the gene HCN4. In the atria the protein HCN4 is the 
predominant subunit of the ion channel responsible for the If pacemaker current. The If 
channel-blocker ivabradine is licensed for use to limit the heart rate in patients with 
angina pectoris and chronic heart failure. The sick sinus syndrome, which is 
characterised by sinus bradycardia, is commonly associated with AF, and AF in these 
circumstances may represent an escape rhythm from profound bradycardia or sinus 
arrest. AF is reported as a very rare (less than 1 in 10,000) side effect of ivabradine 
treatment but the magnitude of the risk of AF is unknown. This study quantified the 
risk of AF associated with ivabradine treatment for any indication by meta-analysis of 
clinical trial data. 
Medline, Embase, Web of Knowledge and the Cochrane central register of controlled 
trials were searched for double-blinded randomised controlled trials of ivabradine with 
a follow-up period of at least four weeks. For studies where AF data were unpublished 
AF incidence was sought from the European Medicines Agency (EMeA) website and by 
personal communication. The main study outcome was defined as incident AF during 
the trial follow-up period. Studies were appraised for risk of bias using components 
recommended by the Cochrane Collaboration. Meta-analyses were performed of 
relative risk of AF and absolute risk difference of AF per year of treatment.  
AF incidence was reported in the published manuscript for one of ten studies 
identified, AF incidence was reported in the safety data on the EMeA website for one 
study and AF incidence was provided by personal communication for four studies. We 
also included in our analysis safety data from the 'Overall Oral Safety Set' (OOSS), a 
combination of clinical trials with aggregated safety data reported by the EMeA. 
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Ivabradine treatment was associated with a relative risk increase of AF of 15% 
compared with controls (95% CI 7%-24%, p=0.0027). From this we estimated that 208 
patient years of treatment (95% CI 122-667) would be required to cause one new case 
of AF.  
By demonstrating that If blockade increases the risk of incident AF, this study confirms 
the role of HCN4 in the pathogenesis of AF identified by GWAS. In particular, this result 
indicates that the risk variants are likely to act by reducing the activity of the If current. 
In addition, this study has shown that AF is a substantially more common side effect of 
ivabradine treatment than 1 in 10,000, the risk reported in the product literature. The 
incidence of AF has not routinely been reported in clinical trials of ivabradine. The risk 
of AF needs to be taken into consideration when weighing the balance of risk and 
benefits of ivabradine treatment. 
 
3.2 Introduction 
Genome-wide association studies have identified associations between genetic 
variants in the region of the gene HCN4 and both heart rate and atrial fibrillation 
(AF).28,109 HCN4 is the predominant ion channel subunit in the hyperpolarisation-
activated, cation non-selective (HCN) family in human atria246. HCN ion channels are 
responsible for the If current, which leads to the spontaneous depolarisation of cardiac 
nodal tissue and therefore regulates the heart rate246.  The effect of these variants on 
the If current is unknown. Bradycardia and AF are both components of sinus node 
dysfunction and permanent pacing prevents AF in patients with bradycardia due to 
sinus node dysfunction. In addition, the pulmonary venous myocardium, which is an 
important source of AF initiation and maintenance4, demonstrates an If current
247.  
AF risk variants may operate in one of two ways. The AF risk and heart rate associated 
variants lie on either side of exon one of HCN4 and are in perfect LD in the 1000 
genomes CEU population248. It is possible, therefore that they are in LD with a coding 
variant which alters If activity. There are six missense, five synonymous and one 
frameshift variant reported in HCN4 exon one in build 138 of dbSNP39, of which one 
missense variant, rs143090627, and  one synonymous variant, rs201193660, have a 
minor allele frequency (MAF)>1%. The functional effects of these polymorphisms are 
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not known.  MutationTaster249 identifies rs201193360 as a likely disease-causing 
variant, due to the presence of regulatory features, including a DNase hypersensitive 
site and methylation sites at this position. The alternative hypothesis is that the AF-
associated variants regulate expression of HCN4. HCN4 forms heteromultimers with 
HCN2, which is also expressed in human atria246. Co-expression of HCN4 and HCN2 
results in an If current with faster gating kinetics and activation at more depolarised 
potentials than when either isoform is expressed alone. In addition, the kinetics are 
faster when HCN4 and HCN2 are expressed in the ratio, 10:1, which is close to the ratio 
of expression in human atria, than at other ratios250. This raises the possibility that 
either increased or decreased expression of HCN4 will have the same effect on the If 
current, namely slower gating kinetics resulting in reduced automaticity and 
bradycardia. Sick sinus syndrome (SSS) is characterised by sinus bradycardia but is also 
associated with atrial fibrillation in the tachycardia-bradycardia syndrome. The longer 
time period between sinus beats in sinus bradycardia facilitates the conditions for 
developing AF by causing an increase in atrial ectopy and an increase in the dispersion 
in atrial refractoriness (i.e. the degree of heterogeneity in the length of the refractory 
period of the atrial myocytes), which are the main initiators of AF251. 
Ivabradine (Procoralan®, Servier) is a heart-rate-lowering drug which acts by 
specifically inhibiting the pacemaker If current
252.  Ivabradine was approved for use by 
the European Medicines Agency (EMeA) in 2005 for use in the treatment of stable 
angina pectoris in patients with normal sinus rhythm who are not able to tolerate 
beta-blocker therapy. In 2010 the indication was extended to include treatment in 
patients with uncontrolled angina symptoms and a heart rate in excess of 60 beats per 
minute (bpm) despite beta-blocker therapy, following the results of the results of the 
BEAUTIFUL trial.174 A new indication was approved in 2012, following the results of the 
SHIFT trial, for the treatment of chronic heart failure (New York Heart Association class 
II to IV) with systolic dysfunction, in patients in sinus rhythm and whose heart rate is 
greater than 75 bpm. To be used in combination with standard therapy, including beta-
blocker therapy, or when beta-blockers are contraindicated or not tolerated.172 Use of 
ivabradine is not yet approved by the US Food and Drug Administration.  
Atrial fibrillation is common in patients with coronary artery disease and cardiac 
failure6 and so incident AF in the target population for ivabradine treatment would not 
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necessarily be attributed to the drug.  Atrial fibrillation is reported as a very rare (less 
than 1 in 10 000) side-effect of ivabradine treatment in the British National Formulary 
and the product literature.173 The incidence of AF in patients randomised to ivabradine 
treatment vs. placebo was significantly increased in the SHIFT trial however [risk 
difference (RD) 1.76%, 95% confidence interval (CI) 0.41%-3.31%, p=0.03], suggesting 
that the risk may be higher than previously thought.  
 
3.3 Aims 
1. To determine whether treatment with ivabradine, which inhibits the HCN4-
mediated If current, was associated with an increase in the risk of AF. 
2. To quantify that risk, both in terms of relative risk increase and number needed to 
harm per year.  
 
3.4 Methods 
The study was performed in accordance with the recommendations of the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (Table 
3.1).253  
3.4.1 Eligibility criteria, information sources and search protocol 
The following studies were included in the analysis: randomised controlled double-
blind trials of ivabradine, for any indication and of any size, which followed patients up 
for at least 4 weeks. Studies were not necessarily excluded if the AF incidence was not 
reported in the published manuscript, but instead attempts were made to obtain the 
AF data by contacting the study authors and by searching the European Medicines 
Agency (EMeA) website. Both placebo-controlled studies and non-inferiority studies 
where an alternative drug treatment was used as a comparator were included. The 
following were excluded: open or single-blinded studies, studies where the follow-up 
period was less than 4 weeks and studies where there was significant risk of bias, as 
assessed by the methods recommended by the Cochrane collaboration. A systematic 
search was performed, without language restriction, for randomized clinical trials of 
ivabradine treatment for any indication, using the search term ‘Ivabradine’ and the 
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document type ‘clinical trial’ or ‘randomized controlled trial’. Medline, Embase, the 
Web of Knowledge from 1980 to October 2013 and the Cochrane Central Register of 
Controlled Trials were searched. The reference lists of published trials, review articles 
and meta-analyses were also examined to identify other eligible trials. The scientific 
discussions of the EMeA were read to identify unpublished studies and to identify the 
incidence of AF in published studies where this information was not included in the 
published report. Contact was made directly with the authors and, in the case of 
industry-sponsored trials, the sponsors, of studies which did not report the AF 
incidence in the original manuscript. 
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Table 3.1 PRISMA checklist 
Section/topic  # Checklist item  
Reported 
on page # 
TITLE  
Title  1 Identify the report as a systematic review, meta-analysis, or both.  64 
ABSTRACT  
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study 
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; 
limitations; conclusions and implications of key findings; systematic review registration number.  
65 
INTRODUCTION  
Rationale  3 Describe the rationale for the review in the context of what is already known.  66 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS).  
66 
METHODS  
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provide registration information including registration number.  
68 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
68 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last searched.  
69 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it 
could be repeated.  
69 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 73 
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applicable, included in the meta-analysis).  
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and 
any processes for obtaining and confirming data from investigators.  
73 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made.  
73 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of 
whether this was done at the study or outcome level), and how this information is to be used in any 
data synthesis.  
73 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  74 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures 
of consistency (e.g., I2) for each meta-analysis.  
74 
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, 
selective reporting within studies).  
74 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if 
done, indicating which were pre-specified.  
74 
RESULTS  
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram.  
74 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-
up period) and provide the citations.  
74 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 
12).  
77 
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Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for 
each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
80 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of 
consistency.  
79-80 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  77 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see 
Item 16]).  
80 
DISCUSSION  
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider 
their relevance to key groups (e.g., healthcare providers, users, and policy makers).  
82 
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3.4.2 Selection and quality assessment 
Studies were assessed on the basis of their title or abstract and those studies which 
appeared to meet the eligibility criteria were selected for full text review. Trials were 
assessed for eligibility and risk of bias using the components recommended by the 
Cochrane Collaboration. These include: sequence generation, i.e. the method by which 
subjects were assigned to study groups; allocation concealment, whether patients 
were aware of the order in which participants would be assigned to each arm of the 
study; blinding of participants, personnel and outcome assessors after allocation; 
incomplete outcome data; selective outcome reporting, such as the reporting of only 
AF that resulted in hospitalisation, rather than all new cases; and other sources of bias 
such as the exclusion of patients at high risk of AF 254. Any trial with a high or unclear 
risk of bias, by any of the Cochrane criteria was considered to be at high risk of bias; all 
other studies were considered to be at low risk of bias. Non-inclusion of AF incidence 
in the study report could be considered to be an example of selective outcome 
reporting. However where complete AF incidence data were available from another 
source, namely by personal communication or in the EMeA documentation, non-
reporting of AF incidence alone was not considered to be evidence of a high risk of 
bias.  
 
3.4.3 Outcome measures and data collected 
The main outcome measure was incident AF reported during the trial follow-up period. 
Where data on AF incidence were not reported, the authors were contacted by email 
on at least two occasions. AF incidence reported in the EMeA scientific discussions 
where trials were submitted as evidence for licensing was identified and, in the case of 
trials sponsored by the manufacturer, contact was made with the manufacturer 
directly. Study data was collected on data collection forms which recorded reference 
data, ethical approval, randomisation, blinding, control agent (placebo or other drug), 
follow-up duration, inclusion and exclusion criteria and sponsorship and funding 
information as well as numbers of patients in the ivabradine and control arms with 
incident AF. 
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3.4.4 Statistical analyses 
Meta-analysis of intention to treat outcomes was performed using the metafor library 
in R statistical software package version 3.0.2.245,255 A two-step approach256 was used 
by estimating heterogeneity (τ2) using the empirical Bayes estimator257 and then fitting 
a generalised linear mixed-effects model. The confidence interval, and therefore p-
value, for τ2 was calculated using methods described by Veichtbauer.258 We modelled 
the effect of ivabradine as a random effect as this best accounts for both within-study 
and between study variance.259 The Knapp and Hartung adjustment was used to 
account for the uncertainty of τ2. 260 When estimating absolute risk difference we 
included length of follow-up as a factor in the model, assuming a risk difference of zero 
at zero days of follow-up, as the absolute risk of developing AF can reasonably be 
expected to be related to length of exposure. This allows an estimation of the absolute 
risk difference (or number needed to harm) per year of treatment. Heterogeneity was 
assessed using the I2 statistic, considering I2>50% to be significant261 as well as 
reporting the p-value for unexplained heterogeneity. Publication bias was estimated 
using the rank test,262 the regression test263 and by visual analysis of funnel plots. In 
order to determine the effect of treatment indication a meta-analysis of relative risk, 
including treatment indication as a categorical moderator variable was also performed. 
 
3.5 Results 
3.5.1 Study selection and characteristics of included trials 
The initial search strategy identified 84 published articles. Titles and abstracts were 
reviewed and papers that were not clinical trials, were not of sufficient duration of 
follow-up, or which reported supplementary data from trials published elsewhere 
were excluded. The full texts of the remaining 34 articles were assessed for eligibility. 
Eight papers were translated into English with the assistance of Dr Pogoryelova, see 
acknowledgements. After studies were excluded on the basis of study design (1 study), 
follow-up duration (2), randomisation (9), study blinding (10), and duplication (2) our 
search strategy yielded 10 double-blind randomised controlled trials that enrolled 
20,022 patients for a mean of 1.5 (range 0.076-1.88) years follow-up, for a total of 
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30,090 patient years of follow-up (Figure 3.1, Table 3.2).172,174-177,264-269 Risk of bias of 
the included studies is summarised in Table 3.3. 
 
Figure 3.1  Flow chart of study selection. 
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Table 3.2.  Eligible trials for which AF data was sought.  
The AF data for the INITIATIVE study and from Ruzyllo et al. were not available separately, but were included in the overall oral safety set from the EMeA with 
three other studies. The number of participants includes only those with complete follow-up data. EMeA –European Medicines Agency, STEMI – ST elevation 
myocardial infarction, NSTE-ACS – non-ST elevation acute coronary syndrome, IST – inappropriate sinus tachycardia, bd – twice daily. 
  
Author Year Acronym Number of 
participants 
Indication Control Ivabradine 
dose (bd) 
AF data source 
Tardif et al. 2005 INITIATIVE 939 Angina Atenolol 7.5mg/10mg Included in OOSS 
Ruzyllo et al. 2007  1195 Angina Amlodipine 7.5mg/10mg Included in OOSS 
Fox et al. 2008 BEAUTIFUL 10 907 Heart Failure Placebo 5mg/7.5mg EMeA 
Tardif et al. 2009 ASSOCIATE 875 Angina Placebo 5mg/7.5mg No data 
Fasullo et al. 2009  153 Anterior STEMI Metoprolol 5mg/7.5mg No data 
Swedberg et al. 2010 SHIFT 6492 Heart Failure Placebo 2.5mg-7.5mg Original paper 
Nerla et al. 2012  61 Type II 
diabetes 
Atenolol/ 
placebo 
5mg Personal communication 
Dominguez-Rodriguez et al. 2012  27 NSTE-ACS Placebo 5mg Personal communication 
Cappato et al. 2012  21 IST Placebo 5mg Personal communication 
Villano et al. 2013  46 Microvascular 
angina 
Ranolazine/ 
placebo 
5mg Personal communication 
EMeA Overall Oral Safety Set 2005 OOSS 3936  Atenolol/ 
amlodipine 
/placebo 
5mg-10mg EMeA 
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Table 3.3 Risk of bias  
Study Sequence 
generation 
Allocation concealment 
and blinding 
Outcome data 
included in final 
analysis 
Selective outcome 
reporting 
Other sources of 
bias 
Overall risk of bias 
Tardif et al. 2005 
(INITIATIVE) 
Randomised Double-blinded placebo 
controlled 
94% No AF data reported None Low 
Ruzyllo et al. 2007 Randomised Double-blinded, 
allocation concealed 
97% No AF data reported None Low 
Fox et al. 2008 
(BEAUTIFUL) 
Randomised Double-blinded placebo 
controlled 
100% No AF data reported None Low 
Tardif et al. 2009 
(ASSOCIATE) 
Randomised Double-blinded placebo 
controlled 
100% No AF data reported None Low 
Fasullo et al. 2009 Randomised Double-blinded, 
allocation concealed 
99% No AF data reported None Low 
Swedberg et al. 2010 
(SHIFT) 
Randomised Double-blinded placebo 
controlled 
99% AF incidence 
reported 
None Low 
Nerla et al. 2012 Randomised Double-blinded 
allocation concealed 
92% No AF data reported None Low 
Dominguez-
Rodriguez et al. 2012 
Randomised Double-blinded placebo 
controlled 
100% No AF data reported None Low 
Cappato et al. 2013 Randomised Double-blinded placebo 
controlled 
90% No AF data reported None Low 
Villano et al. Randomised Double-blinded, 
allocation concealed 
100% No AF data reported None Low 
EMeA Overall Oral 
Safety Set (OOSS) 
All randomised 
studies 
Double blinded, 
allocation concealed 
unknown AF data reported Multiple studies 
considered together 
Low 
The inclusion of multiple studies in the OOSS would be more likely to increase imprecision rather than introduce bias. To confirm this, a sensitivity analysis was 
performed with exclusion of the OOSS.
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Of the 10 studies identified, AF incidence was only reported in one, the SHIFT trial. The 
authors of the other studies were contacted by email to request the unpublished AF 
data. Of the five studies not sponsored by the manufacturer, four authors replied with 
AF data. None of the authors of studies sponsored by the manufacturer provided AF 
data. We contacted the manufacturer directly, who declined to provide the 
unpublished data, citing ongoing in-house analyses. The original scientific discussion270 
for ivabradine, published by the EMeA prior to marketing authorisation in 2005, did 
not report safety data, including AF incidence, for each of the submitted trials 
separately. It did report AF incidence in a combined data set which included the 
INITIATIVE study and the study by Ruzyllo et.al. in addition to two phase-three clinical 
trials (for which we were unable to identify a published report), a 1 year dose-
comparison study271 and two very short (four doses and two weeks, respectively) dose-
ranging phase-two studies. All of the studies included in this overall oral safety set 
(OOSS) were randomised, controlled and double-blinded. None of the trials for which 
we obtained AF incidence data separately were included in the OOSS. A subsequent 
update to the scientific discussion, published in 2010, considered the evidence from 
the BEAUTIFUL and ASSOCIATE trials. AF incidence was reported for the BEAUTIFUL 
study, but not the ASSOCIATE study. In order to provide the most accurate estimate of 
the effect of AF the OOSS was included as a single study in the meta-analysis and two 
sensitivity analyses were performed. In the first, the OOSS was excluded; and in the 
second, trials where treatment was not compared with placebo, but instead with an 
alternative agent, such as amlodipine or a beta blocker, were excluded.  
In the full data set for analysis including the OOSS, therefore, there were 21 490 
patients, followed up for a mean of 1.43 years to provide a total of 30 755 patient 
years of follow up. When the OOSS was excluded the data set included 17 508 
patients, followed up for a mean of 1.67 years to give a total of 29 385 patient years of 
follow up. In the placebo-controlled trials only data set there were 17 462 patients 
followed up for a mean of 1.68 years to give a total of 29 380 patient years of follow-
up (Figure 3.2) 
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Figure 3.2 Sources of AF incidence 
 
Numbers of individuals with complete follow-up data from each study are given. For the 
individual studies within the OOSS, the numbers of patients which were included in the data 
set from each study were not reported. Total numbers of patients enrolled are given (*). There 
is no overlap between the OOSS and studies where AF incidence is identified from other 
sources 
 
3.5.2 Incidence of atrial fibrillation 
Compared with controls, treatment with ivabradine was associated with a relative risk 
(RR) of AF of 1.15 times that of alternative treatments [95%CI=1.07-1.24, p=0.0027] 
(Figure 3.3).  The results were largely similar if the OOSS was excluded, RR=1.15 
[95%CI=1.06-1.25, p=0.0065] and if only placebo controlled trials were examined, 
RR=1.15 [95%CI=1.05-1.26, p=0.015]. When treatment indication was included in the 
model, the association between treatment indication and AF risk was not significant 
(p=0.99), although this analysis was limited as the majority of patient years of follow-
up (17 462 /17 508) were in the two trials (SHIFT and BEAUTIFUL) for which the main 
treatment indication was heart failure.  
Reported in manuscript
OOSS: n=3,936
Reported by EMeA Not available
From Personal communication
Eligible studies
Villano et.al.: n=46
Borer et.al.: n=360*
Lopez-Bescos et.al.: n=386*
CL3-018: n=728*
CL3-019: n=318*
CL2-006: n=55*
INITIATIVE: n=939*
Ruzyllo et.al.: n=1195*
BEAUTIFUL: n=10,907 ASSOCIATE: n=875
Fasullo et.al.: n=153
SHIFT: n=6492
Cappato et.al.: n=21
Nerla et.al.: n=61
Dominguez-Rodriguez et.al.: n=27
Randomised studies included in  second 
sensitivity analysis: n=17 462
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Figure 3.3  Forest plot of relative risk of AF in all trials with available data.  
 
RE Model – random effects model. 
 
When the absolute risk of AF was compared between ivabradine and control groups, 
ivabradine treatment was associated with a number needed to harm (NNH) of 208.3 
per year of treatment [95%CI=122.0-666.7, p=0.013]. This effect was very similar when 
the OOSS was excluded, NNH per year was 208.3 [95%CI=113.6-1250, p=0.028], and 
when only placebo-controlled trials were included, NNH per year was 208.3 
[95%CI=105.3-10 000, p=0.048] (Figure 3.4). As ivabradine is indicated for chronic 
treatment of angina or cardiac failure and treatment is likely to continue for more than 
one year, this NNH represents a 50-fold higher risk than that reported in the product 
literature, which classifies AF as a “very rare” (i.e. less than 1:10 000) complication; if 
one year of treatment is considered.  
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Figure 3.4  Number needed to harm per year of follow-up.  
Individual studies are plotted as circles with size proportional to the weighting in the meta-
analysis model. The best fit line (continuous line) with 95% CI (dashed lines) is shown. 
The heterogeneity of relative risk in the trials included was low, I2=0.00%, with the 
observed heterogeneity explained by within-study variance (p=0.96). The same was 
true in the analysis of absolute risk difference, I2=0.00%, where the residual 
heterogeneity after accounting for length of follow-up was explained by within-study 
variance (p=0.86). This explains the similarity of the meta-analysis results between 
sub-groups of trials and suggests that the effect of ivabradine on AF risk is independent 
of treatment indication.  
There was no evidence of publication bias, rank test p=1.00, regression test p=0.64, 
and examination of the funnel plot did not suggest any missing data (Figure 3.5). 
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Figure 3.5 Funnel plot of relative risk vs. standard error.  
 
The plot is largely symmetrical, suggesting that there is no publication bias.  
 
3.6 Discussion 
The results of this study strongly indicate the importance of the If current in the 
pathophysiology of AF. These data also, using as much of the data as was available, 
quantify the risk of AF associated with ivabradine treatment. Use of ivabradine causes 
an approximately 15% increase in the risk of developing AF. This risk is greater than 
previously reported in the product safety information.  
The associations between genetic markers near HCN4, which is responsible for the If 
current, and both AF and heart rate mirror the effects of the If channel blocker 
ivabradine. Although they have different aims, design and methods of analysis, the 
results of GWAS, in this case, indicate similar findings to the results of a Mendelian 
randomisation experiment. Genetic variation is inherited randomly and is present 
before any disease develops and therefore must be causative of any association with 
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disease. Genetic variants can therefore be used to identify whether a phenomenon, in 
this case reduced If current activity, is causative of, rather than simply associated with, 
a disease state272. If the genetic variants identified by GWAS can be demonstrated to 
result in reduced If activity, then this indicates that reduced If activity causes AF, rather 
than the other way around. The effect of AF risk variants on expression of HCN4 and 
any subsequent effects on the If current are not known. Further investigation of the 
effects of the risk SNPs on expression of HCN4 and whether any transcribed 
polymorphisms in strong LD with the AF risk SNPs alter the kinetics of the If current 
would therefore be of interest.  
AF is a common complication of coronary artery disease and cardiac failure. Patients 
with these conditions have a higher rate of complications from AF than patients with 
AF alone273. These risks however need to be balanced against the benefits of 
ivabradine. In the SHIFT study, ivabradine treatment resulted in a reduction in the 
composite endpoint of death or hospitalisation with worsening heart failure; the 
number needed to treat (NNT) was 26, which was largely driven by a reduction in 
hospitalisations.172 A combined analysis of the individual data from the SHIFT trial and 
those patients in the BEAUTIFUL trial with a baseline heart rate ≥70 bpm also identified 
a reduction in the same endpoint, the NNT was 40.7.274 Interestingly, in the same 
analysis, which looked at patients with a higher baseline heart rate, the increase in AF 
incidence was greater than we found in our meta-analysis, the NNH was 58 (albeit over 
a longer follow-up of 19-22 months). This raises the possibility that it is the patient 
group with the most to gain from ivabradine treatment that have the greatest risk of 
developing AF and that the absolute increase in the risk of AF with ivabradine 
treatment in this group is of a similar size to the absolute decrease in risk of 
hospitalisation. 
The results of this analysis also highlight the importance of large safety data sets and 
ongoing post-marketing surveillance of licensed and approved medications to identify 
side-effects which might otherwise be dismissed as complications of the underlying 
disease in a patient group with significant co-morbidity.  
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3.6.1 Limitations 
It was not possible to obtain the incidence of AF for all of the trials which we identified, 
and the funnel plot shows a relative lack of mid-sized trials, which reflects this. The use 
of the OOSS from the EMeA scientific discussion may have resulted in an 
underestimate of the heterogeneity of the data available. Five studies, possibly quite 
different in various ways from each other, were combined to form a single data set 
that was treated in the analysis as a single trial.  This is likely to result in an 
overestimate of within-study variance and an underestimate of between-study 
variance. The sensitivity analyses in which the OOSS is excluded, however, did not yield 
significantly different results to the primary analysis.  
As the AF data for the largest trials which studied patients with angina, rather than 
heart failure, was not available separately for each trial, it was not possible to 
definitively assess the effect of treatment indication on AF risk. It would be possible, 
given the data presented here alone, that AF is less common as a side effect of 
ivabradine treatment in patients with angina pectoris rather than heart failure.  
However, the SIGNIFY trial, which was conducted to examine the effects of ivabradine 
in patients with stable coronary artery disease without clinical heart failure, also 
identified a significant increase in AF incidence with ivabradine treatment vs. 
placebo275. 
We are unable to provide data comparing the AF risk profile of patients who 
developed AF to those that did not in either the ivabradine treatment or control 
groups. It is possible that the increase in AF risk is restricted to a small high-risk 
subgroup within the overall study population for each trial. 
 
3.7 Conclusions 
Ivabradine treatment is associated with a 15% increase in the relative risk of atrial 
fibrillation. This confirms the role of the If current in the pathophysiology of AF. This 
provides further evidence that AF risk variants identified in chromosome 15 may act by 
altering activity of HCN4. We estimate that 208 patient-years of treatment with 
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ivabradine would be required to cause one new case of AF. The risk of AF needs to be 
taken into consideration when weighing the balance of risk and benefits of ivabradine 
treatment. 
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Chapter 4 
Influence of polymorphisms 
at AF-associated loci on gene 
expression in peripheral 
blood  
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4  Influence of polymorphisms at AF-associated 
loci on gene expression in peripheral blood 
4.1 Abstract 
Genome-wide association studies (GWAS) have identified genetic variants in nine 
chromosomal regions that are associated with atrial fibrillation (AF). The mechanisms 
underlying these associations are unknown. None of the genetic variants identified lie 
in coding regions and so the most likely hypothesis is that they act by influencing 
expression of nearby genes. This study investigates the association between genetic 
variants at GWAS-identified loci and expression of nearby candidate genes in 
peripheral blood. 
Tagging SNPs were genotyped to capture common genetic variation at each locus. 
Allelic expression ratios of candidate genes were measured using the Sequenom 
platform and associations with phased genotypes were assessed using a likelihood 
ratio test. For candidate genes where a significant association between genotype and 
allelic expression was seen, total expression was measured using qPCR and 
associations between genotype and total expression were determined. 
Expression of candidate genes at five of nine loci; KCNN3 in 1q21, CAV1 and CAV2 in 
7q31, C9orf3 and FANCC 9q22, SYNE2 and ESR2 in 14q23 and ZFHX3 in 16q22; was 
identified in peripheral blood. The risk [T] allele of the AF-associated SNP rs13376333 
in chromosome 1q21 was associated with a 0.85-fold decrease in expression of KCNN3 
(p=2x10-4). The risk [G] allele of the AF-associated SNP rs3807989 in chromosome 7q31 
was associated with a 0.91-fold decrease in expression of CAV1 (p=4x10-5). The risk [T] 
allele of rs1152591 in chromosome 14q23 was associated with a 1.12-fold increase in 
expression of SYNE2 (p=4x10-27) and a 0.82-fold reduction in CAV1 expression (p=5x10-
3). A coding SNP, rs1051614, in KCNN3 was associated with a 0.83-fold reduction in 
CAV1 expression (p=2x10-4).  
This study has identified associations between AF-associated variants at three loci and 
expression of KCNN3, CAV1, and SYNE2, identifying them as important candidate genes 
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in the development and maintenance of AF. The data also identify cis-acting variants 
which affect ZFHX3 and C9orf3 expression.  
 
4.2 Background 
Genome-wide association studies (GWAS) have identified a number of genetic variants 
which are associated with an increased risk of AF. The latest meta-analysis of GWAS 
studies identified and replicated associations in 9 chromosomal regions, as previously 
summarised in Table 1.2 in Chapter 1105-109. Three of these regions have been 
identified at GWAS significance in multiple independent studies, namely in 1q21, 4q25, 
and 16q22.  
 None of the lead GWAS SNPs for AF are situated within a known spliced transcript, 
and so these polymorphisms are not likely to result in alteration of a diffusible factor 
which might affect expression in trans. It is likely, therefore that the mechanism of 
action of these variants is by affecting gene expression of nearby genes in cis.  
The candidate genes in the regions identified perform a wide range of functions:  there 
are cell structural proteins, (SYNE2, MYOZ1 and SYNPO2L), ion channels (KCNN3 and 
HCN4), transcription factors (PITX2, ZFHX3 and PRRX1), cell-signal transduction 
proteins (CAV1 and CAV2) and genes which regulate endocrine function (ESR2, C9orf3), 
all of which could have a plausible role in the pathophysiology of AF. It is important to 
demonstrate an association between the variants of interest and expression of any 
candidate gene, as genetic influences can operate over large distances, even between 
chromosomes, and so the genes responsible for AF risk may not simply be those 
closest to the variants identified. Perhaps more importantly, identifying an association 
between a risk allele and gene expression also provides information on the direction of 
the effect, i.e. whether the variant up-regulates or down-regulates expression. This 
provides a guide as to the likely effects of any pharmacological intervention which 
increases or decreases activity of the protein product. 
Polymorphisms may also modify expression of particular transcript variants. 
Cardiovascular risk-associated variants at chromosome 9p21 are associated with 
expression of some, but not all, of the transcript variants of the long non-coding RNA 
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ANRIL276. The transcripts which are associated with cardiovascular risk variants 
demonstrate stronger trans-acting influences on pro-atherosclerotic gene networks277. 
It is therefore important to consider the relationship between risk variants and 
expression of not only the gene, but also individual transcripts, which may have non-
overlapping or even opposite effects.  
As described in the introduction, associations between genetic variation and gene 
expression can be assessed by measuring total expression (eQTL mapping) or by 
measuring allelic expression ratios (aerQTL mapping). Previous studies have 
demonstrated the power of the aerQTL approach in identifying genetic variants that 
are associated with gene expression229,278. 
Genome-wide eQTL studies have been performed in a number of different tissues and 
in lymphoblastoid cell lines (LCLs)193,196,279.  Associations have been demonstrated 
between the AF risk SNP rs1152591 in Chr 14q23 and ESR2 expression in LCLs, and 
adipose tissue, between the AF risk SNP rs3807989 and CAV1 in LCLs, adipose tissue 
and skin, and between rs3807989 and CAV2 in LCLs193,194,196. However no associations 
have been demonstrated at the other seven loci which could explain the mechanisms 
of action of these variants. Moreover the 14q23 association is of doubtful significance 
since ESR2 is expressed at very low levels in atrial tissue. 
As discussed in Chapter 1, there are differences in genetic architecture between 
different human populations. This provides the opportunity for fine mapping of genetic 
associations. If, in a region of interest, the pattern of linkage disequilibrium is finer in a 
particular population, then that population in which the haplotype blocks are smaller 
can be used to map the association to a smaller region, and therefore reduce the 
number of variants which may explain the association.   
 
4.3 Aims 
1. To identify which AF risk loci candidate genes are expressed in whole blood. 
2. To perform aerQTL mapping of candidate genes at those loci. 
3. To perform eQTL mapping for selected primary candidate genes in each region.  
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4. To determine whether multiple loci are independently associated with gene 
expression in any genetic region 
5. To determine whether AF-associated variants correlate with gene expression. 
6. In conjunction with the results presented in Chapter 6, to determine the 
concordance of eQTL and aerQTL mapping in blood with cardiac tissues, and thus to 
investigate the utility of peripheral blood as a surrogate marker for cardiac expression. 
7. To determine whether there are differences in genetic architecture and genetic 
influences on expression between North of England and South African populations 
8. To determine the power of trans-ethnic fine-mapping to refine the localisation of 
aerQTLs in the genetic regions identified in multiple independent GWAS of AF. 
 
4.4 Materials and methods 
4.4.1 Participants and materials 
Study participants and ethical approvals were as set out in Chapter 2.  
Nucleic acid extraction and cDNA synthesis was performed as described in Chapter 2. 
RNA integrity was determined on a random subset of samples using the Agilent 2100 
bioanalyser, as set out in Chapter 2.  
 
4.4.2 Determination of candidate gene expression in peripheral blood 
The main candidate genes at each AF risk locus were selected on the basis of proximity 
to the risk variants and an assessment of the biological plausibility of the gene’s role in 
AF risk. The following genes were identified at each locus: KCNN3 at 1q21, PRRX1 at 
1q24, PITX2 at 4q25, CAV1 at 7q31, C9orf3 at 9q22, SYNPO2L at 10q22, SYNE2 at 
14q23, HCN4 at 14q23 and ZFHX3 at 16q22. Primers to determine the expression 
patterns of candidate genes were designed using Primer3 software v0.4.0280,281.  PCR 
was carried out with cDNA from 25ng RNA, using HotStar Taq reagents (Qiagen, 
Germany), according to the manufacturer’s protocols and PCR products were 
visualised by gel electrophoresis. 
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4.4.3 Selection of transcribed SNPs for allelic expression analysis 
Using the UCSC genome browser 282,283 transcribed SNPs with minor allele frequency 
(MAF) >0.05 were identified as suitable candidates for use in the allelic expression 
assays. The following transcribed SNPs were selected: rs1051614, in KCNN3, 
rs1049334, rs1049337 and rs9920 in CAV1, rs8940 in CAV2, rs4657 in C9orf3, 
rs4647554 in FANCC, rs1152582 and rs7161192 in SYNE2, rs1256049, 4986938 and 
rs928554 in ESR2, and rs740178 and rs10852515 in ZFHX3.  
 
4.4.4 Selection of mapping SNPs 
Tag SNPs required to capture common variation in the core regions of interest (15kb 
either side of those candidate genes expressed in blood) were selected using 
HaploView 4.0 tagger software using the following parameters: HapMap population: 
CEU, minimum minor allele frequency: 0.05, pairwise tagging, r2 threshold: >0.8. SNPs 
previously reported to be associated with disease phenotypes were forcibly included in 
the set of selected SNPs108,109,131,284-287. Details of included SNPs are given in the results 
section, below. 
 
Figure 4.1 Selection of mapping SNPs 
 
Example output from the HaploView software. Haplotype blocks have been identified for SNPs 
(labelled 001 to 050) in this region by the software on the basis of allele frequencies in the CEU 
population. The frequency of each haplotype in the population is shown (closed arrow), as is 
the degree of LD between each haplotype (open arrow). The thick and thin lines indicate 
haplotypes which are continuous in at least 10% and 1% of the population respectively. The 
small triangles beside the SNP number indicate the minimum SNPs which need to be 
genotyped in order to reconstruct the haplotypes in this population. 
 
  
92 
 
4.4.5 Genotyping 
Multiplex SNP genotyping was performed on the NE cohort, using the Sequenom 
platform as set out in Chapter 2. 202 SNPs were typed in 9 separate multiplex 
reactions (Table A1.2). Genotyping was also performed for the chromosome 1q21 and 
16q22 SNPs in the SA cohort. Primer sequences are shown in Appendix 1. For one SNP, 
rs3807989, which could not  be typed on the Sequenom platform, genotyping was 
carried out using a custom TaqMan SNP Genotyping assay (C_2972990_10, Life 
Technologies), as described in Chapter 2.  
 
4.4.6 Measurement of allelic expression ratios 
Allelic expression ratios (AER) in NE cohort RNA samples were determined for all genes 
within 100kb of the GWAS-associated SNP at each locus. Due to the limited amount of 
RNA available, AER were determined in the SA cohort only for KCNN3 and ZFHX3, the 
candidate genes which were expressed in peripheral blood and for which associations 
have been identified in individual GWAS studies as well as by meta-analysis. Assays for 
the measurement of allelic expression were identical to those used for genotyping the 
transcribed SNPs, as the amplicons for each were wholly contained within a single 
exon. Primer sequences are shown in Appendix 1.  
Quantification of the allelic expression ratio was performed using the Sequenom 
platform as set out in Chapter 2. The gDNA ratios were relatively homogenous with 
little inter-individual variability compared to cDNA ratios (Figure 4.5). AER values were 
excluded where the standard error of the technical replicates was high (S.E. >0.5). 
Outliers were excluded using Grubb’s test. 
 
4.4.7 Quantification of normalised total gene expression using real-time PCR 
Quantification of total gene expression was performed as described in Chapter 2. Real-
time PCR assays were performed in two separate assay arrangements. KCNN3 and 
ZFHX3 transcript levels were normalised to ACTB, GAPDH and RN18S1. ZFHX3a, CAV1, 
C9orf3 and SYNE2 levels were normalised to ACTB, GAPDH and HPRT1. RN18S1 was 
replaced by HPRT1 as a reference gene in the latter experiments. This was because 
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absolute expression of RN18S1 was found to be substantially higher than the other 
reference genes (~8900-fold), raising the possibility that excessive amplification of 
RN18S1 might interfere with amplification of the other transcript in a duplex PCR 
reaction. In the KCNN3 and ZFHX3 experiments, neither transcript was measured in 
duplex with RN18S1, and therefore measurement of KCNN3 and ZFHX3, would not 
have been affected by high expression of RN18S1. Assay details are given in Table A1.1. 
Assays were performed using cDNA synthesised from 25ng of RNA in a 15µl reaction 
volume.  
 
4.4.8 Statistical analyses 
Phasing was performed using the BEAGLE software package and aerQTL analysis using 
a likelihood ratio test in the R software package for transcripts with a single 
transcribed SNP or in the Matlab software package for transcripts with more than one 
transcribed SNP, as described in Chapter 2. Associations between total expression and 
SNP genotype were assessed as described in Chapter 2.  
In order to correct for the testing of multiple associations, the threshold for statistical 
significance at each locus was determined using the Bonferroni correction244. For 
trans-acting associations the threshold was determined using a Bonferroni correction 
for the total number of SNPs typed at all loci. For example, the significance threshold 
for cis acting effects of the 16 SNPs in chromosome 7q31 was set at 0.05/16: p=0.0031, 
whereas trans-acting effects were assessed for all 202 SNPs and so the threshold for 
significance was set at 0.05/202: p=0.00024. Full results are presented in Appendix 2. 
For those genes where total expression and allelic expression ratios were measured, 
the relative contribution from cis-acting influences to the total variance was calculated 
as described in Chapter 2.  
 
4.4.9 Analysis of linkage disequilibrium 
LD was calculated using phased genotypes in HaploView v4.2 and haplotype blocks 
were identified using the confidence interval algorithm43,243. 
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4.5 Results 
4.5.1 Quality control  
PCR without reverse transcription demonstrated absence of genomic DNA 
contamination of the extracted RNA (Figure 4.2). The median RNA integrity number for 
the samples analysed by bioanalyser was 7.85 (Figure 4.3). Visual inspection of mass 
spectroscopy traces for the allelic expression assay of CAV1 using rs9920 revealed 
failure of the extension reaction in 468 of 1744 assays (Figure 4.4). This may be the 
result of an unrecognised SNP interfering with the binding of the unextended primer 
and therefore could introduce bias into the assessment of AER. This assay was 
excluded from further analysis. 
 
Figure 4.2 Demonstration of adequate DNase treatment 
 
Gel electrophoresis of PCR products with the following templates: water (-ve control), RNA 
without a reverse transcription reaction (three central wells) and genomic DNA (+ve control). 
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Figure 4.3  Agilent Bioanalyser electropherogram 
 
Time in seconds (indicating fragment size) is plotted on the x-axis and fluorescence (indicating 
amount of RNA) on the y-axis. An example electropherogram from an RNA sample with a RIN 
of 8.6 is shown in the upper panel. There are clear 18s and 28s peaks in a ratio of 1:2, with no 
evidence of degraded RNA, indicating good RNA quality. By contrast the sample in the lower 
panel is significantly degraded with a RIN of 4.4; 18s and 28s peaks remain visible but there is a 
significant amount of RNA in shorter fragments, circled. 
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Figure 4.4  Example of failed extension reaction 
 
A clear spectral peak can be seen for the unextended primer on the left of the image, marked 
‘UEP.rs9920’. By contrast there are no peaks at either of the expected positions for the C or T 
alleles, indicating that the extension reaction has failed. 
 
4.5.2 Expression profiling 
In five regions we found that the main candidate genes were expressed in blood: 
KCNN3 in chromosome 1q21, CAV1 in chromosome 7q31, C9orf3 in chromosome 
9q22, SYNE2 in chromosome 14q23, and ZFHX3 in chromosome 16q22. Expression of 
the following nearby genes in each of these three regions was also confirmed; CAV2 in 
chromosome 7q31, FANCC in chromosome 9q22, and ESR2 in chromosome 14q23 
(Figure 4.5). 
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Figure 4.5  Expression profiles of candidate genes 
 
 
 
PCR products after electrophoresis on agarose gel alongside a 100bp DNA ladder. Arrows 
indicate the expected position of DNA bands. 
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4.5.3 Inter individual variation in expression 
All of the genes for which total expression was measured demonstrated variability in 
expression levels in our sample. Total expression levels demonstrated greater 
variability for KCNN3 and CAV1 levels than C9orf3, SYNE2, or ZFHX3 levels. Allelic 
expression ratio (AER) ranges differed for each gene, depending on which transcribed 
SNP was used (Table 4.1, Figure 4.6). This is not wholly surprising as the individuals 
who are heterozygous at one transcribed SNP may not be heterozygous at another, 
and so the allelic expression ratios for each transcribed SNP represents the values for a 
subset of the total cohort. The number of heterozygotes for the transcribed SNP, 
rs1256049 was lower than at the other loci, due to the low MAF (MAF=0.034 in the NE 
cohort cf. MAF=0.031 in the HapMap CEU cohort). For KCNN3, a relatively large 
proportion (17.4%) of the total variance in expression was due to cis-acting effects. 
 
Table 4.1  Variance of normalised total and allelic expression  
Inter-quartile ranges are given for total expression and the 1st and 3rd quartiles for the allelic 
expression ratio measured using each transcribed SNP. 
Gene Total expression 
IQR 
Transcribed 
SNP 
AER 1st and 3rd 
Quartiles 
Proportion of 
variance due to 
cis-acting effects 
KCNN3 1.91-fold rs1051614 0.84-1.42 17.4% 
CAV1 2.18-fold rs1049334 0.62-0.84 8.7% 
  rs1049337 0.94-1.20  
CAV2  rs8940 0.92-1.42  
C9orf3 1.55-fold rs4657 0.95-1.09 6.3% 
FANCC  rs4647554 0.83-1.13  
SYNE2 1.50-fold rs1152582 0.83-0.95 6.0% 
  rs7161192 0.51-0.57  
ESR2  rs1256049 0.87-1.24  
  rs4986938 0.89-1.02  
  rs928554 0.97-1.07  
ZFHX3 1.61-fold rs740178 0.96-1.10 3.7% 
  rs10852515 0.63-0.86  
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Figure 4.6  Variance in allelic expression ratios 
 
KCNN3 
CAV2 
CAV1 
KCNN3 
SYNE2 
CAV1 FANCC 
C9orf3 
SYNE2 
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Log allelic expression ratios are shown for each of the transcribed SNPs listed in Table 4.1. For 
each SNP, the log AER for each heterozygous individual is plotted in red with error bars 
representing the standard error of the technical replicates. The AER measured in genomic DNA 
samples used for normalisation are plotted in blue. AER values were normalised to the mean 
allelic ratio measured in genomic DNA, as described in Chapter 2.  
 
  
ESR2 
ESR2 
ESR2 ZFHX3a 
ZFHX3 
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4.5.4 AF-associated SNPs on chromosome 1q21 are associated with increased 
KCNN3 expression  
Allelic expression ratios were measured for KCNN3 on 1q21. No associations were 
demonstrated between the allelic expression ratios of KCNN3 and any SNP in the NE 
cohort. However, eQTL mapping of KCNN3 expression identified 6 SNPs that were 
significantly associated with KCNN3 expression. The strongest association was with the 
minor allele of rs2335407, which was associated with a 1.24-fold increase in expression 
of KCNN3 (p=3.1x10-7). The risk [T] allele of one the lead AF SNPs, rs13376333, was 
associated with a 0.85-fold decrease in KCNN3 expression (p=2.1x10-4) (Figures 4.7 and 
4.8, Table A2.1). After correction for the effect of the strongest eQTL SNP, rs2335407, 
the minor allele of a second SNP, rs7532286, remained significantly associated with a 
1.13-fold increase in KCNN3 expression.  
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Figure 4.7  Associations at chromosome 1q21 in the NE cohort 
 
Individual variants are plotted by chromosomal position on the x-axis and significance of the 
association (as -log p value) on the y-axis. Effect size associated with the minor allele (log fold-
change, β) is represented by colour, with increased expression in red and reduced expression 
in green. The results of aerQTL experiments are represented as circles and of eQTL 
experiments as triangles. The chromosomal positions of KCNN3 and the GWAS hit SNP for AF 
are marked.  
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Figure 4.8 Normalised total KCNN3 expression by genotype. 
 
Top: total expression of KCNN3 is shown by genotype at the AF-associated SNP, rs13376333. 
Bottom: expression of KCNN3 by genotype of rs2335407, the most strongly associated eQTL 
SNP for KCNN3.  
The discrepancy between the results of the eQTL and the aerQTL experiment raises the 
possibility that there was a technical problem with the assay using the transcribed SNP 
rs1051614. However, on inspection of the mass spectra, there were no obvious salt or 
interference peaks and the assay peaks are large relative to the background signal. 
Furthermore in the cluster plot, the genotyped samples fall into three reasonably well-
defined clusters, with little variation in the ratio of peak heights in heterozygotes, 
suggesting good assay performance. One sample, circled in Figure 4.9, did not fall 
within any cluster and was problematic in several assays; it was therefore excluded 
from analysis in all assays. 
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Figure 4.9 rs1041615 assay performance 
  
Top: mass spectrometry trace of rs1051614 in cDNA. Bottom: genotyping cluster plot from 
genomic DNA. Symbols indicate genotype automated calls as per the key at the top of the plot. 
The circled individual did not cluster in many of the genotyping assays (possibly indicating 
contamination with DNA) and was excluded from all analyses.
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4.5.5  AF-associated SNPs in chromosome 7q31 are associated with decreased CAV1 
expression 
Allelic expression ratios were measured for two genes at chromosome 7q31, CAV1 and 
CAV2. Associations were seen between 7 of 16 SNPs and CAV1 expression. The 
strongest association was observed for the minor allele of the transcribed SNP 
rs1049334 (p=7.5x10-09), which was associated with a 1.26-fold increase in expression. 
The risk [G] allele of the GWAS associated SNP for AF, rs3807989, was associated with 
a 0.91-fold decrease in expression (p=4.2x10-5). Five of 16 SNPs were associated with 
CAV2 expression. The most significant association was seen for rs17138749, which 
caused a 0.65-fold decrease in expression (p=1.6x10-8) and lies 6.5kb upstream of the 
CAV2 transcription start site. The AF associated GWAS SNPs were not associated with 
CAV2 expression. The transcribed SNP rs1049334 had significant effects on both CAV1 
and CAV2 expression, but in opposite directions, the minor allele was associated with a 
1.26-fold increase in CAV1 and a 0.57-fold decrease in CAV2. eQTL mapping of CAV1 in 
the 7q31 locus did not identify any SNPs significantly associated with total expression 
(Figure 4.10, Table A2.2). 
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Figure 4.10 Associations at chromosome 7q31 
 
Top: Associations between genotype and expression of CAV1. Bottom: Associations between 
genotype and expression of CAV2. 
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4.5.6 Variants in chromosome 9q22 are associated with C9orf3 expression 
Allelic expression ratios were measured for two transcripts in the chromosome 9q22 
region, C9orf3 and FANCC. Three of 17 SNPs were significantly associated with C9orf3 
expression. The strongest association was seen for rs10993391, the minor [G] allele 
which was associated with a 1.27-fold increase in expression (p=4.1x10-7). No SNPs 
were associated with FANCC expression. The AF associated SNP, rs10821415, was not 
associated with C9orf3 or FANCC expression. eQTL mapping of C9orf3 expression 
confirmed a 1.23-fold increase in expression with rs10993391 (p=3.6x10-6), but not 
rs356122 or rs7048941 (Figures 4.11 and 4.12, Table A2.3).  
 
Figure 4.11 Associations at chromosome 9q22 
 
Top: Associations between genotype and expression of C9orf3. Bottom: Associations between 
genotype and expression of FANCC. 
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 Figure 4.12 C9orf3 total expression by genotype at the 9q22 locus 
 
 
4.5.7 AF associated variants in chromosome 14q23 are associated with increased 
SYNE2 expression 
Allelic expression ratios were measured for two genes at the chr 14q23 loci SYNE2 and 
ESR2. Allelic expression of SYNE2 was significantly associated with 24 of 37 SNPs. The 
strongest association was seen with the minor allele of the transcribed SNP rs1152582, 
which was associated with a 1.13-fold increase in expression (p=6.2x10-37). The risk [T] 
allele GWAS hit SNP for AF, rs1152591, was associated with a 1.12-fold increase in 
expression of SYNE2 (p=7.5x10-24). After correction for the effects of the most 
significantly associated aerQTL SNP, rs11852582, a single SNP, rs11158533, was 
significantly associated with a 1.14-fold increase in SYNE2 expression. No SNPs were 
significantly associated with ESR2 expression. eQTL mapping of SYNE2 expression did 
not identify any significant associations (Figure 4.13, Table A2.4).  
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Figure 4.13 Associations at chromosome 14q23 
 
Top: Associations between genotype and expression of SYNE2. Bottom: Association between 
genotype and ESR2 expression.  
 
4.5.8 Variants on chromosome 16q22 are associated with ZFHX3 expression in a 
transcript-specific manner 
aerQTL mapping of both transcripts of ZFHX3 together identified a single significantly 
associated SNP, rs8060701, the minor allele of which was associated with a 1.18-fold 
increase in expression (p=1.3x10-4). After correcting for the effect of rs8060701, no 
further associations were seen in either cohort. eQTL mapping did not identify any 
significant associations between SNP genotype and expression of ZFHX3. 
aerQTL mapping of ZFHX3 isoform a in the NE cohort revealed several strongly 
associated SNPs. The most strongly associated SNP was the transcribed SNP, 
rs10852515, which was associated with a 0.76-fold reduction in expression 
(p=7.5x10-15). After correction for the effects of rs10852515, no other variants were 
independently associated with expression (Figure 4.14, Table A2.5). The aerQTL SNP 
associated with expression of both transcripts, rs8060701, was not independently 
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associated with ZFHX3a expression, rs10852515 and rs8060701 were not in significant 
LD in the SA cohort (r2=0) or the NE cohort (r2=0.005). 
 
Figure 4.14 Associations with expression at chromosome 16q22 
 
Top: Associations between genotype and expression of ZFHX3. Bottom: Associations between 
genotype and ZFHX3a expression. 
 
4.5.9 Patterns of linkage disequilibrium differ between the NE and SA cohorts 
Patterns of LD at 1q21 and 16q22 in the two populations are shown in Figures 4.15 and 
4.16. The pattern of LD and the haplotype blocks, calculated using the confidence 
intervals method, differed between the two populations. In both regions the SA 
population had a finer haplotype structure with fewer and smaller haplotype blocks 
identified. At 1q21, 12 haplotype blocks were identified in the NE cohort, but in the SA 
cohort the pattern of LD was much finer with only 8 small LD blocks identified. There 
was a significant degree of LD between the lead eQTL SNP and the AF risk SNP in both 
cohorts (r2=0.67 and r2=0.41 for the NE and SA cohorts, respectively).  
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Figure 4.15 Linkage disequilibrium at chromosome 1q21 
 
LD between individual SNPs, at the top, is represented by colour with red indicating D’=1 and 
white indicating D’=0. The AF associated SNP, rs13376333 is indicated by a red arrow and the 
lead eQTL SNP, rs2335407 by a black arrow. Top: LD in the NE cohort. Bottom: LD in the SA 
cohort.  
 
 
At the 16q22 locus, 16 haplotype blocks were identified in the NE cohort: whereas in 
the SA cohort, the pattern of LD was finer than in the NE cohort; 14 smaller haplotype 
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blocks were identified. The GWAS hit SNPs for AF were in LD in both cohorts (r2=0.85 
and r2=0.69 in the NE and SA cohorts, respectively). The aerQTL SNP for ZFHX3, 
rs8060701, did not lie in a large haplotype block in either cohort. The aerQTL lead SNP 
for ZFHX3a was in LD with a number of SNPs upstream of its position (to the left in 
Figure 4.14) in the NE cohort, but less so in the SA cohort.  
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Figure 4.16 Linkage disequilibrium at chromosome 16q22 
 
Black arrows indicate the aerQTL lead SNP, rs10852515, centre left and the eQTL SNP, 
rs8060701, right. Red arrows indicate GWAS hit SNPs for Kawasaki disease, AF and AF from left 
to right, respectively. Top: LD in the NE cohort. 16 haplotype blocks were identified. The GWAS 
hit SNPs for AF were in significant LD. The aerQTL lead SNP is in LD with a number of SNPs 
upstream of its position (to the left). The eQTL lead SNP lies in a small haplotype block, but is 
not otherwise in strong LD with nearby SNPs. Bottom: LD in the SA cohort. The pattern of LD is 
finer than in the NE cohort, 14 smaller haplotype blocks were identified. The aerQTL lead SNP 
is in less strong LD with upstream SNPs. 
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4.5.10 Trans-ethnic fine mapping allows finer localisation of aerQTL signals 
In order to investigate the differences in aerQTLs between different populations, 
aerQTL mapping was repeated in the SA cohort. Again in the chromosome 1q21 
region, none of the genotyped variants were significantly associated with expression of 
KCNN3.  In the 16q22 region, the association between ZFHX3 expression and 
rs8060701 was replicated (p=0.003) No other SNPs were identified as being associated 
with ZFHX3 expression. The association between ZFHX3a expression and rs10852515 
was also replicated (p=1.7x10-18). Again, no SNPs were significantly associated with 
ZFHX3a expression after correcting for the effect of the lead SNP. Fewer SNPs in a 
smaller chromosomal region were significantly associated with ZFHX3a expression in 
the SA cohort. The aerQTL in the NE cohort included 12 significantly associated SNPs in 
a 93kb region. By contrast, in the SA cohort the aerQTL was confined to three SNPs in a 
7kb region (Figure 4.17, Table A2.6). In both cohorts, the significantly associated 
variants were in LD with the lead aerQTL SNP, rs10852515.  
 
Figure 4.17 Comparison of aerQTLs between the NE and SA cohorts for ZFHX3a 
 
The significantly associated SNPs from analysis of the NE cohort (circles) are distributed over a 
93kb region (black bar, top), whereas the significantly associated SNPs from the analysis of the 
SA cohort lie within a 7kb region. 
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4.5.11 Analysis of a combined data set provides greater power to identify aerQTLs 
In order to maximise the power to detect aerQTLs at the 1q21 and 16q22 regions, the 
data from the NE and SA cohorts were combined to form a single data set. The phased 
haplotypes were used from the previous analysis. In the combined data set, two SNPs, 
rs11584635 and rs2798601, were significantly associated with a 1.27-fold and 1.30-fold 
increase in allelic expression of KCNN3, respectively (p=2.9x10-4, p=3.0x10-4) (Figure 
4.18, Table A2.7). After correction for the effects of rs11584635, rs2798601 was not 
significantly associated with allelic expression. 
 
Figure 4.18 Associations with expression at chromosome 1q21 in the combined 
data set 
 
.  
4.5.12 Trans-acting eQTLs 
Trans eQTL mapping was also performed to identify genotype-gene expression 
associations between AF risk regions. There were two findings of interest. First, the 
minor allele of the transcribed SNP, rs1051614, in chromosome band 1q21 was 
associated with a 0.83-fold decrease in expression of CAV1 (p=2.0x10-4). Second, the 
risk allele of rs1152582 at 14q23 was associated with a 0.82-fold reduction in CAV1 
expression (p=1.3x10-3),which was  the same dissection of effect of the AF risk allele of 
rs3807989 on chromosome 7, but this did not reach the significance threshold for 
trans-acting associations (Figures 4.19 and 4.20, Table A2.8).  
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Figure 4.19 Associations with CAV1 expression in trans 
 
Top: associations between expression and markers in chromosome 1. Bottom: associations 
between expression and markers in chromosome 14. 
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Figure 4.20 Normalised total gene expression of CAV1 by genotype  
 
Top: Expression of CAV1 in chromosome 7q31 by genotype at the KCNN3 transcribed SNP 
rs1051614. Bottom: Expression of CAV1 in chromosome 7q31 by genotype at the KCNN3 
transcribed SNP rs11152591. This association did not reach significance when allowing for 
multiple testing. 
 
4.6 Discussion 
This chapter describes a comprehensive investigation of the associations with 
expression phenotypes that may underlie the associations between common genetic 
variants and AF, using peripheral blood. The results demonstrate associations between 
GWAS hit SNPs for AF and gene expression at several loci. Risk variants for AF are 
associated with increased expression of KCNN3 and SYNE2, and reduced expression of 
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CAV1. This strongly suggests that altered expression of KCNN3, CAV1 and SYNE2 may 
be important molecular genetic contributors to AF susceptibility. In addition, these 
results demonstrate an association between a GWAS hit SNP for primary open-angle 
glaucoma and increased expression of CAV2, suggesting that up-regulation of CAV2 
expression plays an important role in the pathogenesis of primary open angle 
glaucoma. The associations between disease associated SNPs and KCNN3, CAV2 and 
SYNE2 expression have not previously been reported in primary human tissues (Table 
4.2).  
 
Table 4.2 Previously published associations between AF GWAS SNPs and gene 
expression 
SNP  Chromosome 
Band 
Gene LCL eQTL Human tissue 
eQTL 
eQTL or aerQTL 
in this study 
rs6817105  4q25 PITX2    
rs7164883  15q24 HCN4    
rs2106261  16q22 ZFHX3    
rs6666258  1q21 KCNN3   Yes 
rs3903239  1q24 PRRX1    
rs1152591  14q23 SYNE2 Yes193  Yes 
   ESR2 Yes193,194 Yes193,194  
rs3807989  7q31 CAV1 Yes193,194,196 Yes193,194 Yes 
   CAV2 Yes193   
rs10821415  9q22 C9orf3    
rs10824026  10q22 SYNPO2L    
 
 
4.6.1 eQTL and aerQTL mapping at AF-associated loci 
On chromosome 1q21, the associations that were seen in the eQTL experiment 
differed significantly from those seen in the aerQTL experiment. The eQTL experiment 
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identified a strong association between a SNP, rs2335407, in the promoter region of 
KCNN3 and KCNN3 expression. This site has a score of 4 (minimal evidence for binding) 
in RegulomeDB, due to the presence of a DNase hypersensitivity binding cluster and 
transcription factor binding288. A variant at this position would be expected to act in cis 
by altering the binding of transcription factors to the promoter region. The absence of 
a signal at this SNP in the aerQTL experiment, even after the addition of the SA cohort 
to improve power, is surprising, therefore. There are three possible explanations for 
this discrepancy. The first explanation is that the allelic expression assay using 
rs1051614 has failed to measure expression of KCNN3 adequately. This seems unlikely 
as the mass spectrometry traces show no evidence of salt or other interference peaks 
(Figure 4.18), the genotyping cluster plots using the same primers show clean clusters 
of genotypes, and an aerQTL was detected elsewhere in the gene, at rs11584635. 
Another possible explanation of this discrepancy is that the effect of this SNP is in 
trans. It has already been pointed out that aerQTL mapping is not able to detect trans-
acting effects, as they would be expected to operate on both alleles. If rs2235407 
affects expression in trans, therefore, the effect would not be detected by the aerQTL 
assay. This implies that there is a diffusible factor, such as a non-coding RNA, produced 
at or near rs2235407. There are no transcripts which fit this description annotated in 
the UCSC or Ensembl databases145,283 or identified by RNAseq289, however to explain 
this.  
The most likely explanation, therefore is that the two experiments rely on the 
measurement of different transcripts. The TaqMan assay for KCNN3 is situated on the 
exon 9-10 boundary whereas rs1051614 is situated in exon 3. Both assays measure all 
three RefSeq transcripts, but the UCSC genome browser reports an unconfirmed 
truncated splice variant which would not be detected by the qPCR assay. It is possible 
therefore that, if a sufficiently large amount of this splice variant were present, that 
the effect of rs2335407 on expression of the RefSeq transcripts would be masked in 
the allelic expression experiment. In order to determine whether this is the case, it 
would be necessary to repeat the AER experiment using one or more transcribed SNPs 
which are located in the distal exons of KCNN3, i.e. they would not be affected by the 
truncated splice variant. Ideally, one would use a transcribed SNP from Exon 9 or 10, 
where the TaqMan assay binds. This experiment was not performed as part of the 
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original study as the association with the AF GWAS SNP had not been identified and so 
this experiment lay beyond the scope of the original hypothesis.  
 
4.6.2 Transcript-specific mapping of aerQTLs 
The current study identified very different effects on gene expression when 
considering both transcripts of ZFHX3 compared to analysis of ZFHX3a expression 
alone. SNPs at exon boundaries have been shown to result in exon skipping and 
production of functional proteins without affecting total gene expression levels216. 
Alterations in the relative expression of two transcript variants of a single gene may 
therefore not be detectable using an assay which measures both transcripts. Previous 
genome wide microarray eQTL analyses have identified the same association as this 
study between rs8060701 and ZFHX3193,196, but the microarray probe is not transcript-
specific, and would not be able to detect the effect of rs10852515 on ZFHX3a. Splice 
variants can have distinct functions. For example Pitx2c but not Pitx2a or Pitx2b, is 
expressed asymmetrically in the left lateral plate mesoderm in vertebrates122 and is 
required for normal anatomical development of the atria290. This considerably 
complicates the analysis of mechanisms of action of disease-associated variants; 
candidate genes may have a great number of annotated, and possibly even more un-
annotated, transcript variants; for example a recent analysis of SYNE2 identified 14 
isoforms, in contrast to the 4 RefSeq transcripts identified138. It is possible therefore, 
that the discrepancy between the results of the eQTL and aerQTL analyses of SYNE2 is 
a result of the chosen assays binding to different isoforms of the gene. This study 
demonstrates that aerQTL mapping allows detection of transcript-specific effects and 
provides a useful technique for the investigation of the effects of genetic variants on 
genes where multiple transcript variants are present. 
 
4.6.3 Trans-ethnic fine mapping 
Fine localisation of variants associated with phenotypic traits can be limited by linkage 
disequilibrium in the region of interest. Greater haplotype diversity and fine LD 
structure therefore allows improved localisation of eQTLs. African populations, and in 
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particular the Cape Mixed Ancestry population of South Africa, as a result of a mixed 
ancestral background, have a greater haplotype diversity than European populations. 
Therefore a trans-ethnic fine-mapping approach comparing different populations 
would be expected to allow better identification of functional variants than mapping in 
a single population. 291,292. This approach has been demonstrated previously293. The SA 
cohort used for this experiment has previously been used for fine-mapping of aerQTLs 
of the long non-coding RNA, ANRIL, at chromosome 9p21, where the refinement of the 
aerQTL was less dramatic than the effect shown here at 16q22. This demonstrates that 
the power of trans-ethnic fine-mapping to refine the aerQTL signal is dependent on the 
differences in LD structure between the two populations in the region(s) of interest, 
and will be variable throughout the genome 
Combined analysis of data from different cohorts has also been previously shown to 
improve the power to detect eQTLs221. The current study also demonstrates the utility 
of this approach.  Combined analysis of the NE and SA cohorts, by increasing the 
number of individuals studied, allowed identification of a cis-acting aerQTL for KCNN3 
which was not possible in either cohort when analysed separately.   
 
4.6.4 Trans acting eQTLs between chromosomal regions 
The current study identified a single trans-acting variant in KCNN3 which appeared to 
be associated with CAV1 expression. rs1051614 is a synonymous variant, but it is 
situated within 1000bp of four non-synonymous coding variants. It is possible, 
therefore, that the change in CAV1 expression could be effected, directly or indirectly, 
by a conformational change in the SK3 Ca2+-gated K+ channel. The degree of LD 
between rs1051614 and nearby coding variants has not been established in the 
HapMap or 1000Genomes studies, however. The alternative explanation is that the 
trans acting eQTL operates via altered expression of KCNN3, which in turn affects CAV1 
expression. This seems less likely as no change in KCNN3 expression was demonstrated 
to be associated with genotype at rs1051614.  
No other SNPs in the chromosome 1q21 region, including the AF associated SNP 
rs13376333, were associated with or had a tendency to be associated with CAV1 
expression. In light of this, the association seen between rs1051614 and CAV1 
  
122 
 
expression must be treated with some degree of circumspection and replication 
and/or functional analysis would be of interest.  
The association between the AF-associated SNP in chromosome 14q23, rs1152591, 
and CAV1 expression did not reach the threshold for significance allowing for multiple 
testing.  The direction of effect was in keeping with the results for the chromosome 
7q31 SNPs, which supports the finding, but replication and functional evidence would 
be important to rule out association by chance alone. 
 
4.6.5 The utility of peripheral blood for investigating AF risk variants 
It is important to note that in most cases, the increased risk of AF will not be mediated 
by changes in gene expression in blood, but instead in another, less-accessible tissue, 
probably in the atrium itself. A number of factors might preclude the detection of 
associations between risk SNPs that are in fact causally related to AF risk and gene 
expression in blood. First, candidate genes may not be expressed in blood at sufficient 
levels to accurately measure expression differences. Second, eQTLs identified in blood 
may not be present in other tissues and vice versa: the MuTHER study estimated that 
56–83% of eQTLs were shared across tissues, with the remainder displaying tissue 
specificity193. Therefore eQTL mapping in peripheral blood is an imperfect surrogate 
for eQTL mapping in the relevant tissues.  Nevertheless, peripheral blood remains the 
most easily accessible human tissue and even though the absence of an eQTL in blood 
does not exclude an eQTL in another tissue, the presence of an eQTL provides 
evidence that a variant regulates expression and that this regulatory effect may 
operate in other tissues.  
Primary candidate genes in only five of nine regions associated with AF were expressed 
in peripheral blood. Therefore, in almost half of the regions of interest, eQTL and 
aerQTL mapping in peripheral blood was not possible, providing no insight to the 
mechanisms of action of these risk variants. This was the case for variants in 
chromosome 4q25, the most strongly associated AF risk locus in all of the GWAS 
published to date. In addition no association between gene expression and AF risk 
variants was demonstrated at two of the five regions studied. Fine mapping of 
expression-genotype associations in blood has, therefore, allowed identification of 
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potential risk mechanisms in three of the nine regions identified. This is a modest 
improvement on the results from microarray studies in LCLs, which identified eQTLs for 
AF risk SNPs at two of the risk regions, CAV1 and CAV2 in chromosome band 7q31 and 
ESR2 in chromosome band 14q22193,196. The difficulty in identifying risk mechanisms is 
not, perhaps, wholly surprising. In the MuTHER study, GWAS hits for inflammatory and 
auto-immune diseases were more likely to be identified as eQTLs in LCLs than in 
adipose tissue or skin193. eQTL mapping in atrial tissue, therefore, is more likely to 
identify AF risk mechanisms, as is demonstrated in Chapter 6. 
 
4.6.6 Mechanisms of action of AF-associated SNPs 
The AF risk allele was associated with a decrease in expression of KCNN3.  KCNN3 
codes for SK3, one of three members of the Ca2+-gated K+ channel family. All three 
subunits are expressed in human atrium and from heteromultimers via the interaction 
of coiled-coil domains in the C termini111,294. The SK channels significantly contribute to 
the repolarisation phase of the cardiac action potential111.  In a mouse model, over-
expression of SK3 resulted in shortened action potential duration, increased 
inducibility of atrial arrhythmias and increased frequency of sudden death295,296. Any 
perturbation of SK3 levels may result in altered stoichiometry of SK2/SK3 
heteromultimers, which, in turn, may affect repolarisation in ways which are not easily 
predictable. Either over- or under-expression, therefore, may result in loss of function 
of the SK3/SK2 ion channel, and therefore provide the same arrhythmic substrate.  
This study demonstrates an association between decreased CAV1 but not CAV2 
expression and the risk alleles of AF-associated SNPs in chromosomes 7 and 14. CAV1 
and CAV2 are widely expressed in human tissues and encode caveolins 1 and 2, which 
are involved in the formation of caveolae. Caveolae are specialised invaginations of the 
cell membrane with an important role in the transcytosis of macromolecules, signal 
transduction and cholesterol transport in various cell types297-299. Atrial fibrosis is an 
important component in the pathophysiology of AF300. A recent study of CAV1 and 
CAV2 expression in human right atrial appendage demonstrated that CAV1 but not 
CAV2 expression was reduced in patients with AF, which is also demonstrated in 
Chapter 5, and that TGF-β1 stimulation of atrial fibroblasts in vitro suppressed CAV1 
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expression. A CAV1 gain-of-function assay showed attenuation of the TGF-β1 pro-
fibrotic signalling pathway, suggesting that CAV1 is an important anti-fibrotic mediator 
which is protective against AF301. The chromosome 7 AF-associated SNP was also 
associated with CAV1 but not CAV2 expression in the adipose tissue and skin arms of 
the MuTHER study193.  
The importance of relative expression of CAV1 and CAV2 is indicated by identification 
of opposite effects on expression of a variant in the region, suggesting that some 
regulatory sites act to increase expression of one gene and suppress expression of 
another. 
We have demonstrated variants at chromosome 9q22 are associated with C9orf3 
expression in blood, but that the GWAS-associated SNP for AF is not. Given that blood 
is not the primary site of expression of C9orf3, it is possible that the AF-associated SNP 
regulates expression in another tissue type. It has been estimated that only 56-83% of 
eQTLs are present across multiple tissue types and genome-wide attempts to identify 
eQTLs at GWAS hit sites have found greater numbers of associations in tissues which 
are relevant to the disease phenotype193. 
The results from aerQTL mapping and eQTL mapping of CAV1, the regulatory variants 
identified in the aerQTL experiment were very significantly associated with allelic 
expression (p=6x10-37) but not at all associated with total expression. This is a little 
difficult to explain by differences in power between the two approaches alone. There 
are two likely explanations for this. First, the power of the eQTL mapping may be 
adversely affected  by very large variance in total expression, from a combination of 
trans-acting and experimental factors. However, the variance in SYNE2 expression and 
the estimated proportion of the total variance due to cis-acting factors was similar to 
that seen for other transcripts, making this unlikely. Second, it is possible that the two 
assays did not measure the same transcripts. The qPCR probe and rs1152582 both 
measure the same four RefSeq transcripts of SYNE2, but are not situated on the same 
exon. It has recently been shown that SYNE2 encodes multiple transcripts which have 
diverse structural roles within the cell and that these are expressed in tissue-specific 
patterns (Figure 4.19)138. These new isoforms were identified in brain, skeletal muscle 
and HeLa cDNA libraries; more isoforms may be found in other tissue types. It is 
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possible that the AF risk SNP is associated with an altered relative abundance of these 
different transcripts, possibly in a tissue specific manner. The allelic expression assays 
used here may, therefore, capture an effect on expression that does not act on the 
exons which are bound by the qPCR assay. 
Figure 4.19 Nesprin 2 isoforms 
 
Reproduced from Rajgor et.al.138. Many new transcript variants of SYNE2 are identified, which 
encode multiple different Nesprin-2 isoforms. CH domain: calponin homology domain, which 
binds directly to F-actin. Spectrin repeat: a structural domain, common in cytoskeletal 
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proteins. KASH domain:  Klarsicht/ANC-1/Syne homology transmembrane domain, which acts 
as a nuclear envelope targeting motif. A: genomic map of SYNE2 with position of transcription 
start sites and UTSs identified to date. The transcribed SNPs rs7161192 and rs1152582 are 
located in exon 94 and the exon 116 3’UTR, respectively (arrows). The qPCR probe binds to the 
exon 113-114 boundary (bar). B: Nesprin-2 isoforms. There are a large number of protein 
isoforms which have differing structural components and patterns of expression. 
It was not possible to demonstrate an association between expression of ZFHX3 or 
ZFHX3a and AF risk SNPs. This study did demonstrate a transcript-specific aerQTL for 
ZFHX3 expression. Changes in the relative expression of the two isoforms of ZFHX3 
have been shown to determine the rate of differentiation of C2C12 myoblasts, the B 
transcript accelerated myogenic differentiation and the A isoform resulted in 
persistence of an undifferentiated phenotype 302. It is likely that the portion of the 
gene common to both transcripts, i.e. that part which makes up the B isoform, is 
responsible for tumour-suppressor functions, as it contains the site of interaction with 
the oestrogen receptor in breast cancer and is the most common site for somatic 
mutations in gastric carcinoma 149,303.  This suggests that transcript-specific regulation 
of ZFHX3 expression plays an important role in control of differentiation and cellular 
proliferation. 
 
4.7 Conclusions 
Results of experiments in this chapter have identified multiple associations between 
gene expression and genetic variants associated with AF. AF risk variants are 
associated with increased expression of KCNN3 and SYNE2 and decreased expression 
of CAV1.  This provides further evidence for the roles of CAV1, SYNE2, and KCNN3 in 
the pathophysiology of AF, and identifies them as targets for further study.  
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Chapter 5 
Influence of polymorphisms 
at AF-associated loci on gene 
expression in cardiac and 
vascular tissues   
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5  Influence of polymorphisms at AF-associated 
loci on gene expression in cardiac and vascular 
tissues 
5.1 Abstract 
The previous chapter investigated the associations between genotype of AF risk 
variants and total and allelic expression of candidate genes in peripheral blood. Not all 
of the candidate genes identified in the AF risk regions are expressed in peripheral 
blood. In addition, it is possible that the effects of AF risk variants are tissue specific. 
This chapter examines the effect of AF risk variants on total expression and AER in left 
atrial appendage, right atrial appendage and internal mammary artery tissue, using the 
methods described in Chapter 2. 
Total expression of 16 transcripts and allelic expression ratio of 15 transcripts were 
measured in RAA, LAA and IMA. Expression of PITX2 was significantly increased in left 
versus right atrial appendage (p=4x10-4), whereas expression was greater in the right 
atrial appendage for HCN4 (p=4x10-5), C9orf3 (p=3x10-4) and FANCC (p=4x10-4). A 
history of AF was associated with reduced expression of SYNE2 (p=0.003), HCN4 
(p=0.01) and CAV1 (p=0.03). AF risk variants were associated with increased expression 
of non-c isoforms of PITX2 (p=6x10-4), and decreased expression of MYOZ1 (p=6x10-15), 
CAV1 (p=6x10-8), C9orf3 (2x10-5), and FANCC (p=9x10-8). 
These results confirm the association between decreased levels of CAV1 and AF risk 
variants, identified in Chapter 4. Additionally they demonstrate an association 
between AF risk variants and increased expression of the non-c isoforms of PITX2 as 
well as decreased expression of MYOZ1, CAV1 and FANCC.  
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5.2 Background 
The previous chapter investigated the associations between genetic variation in 
regions which have been associated with AF by GWAS studies and gene expression in 
peripheral blood. As discussed in that chapter, peripheral blood, whilst having the 
virtue of being easily accessible, is an imperfect surrogate for investigating the effects 
of genetic variation on gene expression in more disease relevant tissues. In four of nine 
regions identified by GWAS109, the primary candidate genes were not adequately 
expressed in peripheral blood to allow eQTL or aerQTL mapping. In addition, in two of 
the regions studied in the previous chapter, no effect on expression of the AF-
associated SNPs could be identified. One of the more likely explanations for this is that 
the effects of the AF-associated variants are specific to a tissue more relevant for 
disease, namely the atrium, and therefore have no measurable effect in peripheral 
blood.  
The importance of transcript-specific effects on expression was discussed in Chapter 4. 
Of the candidate genes identified in each of the nine regions two, HCN4 and MYOZ1, 
have a single RefSeq transcript variant283. Most of the candidate genes have multiple 
transcripts, which encode different proteins. For ZFHX3 and SYNE2, there is evidence 
that the different isoforms have different functions or patterns of expression138,302. 
PITX2 is a special case however; firstly because it is the candidate gene for the 
strongest AF risk locus, and secondly because there is specific evidence that the 
different isoforms have differing roles in cardiac tissue. The PITX2 gene encodes four 
major isoforms of the PITX2 protein in humans, PITX2a, PITX2b, PITX2c and PITX2d, 
which play roles in development of the heart, as well as the eye, gut, spleen, lungs and 
in limb myogenesis118. PITX2a and PITX2b share a promoter region and are 
differentially spliced. PITX2a consists of exons 1, 2, 5 and 6; PITX2b also includes exon 
3122. PITX2c has a different promoter region and consists of exons 4, 5 and 6. All three 
isoforms share the same C-terminus and homeobox domain (Figure 5.1).  PITX2d also 
has a different transcription start site and consists of part of exon 4 and exons 5 and 6; 
it does not contain the nucleic acid binding homeobox domain, and has an inhibitory 
effect on the other isoforms123. 
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Figure 5.1  PITX2 structure  
 
A, genomic organization of the PITX2 gene; intron sizes are shown on the top, and exon sizes 
are at the bottom; exons are numbered. B, the protein structure is shown with the location of 
the homeodomain (HD) and 14-amino acid conserved OAR domain. Chequered and stippled 
boxes denote the differences in the N-terminal region of the isoforms. The exons that code for 
the respective proteins are shown below each isoform. PITX2C and PITX2D RNA is transcribed 
using an internal promoter shown as a striped box flanking exon 4. Figure from Cox et al.123 
 
PITX2c is the only isoform to be asymmetrically expressed in the left lateral plate 
mesoderm, consistent with its role in the development of the left-right axis.122 PITX2c 
is the only isoform to be identified in RNAseq studies of human atrium thus far124, 
however a qPCR study demonstrated that the other isoforms of PITX2 are also 
expressed, predominantly PITX2a, without significant differences between LAA and 
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right atrial appendage (RAA)125. As a result, PITX2c has been considered the most 
important cardiac isoform, and the roles of PITX2a and PITX2b in the developing and 
adult atrium have been less well studied.   
The collection of disease-relevant tissue for eQTL mapping of GWAS hits for cardiac 
disease is necessarily problematic. For many other organ-specific diseases, tissue 
biopsy is a safe and routine part of clinical care and surplus biopsy material can be 
used for RNA analysis. For cardiac disease, with the possible exception of allograft 
rejection monitoring, there is no definite indication for cardiac biopsy, due to the 
relatively high risk and low diagnostic yield304. Alternative sources of tissue that have 
been used for eQTL experiments include post-mortem samples and explanted organs 
from cardiac transplant recipients130,305,306. A more easily available source of cardiac 
tissue for analysis is provided at the time of cardiac surgery. All patients requiring 
cardiopulmonary bypass at the time of cardiac surgery have at least one cannula 
placed in the right atrium to drain blood from the heart. The most common access 
point is through the right atrial appendage (RAA), and tissue is routinely discarded 
from the cannulation site to facilitate closure. In addition, many patients undergoing 
surgery involving the mitral valve have the left atrial appendage (LAA) removed to 
prevent formation of left atrial appendage thrombus and subsequent stroke in the 
event that they have or develop AF307.  A third source of tissue at the time of cardiac 
surgery is the internal mammary artery (IMA). The left IMA (LIMA) is preferentially 
used to bypass atherosclerotic lesions in the left anterior descending artery308. When 
the LIMA is harvested, the terminal portion is removed and discarded in order to 
provide a clean end to the artery with which to perform an anastomosis. None of these 
approaches allows the collection of cardiac tissue from healthy individuals. Collection 
of tissue at the time of cardiac surgery has two advantages. First, large numbers of 
cardiac operations are performed in many centres, meaning that collection of a 
sufficiently large cohort for eQTL mapping is practicable. Second, there is no additional 
risk to the tissue donors as the tissue collected would be routinely discarded in the 
course of their usual care. 
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5.3 Aims 
1. To determine which of the candidate genes at each locus are expressed in RAA, LAA 
and IMA. 
2. To compare expression levels of candidate genes between RAA, LAA and IMA. 
3. To perform eQTL and aerQTL mapping of candidate genes. 
4. To determine the concordance of the eQTL and aerQTL mapping results with the 
results from peripheral blood. 
 
5.4 Methods 
5.4.1 Participants and ethics statement 
Study participants and ethical approvals were as set out in Chapter 2. Participants 
were recruited from volunteers undergoing cardiac surgery at five centres in the north 
of England. 52 of the participants were also included in the NE cohort used for 
peripheral blood analysis in the previous chapter. 
 
5.4.2 DNA and RNA extraction 
Nucleic acid extraction and cDNA synthesis was performed as described in Chapter 2. 
RNA integrity was determined on a random subset of samples using the Agilent 2100 
bioanalyser, as set out in Chapter 2.  
 
5.4.3 Selection of transcribed SNPs for allelic expression analysis 
For regions investigated in peripheral blood, the same transcribed SNPs were used for 
allelic expression ratio (AER) analysis. For genes expressed in atria but not peripheral 
blood, the following SNPs were identified for use in AEI analysis: rs58473244 and 
rs3820416 in PRRX1, rs913257 and rs7552922 in GORAB, rs2739200 in PITX2a/b, 
rs6533526 and rs75911264 in PITX2 (all isoforms), rs60632610, rs4746139, rs3812629 
and rs34163229 in SYNPO2L, rs41280400 in MYOZ1, rs529004, rs35177144 and 
rs3743496 in HCN4. All of the transcribed polymorphisms in PITX2 were present either 
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in exons common to PITX2a and PITX2b or in exons common to all three isoforms. 
Therefore it was not possible for AER to be assessed for any transcript individually. 
 
5.4.4 Selection of mapping SNPs 
For regions investigated in peripheral blood, the same mapping SNPs were used. Tag 
SNPs were selected for the other regions using the same approach described in 
Chapter 2. 
 
5.4.5 Genotyping 
The assays described in Chapter 4 were used to genotype SNPs in the regions studied 
previously. Genotyping of 91 SNPS in the other regions was performed in 4 multiplex 
reactions on the Sequenom platform as described in Chapter 2. For one SNP, 
rs10824026, where genotyping could not be performed on the Sequenom platform, 
genotyping was attempted using a custom TaqMan SNP genotyping assay 
(C__31474386_10), as described in Chapter 2. As this approach was also unsuccessful 
genotypes for this variant were imputed using BEAGLE software242 and phased 
genotype data in BEAGLE format from phase 1 of the 1000 Genomes Project309. 
 
5.4.6 Measurement of allelic expression ratio and total expression 
The assays described in Chapter 4 section 4.4.6 were used to measure AER in the 
regions studied previously. Measurement of AER of the other transcripts was 
performed in 3 multiplexes as set out in Chapter 2, Section 2.3.5. Assays were identical 
to those used for genotyping as the amplicons for AER measurement were contained 
wholly within a single exon. Primer sequences are shown in Appendix 1. The TaqMan 
assays described in Chapter 4, Section 4.4.7 were used to measure total expression in 
the regions previously studied. In addition, normalised gene expression was measured 
for the non-primary candidate genes in each region, and all candidate genes in the 
regions not previously studied, i.e. PRRX1, GORAB, PITX2, CAV2, FANCC, SYNPO2L, 
MYOZ1, HCN4, ESR2, and ZFHX3a. As PITX2a and PITX2b are reported as having 
differing expression patterns to PITX2c122 and given that PITX2c has been identified as 
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the most important isoform for cardiac development, a single assay was selected to 
measure PITX2a and PITX2b expression together (PITX2a/b) and an alternative assay to 
measure PITX2c expression. In all, total expression of 16 transcripts was measured in 
two separate experimental plate arrangements, with expression levels normalised to 
expression of the reference genes ACTB, GAPDH and HPRT1. Assay details are given in 
Table A1.1.  
 
5.4.7 Statistical analyses 
M values, indicating stability of reference genes, were calculated using the geNorm 
algorithm in the Excel software package (Microsoft, USA)234. All statistical analyses 
were performed as described in chapters 2 and 4. Phasing was performed using the 
BEAGLE software package, aerQTL analysis was performed using the R and Matlab 
software packages and eQTL mapping was performed using the R software package as 
described in Chapter 2. The significance threshold for regulatory effects on expression 
was determined using the Bonferroni correction as described previously. The relative 
contribution from cis-acting influences on total expression was determined as 
described in Chapter 2.  
 
5.5 Results 
5.5.1 Comparison of reference gene expression between RAA, LAA and IMA 
Reference gene Ct values were well correlated within each tissue type (Figure 5.2). 
ACTB showed a greater degree of variability (as indicated by higher M values) than 
HPRT1 and GAPDH, particularly between tissues. Expression levels of ACTB were not 
stable (M>1.5) in LAA and across tissue types, therefore expression levels were 
normalised to GAPDH and HPRT1 levels alone when making comparisons between 
tissue types.  
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Table 5.1 Comparison of reference gene stability within and between tissues 
 M value 
Gene RAA LAA IMA All Tissues 
ACTB 1.191 1.958 1.386 2.222 
GAPDH 0.799 1.357 0.963 1.490 
HPRT1 0.796 1.222 1.014 1.405 
ACTB expression was less stable in all tissues and when samples were compared across tissue 
types.  
 
Figure 5.2 Stability of reference gene expression  
 
Comparison of Ct values of the three reference genes by tissue type. Each point represents a 
single sample of RNA from IMA (red), LAA (green), or RAA (blue).  
  
136 
 
 
5.5.2 Comparison of total expression of candidate genes between RAA, LAA and 
IMA         
With the exception of PITX2 and ESR2, expression levels in left and right atrium were 
more alike than in IMA. The significance levels for the differences in expression are 
presented in Table 5.2. PITX2a/b and PITX2c were expressed at increased levels in LAA 
compared with RAA. C9orf3, FANCC and HCN4 were expressed at lower levels in LAA 
compared to RAA. Expression levels of PITX2c in RAA and IMA, HCN4 in IMA and 
SYNPO2L in IMA were too low to allow reliable measurement of expression levels and 
therefore they were not included in further analyses (Figure 5.3, Table 5.2). 
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Figure 5.3 Comparison of candidate gene expression by tissue 
 
Boxplots are shown indicating expression of candidate genes in each of the three tissue types. 
The number of observations on which each boxplot is based are indicated above.  
63 11 120 
65 10 121 35 11 117 63  9  116 
64 10 122 63 11 120 34 10 84 13 11 13 67  9  121 67 10 122 64 11 120 
13  9  119 63  9  119 49 11 116 67 11 122 67 11 120 
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Table 5.2 Comparison of gene expression between tissues 
Gene fold-change: LAA vs RAA p value fold-change: IMA vs RAA p-value 
KCNN3 0.86 0.08 1.22 0.03 
PRRX1 0.63 0.11 5.05 3.6x10-44 
GORAB 0.72 0.002 2.03 4.7x10-34 
PITX2a/b 6.30 4.6x10-4 2.21 2.8x10-4 
PITX2c 120 5.1x10-11 3.80 4.0x10-4 
CAV1 0.79 0.03 2.37 2.0x10-37 
CAV2 0.78 0.1 1.96 2.9x10-29 
C9orf3 0.64 2.6x10-4 2.40 3.3x10-28 
FANCC 0.62 4.1x10-4 1.31 5.1x10-5 
SYNPO2L 1.22 0.05 0.004 2.6x10-26 
MYOZ1 0.80 0.70 1.41 2.0x10-4 
HCN4 0.17 3.5x10-5 0.004 2.7x10-11 
SYNE2 0.93 0.55 1.30 0.003 
ESR2 0.62 0.01 1.27 0.12 
ZFHX3a/b 0.79 0.02 6.92 1.3x10-64 
ZFHX3a 0.84 0.21 9.63 1.3x10-53 
Expression levels between tissue types were compared using an unpaired t-test. Mean fold-
change and p values are shown for comparisons of gene expression between LAA and RAA and 
IMA and RAA. Values which reached statistical significance threshold of 1.0x10-3, calculated 
using the Bonferroni correction for 48 comparisons (16 genes in three tissues), are highlighted 
in bold. 
 
5.5.3 Associations between AF status and gene expression. 
The current study did not aim to detect changes in gene expression associated with AF, 
therefore only a small number of study participants had a history of AF (17/123 RAA 
samples, 6/12 LAA samples and 7/67 IMA samples). None of the associations between 
AF status and expression level remained significant after a Bonferroni correction. 
However, in participants with a history of AF compared to those without, expression of 
CAV1, HCN4 and SYNE2 was reduced in RAA and expression of CAV1 was reduced in 
LAA at a nominal significance level of 0.05 (Table 5.4). 
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Table 5.4 Change in gene expression associated with a history of AF 
Gene 
Fold change in 
RAA 
p 
value 
Fold change in 
LAA 
p 
value 
Fold change in 
IMA 
p 
value 
KCNN3 0.9 (0.73-1.12) 0.34 1.07 (0.72-1.59) 0.70 0.76 (0.52-1.1) 0.13 
PRRX1 0.83 (0.67-1.03) 0.08 1.29 (0.92-1.8) 0.11 0.96 (0.77-1.21) 0.74 
GORAB 0.95 (0.79-1.14) 0.57 1.15 (0.86-1.52) 0.29 1.05 (0.82-1.35) 0.66 
PITX2a/b 1.38 (0.81-2.34) 0.22 1.25 (0.47-3.33) 0.54 0.74 (0.2-2.78) 0.59 
PITX2c 
  
0.77 (0.48-1.22) 0.22 
  
CAV1 0.85 (0.72-0.99) 0.03 0.84 (0.72-0.98) 0.03 1.12 (0.85-1.46) 0.38 
CAV2 0.97 (0.84-1.12) 0.68 0.94 (0.73-1.22) 0.59 1.21 (0.94-1.56) 0.13 
C9orf3 0.96 (0.79-1.16) 0.65 1.5 (0.96-2.34) 0.07 1.01 (0.82-1.26) 0.90 
FANCC 0.87 (0.72-1.05) 0.14 1.04 (0.77-1.41) 0.73 1.11 (0.78-1.6) 0.52 
SYNPO2L 1.05 (0.89-1.24) 0.52 1.06 (0.65-1.74) 0.77 
  
MYOZ1 1.16 (0.74-1.82) 0.50 0.84 (0.11-6.48) 0.85 1.17 (0.84-1.63) 0.31 
HCN4 0.64 (0.46-0.88) 0.01 1.19 (0.33-4.29) 0.76 
  
SYNE2 0.76 (0.64-0.91) 0.003 1.28 (0.58-2.8) 0.46 1 (0.66-1.52) 0.98 
ESR2 0.78 (0.57-1.06) 0.11 1.58 (0.64-3.9) 0.27 0.58 (0.27-1.28) 0.16 
ZFHX3a/
b 0.95 (0.8-1.12) 0.50 1.28 (0.98-1.67) 0.06 1.04 (0.86-1.25) 0.68 
ZFHX3a 0.97 (0.81-1.16) 0.71 1.29 (0.91-1.84) 0.12 1.07 (0.7-1.63) 0.72 
Expression levels between AF cases and controls were compared using an unpaired t-test. 
Mean fold changes are presented as expression in individuals with a history of AF compared to 
those without. 95% confidence intervals for the fold change are given in brackets.  Significant 
associations (p<0.05) are highlighted in bold. 
 
5.5.4 Variants in chromosome 1q21 are associated with KCNN3 expression 
Total expression and allelic expression ratios of KCNN3 were measured in RAA, LAA 
and IMA. No associations were detected by eQTL analysis. However, aerQTL mapping 
of this region identified six SNPs which were significantly associated with expression of 
KCNN3 in RAA, of which two were significantly associated with expression in IMA and 
one in LAA. The most strongly associated SNP in all three tissues was the transcribed 
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SNP rs1051614.  The minor allele was associated with a 0.73-fold decrease in KCNN3 
expression in RAA, a 0.70-fold decrease in LAA and a 0.74-fold decrease in IMA 
(p=5.4x10-21, p=6.3x10-8 and p=4.9x10-5, respectively). The AF-associated variant, 
rs13376333, was not associated with expression in any tissue (Figures 5.4 & 5.5, Tables 
A2.9 & A2.10). 
 
Figure 5.4 Associations with total expression of KCNN3 in chromosome band 
1q21 
 
 
Figure 5.5 Associations with allelic expression ratio of KCNN3 in chromosome 
band 1q21 
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5.5.5 An AF-associated variant in chromosome band 1q24 is associated with allelic 
expression of GORAB in LAA 
Total expression and allelic expression ratios were measured for PRRX1 and GORAB in 
all three tissues. There were an insufficient number of heterozygotes for the 
transcribed SNP rs3820416, which distinguished PRRX1 allelic expression, in the LAA 
cohort to allow further analysis of AER for this gene in left atrial tissue.  
No associations with PRRX1 expression in any tissue were detected by eQTL analysis. 
However aerQTL analysis identified ten variants that were significantly associated with 
expression of PRRX1 in RAA, of which 6 were significantly associated with expression in 
IMA. The most significantly associated SNP in both tissues was the transcribed SNP, 
rs3820416, of which the minor allele was associated with a 0.51-fold decrease in 
expression in RAA and a 0.50-fold decrease in expression in IMA (p=5.7x10-35, and 
p=7.5x10-24, respectively). The AF-associated SNP, rs3903239, was not associated with 
expression of PRRX1 in either tissue (Figures 5.6 & 5.7, Tables A2.11 & A2.12). 
The minor allele of a single SNP, rs12038255, was significantly associated with a 1.27-
fold increase in expression of GORAB in RAA (p=3.1x10-5), but not in LAA or IMA. 
Mapping using aerQTL analysis identified eight variants that were associated with 
expression of GORAB in RAA, of which three were also associated with expression in 
IMA. For a further three variants, not associated with expression of GORAB in RAA or 
IMA, an association was found with expression in LAA. The minor allele of the most 
strongly associated SNP in RAA and IMA, rs913257, was associated with a   1.25-fold 
increase in expression in RAA and a 1.36-fold increase in expression in IMA 
(p=1.8x10-12 and p=3.9x10-7, respectively). The most strongly associated SNP in LAA 
was rs502612, of which the minor allele was associated with a 0.87-fold decrease in 
GORAB expression (p=0.010). The risk [G] allele of the AF-associated SNP, rs3903239, 
was associated with a 1.18-fold increase in expression of GORAB (p=0.049) (Figures 5.6 
& 5.7, Tables A2.13 & A2.14). 
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Figure 5.6 Associations with total expression in chromosome band 1q24 
 
 
Figure 5.7 Associations with allelic expression ratio in chromosome band 1q24 
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5.5.6 AF risk variants in chromosome band 4q25 are associated with increased 
expression of the non-c isoforms of PITX2 in RAA 
Total expression of PITX2 was measured using two different assays, as described in the 
methods section. One assay was specific for the c isoform, PITX2c, and the other was 
specific for the non-c isoforms, PITX2a and PITX2b (this assay is hereafter referred to 
as PITX2a/b). There were no individuals in the study population who were 
heterozygous for the transcribed markers that were specific to PITX2c or PITX2a/b. It 
was only possible, therefore, to measure the allelic expression ratio of all three PITX2 
isoforms together. Four SNPs were significantly associated with expression of PITX2a/b 
in the RAA samples. The strongest association was seen for the risk allele [A] of the AF-
associated SNP, rs17042171, which was associated with a 2.01-fold increase in 
expression (p=0.0006). The risk allele [T] of the AF-associated SNP rs2200733 was 
associated with a 1.98-fold increase in expression (p=0.0010) and the risk allele [G] of 
the AF-associated SNP rs6843082, was also associated with a 1.79-fold increase in 
expression (p=0.0011). The other significantly associated SNP was rs16997168, the 
minor allele of which was associated with a 1.94-fold increase in expression (p=0.0007) 
and was in significant LD with rs17042171 (r2=0.34). No association was seen for the AF 
risk SNP rs10033464. After correction for the effects of rs17042171, no significant 
association was seen for any other genotyped SNP. There were no significant 
associations between genotype and expression of PITX2a/b or PITX2c in LAA or IMA.  
There were no significant associations between allelic expression ratio of PITX2 and 
any of the typed SNPs (Figures 5.8 & 5.9 Tables A2.15-A2.17).  
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Figure 5.8 Associations with total expression in chromosome band 4q25 
 
 
Figure 5.9 Associations with allelic expression ratio in chromosome band 4q25 
5.5.7 AF associated SNPs in chromosome band 7q31 are associated with decreased 
expression of CAV1 in right atrial appendage 
Total expression and allelic expression ratios were measured for CAV1 and CAV2 in 
RAA and IMA. There were an insufficient number of individuals heterozygous at the 
transcribed marker, rs8904, to measure allelic expression ratio of CAV2 in the LAA 
cohort.  
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eQTL analysis identified a single SNP, rs9920, which was associated with expression of 
CAV1 in RAA, the minor [C] allele being associated with a 1.22-fold increase in 
expression (p=0.0040). Two of 11 SNPs were associated with expression of CAV2 in 
RAA. The most strongly associated was rs9920, the minor allele of which was 
associated with a 1.21-fold increase in expression (p=0.0007). The other significantly 
associated SNP was the PR interval-associated SNP, rs1773845, the risk [A] allele of 
which was associated with a 0.90-fold reduction in expression (p=0.0037). No SNPs 
were associated with total expression of CAV1 or CAV2 in either LAA or IMA. 
aerQTL analysis demonstrated that five of 11 SNPs were associated with expression of 
CAV1 in RAA. The most strongly associated SNP was rs1049337 with the minor [T] 
allele being associated with a 0.75-fold reduction in expression (p=5.1x10-19). The risk 
[G] allele of the AF-associated SNP, rs3807989, was associated with a 0.89-fold 
reduction in expression (p=5.9x10-8). Two SNPs were significantly associated with CAV1 
expression in IMA. Again, the strongest association was with rs1049337, the minor 
allele being associated with a 0.71-fold reduction in expression (p=1.5x10-7). 
Using aerQTL analysis, three of 11 SNPs were significantly associated with expression 
of CAV2 in RAA. The strongest association was with the transcribed marker, rs8940, 
the minor allele of which was associated with a 0.89-fold reduction in expression 
(p=2.5x10-8). The AF and PR interval-associated SNPs were not associated with 
expression. No SNPs were significantly associated with expression in IMA (Figures 5.10 
& 5.11, Tables A2.18- A2.21). 
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Figure 5.10 Associations with total expression in chromosome band 7q31 
 
 
Figure 5.11 Associations with allelic expression ratio in chromosome band 7q31 
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5.5.8 An AF risk SNP in chromosome band 9q22 is associated with decreased 
expression of C9orf3 and FANCC 
Total expression and allelic expression ratios of C9orf3 and FANCC were measured in 
all three tissues. No significant associations were identified between genotype at any 
of the SNPs and expression of either C9orf3 or FANCC in any tissue by eQTL analysis.  
Using aerQTL analysis, significant associations with expression of C9orf3 were 
identified for five of 15 SNPs. The most significant association was with the transcribed 
SNP, rs4657, the minor [C] allele of which was associated with a 0.91-fold decrease in 
expression (p=7.7x10-12). The risk [A] allele of the AF-associated SNP, rs10821415, was 
associated with a 0.91-fold reduction in expression (p=1.5x10-5).The minor allele of 
rs4657 was also associated with a 0.91-fold reduction in expression in LAA 
(p=1.6x10-5). No SNPs were significantly associated with allelic expression in IMA.  
Four SNPs were significantly associated with expression of FANCC in RAA. The AF-risk 
SNP, rs10821415, was the most strongly associated, the risk [A] allele being associated 
with a 0.94-fold reduction in expression (p=8.9x10-8). The same risk allele was 
associated with a 0.96-fold reduction in expression in IMA (p=0.0019). Only the 
transcribed SNP, rs4647554, was associated with expression in LAA (p=0.0030) (Figures 
5.12 & 5.13, Tables A2.22-A2.25). 
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Figure 5.12 Associations with total expression in chromosome band 9q22 
 
 
Figure 5.13 Associations with allelic expression ratio in chromosome band 9q22 
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5.5.9 An AF risk SNP in chromosome band 10q22 is associated with increased 
expression of MYOZ1 
Total expression and allelic expression ratios were measured for MYOZ1 and SYNPO2L 
in RAA. There were an insufficient number of individuals heterozygous for the 
transcribed SNP rs41280400, used to measure allelic expression ratios of MYOZ1, in 
the LAA and IMA cohorts to permit further analysis. It was not possible to type the AF-
associated SNP in this region, rs10824026, using either Sequenom or TaqMan assays. 
Genotypes for this variant were therefore imputed as described in the methods 
section of this chapter. 
By eQTL analysis, eight of nine variants were associated with expression of MYOZ1 in 
RAA. The strongest association was for rs3182629, the minor [A] allele of which was 
associated with a 2.58-fold increase in expression (p=4.7x10-15). The risk allele [A] of 
the AF risk SNP, rs10824026, was associated with a 0.39-fold decrease in expression 
(p=5.5x10-15). The AF risk allele was associated with an even greater 0.14-fold 
reduction in expression in LAA (p=0.0008), but there were no SNPs associated with 
expression in IMA. No variants were significantly associated with expression of 
SYNPO2L in any tissue. 
By aerQTL analysis, seven of nine variants were associated with expression of MYOZ1 
in RAA. The AF risk SNP, rs10824026, was among the most strongly associated with the 
risk allele being associated with a 0.26-fold reduction in expression (p=5.7x10-5). As a 
result of the small numbers of heterozygous individuals in the sample and strong 
linkage disequilibrium, several SNPs had identical p-values and effect sizes.  
Five of nine variants were associated with expression of SYNPO2L in RAA. The 
strongest association was seen for the transcribed SNP, rs4746139, the minor allele of 
which was associated with a 0.87-fold reduction in expression (p=6.5x10-8). The AF risk 
SNP was not associated with expression. The effect size of the SYNPO2L transcribed 
SNPs is small, this modest effect size and the fact that the transcribed SNPs are not in 
perfect LD with the AF risk SNP explains the lack of association of the AF risk SNPs with 
SYNPO2L AER, despite the strong LD in the region. There were no associations between 
any variant and allelic expression in LAA or IMA (Figures 5.14 & 5.15, Figures A2.26-
A2.29). 
  
150 
 
Figure 5.14 Associations with total expression in chromosome band 10q22 
 
 
Figure 5.15 Associations with allelic expression ratio in chromosome band 10q22 
  
151 
 
5.5.10 Variants in chromosome band 14q23 are associated with allelic expression of 
SYNE2 
Total and allelic expression of SYNE2 and ESR2 were measured in all three tissues. 
There were no associations between any SNP and SYNE2 expression in RAA or IMA. 
eQTL analysis demonstrated that the minor allele of a single SNP, rs4986938, was 
associated with a 1.59-fold increase in expression of SYNE2 in LAA (p=0.0014). No SNPs 
were associated with expression of ESR2 in any tissue.  
Using aerQTL analysis, associations were shown with expression of SYNE2 in RAA in 
five of 33 SNPs. The strongest association was seen for rs1256064, the minor allele of 
which was associated with a 0.89-fold decrease in expression (p=8.6x10-6). Three SNPs 
were associated with expression in IMA, the minor allele of the transcribed SNP, 
rs1152582, being associated with a 1.12-fold increase in expression (p=1.1x10-6). No 
variants were associated with expression in LAA. The AF risk SNP was not associated 
with expression in any tissue.  
The minor allele of a single variant, rs17101651, was associated with a 0.88-fold 
decrease in expression of ESR2 in RAA. No variants were associated with expression in 
LAA or IMA. The AF risk variant was not associated with expression in any tissue 
(Figures 5.16 & 5.17, Tables A2.30-A2.33). 
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Figure 5.16 Associations with total expression in chromosome band 14q23 
 
 
Figure 5.17 Associations with allelic expression ratio in chromosome band 14q23 
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5.5.11 Variants in chromosome band 15q24 are associated with expression of HCN4 
Total expression and allelic expression ratios were measured for HCN4 in all three 
tissues. Expression levels of HCN4 in IMA were too low to permit further analysis. 
Using eQTL analysis, the minor allele of a single SNP, rs3826046, was associated with a 
1.60-fold increase in expression of HCN4 in RAA (p=0.007). No variants were associated 
with expression of HCN4 in LAA.  
Using aerQTL analysis, ten SNPs were significantly associated with expression of HCN4 
in RAA and 12 SNPs were significantly associated with expression in LAA. Of these, 
there were nine SNPs that were significantly associated with expression of HCN4 in 
both tissues. The minor allele of rs488156, the most strongly associated SNP in RAA, 
was associated with a 1.11-fold increase in expression of HCN4 (p=3.8x10-6). The minor 
allele of rs3743496, the most strongly associated SNP in LAA, was associated with a 
0.97-fold decrease in expression (p=0.003). The AF risk SNP, rs7164883, was not 
associated with allelic expression in any tissue (Figures 5.18 & 5.19, Tables A2.34 & 
2.35).  
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Figure 5.18 Associations with total expression in chromosome band 15q24 
 
 Figure 5.19 Associations with allelic expression ratio in chromosome band 15q24 
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5.5.12 No variants in chromosome band 16q22 are associated with expression of 
ZFHX3 or ZFHX3a 
Total expression was measured for ZFHX3 transcript A, (ZFHX3a) and both A and B 
transcripts of ZFHX3 together in all three tissues. There were insufficient heterozygous 
individuals at either of the transcribed SNPs, rs740178 and rs10852515, to permit 
measurement of the allelic expression ratios of ZFHX3 or ZFHX3a in the LAA cohort. No 
association between genotype and expression of either ZFHX3 or ZFHX3a was seen in 
any tissue by using either eQTL or aerQTL analysis (Figures 5.20 & 5.21, Tables A2.36-
A2.39).  
 
Figure 5.20 Associations with total expression in chromosome band 16q22 
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Figure 5.21 Associations with allelic expression ratio in chromosome band 16q22 
 
 
5.6 Discussion 
5.6.1 Patterns of expression of candidate genes in LAA, RAA and IMA 
It is unsurprising that the levels of expression of the candidate genes studied here 
were significantly different between atrial tissue, which consists largely of cardiac 
muscle cells, and internal mammary artery tissue, which is mostly made up of smooth 
muscle cells. The largest differences were seen for HCN4, which encodes the major 
subunit of the If pacemaker channel and is not known to play an important role in 
smooth muscle electrophysiology; and SYNPO2L which encodes a structural 
component of the Z-disc in striated muscle135.  
Increased expression in IMA was noted for the transcription factors ZFHX3, PRRX1 and 
PITX2. The two greatest differences identified in LAA vs RAA expression were also 
reported in the top 20 differences reported by a recent RNAseq study of LAA and RAA 
by Hsu et.al. HCN4 was over-expressed 5.88-fold in the RAA compared to LAA in the 
present study, compared to 7.53-fold over-expression in the RAA samples from Hsu 
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et.al. PITX2c levels were over-expressed 120-fold in the LAA in the present study 
compared to 116-fold in the study by Hsu et.al.  Expression levels of the oestrogen 
receptor ESR2 were very low in all tissues, suggesting that it is unlikely to play an 
important role in AF pathogenesis.  
Previous studies of PITX2 expression in atrial tissue have not demonstrated levels of 
non-c isoform expression commensurate with my findings. A previous RNAseq study 
identified only PITX2c in adult human LAA and RAA124. This study used 3’ library 
selection to isolate RNA, a technique that would be expected to favour detection of 
the 3’ end of the transcript, which all three isoforms share. Bias against the longer, 
non-c transcripts may, as acknowledged by the authors of that paper, have thereby 
been introduced124. We prepared cDNA using random hexamer primers, which would 
not be likely to result in the same bias. In addition RNAseq has a higher error rate than 
qPCR for transcripts such as PITX2 expressed at low levels223. A qPCR study reported 
that the c isoform represented >99% of PITX2 expression in LAA and approximately 
90% of PITX2 expression in the RAA; with PITX2c expression being 100-fold greater in 
LAA compared to RAA125. However a later study by the same group presented a 
western blot of PITX2, using a non-isoform specific antibody, showing a difference in 
protein levels between LAA and RAA of only 2-fold310. This discrepancy may be due to 
expression of non-c isoforms of PITX2 detected at the protein but not the RNA level. 
The original description of MYOZ1 noted that its protein product, Calsarcin-2, is only 
transiently expressed in fetal development in mouse heart and that expression levels 
were not detected by Northern blotting, in adult human heart and mouse atria. In the 
current experiment we demonstrated expression of MYOZ1 at levels approximately 32-
fold lower than the mean expression of the selected reference genes. The discordance 
between these and previous results may simply derive from the greater sensitivity of 
the qPCR approach. Alternatively MYOZ1 expression may vary throughout the heart, 
with greater expression in the atrial appendage than in the material used in the 
experiment by Frey et al.  A microarray-based genome-wide eQTL mapping experiment 
performed using LAA and RAA detected sufficient levels of MYOZ1 to allow 
identification of an eQTL in both tissues. The BLAST tool was used to ensure that the 
primer sequences used were specific to MYOZ1 and would not wrongly detect MYOZ2 
expression311. 
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5.6.2 Associations between gene expression and AF status. 
Previous studies have examined gene expression changes in human atria with AF. An 
eQTL mapping study of PITX2c expression in LAA identified an increase in PITX2c 
expression in patients who were in AF at the time of surgery compared to those who 
had a history of AF but were in sinus rhythm. However, there were no significant 
differences between either group and the smaller number of patients who had no 
history of AF129. Conversely, two small studies found that PITX2c levels were lower in 
atrial tissue from patients in AF than in atrial tissue from patients in sinus rhythm125,267. 
PITX2b potentiates the action of PITX2c on gene expression123, and so upregulation of 
non-c isoforms is likely to result in greater PITX2c-mediated transcriptional activity, 
which may result in increased AF risk. 
This study was designed to detect eQTL associations, and so was not powered to 
detect associations between AF status and gene expression. Nevertheless, this study 
has replicated a previously identified301 reduction in CAV1 expression in association 
with AF at the p<0.05 significance level (Table 5.4). The same study found no 
difference in CAV2 expression between AF cases and controls, which is consistent with 
the results presented here.  I found no significant differences between AF cases and 
controls in expression of either PITX2c or PITX2a/b in LAA or PITX2a/b in RAA. Due to 
the limited phenotypic data available, it was not possible to divide patients with a 
history of AF into groups by rhythm status at the time of surgery, and the small 
number of patients with a history of AF would have rendered results from such a 
subgroup analysis unreliable.  
 
5.6.3 eQTL and aerQTL mapping of genetic effects on expression in tissue 
This study has systematically mapped genetic effects on gene expression at loci 
associated with AF risk by measuring both total expression and allelic expression 
ratios. The results from Chapter 4 have demonstrated that, in general, aerQTL mapping 
performs better than eQTL mapping in identifying cis-acting genetic variants. As 
previously discussed the performance of the aerQTL approach is dependent on the 
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presence of one or more transcribed SNPs with a minor allele frequency high enough 
that a sufficient number of individuals in the population studied are heterozygotes. 
This is the case with the results from this chapter, where no significant associations 
were found between total expression and genotype at most of the loci studied, despite 
there being significant associations with allelic expression at the same loci. The size of 
the cohorts studied in this chapter were smaller than those in the experiments using 
peripheral blood, showing that the aerQTL approach is able to demonstrate effects in 
quite small cohorts whereas eQTL mapping is less powerful.  
The importance of identifying transcribed SNPs is demonstrated by the findings at 
4q25, however. By using transcript specific primers, it has been possible to show that 
AF-associated SNPs affect expression of the non-c isoforms of PITX2, but not PITX2c. 
Transcribed SNPs specific for the c and non-c isoforms of PITX2 were genotyped, but 
the minor alleles of these variants were not present in the study population. It was 
therefore not possible to measure transcript-specific effects on allelic expression ratio, 
and no effects of the AF-associated SNPs on allelic expression ratio could be identified 
when all of the PITX2 isoforms were measured together. The minor allele frequency of 
the transcript-specific transcribed SNPs is reported as very low in the 1000 genomes 
study, and so our findings are not entirely surprising309. 
 
5.6.5 Mechanisms underlying genetic associations with AF 
No association was demonstrated between expression of HCN4 and the AF risk 
variants. As has been shown in Chapter 3, inhibition of the If current increases the 
incidence of AF. HCN4 therefore remains the most likely candidate gene in this region. 
It has been demonstrated here that expression of HCN4 differs between right and left 
atrial appendage. This is unsurprising as HCN4 is primarily expressed in nodal tissue. 
The sino-atrial (SA) node is a relatively compact structure in the high right atrium, and 
HCN4 expression has been shown to vary within the right atrium with higher 
expression seen at the site of the anatomical SA node312. Differential SNP effects on 
expression in apparently similar tissues have been demonstrated previously. For 
example; rs143383, which is associated with risk of osteoarthritis, has been shown to 
affect expression of GDF5 in the knee, but not the hip313. It is likely, therefore that 
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regulation of HCN4 expression differs between the SA node and RAA, and any SNP 
effect may be specific to nodal tissue. 
Alternatively, the AF risk SNP rs7164883 is in LD with a coding region of the nearest 
gene, HCN4 (Figure 5.22). It is possible, therefore, that the effect of rs7164883 is not 
mediated by reduced expression of HCN4, but instead is a consequence of linkage 
disequilibrium with a coding variant which alters the physiological properties of the If 
channel. There are 17 coding variants listed in build 138 of dbSNP in exon 1 of HCN4. 
None are sufficiently common that LD values are available in the HapMap or 1000 
genomes data sets. Fine mapping of the AF association signal at this locus with typing 
of low frequency variants may allow identification of coding risk variants which would 
merit further study.  
 
Figure 5.22 Linkage disequilibrium between AF risk variant and the first exon of 
HCN4 
 
LD is indicated by the inverted mountain plot with darker shades of red indicating higher r2 
values. The AF risk variant, rs7164883, is indicated in green at the far left of the plot. LD values 
are taken from the CEU population in phase II of the HapMap project.  
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The role of the SK3 channels encoded by KCNN3 has already been discussed in Chapter 
4. Neither of the approaches used here were able to identify an association between 
the AF associated SNPs and expression of KCNN3 in any of the tissues studied here. 
SK3 channels are expressed in a range of non-cardiac tissues, however, including 
vascular smooth muscle. SK3 channels regulate blood pressure in mice by affecting 
arteriolar vasodilatation314. There are no GWAS hits for blood pressure near KCNN3, 
despite large studies having been performed, making effects on systemic blood 
pressure an unlikely mechanism of action315-317. SK3 channels are expressed in human 
pulmonary endothelium and pharmacological activation of these channels results in 
dilatation of bronchioles and pulmonary arteries318. Pulmonary hypertension increases 
the risk of developing AF319, and one could speculate that subclinical changes in 
pulmonary artery pressure might have a similar effect. To determine whether this 
mechanism is important in AF risk, it would be necessary to demonstrate that the AF 
risk SNPs were associated with pulmonary artery pressure, measured by right heart 
catheterisation or echocardiography, and subsequently that variations in pulmonary 
pressure are associated with AF risk. This highlights the importance of tissue specificity 
when attempting to identify the mechanisms of action of disease-associated genetic 
variants. We were not able to demonstrate an association between expression and 
genotype in tissue taken from the atrial appendage or from a medium-sized artery, but 
this does not exclude an effect in small arteries, arterioles or the pulmonary 
vasculature. 
The AF risk variants in chromosome band 1q24 were not consistently associated with 
expression of either PRRX1 or GORAB in RAA or IMA. An association was identified 
between the risk allele for AF and an increase in expression of GORAB in LAA, but this 
only just reached significance at the 5% threshold and would require replication in a 
second cohort to be considered robust.  
No association was determined between the AF risk variants in chromosome band 
16q22 in any of the tissues studied. Nor was any association demonstrated between 
expression and genotype of a genetic variant associated with Kawasaki disease: either 
in atrial or arterial tissue. The inability to demonstrate an association here may, as has 
been suggested previously, be due to the effects of AF risk variants being limited to 
specific tissues or cell types, not studied here or, particularly in the case of 
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transcription regulators such as ZFHX3, being limited to specific time points in 
development, which are not captured in this sample from an adult population.  
The associations between genetic variants and allelic expression of SYNE2 in right atrial 
appendage followed a similar pattern to those identified in peripheral blood, but did 
not reach the same level of statistical significance in the smaller tissue cohorts. A 
significant association was not identified between the AF risk SNPs and allelic 
expression ratio. This may be for one of two major reasons. The current experiment 
may simply be underpowered, with too few subjects to detect a modest effect size. 
The other possible explanation is that the risk SNPs do not exert their influence by 
affecting expression of SYNE2 in atrial tissue. The presence of AF as part of the 
phenotype associated with deleterious SYNE2 mutations has already been discussed in 
Chapter 4 and SYNE2 remains a likely candidate gene. It is possible that the effects of 
SYNE2 on AF risk are mediated indirectly. Heart failure, with impaired or preserved 
ejection fraction, is associated with an increased risk of AF320-322, and the Emery 
Dreifuss phenotype includes cardiomyopathy139. The increased incidence of AF, 
therefore, may be mediated by higher ventricular filling pressures rather than by a 
direct effect of SYNE2 expression in the atria themselves. In order to investigate 
whether an intermediate phenotype of the left ventricle underlies this association, it 
would be necessary to establish whether the AF risk SNPs are associated with changes 
in left ventricular function or filling pressures. As in peripheral blood, there were no 
associations between the AF risk SNPs and total expression or the allelic expression 
ratio of ESR2. 
The risk variants of multiple AF-associated SNPs in chromosome 4q25 upregulate 
expression of the a and b isoforms of PITX2 in human RAA. The risk allele of the AF-
associated SNP rs17042171 was associated with a 2.01-fold increase in expression of 
the PITX2a and b isoforms (p=0.0005). This is the first demonstration of a gene 
expression phenotype associated with AF risk SNPs in this region. These SNPs have 
been identified as the common variants with the strongest association with AF in 
multiple GWAS to date. Our observations implicate the non-c isoforms of PITX2 in lone 
AF. Furthermore, we demonstrate that the non-c isoforms of PITX2 are expressed in 
both left and right atrium, with a higher expression in LAA vs. RAA.  
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The pattern of association between expression of PITX2a and PITX2b and SNP 
genotype is very similar to the pattern of association between AF risk and SNP 
genotype. With the exception of rs10033464, which was identified in a GWAS of an 
Icelandic population, and has not been replicated at GWAS significance in other 
populations105, AF risk SNPs in the region were associated with expression and there 
were no SNPs associated with expression that are not in LD with the AF risk SNPs. The 
lack of association at rs10033464 may be due to differences in LD structure between 
the GWAS population and the population in the present study, in which LD between 
rs10033464 and the lead eQTL SNP is weak (r2=0.013). 
Two previous studies have examined the relationship between GWAS hit SNPs at 4q25 
and PITX2 expression in atrial tissue. A recent eQTL mapping study did not detect 
associations between AF risk SNPs and PITX2c expression129; however expression of 
the other isoforms was not investigated in that study. A recent genome wide eQTL 
mapping study using the Affymetrix U133 array, on which the PITX2 probes are not 
isoform-specific, found no association between PITX2 expression and the AF risk 
variants on 4q25. Neither of these studies specifically examined the non-c isoforms of 
PITX2.  
To date, animal models involving gene targeting of Pitx2 have not addressed the 
contribution of the non-c isoforms to arrhythmic susceptibility. A homozygous mouse 
knockout model of Pitx2c alone demonstrated left-right atrial isomerism and early 
postnatal death323.  The heterozygote exhibited increased susceptibility to pacing 
induced arrhythmias and increased expression of genes associated with the sino-atrial 
node in the left atrium125,127. A Pitx2a/b knockout mouse model retained normal left-
right atrial architecture even when combined with a hypomorphic PITX2c allele, but 
has not, to our knowledge, undergone electrophysiological testing290. It is possible that 
the Pitx2a/b knockout mouse would also exhibit electrophysiological abnormalities, 
due to interaction between Pitx2 isoforms; further investigation in this model would 
be of interest. 
The associations identified in chromosome band 7q31 in right atrial appendage 
confirm the findings in peripheral blood. There is a clear association between allelic 
expression ratio of CAV1 but not CAV2. This finding, and the observation that CAV1, 
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but not CAV2 levels, are associated with AF status in this cohort and in previously 
published studies301, provides strong evidence for the role of CAV1 in AF risk. The 
observation that expression of CAV2 in internal mammary artery is associated with one 
of the AF-associated SNPs in the region is interesting. The strength of the association is 
not very great, and the lack of an association in the allelic expression experiment, 
which would be expected to have greater power, raises the possibility that this arises 
from the play of chance. Replication in an independent cohort would be of value. 
The AF risk SNPs in chromosome band 9q22 were associated with a modest but very 
significant effect on allelic expression of FANCC in both RAA and IMA and a larger 
effect on allelic expression of C9orf3 in RAA only.  It is not possible to determine which 
of the candidates plays a role in AF risk, or whether both are important. Fanconi 
anaemia (FA) is a disease with a broad phenotype characterised by increased 
susceptibility to a variety of cancers, bone marrow failure and developmental 
abnormalities. FA is caused by a failure of the FA complex of proteins, which plays an 
important role in DNA repair. FANCC encodes member C of the FA complex and 
biallelic mutation in any of the 15 FA complex proteins can cause FA324. FA proteins 
may have a wider array of functions, however; for example FANCC is required by 
Hsp70 to prevent apoptosis of haemopoetic stem cells325. Loss of function of FANCC in 
a cell line resulted in dysregulation of a large number of transcripts but most 
prominently caused downregulation of CAV1 expression326, providing a possible 
mechanism whereby reduced FANCC expression might result in increased AF risk. AF is 
not reported as part of the phenotype associated with FANCC mutations but any 
association may be masked by the poor prognosis associated with FA. 
As discussed in Chapter 4, underexpression of C9orf3 might result in increased activity 
of the renin-angiotensin-aldosterone system (RAAS) by reduced breakdown of 
angiotensin III by the protein encoded by C9orf3, aminopeptidase O. The role of RAAS 
in the electrical and structural remodelling which is associated with AF is well 
established327-329, and inhibition of RAAS prevents AF330.  The results of the present 
study do not indicate whether the AF risk SNPs in this region operate primarily by 
upregulating RAAS or by FANCC-mediated downregulation of CAV1. The two 
mechanisms are not mutually exclusive, however, and it is possible that both 
mechanisms contribute to the overall effect. 
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Both of the candidate genes identified in chromosome band 10q22, MYOZ1 and 
SYNPO2L, encode components of the Z-disc in striated muscle. MYOZ1 encodes 
Calsarcin-2, which tethers calcineurin to α-actinin136. MYOZ1 has been considered as a 
candidate gene in idiopathic dilated cardiomyopathy but no MYOZ1 mutations were 
found in a cohort of 185 unrelated DCM probands331. A genome-wide eQTL mapping 
study in atrial tissue identified an association between total expression of MYOZ1 and 
SNPs in the region, but did not report on the lead AF GWAS SNP itself130. It was not 
possible to genotype the AF-risk SNP, rs10824026, using two different technologies in 
the present study, which indicates that this is a difficult to genotype variant. The lead 
variant identified in the genome-wide study, rs3740293, is in strong LD with the AF risk 
SNP in the 1000 Genomes cohort (r2=0.75, D’=1). Genotype at rs3740293 was 
determined by imputation in the present study. The findings of this study and the 
strong LD between rs10824026 and rs3740239 strongly indicate that decreased 
expression of MYOZ1 is the mechanism by which AF risk at this locus is mediated. By 
contrast, neither in the present study, nor in the experiment by Lin et.al., was 
expression of SYNPO2L affected by genotype of the AF-associated SNPs.  
 
5.7 Conclusions 
Results of experiments in this chapter have demonstrated novel associations between 
AF risk variants and gene expression in cardiac tissue. AF risk variants were associated 
with increased expression of PITX2a/b and decreased expression of MYOZ1, CAV1, 
C9orf3 and FANCC in right atrial tissue; these associations have not been demonstrated 
previously. Furthermore, although this experiment was not primarily designed to 
detect difference between AF cases and controls, AF has been shown to be associated 
with reduced expression of SYNE2, HCN4 and CAV1. These results provide clear 
evidence for the roles of these genes in the pathogenesis of atrial fibrillation. 
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Chapter 6 
General discussion and 
future directions 
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6 General discussion 
6.1 Preamble 
In Chapter 3 the emergence of the parallel discoveries of ivabradine as an inhibitor of 
the If current, mediated by HCN4 and of the HCN4 region as a susceptibility locus for 
AF led me to investigate the effects of ivabradine on AF risk.  To my knowledge, this is 
the first example to date where a drug has been demonstrated to have a side effect 
hypothesised as a result of findings from a genetics study. The identification of genetic 
effects which mirror drug side effects is not new, however. The best example perhaps, 
being that of rs1800693, which predisposes individuals to multiple sclerosis by 
upregulating the expression of a soluble version of the TNF receptor with decoy 
activity216.  The SNP mimics the effect of TNF-blocking drugs which increase multiple 
sclerosis risk, and exacerbate the condition if it is present already, in patients treated 
with anti-TNF therapy for inflammatory conditions. As well as identifying potential side 
effects of drug treatment, this finding demonstrates the potential utility of genetic 
association studies in identifying drug targets. Current antiarrhythmic drug therapy has 
a relatively poor success rate in maintaining sinus rhythm. Approximately 50% of 
patients treated with an antiarrhythmic drug will have no improvement in their 
symptoms332. There is a clear need therefore to identify suitable targets for further 
study.  
As has been pointed out previously, GWAS only indicate loci which are associated with 
a phenotype. Unless the variants identified are within a coding region, which is rarely 
the case, the responsible gene must be identified. An important example is provided 
by the link between genetic variants within introns of the gene FTO and obesity. FTO 
was identified as the strongest GWAS locus for body mass, and knockout of the gene in 
a mouse model produced the anticipated effects on body mass.  However, no 
association in human tissue was ever demonstrated between risk variants and FTO 
expression. A recent study has identified that the obesity risk SNPs within FTO regulate 
expression of a distant gene, IRX3, and that modulation of IRX3 expression levels, 
rather than FTO expression levels, affects body mass and composition333. This 
demonstrates the importance of identifying eQTLs as the first phase of the 
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investigation of risk variants identified by GWAS, in order that research efforts can be 
focussed on the most appropriate target.  
In this chapter I will discuss the utility of the methods used in Chapters 4 and 5 in 
identifying SNP effects on expression. I will then discuss the limitations of the eQTL and 
aerQTL analyses described in Chapters 4 and 5, focussing on the issues of power, 
phenotypic characterisation, the identification of candidate genes, the site and timing 
of expression and the statistical methods used. I will then consider future experiments, 
discussing how new approaches might address some the limitations of the present 
study and describing experiments that might build on the results described here. 
 
6.2 The relative utility of eQTL and aerQTL analysis in identifying SNP effects on 
expression 
In most of the regions analysed in chapters 4 and 5 the aerQTL approach was more 
powerful than the eQTL approach in detecting cis-acting effects. For CAV1, SYNE2 and 
ZFHX3 aerQTL mapping detected effects which were not seen in eQTL mapping. In the 
chromosome 9q22 region, both methodologies detected effects on C9orf3 expression. 
It has previously been shown that eQTL mapping and aerQTL mapping identify the 
same cis-acting loci185,293. In this experiment we have shown that the increase in power 
from the aerQTL approach can prove decisive in identifying regulatory elements, 
where eQTL mapping has not been able to do so. This has implications for future 
investigations of the regulatory effects of variants at other loci, including the 
thousands identified by GWAS30. 
It has already been pointed out that the aerQTL method would be expected to have 
greater power than the eQTL approach due to the large number of trans-acting 
influences on expression which are difficult to identify and control for. We did not 
include potential trans-acting influences on expression in our analysis. Published eQTL 
studies in similarly sized cohorts have shown that the inclusion of age, gender and 
medical history in eQTL mapping models has had little effect on the results of the 
analysis129,185. This is likely because the trans-acting effects which have been identified 
contribute relatively little to the total influences which act on expression in trans. The 
proportion of the variation in expression that can be explained by known factors, 
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therefore, is small and their inclusion in a statistical model does not greatly impact on 
the power to detect regulatory effects. It is important to note that aerQTL mapping 
relies on linkage disequilibrium between the transcribed marker and the putative 
regulatory SNP. This can significantly reduce the power of this approach. 
Another important reason why the aerQTL approach may have greater power to 
detect cis-acting effects lies in the regulation of overall gene expression. Gene 
expression is often regulated by trans-acting negative feedback mechanisms334,335, 
which serve to maintain relatively constant transcript levels. Any change in overall 
expression mediated by a cis-acting variant may, therefore, not result in a detectable 
change in total transcript levels. If the cis-acting variant is in the heterozygous state, 
however, the altered ratio of the two alleles will remain. This may be the case in the 
regions studied here, especially in the case of SYNE2, where a very strong association is 
seen in the aerQTL experiment, but not in the eQTL experiment. By contrast, in the 
case of C9orf3, the aerQTL and eQTL experiments demonstrated very similar power to 
detect the effects of rs10993391 on expression, suggesting that overall transcript 
levels are under looser control. This raises the question: if overall transcript levels are 
not significantly different, as a result of cis-trans regulation, how does the SNP affect 
AF risk? The simplest explanation is that the overall levels are affected by the variable 
to a small degree, which is sufficient to affect AF risk on a population-wide basis, but is 
not detectable in a cohort of the size studied here. A second explanation is that the 
effects acting in cis and trans differ between tissues, such that regulation of total 
expression may be looser, allowing cis-acting effects to have a greater influence on 
overall transcript levels. The third explanation is that there is an effect only under 
certain circumstances (e.g. for components of the immune system when challenged by 
a pathogen), this would also be expected to be the result of trans-acting effects.  
This study used up to three transcribed markers to perform aerQTL mapping at several 
different loci. The use of two transcribed markers improves the power of aerQTL 
mapping to identify cis-acting effects185, and this methodology was used here to 
incorporate information from a third marker in the case of ESR2. There are two main 
constraints to the use of multiple transcribed markers in this situation. The first is 
resource limitation. An increase in the number of assays performed requires the use of 
greater amounts of RNA, which when taken from an easily accessible tissue, such as 
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blood, is rarely a limiting factor, but may be problematic in the case of less accessible 
tissues, where less total RNA may be available. The other major difficulty lies in the 
identification of suitable transcribed variants for analysis. SNPs are less frequent in 
coding regions than in non-coding regions and for some transcripts there are very few 
transcribed variants336. The usefulness of a transcribed marker for aerQTL mapping is 
also dependent upon its minor allele frequency (MAF), as allelic imbalance can only be 
measured in individuals who are heterozygous at the transcribed marker. The power of 
the test therefore is dependent on the number of heterozygotes which, for biallelic 
markers, falls from 50% of the sample when MAF=0.5 to 18% when MAF=0.1 and less 
than 2% when MAF=0.01204.   
 
6.3 Limitations 
The present study did not identify effects on expression at every locus examined, 
leaving some of the mechanisms which underlie AF risk variants unexplained. There 
are a number of limitations to the study which may explain the lack of association 
identified. In the case of HCN4, it is possible that the mechanism of action of the risk 
SNP is not via gene expression, as the AF risk SNP is in LD with the first exon of HCN4. 
In the case of the other variants, however, the GWAS hit SNP is not in LD with a coding 
region. 
 
6.3.1 Power 
As described in Chapter 2, power calculations performed on the basis of simulations 
indicated that around 200 individuals would be required in each cohort to adequately 
detect a biologically meaningful effect. Only the blood cohort met this level and the 
RAA and IMA cohorts were somewhat smaller. This may mean that the studies 
performed in tissue were underpowered to detect SNP effects.  Notwithstanding, the 
tissue cohort was the largest that I could assemble given the resource and time 
limitations of my MD studies, and it has yielded several novel and potentially 
important associations with expression. 
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6.2.2 Phenotypic characterisation 
In order to facilitate recruitment within a constrained time period the study protocol 
called for a minimal amount of phenotypic data to be collected on recruitment, namely 
AF status. A greater amount of phenotypic data, such as BMI, blood pressure, 
medication history would have allowed further analysis to be performed. However, as 
outlined in the Introduction Chapter, these phenotypic traits and the trans acting 
influences on expression with which they might be associated would not be expected 
to influence allelic expression ratio. The adoption of a more complex recruitment 
protocol, with the attendant time, training and data protection costs, would almost 
certainly have resulted in recruitment of a smaller cohort, exacerbating the problems 
of inadequate power. 
 
6.3.3 Selection of candidate genes 
Due to the constraints of the current project, only a limited number of transcripts were 
analysed at each AF risk locus. Care was taken to ensure that the assays used were 
designed to capture as many of the transcripts of each candidate gene as possible, and 
in the case of PITX2 and ZFHX3 to measure more than one transcript of the gene. As 
illustrated by the case of the IRX1 gene described above, however, careful selection of 
one or two candidate genes at a locus may miss the transcript which mediates the 
disease risk. Furthermore, for almost all of the candidate genes, several different 
transcripts have been identified. The results from analysis of ZFHX3 and PITX2 
expression indicate that there are transcript-specific regulators of expression. Some of 
the genes studied, particularly SYNE2, have a great number of transcripts, which are 
differentially expressed in different tissues.   It is possible, therefore, that the current 
study has not examined the correct gene or transcript, and that the AF risk SNPs affect 
expression of other transcripts, either splice variants or alternative genes, not 
examined here.  
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6.3.4 Site of expression 
Tissue specificity of gene expression is well recognised, and it has been shown that 
50-80% of eQTLs identified in one tissue can be replicated in another193. This study 
examined expression of transcripts in three tissues; peripheral blood, RAA and IMA. It 
is not surprising that by analysing atrial tissue, it has been possible to identify 
associations between AF risk SNPs and gene expression that were not identified in 
peripheral blood. It is interesting however, that in two cases, those of SYNE2 and 
KCNN3, associations which were identified in blood could not be reproduced in RAA. It 
is possible that this is simply due to the reduced power to detect effects in the smaller 
RAA cohort. This observation is important as, due to the relative ease with which 
peripheral blood samples can be obtained for gene expression analysis when 
compared with other tissues, it will always be easier to study large cohorts of 
peripheral blood samples, and so conduct adequately powered investigations. The 
alternative explanation for the discrepancy in results between the two experiments is 
that there are effects on expression in peripheral blood that do not operate in atrial 
appendage. This might be assumed to mean that the effects are not, therefore, 
important in the pathophysiology of AF; given that the atria are the tissue in which AF 
exists. However, AF often develops as a consequence of other pathophysiological 
processes which in turn place strain, usually in the form of elevated atrial pressures, on 
the atria. It is entirely plausible therefore that a genetic variant which has no effect at 
all on gene expression in the atria themselves may, by affecting expression of a gene in 
a distant tissue, increase the risk of AF. For example, genetic variants near PITX2 and 
ZFHX3 have been identified in GWAS of stroke337 .  These are not likely to operate by 
affecting gene expression in the brain, but rather by affecting the risk of AF. In this 
case, the identification of genetic effects from a cohort of blood samples is not inferior 
to the use of a cohort of atrial tissue samples.  
 
6.3.5 Timing of expression 
PITX2 is a transcription factor with a well documented role in cardiac development. 
The function of PITX2 expression in the adult heart is less well understood. It is 
possible that the AF risk SNPs operate not in the adult at all, but instead affect 
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expression at a key stage in development which has lasting effects on AF risk in the 
adult. Patterns of gene expression vary throughout development. It is likely therefore 
that different regulatory components are active at different time points in the 
development of the organism. There is good evidence from a study in Caenorhabditis 
elegans nematodes that eQTLs operate at specific time points of the development 
cycle338. It is likely that the same is true of other organisms, including humans. This 
raises the possibility that risk variants operate at a specific time point in fetal 
development and that studies performed in adults would not be able to identify the 
target transcript.  
 
6.4 Future considerations 
One of the first steps that I would like to take in order to follow up the results 
presented here would be to confirm our findings using an alternative methodology. 
One established technique for measuring gene expression is cap analysis of gene 
expression (CAGE), which captures the 5’ ends of RNA transcripts for quantification. 
This approach has the benefits of allowing differentiation between transcripts with 
different transcription start sites which will be useful in separating out the transcripts 
of those genes which exist in multiple forms. An alternative technique to confirm the 
results presented here is RNA sequencing (RNAseq). RNA sequencing is an increasingly 
affordable tool in which the entire transcriptome is sequenced. This allows not only 
qualitative assessment of which transcript variants are expressed in a particular tissue, 
but also quantification of the amount of those transcripts present. The use of RNAseq 
data therefore offers the opportunity to overcome one of the important limitations 
outlined above, namely the need to select candidate transcripts; all expressed 
transcripts will be captured, even those which have not previously been described, 
negating any bias that might arise from selecting specific transcripts for study. RNAseq 
also, therefore, offers the possibility of identifying trans acting effects from distant 
sites. RNAseq has a greater dynamic range than the other technologies available for 
genome-wide eQTL analysis. RNAseq will also capture every transcribed SNP in each 
individual studied. This will allow use of a far greater number of transcribed SNPs in 
each transcript, allowing more reliable estimation of the AER in a greater number of 
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individuals, thereby increasing the power of the aerQTL approach. The use of RNAseq 
data therefore may allow a more powerful analysis of the regions already studied. This 
may allow identification of eQTLs for genes which were not able to be examined here.  
RNAseq will be particularly useful in defining the specific transcripts of SYNE2 and 
PITX2 which are regulated by AF risk SNPs. Additionally, for several of the genes 
studied here, particularly MYOZ1 and PITX2, the levels of expression that we have 
identified differ from those described in the previously published literature. The 
possible reasons for these differences have been discussed above, but an RNAseq 
study of a large number of atrial samples would be justified to provide a reliable 
comprehensive atlas of gene expression in human atria. Unfortunately, due to the cost 
and complexity of both CAGE and RNAseq, these confirmatory experiments are beyond 
the scope of the current MD project. 
The other line of enquiry which will be of interest will be to further investigate the 
associations identified here. Increased expression of CAV1 is associated with 
protection from AF. Overexpression of CAV1 has been shown to reduce activity in the 
TGF1β pathway. It seems possible therefore that agents which promote expression of 
CAV1 might have a protective effect in AF. CAV1 is upregulated by the transcription 
factor, PPARγ and activation of PPARγ by drugs such as pioglitazone also upregulates 
CAV1 expression339. Small studies have suggested that pioglitazone may prevent 
recurrence of AF following catheter ablation and prevent progression of AF in diabetic 
patients340,341. Furthermore, telmisartan an angiotensin II receptor which is, uniquely 
in its class, a partial PPARγ agonist, appears to be better than other antihypertensives 
at preventing AF342,343. 
MYOZ1 presents a broader challenge for future investigation as very little is known 
about its role in cardiac tissue. In the mouse Myoz2 but not Myoz1 is expressed in 
cardiac tissue. This suggests that the mouse model is poorly suited to elucidate the 
role of MYOZ1 in AF risk. Anatomical studies will allow definition of the pattern of 
expression of MYOZ1 in the human heart. Tissue culture models may provide insights 
to the effects of increased and decreased expression and identify physiological 
consequences and downstream targets of altered MYOZ1 expression. 
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Similarly the roles of C9orf3 and FANCC in the heart are poorly understood. aerQTLs 
were identified for an AF risk SNP and both genes. It is possible that only one of these 
genes mediates the increase in AF risk and that the other is a bystander. Alternatively 
they may interact in some way. In order to elucidate these mechanisms further work 
must be done to identify the physiological role, site of action and importance of 
C9orf3. Tissue culture experiments may allow identification of downstream 
consequences of upregulation or down-regulation of expression.  
 
6.5 Conclusions 
By performing meta-analysis of randomised controlled trials of ivabradine, an If 
inhibitor, I demonstrated an increase in risk of incident AF in patients treated with 
ivabradine vs. controls, supporting the role of HCN4 in AF susceptibility. 
Analysis of total expression and allelic expression ratios in whole blood of candidate 
genes identified associations between AF risk variants and increased expression of 
KCNN3 and SYNE2 and decreased expression of CAV1.   
Analysis of total expression and allelic expression ratios in right atrial appendage tissue 
identified further associations between AF risk variants and increased expression of 
PITX2a/b and decreased expression of MYOZ1, CAV1, C9orf3 and FANCC in right atrial 
tissue. Furthermore, although the experiments were not designed to detect 
differences between AF cases and controls, I have shown that AF is associated with 
reduced expression of SYNE2, HCN4 and CAV1. 
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Assay details 
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A1 Assay details 
Table A1.1 Real-time PCR assays 
Transcript Assay 
ACTB Hs99999903_m1 
GAPDH Hs03929097_g1 
HPRT1 Hs02800695_m1 
KCNN3 Hs01546820_m1 
PRRX1 Hs00246567_m1 
GORAB Hs01552848_m1 
PITX2a/b Hs00165626_m1 
PITX2c Hs04183413_m1 
CAV1 Hs00971716_m1 
CAV2 Hs00184597_m1 
C9orf3 Hs00262414_m1 
FANCC Hs00984545_m1 
SYNPO2L Hs00227591_m1 
MYOZ1 Hs01122904_m1 
HCN4 Hs00975492_m1 
SYNE2 Hs00794881_m1 
ESR2 Hs01100353_m1 
ZFHX3 Hs00199344_m1 
ZFHX3a Hs00994898_m1 
Assay details are given as Life Technologies assay codes.
  
 
 
2
1
0
 
Table A1.2 Genotyping assays 
Multiplex SNP Forward primer Reverse primer 
Amplicon 
length Extension primer 
W1 rs117951282 ACGTTGGATGGGAAAAGTTAAGCACTCCC ACGTTGGATGGCTACAAGTCCTCAACACTC 100 GCACTCCCACTTTCA 
W1 rs1419110 ACGTTGGATGGCCCACTGGAAAATACCTTG ACGTTGGATGCTTGGAGAAATGTGGACCTG 111 ACACTCAGCAGTGAC 
W1 rs13376333 ACGTTGGATGATTGGGAGGTCATGGGATCG ACGTTGGATGGGCTTTGCTCTGGAGAGAAC 99 GGTTCTGCTCCTTCCT 
W1 rs16971384 ACGTTGGATGTCAGTCCATTGAACTGGAGG ACGTTGGATGGTGGTTGCTGTCTTTCCCTG 100 GCCCCATGATGGAAGA 
W1 rs1061122 ACGTTGGATGAGGAGTAGGTGCCAGCTCAG ACGTTGGATGGAGTGCTGCTCAGTGTCAAA 100 ctCCAGCTCAGTCCCTG 
W1 rs10852515 ACGTTGGATGTAATCACACACCTCGCACCG ACGTTGGATGAATATCAGTAGCTCCTGCGG 100 TTGGTTTTTGGTTTGGT 
W1 rs1051614 ACGTTGGATGGATGACTGGCGGATAGCCAT ACGTTGGATGATGGCGCACACCAGCATCTC 91 gaaCTACGAGCGCATCCT 
W1 rs4492614 ACGTTGGATGCTAGATGGTCTTACCCTCTC ACGTTGGATGGTGTCATCTCACTCCCAATG 81 acTACCCTCTCCTCTCCTT 
W1 rs4845663 ACGTTGGATGTTGCAGGTTCTCCGATAGTG ACGTTGGATGGCATGACTGTAACTTCAAGG 99 cCTGATCATCACTCAGCCT 
W1 rs6682291 ACGTTGGATGGTACGAAAAAAACTAGCCACG ACGTTGGATGCTTTCCTCTTCCTCATTGGC 98 ctCCACGAATGAGCAGTTT 
W1 rs7199343 ACGTTGGATGGCCCTGATAGGGTTTTAAGC ACGTTGGATGCATGGATTCTGCTGGCACTC 92 GCTTTGGAATTTGGAAGTC 
W1 rs2157786 ACGTTGGATGCACCCTATTCACCATTCTCC ACGTTGGATGCTCTAGGTGAGGATGACTAC 95 tcCCATTCTCCCTGGTTAAA 
W1 rs740178 ACGTTGGATGACCTCCTGGCAATGGGAGAC ACGTTGGATGTCCTCCTTGTCTTCCTCAAC 90 ATGGGAGACCCCACTCTGGC 
W1 rs76110919 ACGTTGGATGACTCCTCTCCCACCGCTTTC ACGTTGGATGTGGAGGAAGGGTGGAGGAT 89 AGGGCCCCCCCTTCGTCCAAC 
W1 rs7193343 ACGTTGGATGGAGGGGAAAGTTTGAACAGC ACGTTGGATGAAATGTCGAGTCCTAATGGC 89 GAAAGTTTGAACAGCTTGTTT 
W1 rs1218601 ACGTTGGATGCTTGGGATAACTCCTTCCTC ACGTTGGATGGCCCCCCAATCTTGTAATTC 113 agAACTCCTTCCTCCACTCGCA 
W1 rs16971474 ACGTTGGATGTAGGCAGACCCCATCATTTC ACGTTGGATGCCCACAGGCAAGATCTTGTC 100 cGACCCCATCATTTCGAGATTA 
W1 rs4788482 ACGTTGGATGAGGAACTGCTGGATTCTTGG ACGTTGGATGTGTTCCTGCTGCGAGAGTTC 118 caTTAGCATGGGCCTTTCTCAA 
W1 rs2228200 ACGTTGGATGAGAGCTTGCACTGGTATGAG ACGTTGGATGCTGCACATGAACGTGGAGC 99 cTCACCGCCTTCCACTCGTCCTC 
W1 rs2106261 ACGTTGGATGCACAGATAGAGCTCGTCCAG ACGTTGGATGAGAGCAGTCTCTGGCACACT 100 ATAGAGCTCGTCCAGAGAATTGT 
W1 rs6691316 ACGTTGGATGGGCTCAACTCATGCTCAATG ACGTTGGATGAAGAGGTGCTCGATGCACAG 101 ggGAATGAGTGAATAAGCTGATC 
W1 rs9940520 ACGTTGGATGCAGTTCAGACTCTCTGTTAG ACGTTGGATGAAGCAACATAAGGCAGGCTC 82 CAGACTCTCTGTTAGAGGCCTACT 
W1 rs1218565 ACGTTGGATGAACACCTCAGAATCCTTCCC ACGTTGGATGGTGCAGGAACAGCAAATAGG 116 CACCTCAGAATCCTTCCCAACACAG 
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Multiplex SNP Forward primer Reverse primer 
Amplicon 
length Extension primer 
W1 rs7193297 ACGTTGGATGCATTCGTTGCAGGTGACCTC ACGTTGGATGAATGAGCGCCTCGCGGAGA 100 GTGACCTCCTTGCTGGCGGGCTCGG 
W1 rs16971464 ACGTTGGATGAGGAGTCACTCAGATGTTTG ACGTTGGATGCTCATTTGACCTCTAACAATC 120 tgAACCTGTAAAATCGAAAATATGA 
W1 rs4788679 ACGTTGGATGACCTACCTACAGCCTTATGG ACGTTGGATGGAAGAAAGCCAGGTACGAAG 84 CCTACCTACAGCCTTATGGAACGACC 
W1 rs2266943 ACGTTGGATGTTCCCAAAAGGCCATTCCAC ACGTTGGATGTGGCTCTGTTTTGACTGGTG 111 ccTCAATTTCAAGACACCTTGCTCCCT 
W1 rs1476646 ACGTTGGATGTTCAGTAGCAACTCAGAGCG ACGTTGGATGCCCGGGAATACTTTCACATC 119 CAGAGCGTCGTGCTCTCTTGTCTTTGT 
W1 rs2106258 ACGTTGGATGTTAGATCCTGGTTAGCGGAG ACGTTGGATGAGCCTGAACAGAGCCAAATC 101 tTTAGATCCTGGTTAGCGGAGCCTTCG 
W1 rs8052905 ACGTTGGATGACCAAAGTATTCCCCAGTCC ACGTTGGATGCCACTACATGCAGCTTCTTG 109 GGGAAAGCAAGATCCTGAGAAAGAATA 
W1 rs8056528 ACGTTGGATGAAGCTAAGTAGCCTAAGGAC ACGTTGGATGCTTGTGAATTAGCGAGAACC 97 agTTTTGTGAAGCATCTTTGCTGCTTTT 
W1 rs6695232 ACGTTGGATGACACCCCGATCCTATTTCAC ACGTTGGATGTCTCACCTTACTTGCTGCTG 119 ctGAAGATATGGACATGATTTATGCCCC 
W2 rs11640106 ACGTTGGATGAACAGACTGTCCTTCTCCAC ACGTTGGATGAAATCTGAAGGCCCTGAGTG 113 CTCACCCTGCCCCCA 
W2 rs925042 ACGTTGGATGGCCGCTTCTCGTTTTCAAAG ACGTTGGATGGAAAGTGGAGATGGAGGGC 119 TTGGTCCTTGCACAA 
W2 rs756720 ACGTTGGATGTGTTTTCCTGATCACCAGGG ACGTTGGATGGCAGCATTGGACTAAATGGG 96 tATCCTCAGCCTTCCC 
W2 rs12929452 ACGTTGGATGTATAAGGAACACCATCCTGC ACGTTGGATGGCACAGGGTGTTATATTGGC 98 ACCATCCTGCCACTTA 
W2 rs4788480 ACGTTGGATGGAAGAGTCTGCTTCAAGAGG ACGTTGGATGTTTGCAGAACTGTGGCCCTC 101 CTGTATGCAGAACGGA 
W2 rs8051826 ACGTTGGATGAACTTCCCTAGTATGGCCAG ACGTTGGATGAGGGTTGGAACCCATGTAAC 96 tGAGGCTGGAAAACCA 
W2 rs12373097 ACGTTGGATGGAGAGGGTGAAACGAGCATT ACGTTGGATGTACAACAGACTTACTGCTTC 106 CATTTCTAGAGGCTCCC 
W2 rs739414 ACGTTGGATGGAGAACGAGCTTCCCAAATC ACGTTGGATGTTTCCGAAAGAGCTGTCGTC 84 tcCCCAAATCCAACTCCA 
W2 rs12029542 ACGTTGGATGTACATCATGCCCAAGTAGCG ACGTTGGATGCCCTTTGAGCCTCTGTTTTC 94 ATCCCAGGAATGCAAATA 
W2 rs10908435 ACGTTGGATGAATTCCTAGCACAGTGCCTG ACGTTGGATGTGCTCTCATGAGAGACTTGC 106 GTGAATAGCAGAGCTCCA 
W2 rs11641701 ACGTTGGATGTGATGCTTGCTAGACACTCC ACGTTGGATGTTCCAGCAGTCTGTAATCAC 120 cccaGGCCTGGCTCATCTT 
W2 rs1106236 ACGTTGGATGCCTCATAGATGTGAAAACCC ACGTTGGATGTACATTAGCAAGCGCCTCAG 107 ggaAAAGCGCTAGACAAGA 
W2 rs1218574 ACGTTGGATGCTGAGATGGTGACTGAGTTC ACGTTGGATGTTCCTGAGGTCTGCAGATCG 114 tctcGCATAACCACGTGCCC 
W2 rs1131820 ACGTTGGATGCTAATGGACTTTCTGCTCCC ACGTTGGATGGCTCGTAGGTCATGGCTATC 100 aAGCTCTTCGTGATCGACAA 
W2 rs9930445 ACGTTGGATGTTTGCTTTGTTGAGGCACAG ACGTTGGATGACCAGTGATGGCAATGTGTC 100 cGTTGAGGCACAGATTAGGT 
W2 rs11264261 ACGTTGGATGAATTCTCCACCTCCATCCTG ACGTTGGATGCTAACCTAGAGGCCTTGGTC 117 TCCATCCTGTACTTAGTAACC 
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Multiplex SNP Forward primer Reverse primer 
Amplicon 
length Extension primer 
W2 rs1106235 ACGTTGGATGATAGAGAGAGGAGCTACACC ACGTTGGATGGCTCTGAGCTTTCTGTCTTC 119 aAACACCATGGAATAAATCCT 
W2 rs4788683 ACGTTGGATGATTACACAGTGCGACTGTTC ACGTTGGATGGGTGCAGTTATGACGAAGGG 104 tcccGTGCGACTGTTCATGTTT 
W2 rs1858800 ACGTTGGATGGATCAGTATGTGGTGATGGG ACGTTGGATGTCTAAAGCCCATGTCTCAGG 109 CACGATGTGTGAGACTGATAAC 
W2 rs8057081 ACGTTGGATGTATTCCAGAGCTGCACCATC ACGTTGGATGTCGAGACAAGCCACATGTCAC 98 tcGCCACCGACCCTTGTCACTAC 
W2 rs10908429 ACGTTGGATGCCGTGACAACCTTACGTATC ACGTTGGATGGACCAGAAATCTGAATTGGC 103 CTTACGTATCTGAAAATGTCTTC 
W2 rs4845671 ACGTTGGATGTATGTGCAGAATCACCTGGC ACGTTGGATGGGGAGACACAATTCAGTTC 111 agGGGTAATTTTGACACAAAAGG 
W2 rs954785 ACGTTGGATGACTAGCCTGGAAGCTCTATG ACGTTGGATGTTACACTGTTCCTGGCACTG 100 GGATCATATCTGTCCTGTTCATTA 
W2 rs12740456 ACGTTGGATGTCTACCAGGTATTGTCTCCC ACGTTGGATGCAAGCAAAGATGTCTGCAGG 89 aggaTCTCCCTACTACATCCCCATC 
W2 rs9940321 ACGTTGGATGTCACATTGCTTATACCGCTC ACGTTGGATGACTCAGATATCCAGGAGCAG 119 tcCCGCTCAAACTTATGACCAGTTC 
W2 rs6426905 ACGTTGGATGAGAGGACTCACCTTCACCAG ACGTTGGATGGAACCCTAATGAAAGCCCAG 110 cacaAGCTCCCTTGCTGCACTTTGT 
W2 rs883319 ACGTTGGATGTGGCCTCCTAAGCACTTTTC ACGTTGGATGTAGTTGCTATGAGGTCTGGG 113 gggAACTCTTTGAGTCTCACAATAG 
W2 rs11264268 ACGTTGGATGGGCCCACTGGAGATACAAAG ACGTTGGATGGCTCAGCAAATGAGAAGTGG 108 CTAATAAAGTAACTAATTCATTCACT 
W2 rs8055406 ACGTTGGATGTTGGGCAAAAACAGACCCTA ACGTTGGATGGTTTCTTTGAAGAAAGCATC 100 gcagAAATTACAGTGCACAGAGCTCC 
W2 rs16971456 ACGTTGGATGGGATGATGGAGGTGGATTAG ACGTTGGATGAGTCCTAAGAGAGCGTGGAG 115 ggcgGCTACATCTGTAAAAGAGTAAA 
W2 rs9936884 ACGTTGGATGTTTGCGTCTCTGTCTCTCTC ACGTTGGATGTCTGGCTTTTGTTACTTGGG 99 agagCACACTCTCACTCTATCCTGCCC 
W2 rs12145386 ACGTTGGATGCTGTAGGTGACTTTATCATCC ACGTTGGATGACAATCTCAGGGAGGGAATG 101 TCATCCTTTAATTTATAATTAGCAGTT 
W2 rs4845391 ACGTTGGATGAGCCTACAGGGTTTAGCTTG ACGTTGGATGGGAAAGTGGTCATTACAGGG 94 cttcGCTTGCAGGCTTCCATCAACCCCA 
W2 rs6499594 ACGTTGGATGTGACCTCTCTTTACCCTTGC ACGTTGGATGGACATTCCCTGATGAAGGAC 115 acAAAGCTTGCTGAAATTTACAATCCCT 
W2 rs960182 ACGTTGGATGTTCCATGGCCTTCTAGCTTC ACGTTGGATGGAGGCCAAATACAAAGAACC 100 cgcgTCCAGTGTTGCTGTCAAAAAGTCC 
W2 rs9940310 ACGTTGGATGCACGTGATCAGTGAACACAG ACGTTGGATGTGAGTGCTTCCTATCAAGGG 98 tgacCACAGGACGTGTGCATGTCAGTAC 
W3 rs1218578 ACGTTGGATGAAGCATCACTCGTTCTGCTG ACGTTGGATGAACTCCTCCTCCTGGTTCCT 105 GTTCTGCTGCCTTCC 
W3 rs11863932 ACGTTGGATGAGAAGGCTCTCTAGGAACGG ACGTTGGATGCCTGGAGATTGTGAGTCATC 100 TGAGACGTTGCTTCC 
W3 rs2335407 ACGTTGGATGGGAAATAACAGAGAGGACCC ACGTTGGATGCTAACACCCGGTGGATAAAC 98 GAACACGAGGCGTAG 
W3 rs10494301 ACGTTGGATGTGGGCAGAAAATGAGATGGG ACGTTGGATGATTCTTCAGCCTCCTCCTTC 110 GGGGAACAAGTTGCGT 
W3 rs884664 ACGTTGGATGTACCTCCCATCGGTTAGTAG ACGTTGGATGTGGTAAGAAGCGTCTTTCCC 101 CATAGCACCAACTGTCA 
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Multiplex SNP Forward primer Reverse primer 
Amplicon 
length Extension primer 
W3 rs1506982 ACGTTGGATGATAGTGGCTCGCTCAAATGC ACGTTGGATGAAATCCTTTCCCCTGTCCTC 89 AATGCCGAAACTTGGCT 
W3 rs6499600 ACGTTGGATGAGATTTCGCCTGCATGCCCT ACGTTGGATGTCCCACCAGCACCAACCATC 106 cGCCTGCGGTTCATTTCC 
W3 rs16971366 ACGTTGGATGAGATACCTGTAGGAGGTGAC ACGTTGGATGAACCCTTCAGAAATAACCCC 99 tcCTGGGGATGAGGTCCA 
W3 rs4788489 ACGTTGGATGGCAACTTAATAACCACTGACC ACGTTGGATGTTCCGCATTAATGCTCTTCC 101 tacCCACTGACCACCTTCT 
W3 rs8060701 ACGTTGGATGAAAACAATGGCAGGTTCCCG ACGTTGGATGTGGAATCACATACGCAGAGG 109 ttGCAGGTTCCCGGCCACT 
W3 rs1218551 ACGTTGGATGTTTTCTCACAGCTGTTAGGG ACGTTGGATGTGCATGCTTCTCTTTGTGTG 102 TGAGATGAGATCATGCATA 
W3 rs6681725 ACGTTGGATGTCCCTACATCAATCAACTGG ACGTTGGATGGATGCTTTCAGACCCCTTTG 119 ACAGCTCACAATGTTTTCCA 
W3 rs2256209 ACGTTGGATGTTCTCTTCTTCCAGAGCCAG ACGTTGGATGGACTGCATGTGTATGTGTGG 105 GCAGTATTGGCTGTAAAACT 
W3 rs4845394 ACGTTGGATGATGTCAGTTTAGGGCTTTCC ACGTTGGATGTTCCATCTGTGGGTTAGGAG 120 gtagTTGATGCTGGGAGGTA 
W3 rs8058014 ACGTTGGATGTAACTAGCCACAGACAAGAG ACGTTGGATGGGGACAGTTGTAGAGCATTA 118 AGCCACAGACAAGAGAAATCT 
W3 rs9925261 ACGTTGGATGCCACACTCTAGCTCATGTTG ACGTTGGATGAATGGCTCTCAAAGTGGCAG 99 cccgCTTACACTGCCATGAATT 
W3 rs756717 ACGTTGGATGTAAGAGGAGAACGGAGCAAG ACGTTGGATGAAAGCCAATCTCCTCTCCAG 115 cGCCCACCAATTAATTGGTAAA 
W3 rs7523074 ACGTTGGATGACCACCCTGCAGACTTGCTC ACGTTGGATGGAGTGTGGAATAGAACAGGG 118 cccaCCGGCTGCCCTCTCTTTCA 
W3 rs2335406 ACGTTGGATGGGCAGATTTACTCCCTCCTC ACGTTGGATGTCAGGCTCTCAGCCTGTTAG 83 gCTCCTCATTCTAAGGAGAAAGT 
W3 rs2040508 ACGTTGGATGTTGGGATCCCCTTCCAAATG ACGTTGGATGTGGCTGGAGGACATCTTTAC 99 aAAATGTCAACAAACAAGAAAAG 
W3 rs1995662 ACGTTGGATGCTGCTTATCCCTCCTGAATG ACGTTGGATGGCTTTGTCCTGGATATGCAC 100 ttttGCTTGGCATCCATTTCAAAT 
W3 rs7532286 ACGTTGGATGTCAACAAGGTTAGGCCATTG ACGTTGGATGCTACTTGAGATTGTGCACTG 99 ggatGCCATTGTGGGTATATAAAT 
W3 rs1548373 ACGTTGGATGCTGAGACTCAAACTTCACCC ACGTTGGATGGTGAGAGGTTGAGCTTTGTG 96 gggaACAGGATTGAGACAAGTTAT 
W3 rs10494300 ACGTTGGATGCCTTCCATGTAGGAATGCAA ACGTTGGATGCATGCAATTCCAGTCAACCC 120 ccctATTATTACCATTGTTGCTGAT 
W3 rs906274 ACGTTGGATGGGCCTAATTAATACTGCAGTC ACGTTGGATGAATAGTCTGTACTGGCTGTG 91 AGTCATTATTGATTCAATCCTGAGA 
W3 rs6426987 ACGTTGGATGTGCCTCTGTTGAGTCAAACC ACGTTGGATGTACACTGTGCTCACCATCTG 101 caGGACTCTTCCCTTGAGGCCCTGAT 
W3 rs719353 ACGTTGGATGGGATGTTAAGTCTCTGTGCC ACGTTGGATGGGGTGACTTTGCTTCTGAAA 98 ggacGAAAATTTTATCTTGGGCATAT 
W3 rs4845396 ACGTTGGATGTGACTCAAGGACCCTTGGC ACGTTGGATGTCTGTTAGCAGGGTCATTGG 109 ccccGACCCTTGGCGCTTGCTTTTGCT 
W3 rs906276 ACGTTGGATGACAACTGTCTGGGCTCTTTC ACGTTGGATGGGAACAAAGGAGAAGCATCG 101 ctcaTTCTGTGGTTGCTCAACTCCATC 
W3 rs4788689 ACGTTGGATGTCCAGGACTGGGTTTTACAC ACGTTGGATGCATTCTTCAAGGTGCCATGC 95 ttcaAGGACTGGGTTTTACACACCATA 
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Multiplex SNP Forward primer Reverse primer 
Amplicon 
length Extension primer 
W3 rs4788671 ACGTTGGATGTTCAAGTGCTTAATAGTGCC ACGTTGGATGCAGAACCTTCTGAACTGCTC 98 ggatTGCTTAATAGTGCCATGGGGCTC 
W3 rs4788692 ACGTTGGATGACAGTGGGCCTTCTTTTCAG ACGTTGGATGGAATGCATGAACCAGAACGC 120 gaacGAGGGCCCGTGGTGACCTGCAGAG 
W4 rs4788696 ACGTTGGATGTCCTAAACTCCTTTTCCCCC ACGTTGGATGAGCCATTTGCATTCCTCCAG 99 TTCCCCCCACAAAGC 
W4 rs4999127 ACGTTGGATGAGTGAGAACTGACTCCAAGC ACGTTGGATGCAGCTGTTCTCTTCAGCAGA 96 GAATTTGGCAGCCAC 
W4 rs6426944 ACGTTGGATGCTTACCACATGAGCATTCCC ACGTTGGATGAAAATGCAGAGTTGCACGGG 111 AGCATTCCCAGAGGA 
W4 rs11264270 ACGTTGGATGTGGCCATGCCTGGTGTCTC ACGTTGGATGGTGAGAACAACATCAGTGGG 117 aTGGGGTGACCAGAGC 
W4 rs10128027 ACGTTGGATGTTCCTTCCCTCTAACTTCCC ACGTTGGATGGTCATTGACATGGGATGCTG 116 CAACAGAACACACACCT 
W4 rs11075958 ACGTTGGATGTGCACACCTTCTCTTGCCTG ACGTTGGATGAGCTCTAAGAGCAGGGCAAC 117 ggGCCTGCAGCCAAAGC 
W4 rs699444 ACGTTGGATGATCTGCAGGCAAATCTGGTG ACGTTGGATGGCAGATTGGTCATTTGAGTG 94 ggATCTGGTGACAGCGG 
W4 rs12087736 ACGTTGGATGCCAAGGATGCACACATCCAG ACGTTGGATGAAAGCTGGCAGGACTAGAAC 99 CACACATCCAGTTTCATT 
W4 rs6682000 ACGTTGGATGGGTTTAGACAACTGCCAGAG ACGTTGGATGCCTGGAGTTGTTAATGATCG 113 gGCCAGAGTTTGCACTTG 
W4 rs12445932 ACGTTGGATGTGACTGGTGCTCCTGACTTG ACGTTGGATGTTGGTGAAAGGAGGTTCTGC 102 ccatCACGGATCCCCTCCC 
W4 rs4788684 ACGTTGGATGTTCTTCTTTTGCCCGGGCCT ACGTTGGATGGCCCCATAAGAATACCTAGC 118 cctttCCCGGGCCTCAATTT 
W4 rs17719287 ACGTTGGATGTCCTGGGAAGAGGATTTGTC ACGTTGGATGAATGTGCACAGCACTGTCCC 107 TTGTCTACATTCTACGCACA 
W4 rs11584635 ACGTTGGATGAAGTCGGCTTTGAAATGCAG ACGTTGGATGGCATTTCCCAGTGTTCCTTG 116 TCTTGTTTTGAAGTAACAGC 
W4 rs11264249 ACGTTGGATGTTCAGGAGATAGTAGGTGGG ACGTTGGATGTAGACTCTCAGGCTTAGCTC 101 GTTTTTGAGCAGGAAGTAAT 
W4 rs12402320 ACGTTGGATGGGACAGGCAATCCTTATACC ACGTTGGATGGCCCTTTAGAGGACATGAAG 102 cACCACTTGAAGATGGACACA 
W4 rs16971465 ACGTTGGATGGGTGGTCAGTGGTTATTAAG ACGTTGGATGTTTCTGCCATCACGGTGGAG 115 cGTCTCATTGTTTTCTATCACG 
W4 rs4788488 ACGTTGGATGCCCTTCCCAAGTAACAAAAG ACGTTGGATGGTGTTTGGAAAGTGGAGTCG 96 GCCAGATAAATCCATGGAAGAG 
W4 rs6688473 ACGTTGGATGCATCCATCTCCAGAACTGAC ACGTTGGATGGAGATGATGTGCGAAGAGAG 112 AGAACTGACTTTTGTCATTTTCT 
W4 rs6690388 ACGTTGGATGCACAAGAGCAAGGGAATAAG ACGTTGGATGGCATGCAGTAAGTGCTAATA 98 gaatGGAATAAGAACATGGCCTT 
W4 rs11264274 ACGTTGGATGTTCCCAGTCAACCTTCAGGA ACGTTGGATGAAGGGACAGGGTGGAGGAAG 119 ccccTCAGGACCGGCTCCGTTCTC 
W4 rs4788697 ACGTTGGATGAAACACTCCGACATCCACTC ACGTTGGATGGGAGGTGTTACAAAGAAAGG 101 actaGCCCTGGTATTTTCATGGCA 
W4 rs12135902 ACGTTGGATGATTCCTCTGGACAGGCTTGG ACGTTGGATGCCTGTTCATTTCTAGGGCAC 98 gtttGGTCAGAGGAGACCAACACA 
W4 rs2798601 ACGTTGGATGCGCTCAGCTTCACCAAAACC ACGTTGGATGATGGGAAAGACTGAGGCAAG 105 ggagGCTTCACCAAAACCACCTTGT 
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Multiplex SNP Forward primer Reverse primer 
Amplicon 
length Extension primer 
W4 rs951241 ACGTTGGATGCAAAGGACCGGGATGGTTTC ACGTTGGATGCTGCTGTGGACCTGAGAAGT 103 gaACATGAGGAAAAACATCTGGATA 
W4 rs7204751 ACGTTGGATGGGTCACTTCCCTCTCTCAAC ACGTTGGATGGAAATGGAAAACAGTAGCTC 115 CCCCCACTTTTTTTTTTTTTTTTGAA 
W4 rs6698628 ACGTTGGATGGCATAACTGAGAAGAGCAAG ACGTTGGATGTGGAGGGAAGTGCTGCATAG 100 tcagAACTGAGAAGAGCAAGACACCC 
W4 rs11075954 ACGTTGGATGGCGTGTGAGAGGGTAATAGG ACGTTGGATGTTCTGCTCTGGGATGGAAAG 111 AGGAAATAAAAATAAAAACCCACAATTA 
W5 rs13336412 ACGTTGGATGGGATTGTCATTCCAGTGCTC ACGTTGGATGTTCCTTAGTGGCAAGAGAAG 100 CCCTTTGGTCCCTCA 
W5 rs17719419 ACGTTGGATGCTCTTTGGACAGTTCACAGG ACGTTGGATGTGAATGCACAGCAGTGCCAG 100 TCTAGAGGTGCCCTG 
W5 rs12128882 ACGTTGGATGGGTTAGAGATGTCCTGAGTG ACGTTGGATGGCAGCTTTGACAGTACCTTG 99 GCACTGGCCCTTCTGT 
W5 rs9921395 ACGTTGGATGTGCTGGTGATGGGAACTTTG ACGTTGGATGCAACAATAACTTCACTGTGG 93 TCAATGAAGGTGGTGT 
W5 rs4788668 ACGTTGGATGATCCCATTCGTCAGTGGCTC ACGTTGGATGACAGAGTCTGCCAAGGAACC 106 GTGGCTCAGTTAGTTCC 
W5 rs11264251 ACGTTGGATGGATGTCAGGAGCACACCAG ACGTTGGATGCACTTCCCCATGAATTCAAT 117 GGGAAGTTGTGGGTTTA 
W5 rs7404992 ACGTTGGATGTAGAGGGCTGGAGAGATGAC ACGTTGGATGGCGGGAATTTCCATTCTTTG 99 CGTTCTCCACTGTGGCCC 
W5 rs868108 ACGTTGGATGTTAGGCTGGTGAAAAAGCCC ACGTTGGATGATAAGCAGTTGCTTGGTGGG 106 GTAGCGTTGAGTGCACTGC 
W5 rs8055870 ACGTTGGATGGGAAGAGCATATTTCCTGTC ACGTTGGATGAGCAGCTGGAGAGACAGTTC 98 TCTTTTATGCTCTAGTGACA 
W5 rs7554577 ACGTTGGATGGCTCAACAGTGGATTTCCAG ACGTTGGATGAGCATTCCTGATAACTGCCC 101 CAAGTCTTCAAGTCTTTACAAT 
W5 rs4845390 ACGTTGGATGTCATAGCCTGGCTTGACAAC ACGTTGGATGGTTTATCAGGAACCAGCCAG 118 TCACCTGCCCTCTATTAAATAAGC 
W6 rs117951282 ACGTTGGATGGGAAAAGTTAAGCACTCCC ACGTTGGATGGCTACAAGTCCTCAACACTC 100 GCACTCCCACTTTCA 
W6 rs1419110 ACGTTGGATGGCCCACTGGAAAATACCTTG ACGTTGGATGCTTGGAGAAATGTGGACCTG 111 ACACTCAGCAGTGAC 
W6 rs13376333 ACGTTGGATGATTGGGAGGTCATGGGATCG ACGTTGGATGGGCTTTGCTCTGGAGAGAAC 99 GGTTCTGCTCCTTCCT 
W6 rs16971384 ACGTTGGATGTCAGTCCATTGAACTGGAGG ACGTTGGATGGTGGTTGCTGTCTTTCCCTG 100 GCCCCATGATGGAAGA 
W6 rs1061122 ACGTTGGATGAGGAGTAGGTGCCAGCTCAG ACGTTGGATGGAGTGCTGCTCAGTGTCAAA 100 ctCCAGCTCAGTCCCTG 
W6 rs10852515 ACGTTGGATGTAATCACACACCTCGCACCG ACGTTGGATGAATATCAGTAGCTCCTGCGG 100 TTGGTTTTTGGTTTGGT 
W6 rs1051614 ACGTTGGATGGATGACTGGCGGATAGCCAT ACGTTGGATGATGGCGCACACCAGCATCTC 91 gaaCTACGAGCGCATCCT 
W6 rs4492614 ACGTTGGATGCTAGATGGTCTTACCCTCTC ACGTTGGATGGTGTCATCTCACTCCCAATG 81 acTACCCTCTCCTCTCCTT 
W6 rs4845663 ACGTTGGATGTTGCAGGTTCTCCGATAGTG ACGTTGGATGGCATGACTGTAACTTCAAGG 99 cCTGATCATCACTCAGCCT 
W6 rs6682291 ACGTTGGATGGTACGAAAAAAACTAGCCACG ACGTTGGATGCTTTCCTCTTCCTCATTGGC 98 ctCCACGAATGAGCAGTTT 
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W6 rs7199343 ACGTTGGATGGCCCTGATAGGGTTTTAAGC ACGTTGGATGCATGGATTCTGCTGGCACTC 92 GCTTTGGAATTTGGAAGTC 
W6 rs2157786 ACGTTGGATGCACCCTATTCACCATTCTCC ACGTTGGATGCTCTAGGTGAGGATGACTAC 95 tcCCATTCTCCCTGGTTAAA 
W6 rs740178 ACGTTGGATGACCTCCTGGCAATGGGAGAC ACGTTGGATGTCCTCCTTGTCTTCCTCAAC 90 ATGGGAGACCCCACTCTGGC 
W6 rs76110919 ACGTTGGATGACTCCTCTCCCACCGCTTTC ACGTTGGATGTGGAGGAAGGGTGGAGGAT 89 AGGGCCCCCCCTTCGTCCAAC 
W6 rs7193343 ACGTTGGATGGAGGGGAAAGTTTGAACAGC ACGTTGGATGAAATGTCGAGTCCTAATGGC 89 GAAAGTTTGAACAGCTTGTTT 
W6 rs1218601 ACGTTGGATGCTTGGGATAACTCCTTCCTC ACGTTGGATGGCCCCCCAATCTTGTAATTC 113 agAACTCCTTCCTCCACTCGCA 
W6 rs16971474 ACGTTGGATGTAGGCAGACCCCATCATTTC ACGTTGGATGCCCACAGGCAAGATCTTGTC 100 cGACCCCATCATTTCGAGATTA 
W6 rs4788482 ACGTTGGATGAGGAACTGCTGGATTCTTGG ACGTTGGATGTGTTCCTGCTGCGAGAGTTC 118 caTTAGCATGGGCCTTTCTCAA 
W6 rs2228200 ACGTTGGATGAGAGCTTGCACTGGTATGAG ACGTTGGATGCTGCACATGAACGTGGAGC 99 cTCACCGCCTTCCACTCGTCCTC 
W6 rs2106261 ACGTTGGATGCACAGATAGAGCTCGTCCAG ACGTTGGATGAGAGCAGTCTCTGGCACACT 100 ATAGAGCTCGTCCAGAGAATTGT 
W6 rs6691316 ACGTTGGATGGGCTCAACTCATGCTCAATG ACGTTGGATGAAGAGGTGCTCGATGCACAG 101 ggGAATGAGTGAATAAGCTGATC 
W6 rs9940520 ACGTTGGATGCAGTTCAGACTCTCTGTTAG ACGTTGGATGAAGCAACATAAGGCAGGCTC 82 CAGACTCTCTGTTAGAGGCCTACT 
W6 rs1218565 ACGTTGGATGAACACCTCAGAATCCTTCCC ACGTTGGATGGTGCAGGAACAGCAAATAGG 116 CACCTCAGAATCCTTCCCAACACAG 
W6 rs7193297 ACGTTGGATGCATTCGTTGCAGGTGACCTC ACGTTGGATGAATGAGCGCCTCGCGGAGA 100 GTGACCTCCTTGCTGGCGGGCTCGG 
W6 rs16971464 ACGTTGGATGAGGAGTCACTCAGATGTTTG ACGTTGGATGCTCATTTGACCTCTAACAATC 120 tgAACCTGTAAAATCGAAAATATGA 
W6 rs4788679 ACGTTGGATGACCTACCTACAGCCTTATGG ACGTTGGATGGAAGAAAGCCAGGTACGAAG 84 CCTACCTACAGCCTTATGGAACGACC 
W6 rs2266943 ACGTTGGATGTTCCCAAAAGGCCATTCCAC ACGTTGGATGTGGCTCTGTTTTGACTGGTG 111 ccTCAATTTCAAGACACCTTGCTCCCT 
W6 rs1476646 ACGTTGGATGTTCAGTAGCAACTCAGAGCG ACGTTGGATGCCCGGGAATACTTTCACATC 119 CAGAGCGTCGTGCTCTCTTGTCTTTGT 
W6 rs2106258 ACGTTGGATGTTAGATCCTGGTTAGCGGAG ACGTTGGATGAGCCTGAACAGAGCCAAATC 101 tTTAGATCCTGGTTAGCGGAGCCTTCG 
W6 rs8052905 ACGTTGGATGACCAAAGTATTCCCCAGTCC ACGTTGGATGCCACTACATGCAGCTTCTTG 109 GGGAAAGCAAGATCCTGAGAAAGAATA 
W6 rs8056528 ACGTTGGATGAAGCTAAGTAGCCTAAGGAC ACGTTGGATGCTTGTGAATTAGCGAGAACC 97 agTTTTGTGAAGCATCTTTGCTGCTTTT 
W6 rs6695232 ACGTTGGATGACACCCCGATCCTATTTCAC ACGTTGGATGTCTCACCTTACTTGCTGCTG 119 ctGAAGATATGGACATGATTTATGCCCC 
W7 rs11640106 ACGTTGGATGAACAGACTGTCCTTCTCCAC ACGTTGGATGAAATCTGAAGGCCCTGAGTG 113 CTCACCCTGCCCCCA 
W7 rs925042 ACGTTGGATGGCCGCTTCTCGTTTTCAAAG ACGTTGGATGGAAAGTGGAGATGGAGGGC 119 TTGGTCCTTGCACAA 
W7 rs756720 ACGTTGGATGTGTTTTCCTGATCACCAGGG ACGTTGGATGGCAGCATTGGACTAAATGGG 96 tATCCTCAGCCTTCCC 
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W7 rs12929452 ACGTTGGATGTATAAGGAACACCATCCTGC ACGTTGGATGGCACAGGGTGTTATATTGGC 98 ACCATCCTGCCACTTA 
W7 rs4788480 ACGTTGGATGGAAGAGTCTGCTTCAAGAGG ACGTTGGATGTTTGCAGAACTGTGGCCCTC 101 CTGTATGCAGAACGGA 
W7 rs8051826 ACGTTGGATGAACTTCCCTAGTATGGCCAG ACGTTGGATGAGGGTTGGAACCCATGTAAC 96 tGAGGCTGGAAAACCA 
W7 rs12373097 ACGTTGGATGGAGAGGGTGAAACGAGCATT ACGTTGGATGTACAACAGACTTACTGCTTC 106 CATTTCTAGAGGCTCCC 
W7 rs739414 ACGTTGGATGGAGAACGAGCTTCCCAAATC ACGTTGGATGTTTCCGAAAGAGCTGTCGTC 84 tcCCCAAATCCAACTCCA 
W7 rs12029542 ACGTTGGATGTACATCATGCCCAAGTAGCG ACGTTGGATGCCCTTTGAGCCTCTGTTTTC 94 ATCCCAGGAATGCAAATA 
W7 rs10908435 ACGTTGGATGAATTCCTAGCACAGTGCCTG ACGTTGGATGTGCTCTCATGAGAGACTTGC 106 GTGAATAGCAGAGCTCCA 
W7 rs11641701 ACGTTGGATGTGATGCTTGCTAGACACTCC ACGTTGGATGTTCCAGCAGTCTGTAATCAC 120 cccaGGCCTGGCTCATCTT 
W7 rs1106236 ACGTTGGATGCCTCATAGATGTGAAAACCC ACGTTGGATGTACATTAGCAAGCGCCTCAG 107 ggaAAAGCGCTAGACAAGA 
W7 rs1218574 ACGTTGGATGCTGAGATGGTGACTGAGTTC ACGTTGGATGTTCCTGAGGTCTGCAGATCG 114 tctcGCATAACCACGTGCCC 
W7 rs1131820 ACGTTGGATGCTAATGGACTTTCTGCTCCC ACGTTGGATGGCTCGTAGGTCATGGCTATC 100 aAGCTCTTCGTGATCGACAA 
W7 rs9930445 ACGTTGGATGTTTGCTTTGTTGAGGCACAG ACGTTGGATGACCAGTGATGGCAATGTGTC 100 cGTTGAGGCACAGATTAGGT 
W7 rs11264261 ACGTTGGATGAATTCTCCACCTCCATCCTG ACGTTGGATGCTAACCTAGAGGCCTTGGTC 117 TCCATCCTGTACTTAGTAACC 
W7 rs1106235 ACGTTGGATGATAGAGAGAGGAGCTACACC ACGTTGGATGGCTCTGAGCTTTCTGTCTTC 119 aAACACCATGGAATAAATCCT 
W7 rs4788683 ACGTTGGATGATTACACAGTGCGACTGTTC ACGTTGGATGGGTGCAGTTATGACGAAGGG 104 tcccGTGCGACTGTTCATGTTT 
W7 rs1858800 ACGTTGGATGGATCAGTATGTGGTGATGGG ACGTTGGATGTCTAAAGCCCATGTCTCAGG 109 CACGATGTGTGAGACTGATAAC 
W7 rs8057081 ACGTTGGATGTATTCCAGAGCTGCACCATC ACGTTGGATGTCGAGACAAGCCACATGTCAC 98 tcGCCACCGACCCTTGTCACTAC 
W7 rs10908429 ACGTTGGATGCCGTGACAACCTTACGTATC ACGTTGGATGGACCAGAAATCTGAATTGGC 103 CTTACGTATCTGAAAATGTCTTC 
W7 rs4845671 ACGTTGGATGTATGTGCAGAATCACCTGGC ACGTTGGATGGGGAGACACAATTCAGTTC 111 agGGGTAATTTTGACACAAAAGG 
W7 rs954785 ACGTTGGATGACTAGCCTGGAAGCTCTATG ACGTTGGATGTTACACTGTTCCTGGCACTG 100 GGATCATATCTGTCCTGTTCATTA 
W7 rs12740456 ACGTTGGATGTCTACCAGGTATTGTCTCCC ACGTTGGATGCAAGCAAAGATGTCTGCAGG 89 aggaTCTCCCTACTACATCCCCATC 
W7 rs9940321 ACGTTGGATGTCACATTGCTTATACCGCTC ACGTTGGATGACTCAGATATCCAGGAGCAG 119 tcCCGCTCAAACTTATGACCAGTTC 
W7 rs6426905 ACGTTGGATGAGAGGACTCACCTTCACCAG ACGTTGGATGGAACCCTAATGAAAGCCCAG 110 cacaAGCTCCCTTGCTGCACTTTGT 
W7 rs883319 ACGTTGGATGTGGCCTCCTAAGCACTTTTC ACGTTGGATGTAGTTGCTATGAGGTCTGGG 113 gggAACTCTTTGAGTCTCACAATAG 
W7 rs11264268 ACGTTGGATGGGCCCACTGGAGATACAAAG ACGTTGGATGGCTCAGCAAATGAGAAGTGG 108 CTAATAAAGTAACTAATTCATTCACT 
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W7 rs8055406 ACGTTGGATGTTGGGCAAAAACAGACCCTA ACGTTGGATGGTTTCTTTGAAGAAAGCATC 100 gcagAAATTACAGTGCACAGAGCTCC 
W7 rs16971456 ACGTTGGATGGGATGATGGAGGTGGATTAG ACGTTGGATGAGTCCTAAGAGAGCGTGGAG 115 ggcgGCTACATCTGTAAAAGAGTAAA 
W7 rs9936884 ACGTTGGATGTTTGCGTCTCTGTCTCTCTC ACGTTGGATGTCTGGCTTTTGTTACTTGGG 99 agagCACACTCTCACTCTATCCTGCCC 
W7 rs12145386 ACGTTGGATGCTGTAGGTGACTTTATCATCC ACGTTGGATGACAATCTCAGGGAGGGAATG 101 TCATCCTTTAATTTATAATTAGCAGTT 
W7 rs4845391 ACGTTGGATGAGCCTACAGGGTTTAGCTTG ACGTTGGATGGGAAAGTGGTCATTACAGGG 94 cttcGCTTGCAGGCTTCCATCAACCCCA 
W7 rs6499594 ACGTTGGATGTGACCTCTCTTTACCCTTGC ACGTTGGATGGACATTCCCTGATGAAGGAC 115 acAAAGCTTGCTGAAATTTACAATCCCT 
W7 rs960182 ACGTTGGATGTTCCATGGCCTTCTAGCTTC ACGTTGGATGGAGGCCAAATACAAAGAACC 100 cgcgTCCAGTGTTGCTGTCAAAAAGTCC 
W7 rs9940310 ACGTTGGATGCACGTGATCAGTGAACACAG ACGTTGGATGTGAGTGCTTCCTATCAAGGG 98 tgacCACAGGACGTGTGCATGTCAGTAC 
W8 rs1218578 ACGTTGGATGAAGCATCACTCGTTCTGCTG ACGTTGGATGAACTCCTCCTCCTGGTTCCT 105 GTTCTGCTGCCTTCC 
W8 rs11863932 ACGTTGGATGAGAAGGCTCTCTAGGAACGG ACGTTGGATGCCTGGAGATTGTGAGTCATC 100 TGAGACGTTGCTTCC 
W8 rs2335407 ACGTTGGATGGGAAATAACAGAGAGGACCC ACGTTGGATGCTAACACCCGGTGGATAAAC 98 GAACACGAGGCGTAG 
W8 rs10494301 ACGTTGGATGTGGGCAGAAAATGAGATGGG ACGTTGGATGATTCTTCAGCCTCCTCCTTC 110 GGGGAACAAGTTGCGT 
W8 rs884664 ACGTTGGATGTACCTCCCATCGGTTAGTAG ACGTTGGATGTGGTAAGAAGCGTCTTTCCC 101 CATAGCACCAACTGTCA 
W8 rs1506982 ACGTTGGATGATAGTGGCTCGCTCAAATGC ACGTTGGATGAAATCCTTTCCCCTGTCCTC 89 AATGCCGAAACTTGGCT 
W8 rs6499600 ACGTTGGATGAGATTTCGCCTGCATGCCCT ACGTTGGATGTCCCACCAGCACCAACCATC 106 cGCCTGCGGTTCATTTCC 
W8 rs16971366 ACGTTGGATGAGATACCTGTAGGAGGTGAC ACGTTGGATGAACCCTTCAGAAATAACCCC 99 tcCTGGGGATGAGGTCCA 
W8 rs4788489 ACGTTGGATGGCAACTTAATAACCACTGACC ACGTTGGATGTTCCGCATTAATGCTCTTCC 101 tacCCACTGACCACCTTCT 
W8 rs8060701 ACGTTGGATGAAAACAATGGCAGGTTCCCG ACGTTGGATGTGGAATCACATACGCAGAGG 109 ttGCAGGTTCCCGGCCACT 
W8 rs1218551 ACGTTGGATGTTTTCTCACAGCTGTTAGGG ACGTTGGATGTGCATGCTTCTCTTTGTGTG 102 TGAGATGAGATCATGCATA 
W8 rs6681725 ACGTTGGATGTCCCTACATCAATCAACTGG ACGTTGGATGGATGCTTTCAGACCCCTTTG 119 ACAGCTCACAATGTTTTCCA 
W8 rs2256209 ACGTTGGATGTTCTCTTCTTCCAGAGCCAG ACGTTGGATGGACTGCATGTGTATGTGTGG 105 GCAGTATTGGCTGTAAAACT 
W8 rs4845394 ACGTTGGATGATGTCAGTTTAGGGCTTTCC ACGTTGGATGTTCCATCTGTGGGTTAGGAG 120 gtagTTGATGCTGGGAGGTA 
W8 rs8058014 ACGTTGGATGTAACTAGCCACAGACAAGAG ACGTTGGATGGGGACAGTTGTAGAGCATTA 118 AGCCACAGACAAGAGAAATCT 
W8 rs9925261 ACGTTGGATGCCACACTCTAGCTCATGTTG ACGTTGGATGAATGGCTCTCAAAGTGGCAG 99 cccgCTTACACTGCCATGAATT 
W8 rs756717 ACGTTGGATGTAAGAGGAGAACGGAGCAAG ACGTTGGATGAAAGCCAATCTCCTCTCCAG 115 cGCCCACCAATTAATTGGTAAA 
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W8 rs7523074 ACGTTGGATGACCACCCTGCAGACTTGCTC ACGTTGGATGGAGTGTGGAATAGAACAGGG 118 cccaCCGGCTGCCCTCTCTTTCA 
W8 rs2335406 ACGTTGGATGGGCAGATTTACTCCCTCCTC ACGTTGGATGTCAGGCTCTCAGCCTGTTAG 83 gCTCCTCATTCTAAGGAGAAAGT 
W8 rs2040508 ACGTTGGATGTTGGGATCCCCTTCCAAATG ACGTTGGATGTGGCTGGAGGACATCTTTAC 99 aAAATGTCAACAAACAAGAAAAG 
W8 rs1995662 ACGTTGGATGCTGCTTATCCCTCCTGAATG ACGTTGGATGGCTTTGTCCTGGATATGCAC 100 ttttGCTTGGCATCCATTTCAAAT 
W8 rs7532286 ACGTTGGATGTCAACAAGGTTAGGCCATTG ACGTTGGATGCTACTTGAGATTGTGCACTG 99 ggatGCCATTGTGGGTATATAAAT 
W8 rs1548373 ACGTTGGATGCTGAGACTCAAACTTCACCC ACGTTGGATGGTGAGAGGTTGAGCTTTGTG 96 gggaACAGGATTGAGACAAGTTAT 
W8 rs10494300 ACGTTGGATGCCTTCCATGTAGGAATGCAA ACGTTGGATGCATGCAATTCCAGTCAACCC 120 ccctATTATTACCATTGTTGCTGAT 
W8 rs906274 ACGTTGGATGGGCCTAATTAATACTGCAGTC ACGTTGGATGAATAGTCTGTACTGGCTGTG 91 AGTCATTATTGATTCAATCCTGAGA 
W8 rs6426987 ACGTTGGATGTGCCTCTGTTGAGTCAAACC ACGTTGGATGTACACTGTGCTCACCATCTG 101 caGGACTCTTCCCTTGAGGCCCTGAT 
W8 rs719353 ACGTTGGATGGGATGTTAAGTCTCTGTGCC ACGTTGGATGGGGTGACTTTGCTTCTGAAA 98 ggacGAAAATTTTATCTTGGGCATAT 
W8 rs4845396 ACGTTGGATGTGACTCAAGGACCCTTGGC ACGTTGGATGTCTGTTAGCAGGGTCATTGG 109 ccccGACCCTTGGCGCTTGCTTTTGCT 
W8 rs906276 ACGTTGGATGACAACTGTCTGGGCTCTTTC ACGTTGGATGGGAACAAAGGAGAAGCATCG 101 ctcaTTCTGTGGTTGCTCAACTCCATC 
W8 rs4788689 ACGTTGGATGTCCAGGACTGGGTTTTACAC ACGTTGGATGCATTCTTCAAGGTGCCATGC 95 ttcaAGGACTGGGTTTTACACACCATA 
W8 rs4788671 ACGTTGGATGTTCAAGTGCTTAATAGTGCC ACGTTGGATGCAGAACCTTCTGAACTGCTC 98 ggatTGCTTAATAGTGCCATGGGGCTC 
W8 rs4788692 ACGTTGGATGACAGTGGGCCTTCTTTTCAG ACGTTGGATGGAATGCATGAACCAGAACGC 120 gaacGAGGGCCCGTGGTGACCTGCAGAG 
W9 rs4788696 ACGTTGGATGTCCTAAACTCCTTTTCCCCC ACGTTGGATGAGCCATTTGCATTCCTCCAG 99 TTCCCCCCACAAAGC 
W9 rs4999127 ACGTTGGATGAGTGAGAACTGACTCCAAGC ACGTTGGATGCAGCTGTTCTCTTCAGCAGA 96 GAATTTGGCAGCCAC 
W9 rs6426944 ACGTTGGATGCTTACCACATGAGCATTCCC ACGTTGGATGAAAATGCAGAGTTGCACGGG 111 AGCATTCCCAGAGGA 
W9 rs11264270 ACGTTGGATGTGGCCATGCCTGGTGTCTC ACGTTGGATGGTGAGAACAACATCAGTGGG 117 aTGGGGTGACCAGAGC 
W9 rs10128027 ACGTTGGATGTTCCTTCCCTCTAACTTCCC ACGTTGGATGGTCATTGACATGGGATGCTG 116 CAACAGAACACACACCT 
W9 rs11075958 ACGTTGGATGTGCACACCTTCTCTTGCCTG ACGTTGGATGAGCTCTAAGAGCAGGGCAAC 117 ggGCCTGCAGCCAAAGC 
W9 rs699444 ACGTTGGATGATCTGCAGGCAAATCTGGTG ACGTTGGATGGCAGATTGGTCATTTGAGTG 94 ggATCTGGTGACAGCGG 
W9 rs12087736 ACGTTGGATGCCAAGGATGCACACATCCAG ACGTTGGATGAAAGCTGGCAGGACTAGAAC 99 CACACATCCAGTTTCATT 
W9 rs6682000 ACGTTGGATGGGTTTAGACAACTGCCAGAG ACGTTGGATGCCTGGAGTTGTTAATGATCG 113 gGCCAGAGTTTGCACTTG 
W9 rs12445932 ACGTTGGATGTGACTGGTGCTCCTGACTTG ACGTTGGATGTTGGTGAAAGGAGGTTCTGC 102 ccatCACGGATCCCCTCCC 
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W9 rs4788684 ACGTTGGATGTTCTTCTTTTGCCCGGGCCT ACGTTGGATGGCCCCATAAGAATACCTAGC 118 cctttCCCGGGCCTCAATTT 
W9 rs17719287 ACGTTGGATGTCCTGGGAAGAGGATTTGTC ACGTTGGATGAATGTGCACAGCACTGTCCC 107 TTGTCTACATTCTACGCACA 
W9 rs11584635 ACGTTGGATGAAGTCGGCTTTGAAATGCAG ACGTTGGATGGCATTTCCCAGTGTTCCTTG 116 TCTTGTTTTGAAGTAACAGC 
W9 rs11264249 ACGTTGGATGTTCAGGAGATAGTAGGTGGG ACGTTGGATGTAGACTCTCAGGCTTAGCTC 101 GTTTTTGAGCAGGAAGTAAT 
W9 rs12402320 ACGTTGGATGGGACAGGCAATCCTTATACC ACGTTGGATGGCCCTTTAGAGGACATGAAG 102 cACCACTTGAAGATGGACACA 
W9 rs16971465 ACGTTGGATGGGTGGTCAGTGGTTATTAAG ACGTTGGATGTTTCTGCCATCACGGTGGAG 115 cGTCTCATTGTTTTCTATCACG 
W9 rs4788488 ACGTTGGATGCCCTTCCCAAGTAACAAAAG ACGTTGGATGGTGTTTGGAAAGTGGAGTCG 96 GCCAGATAAATCCATGGAAGAG 
W9 rs6688473 ACGTTGGATGCATCCATCTCCAGAACTGAC ACGTTGGATGGAGATGATGTGCGAAGAGAG 112 AGAACTGACTTTTGTCATTTTCT 
W9 rs6690388 ACGTTGGATGCACAAGAGCAAGGGAATAAG ACGTTGGATGGCATGCAGTAAGTGCTAATA 98 gaatGGAATAAGAACATGGCCTT 
W9 rs11264274 ACGTTGGATGTTCCCAGTCAACCTTCAGGA ACGTTGGATGAAGGGACAGGGTGGAGGAAG 119 ccccTCAGGACCGGCTCCGTTCTC 
W9 rs4788697 ACGTTGGATGAAACACTCCGACATCCACTC ACGTTGGATGGGAGGTGTTACAAAGAAAGG 101 actaGCCCTGGTATTTTCATGGCA 
W9 rs12135902 ACGTTGGATGATTCCTCTGGACAGGCTTGG ACGTTGGATGCCTGTTCATTTCTAGGGCAC 98 gtttGGTCAGAGGAGACCAACACA 
W9 rs2798601 ACGTTGGATGCGCTCAGCTTCACCAAAACC ACGTTGGATGATGGGAAAGACTGAGGCAAG 105 ggagGCTTCACCAAAACCACCTTGT 
W9 rs951241 ACGTTGGATGCAAAGGACCGGGATGGTTTC ACGTTGGATGCTGCTGTGGACCTGAGAAGT 103 gaACATGAGGAAAAACATCTGGATA 
W9 rs7204751 ACGTTGGATGGGTCACTTCCCTCTCTCAAC ACGTTGGATGGAAATGGAAAACAGTAGCTC 115 CCCCCACTTTTTTTTTTTTTTTTGAA 
W9 rs6698628 ACGTTGGATGGCATAACTGAGAAGAGCAAG ACGTTGGATGTGGAGGGAAGTGCTGCATAG 100 tcagAACTGAGAAGAGCAAGACACCC 
W9 rs11075954 ACGTTGGATGGCGTGTGAGAGGGTAATAGG ACGTTGGATGTTCTGCTCTGGGATGGAAAG 111 AGGAAATAAAAATAAAAACCCACAATTA 
W10 rs13336412 ACGTTGGATGGGATTGTCATTCCAGTGCTC ACGTTGGATGTTCCTTAGTGGCAAGAGAAG 100 CCCTTTGGTCCCTCA 
W10 rs17719419 ACGTTGGATGCTCTTTGGACAGTTCACAGG ACGTTGGATGTGAATGCACAGCAGTGCCAG 100 TCTAGAGGTGCCCTG 
W10 rs12128882 ACGTTGGATGGGTTAGAGATGTCCTGAGTG ACGTTGGATGGCAGCTTTGACAGTACCTTG 99 GCACTGGCCCTTCTGT 
W10 rs9921395 ACGTTGGATGTGCTGGTGATGGGAACTTTG ACGTTGGATGCAACAATAACTTCACTGTGG 93 TCAATGAAGGTGGTGT 
W10 rs4788668 ACGTTGGATGATCCCATTCGTCAGTGGCTC ACGTTGGATGACAGAGTCTGCCAAGGAACC 106 GTGGCTCAGTTAGTTCC 
W10 rs11264251 ACGTTGGATGGATGTCAGGAGCACACCAG ACGTTGGATGCACTTCCCCATGAATTCAAT 117 GGGAAGTTGTGGGTTTA 
W10 rs7404992 ACGTTGGATGTAGAGGGCTGGAGAGATGAC ACGTTGGATGGCGGGAATTTCCATTCTTTG 99 CGTTCTCCACTGTGGCCC 
W10 rs868108 ACGTTGGATGTTAGGCTGGTGAAAAAGCCC ACGTTGGATGATAAGCAGTTGCTTGGTGGG 106 GTAGCGTTGAGTGCACTGC 
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W10 rs8055870 ACGTTGGATGGGAAGAGCATATTTCCTGTC ACGTTGGATGAGCAGCTGGAGAGACAGTTC 98 TCTTTTATGCTCTAGTGACA 
W10 rs7554577 ACGTTGGATGGCTCAACAGTGGATTTCCAG ACGTTGGATGAGCATTCCTGATAACTGCCC 101 CAAGTCTTCAAGTCTTTACAAT 
W10 rs4845390 ACGTTGGATGTCATAGCCTGGCTTGACAAC ACGTTGGATGGTTTATCAGGAACCAGCCAG 118 TCACCTGCCCTCTATTAAATAAGC 
W11 rs3784807 ACGTTGGATGCAAGCTTTCCCCAGTCTGTG ACGTTGGATGCTTGTTGTAGCTCACGGAAC 103 TCCCTAGCCCCAACC 
W11 rs4746139 ACGTTGGATGTGACCTCCACCGCTTCTATC ACGTTGGATGCTCAGGAGCCCCTGGGCCT 109 CTTCCTATCTGCGCC 
W11 rs502612 ACGTTGGATGATACAACTTAAAGGCCAAGG ACGTTGGATGGCTAGGTCTTACACTTTGCC 118 GGCCAAGGAGCCCAA 
W11 rs60632610 ACGTTGGATGGGGACACTGTTCAAACTCCG ACGTTGGATGTCCCCCTGATAGTGTGACCA 105 cCCAAGCTGAGCGATG 
W11 rs11947581 ACGTTGGATGCAGCCTAGCTTACAGAAACC ACGTTGGATGATTGAACCTGGAAGACTGGG 113 ACCCTCTGGATTTTCTC 
W11 rs2623998 ACGTTGGATGCCTTGACAGCAAGCTTAGAG ACGTTGGATGCTTTCTTGACCACACTTGGG 85 AAGCTTAGAGGTGTCTG 
W11 rs34163229 ACGTTGGATGTTACAACCCACTGCTCTCTC ACGTTGGATGTGATGCCCTGCTTGGGTGTT 118 CTCTCCCTAAGGCCCAAT 
W11 rs11589602 ACGTTGGATGAATCCCGAGGGAGAATTCTG ACGTTGGATGCAAGGCACAATGATTGGCTC 86 TCTGTTTTCTTGGCTTGT 
W11 rs488156 ACGTTGGATGTAGCTAGTGGCAAGCTGTTC ACGTTGGATGACTGCAGGTGATGAGCTGTG 94 ACTAGTGACCGAAGATGA 
W11 rs3743496 ACGTTGGATGCCGTTAGCTGTAACTTGGAG ACGTTGGATGCTTTTCTCCCAAGGTCGCAG 119 ctttGAGCTCCACTCTGCC 
W11 rs2723296 ACGTTGGATGGAATATTGCGGTAAGGAGGC ACGTTGGATGCTTGTAGTTTACGCAGGCAC 89 GGCCATTAGGCTGGAAACG 
W11 rs913257 ACGTTGGATGCTCTAAACGAACCACTGGTC ACGTTGGATGGTAGAAGCCGATGAAGAGAC 119 CCTTGATTCTACTTCTTGTT 
W11 rs12498374 ACGTTGGATGTTTTCCCACTTAATCTAGGC ACGTTGGATGTAAGCAATACAGGTCTGAGC 105 cctcGTGAATCAGCCCCATA 
W11 rs2723333 ACGTTGGATGCTGCATATGTACGACCCTTG ACGTTGGATGCAAAAACCCACCCAGATTC 120 GAAGAAATGGAGCCTATATC 
W11 rs3853445 ACGTTGGATGGCTCACTGATAAGCCAGTTC ACGTTGGATGACAACTTACTGCCACATGCC 108 GCATTTTCTTAGCCAAGATAC 
W11 rs7674295 ACGTTGGATGATCCTCCTTGAATTTTCTG ACGTTGGATGATAGAAACAGTGCAGTGAGG 100 cCCTTGAATTTTCTGAAGTGC 
W11 rs542331 ACGTTGGATGGCCTATGGTGCTGATATCTC ACGTTGGATGCTCAGGAGAGGTTATCACAC 106 ggccGAAAGTGAGCAGATGTG 
W11 rs11943026 ACGTTGGATGCTAGTTGATCCTCACTTGGC ACGTTGGATGAATGTCTTACTTGGGAAGCG 98 ccctTTGGCTCACTTACCAATT 
W11 rs10824026 ACGTTGGATGCTATAGTCACCCTAGGTGAA ACGTTGGATGTCCACCTCAGCAGAGGAGAC 96 AGTCACCCTAGGTGAAGTATTT 
W11 rs6533526 ACGTTGGATGAAGCATGTTATACAGAAGCG ACGTTGGATGACATACAGTGTGGCATTTAG 98 TACAGAAGCGATTAGGATTTTT 
W11 rs12021752 ACGTTGGATGGCTCACTATGCACTCTCTTG ACGTTGGATGTGAAGCTCTCTGAGGGCTA 119 TTCTCTAACCTTTATTTTGATTG 
W11 rs12247028 ACGTTGGATGTGAGCGTGGTATCTTGAGTG ACGTTGGATGTCTGTGGTATAAACACTGGG 101 gtTATCTTGAGTGGAAAGTAGAT 
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Multiplex SNP Forward primer Reverse primer 
Amplicon 
length Extension primer 
W11 rs2595110 ACGTTGGATGGCCAAATAACCAATTTCAAGG ACGTTGGATGGCCTGCTTGGACTTTAATGG 113 agTTAACAGTCATTTTCTTTTCCC 
W11 rs7164883 ACGTTGGATGCTAAACCACAGATCAACCCC ACGTTGGATGGTGGTATCTTTCTCTGATCC 116 ctatCATGAATAGATCACGTGACC 
W11 rs3826046 ACGTTGGATGTGCCTTACTAGGCCCAGAAG ACGTTGGATGGGGTAATTACTTCTGGGCTC 101 gttgaCTGCAATAATGTCACTGAG 
W11 rs4032971 ACGTTGGATGCTTGTGAACCTGTTAGACTC ACGTTGGATGTGTCCTTAGATACGTGTTTG 118 gggaCTGTTAGACTCTGTTTCTTTG 
W11 rs591715 ACGTTGGATGATACTGGTCTAGACTCCAGC ACGTTGGATGCATTCTCTCACTTGGTAAGC 111 ggaggAGTATACTACTGGGACAGTT 
W11 rs12027180 ACGTTGGATGCCTGCCACAGAAATTCCATC ACGTTGGATGTAGGCTGCCAGGTGTTAAAG 96 cccctACAGAAATTCCATCCATGGAC 
W11 rs374582 ACGTTGGATGACTCTCCCAAGAGAAGAGCC ACGTTGGATGCAGCCTATGCAATGCAGTAG 119 cgCTAATAAATCCTTTAAGACCAACA 
W11 rs41280400 ACGTTGGATGTCCAGATGCCCAAGTTTGAC ACGTTGGATGGGGTTCGATTGAAAGAAGGC 116 aggtGGCCCTTGCTGAGTGAACCCCT 
W11 rs11799764 ACGTTGGATGAGTATGTTCTAGTCTCCTAC ACGTTGGATGGAGAATCCTAACAGCAAACC 97 tgCTATAACAAACATACCTTCATAATG 
W11 rs16863425 ACGTTGGATGACTCTTGTACTAGAAGCTAC ACGTTGGATGTGAAGGCCATGCTGCTTTAC 95 gggagGCTACTTATTACACTAAGTTGA 
W11 rs441624 ACGTTGGATGAAGCAATTCCCTCCCTAGTG ACGTTGGATGGAAAGCTTGAAGCCTTTCTC 98 cccctCCTTTGCAAATTTAATGTCATTC 
W11 rs2429074 ACGTTGGATGAAGAGGACTCCAGTATTTGC ACGTTGGATGGGCTGGGAGAGACATTTTTC 113 CTCCAGTATTTGCTTTAATTTATTTTTG 
W11 rs11938968 ACGTTGGATGTCTCCCAGTGTGGCAAGTTC ACGTTGGATGCTGCCCTGCGAAATATTTCT 117 aaatAGAATTCTAACTTTGAACCTAACC 
W11 rs4307025 ACGTTGGATGAACACTGTGCAGTGGAATCG ACGTTGGATGAAGGTTCAACCTTTTTTCC 116 AAAAATTATAATAAACTAGCATAAGGAC 
W12 rs3812629 ACGTTGGATGTTACAAGACCCTGCCTCACG ACGTTGGATGGAGTCTTAGGAGTCATAGGG 103 CACCTAAGACCCCCC 
W12 rs17571707 ACGTTGGATGCTCAGCTTCTTAAGGCTCAG ACGTTGGATGCAGCCCACTTTCATTCCTAC 103 GCTCAGGGATCAGGA 
W12 rs478438 ACGTTGGATGCTTCATTTCCAGGCCACTAC ACGTTGGATGTTCCCCAAGTTCCATGTGTG 99 ACTACAAGCCTTGCCC 
W12 rs75911264 ACGTTGGATGAAGCATGTTATACAGAAGCG ACGTTGGATGACATACAGTGTGGCATTTAG 98 cCTTGCGAGCAAGGGA 
W12 rs12066968 ACGTTGGATGCTGTAGGAGTCACACTCTGG ACGTTGGATGTGATGGTGTCTTGAACTGGC 95 aACCACTGCTGCTCTAT 
W12 rs3820416 ACGTTGGATGGAAGAGTTCCCCCATTCATC ACGTTGGATGTTGGGATGTACAGTTCCTTC 97 TGTCCCATTAGTTGCTG 
W12 rs12038857 ACGTTGGATGTGTAGGCTTTAAAGTCAGGC ACGTTGGATGCAGATAGGTTAAATTACCAG 97 aTGAAATCCAGGCTCTCT 
W12 rs6533531 ACGTTGGATGAGAGTTCCAACATGACAGGG ACGTTGGATGCTTTGAGCAAAACTGAGTCC 86 ACATGACAGGGAAACCAT 
W12 rs6838973 ACGTTGGATGAGGAATGAAAGTGGGCTGAG ACGTTGGATGTCTCTTCCGATTGGAAACAG 102 GGAGGAATCTGTGGAGTA 
W12 rs3866823 ACGTTGGATGGGCCTGATCTTTAGACCTTC ACGTTGGATGTACTTCGTGTTTGGAATGGC 101 aAAAAATTGGCCTCAACCT 
W12 rs13126975 ACGTTGGATGGATCTAATAGTGGAGGGTGG ACGTTGGATGATTCACAGTGGCCCTATATG 112 tcGTGGAGGGTGGATAGGG 
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Multiplex SNP Forward primer Reverse primer 
Amplicon 
length Extension primer 
W12 rs4033102 ACGTTGGATGCTATGACTTCTGCTAGTCTC ACGTTGGATGAGGAAAAACACCATGTTGAG 86 TCTGCTAGTCTCAGGGAATA 
W12 rs4656799 ACGTTGGATGGGGAGACCAGTTTTACAGAG ACGTTGGATGAGCCATCACCTGTTCTTCAC 99 TGGGACTTGAATTTTATCAG 
W12 rs17513835 ACGTTGGATGGGATAAAAACCGAGAGTAAG ACGTTGGATGAGGAAGCTCAAAGGCAAATC 116 ggggTGTGCCATGTAGTCTTG 
W12 rs1947187 ACGTTGGATGTCACCTTTGGAGACATCAAC ACGTTGGATGGAATATGTTTGGATTTCTTTC 109 TCTTTATAGCACTGTTTCCAAG 
W12 rs12440104 ACGTTGGATGTCTCTCCTTTCCTCGTCGG ACGTTGGATGTATTCTTCACGATGGCCTCC 94 ctttCTCGTCGGAGGCTTATCT 
W12 rs8030574 ACGTTGGATGACATGGCATAGACATTTGGG ACGTTGGATGAGTGGGGCCCTTCTTTCCT 87 gtttGGTCTTTCTAAGGGTACT 
W12 rs10222783 ACGTTGGATGCTAGGACTTGGGTAGGAAAT ACGTTGGATGCCTGCCACTGTGTTTTCCTT 119 ggagATATGAAATGAGCCAGGA 
W12 rs11857639 ACGTTGGATGATAAGGCCGGATGCCAAGAG ACGTTGGATGAGCTGGCATATGGGTACTGG 111 ctcttCTCTCTACCCCATGACCCA 
W12 rs8040516 ACGTTGGATGGTTTGAGTCTTTTCCTGGGC ACGTTGGATGGCTATTGTCAGAAACTGCCC 119 tttgTTCTCACTCCTTTCTGAATG 
W12 rs2200733 ACGTTGGATGCCCCAAACTTTCTGGAAAAT ACGTTGGATGTGGTGGTACTTGGGTTTTG 119 agATTACCTGTTCTAATTTTCTCT 
W12 rs3853444 ACGTTGGATGGAGAGCTGACTTGTAATATG ACGTTGGATGCCGGCAACTGTGAAATCATA 120 GAGCTGACTTGTAATATGTATATA 
W12 rs16997168 ACGTTGGATGCTTGGGCCTTCTGGTGATTA ACGTTGGATGAGCTCATAAAACTCTCCCTC 86 TCTGGTGATTATTTCTTCAACTCAG 
W12 rs529004 ACGTTGGATGTGACTGCTGGACCCCAGAG ACGTTGGATGAAGGAAGGGCCCAGCTCATA 109 ccccAGCCAGTGCGCTCCAAACTGCC 
W12 rs7080456 ACGTTGGATGGCACATGTGTTTGTGCGTGA ACGTTGGATGACACCCATACGCACAAAACC 113 ccctcTGTGCGTGATTATTTGTCTCA 
W12 rs3866836 ACGTTGGATGCAGCCGCGGCATTAGATTTT ACGTTGGATGCAGCAGAGACCCCTCACAT 91 CGGCATTAGATTTTCATAGGAGCATA 
W12 rs12129225 ACGTTGGATGCCTGGGGAGTGTATAATAG ACGTTGGATGAGACTGAGCATTGACATCCC 86 gctgtGGAGTGTATAATAGTCTCTCA 
W12 rs12038255 ACGTTGGATGATCACTATGTCATTTTCAC ACGTTGGATGAAGGCCCTAGGCAGTACAAT 116 cTTTCTTTCTTTCCAATTTTTTAATGA 
W12 rs35177144 ACGTTGGATGCCTGGTTATTTTCTGCTGTC ACGTTGGATGGGTTTAACTGTGATTAGGAG 116 ggagGTCTTTTGTTTTTCTGGTGTGTG 
W12 rs659580 ACGTTGGATGTCCGCGGCGGACTCTCTTTA ACGTTGGATGCACCCCGCTAAGACCTTTTC 117 gtcctCGGCGGACTCTCTTTACTTCGGC 
W12 rs1448799 ACGTTGGATGTCTTAAGCCCATCAGAGCTA ACGTTGGATGTTCAGAAGGGTTTATTGCTC 110 tttcgTAAGCCCATCAGAGCTAAAATCA 
W12 rs570881 ACGTTGGATGGCTTCAAAGTAATCATCTG ACGTTGGATGCCTTTAAACAGATCTTAGTG 86 AATCATCTGTAAAATAAAAAGTTTGAAA 
W13 rs4745718 ACGTTGGATGGCAGGGCCACAGGCTTGAA ACGTTGGATGAAGGTGGAGGAAGATCATGC 109 AGGCTTGAAAGCCCC 
W13 rs2680344 ACGTTGGATGGGCAGTACTTCGATCAGAG ACGTTGGATGACTATGCTGGCCAAACAGAG 104 TGCACCAAATACAGCA 
W13 rs581241 ACGTTGGATGCCTAAGTTTATAACAGGGTG ACGTTGGATGTGGCCATTCATGCATCACAC 88 AACAGGGTGAGCAAAT 
W13 rs11638230 ACGTTGGATGTCACTGCCATTACTCACCTC ACGTTGGATGAAGGCTCATAACCCACACAG 94 CTCCCCAACCCTGACTG 
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Multiplex SNP Forward primer Reverse primer 
Amplicon 
length Extension primer 
W13 rs2623997 ACGTTGGATGGAAGGTTGCCTTCATCAGAG ACGTTGGATGAGGATGCAACTGTGTTGCCG 97 gtATTGCCGGTCTCCAC 
W13 rs619456 ACGTTGGATGCCACAGGTAAGTTGGACAGC ACGTTGGATGGATTTCAATTAAGGTAAGCAG 112 GCAGAAGGCACATACTT 
W13 rs2739200 ACGTTGGATGGCGACGAGAAACGAGGCAG ACGTTGGATGTCCCCTCTCCTTTCGCTCT 108 AGGGAAGCAGATGCCAGC 
W13 rs6843082 ACGTTGGATGTTCTGGTGTCCTGGGATTTG ACGTTGGATGACACTGTTGGTGATGAGTGG 119 catcGCCTCAGAGCTGAAA 
W13 rs976568 ACGTTGGATGGTGTGAAGGTGTGTGTCGC ACGTTGGATGTGTTCGACCCAAGTCGCTG 120 gggCAGAGGGAGGAAGTCT 
W13 rs7552922 ACGTTGGATGAGGTCAGGGCATGATCTACT ACGTTGGATGTTTGGCCACATGAAGTTCTG 106 GGGCATGATCTACTGCAAAA 
W13 rs58473244 ACGTTGGATGTGTCTCCATCTTTGTTGGTC ACGTTGGATGTCCAGTGAGCAGATGTTGTG 103 ctgTGTTGGTCATGGTAAGG 
W13 rs7679158 ACGTTGGATGCACCTGGACTTTGGTAATCG ACGTTGGATGGGAGATTAACCTGACAGTAG 103 ggtagCTTCCTGCCCCAAACA 
W13 rs17570669 ACGTTGGATGCTTTGTGATCCAGTGTAGGC ACGTTGGATGAGGGTAAAGGGTCTTTACTC 105 GATAATGTTCCTAGAAGTTGT 
W13 rs17042171 ACGTTGGATGCCCAAGGCAACATGAGGAAT ACGTTGGATGTAGACAGGGTGCCTGAGGAC 119 AATTAAATTACCTCACTGGAAA 
W13 rs513287 ACGTTGGATGTGATGGTGGAGATGGTTTGC ACGTTGGATGTCATGGGGTATGGTTGTTGC 114 cccctATGGTTTGCTAAATGTCC 
W13 rs6817202 ACGTTGGATGCACAAATCTGTAAACTGGGC ACGTTGGATGCAATTCAACCCAGACAAGCC 107 ctcgGTAAACTGGGCAGTTATTT 
W13 rs561873 ACGTTGGATGTCTTCGGTATCCTCTGTGAC ACGTTGGATGGGGGAAATTGATAGAGTAG 120 GCAAAATTCTGAGTAGTGTATAT 
W13 rs7535322 ACGTTGGATGGCCTTTGAGAGAAGTCTCTT ACGTTGGATGGGAGCTCACTTCTTATGTAA 120 gggTGAGAGAAGTCTCTTGAAATA 
W13 rs10033464 ACGTTGGATGCTGAGGAATTCTAAATGAC ACGTTGGATGAACTCAGAGCTTGATGAAA 109 TTTTTACATTGTTAGAGTCAAGAAA 
W14 rs12905211 ACGTTGGATGAAAGAGTTGCAAAGAGCCCC ACGTTGGATGAGGAAAGAAGGGCCCCACTG 103 GTGGGGAGAGGAGCC 
W14 rs2421494 ACGTTGGATGGCAAGATCCCAGCAGATTGT ACGTTGGATGTTCCCAATCCCTTCCTGCTG 109 AGCAGATTGTAATTTACAGC 
W14 rs7540713 ACGTTGGATGGAGAAGGAACAACTTCTTGC ACGTTGGATGATGACAGTAAGTCTCAGCAG 107 TTACTTGTTTGAGTTCTCTAC 
W14 rs3903239 ACGTTGGATGAAGATGAAAACAATGACCC ACGTTGGATGGTTCACTACCAATCTTTTCC 108 AAATACAATGGACAGGATTAA 
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Table A1.3 Allelic expression ratio assays 
Multiplex Transcribed SNP Froward primer Reverse primer Amplicon length Extension Primer 
W1 rs10852515 ACGTTGGATGTAATCACACACCTCGCACCG ACGTTGGATGAATATCAGTAGCTCCTGCGG 100 TTGGTTTTTGGTTTGGT 
W1 rs1051614 ACGTTGGATGGATGACTGGCGGATAGCCAT ACGTTGGATGATGGCGCACACCAGCATCTC 91 gaaCTACGAGCGCATCCT 
W1 rs740178 ACGTTGGATGACCTCCTGGCAATGGGAGAC ACGTTGGATGTCCTCCTTGTCTTCCTCAAC 90 ATGGGAGACCCCACTCTGGC 
W2 rs3743496 ACGTTGGATGCCGTTAGCTGTAACTTGGAG ACGTTGGATGCTTTTCTCCCAAGGTCGCAG 119 ctttGAGCTCCACTCTGCC 
W2 rs41280400 ACGTTGGATGTCCAGATGCCCAAGTTTGAC ACGTTGGATGGGGTTCGATTGAAAGAAGGC 116 aggtGGCCCTTGCTGAGTGAACCCCT 
W2 rs4746139 ACGTTGGATGTGACCTCCACCGCTTCTATC ACGTTGGATGCTCAGGAGCCCCTGGGCCT 109 CTTCCTATCTGCGCC 
W2 rs60632610 ACGTTGGATGGGGACACTGTTCAAACTCCG ACGTTGGATGTCCCCCTGATAGTGTGACCA 105 cCCAAGCTGAGCGATG 
W2 rs6533526 ACGTTGGATGAAGCATGTTATACAGAAGCG ACGTTGGATGACATACAGTGTGGCATTTAG 98 TACAGAAGCGATTAGGATTTTT 
W2 rs7164883 ACGTTGGATGCTAAACCACAGATCAACCCC ACGTTGGATGGTGGTATCTTTCTCTGATCC 116 ctatCATGAATAGATCACGTGACC 
W2 rs913257 ACGTTGGATGCTCTAAACGAACCACTGGTC ACGTTGGATGGTAGAAGCCGATGAAGAGAC 119 CCTTGATTCTACTTCTTGTT 
W3 rs3812629 ACGTTGGATGTTACAAGACCCTGCCTCACG ACGTTGGATGGAGTCTTAGGAGTCATAGGG 103 CACCTAAGACCCCCC 
W3 rs3820416 ACGTTGGATGGAAGAGTTCCCCCATTCATC ACGTTGGATGTTGGGATGTACAGTTCCTTC 97 TGTCCCATTAGTTGCTG 
W3 rs529004 ACGTTGGATGTGACTGCTGGACCCCAGAG ACGTTGGATGAAGGAAGGGCCCAGCTCATA 109 ccccAGCCAGTGCGCTCCAAACTGCC 
W3 rs75911264 ACGTTGGATGAAGCATGTTATACAGAAGCG ACGTTGGATGACATACAGTGTGGCATTTAG 98 cCTTGCGAGCAAGGGA 
W4 rs2739200 ACGTTGGATGGCGACGAGAAACGAGGCAG ACGTTGGATGTCCCCTCTCCTTTCGCTCT 108 AGGGAAGCAGATGCCAGC 
W4 rs58473244 ACGTTGGATGTGTCTCCATCTTTGTTGGTC ACGTTGGATGTCCAGTGAGCAGATGTTGTG 103 ctgTGTTGGTCATGGTAAGG 
W4 rs7552922 ACGTTGGATGAGGTCAGGGCATGATCTACT ACGTTGGATGTTTGGCCACATGAAGTTCTG 106 GGGCATGATCTACTGCAAAA 
W5 rs4657 ACGTTGGATGATGTGGCTGCTAAAGCCATC ACGTTGGATGATCTGCCTTTTGTGTGTGCC 118 CACAGCCCTGTTCAC 
W5 rs76455830 ACGTTGGATGGCACCTCCTTAAAGCGATAC ACGTTGGATGGTGATTTATTATGACTTCTC 115 ACGTTTTCCTCAGCAG 
W5 rs4986938 ACGTTGGATGTGAGGTGAACTGGCCCACA ACGTTGGATGACAGCAGAAAGATGAAGCCC 102 GGCCCACAGAGGTCACA 
W5 rs7229 ACGTTGGATGATGCACAAATAACCACATCC ACGTTGGATGTTCAGTACCTAGCTCTGCTC 100 AACCACATCCATGCAATA 
W5 rs8940 ACGTTGGATGAACATCTGTCACACTCTTCC ACGTTGGATGGCCTTTTGTAAAGACCTGCC 90 CACACTCTTCCATATTGTCT 
W5 rs928554 ACGTTGGATGGCAGTGACCCTCTAATCAAC ACGTTGGATGTCATGGATTACAATGATCCC 112 ATCTTGGGTAACATTTTCACTTCA 
W5 rs1049334 ACGTTGGATGGGAACACAATGTTGAGCCAC ACGTTGGATGAATCACGCTTTCCTGAATCC 87 gtttAGCCACTAAACCACCC 
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Multiplex Transcribed SNP Froward primer Reverse primer Amplicon length Extension Primer 
W5 rs1049337 ACGTTGGATGCAGGAGCTTTGGACCTAATC ACGTTGGATGTTTATTACTGCCTCCTCCCC 89 GGACCTAATCCAAGCATC 
W5 rs1152582 ACGTTGGATGAATGAGCAGTGGTGTCCATC ACGTTGGATGATCAGCTAAGGGTGCCTATG 115 ATATATTATAGAAGCAAGCGAG 
W5 rs1256049 ACGTTGGATGCTTGCTTTCCCCAGGCTTTG ACGTTGGATGTAACACCTCCATCCAACAGC 99 ccccGCCTGTTCGACCAAGT 
W5 rs4657 ACGTTGGATGATCTGCCTTTTGTGTGTGCC ACGTTGGATGATGTGGCTGCTAAAGCCATC 118 tggtAAAGAGAAGCACCAAGA 
W5 rs7161192 ACGTTGGATGCAGCTCATGGATCAGACTTC ACGTTGGATGTGTTTCGCTTCCTCACTGAC 118 ATCAGACTTCTGGTTTGGTA 
W5 rs9920 ACGTTGGATGAGCAACTCGCTTTAGGTCAG ACGTTGGATGAGCTCAGAGTCAGAAACACG 110 ggaCCTGAAGACCAAAATTAGAATA 
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A2 Associations between genotype and gene expression 
Table A2.1 Associations at chromosome 1q21 in the NE cohort in blood 
SNP Importance Position KCNN3 aerQTL KCNN3 eQTL 
   
Beta p value Beta p value 
rs1995662 
 
154679567 -0.02 8.66E-01 -0.09 2.02E-01 
rs6695232 
 
154681950 0.11 1.78E-01 0.10 1.59E-02 
rs10128027 
 
154691445 -0.01 8.65E-01 0.02 7.20E-01 
rs4845663 
 
154692088 -0.02 7.55E-01 -0.03 5.44E-01 
rs7523074 
 
154692269 0.06 6.17E-01 -0.10 8.30E-02 
rs7554577 
 
154692883 -0.03 7.28E-01 0.12 5.58E-03 
rs11264249 
 
154693181 -0.04 6.46E-01 -0.06 1.54E-01 
rs11264251 
 
154693538 0.01 9.23E-01 -0.01 7.65E-01 
rs12087736 
 
154695678 0.09 5.13E-01 -0.11 9.97E-02 
rs10494301 
 
154701218 -0.14 1.01E-01 -0.04 3.44E-01 
rs12402320 
 
154701406 0.08 3.62E-01 -0.01 8.13E-01 
rs884664 
 
154703725 0.07 4.03E-01 0.04 4.20E-01 
rs6426905 
 
154706620 -0.02 8.93E-01 0.03 7.40E-01 
rs960182 
 
154710756 -0.02 7.85E-01 0.01 8.05E-01 
rs10908429 
 
154710904 0.05 5.41E-01 0.07 1.30E-01 
rs6682000 
 
154711226 -0.03 7.50E-01 0.07 1.11E-01 
rs12145386 
 
154713499 0.00 9.99E-01 0.02 7.74E-01 
rs4999127 
 
154714006 -0.01 9.01E-01 -0.09 1.30E-01 
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SNP Importance Position KCNN3 aerQTL KCNN3 eQTL 
   
Beta p value Beta p value 
rs868108 
 
154720289 -0.13 1.65E-01 0.10 2.94E-02 
rs6698628 
 
154721780 -0.19 4.78E-01 0.10 3.05E-01 
rs906276 
 
154724392 -0.09 4.09E-01 -0.09 1.43E-01 
rs4845390 
 
154726374 -0.13 6.99E-02 0.06 1.27E-01 
rs10494300 
 
154726546 0.15 5.98E-02 -0.07 1.04E-01 
rs6682291 
 
154732776 0.25 4.13E-02 0.02 8.15E-01 
rs4845391 
 
154739104 -0.06 4.54E-01 -0.07 9.68E-02 
rs1051614 KCNN3 Transcribed 154744807 0.13 2.17E-02 -0.10 2.52E-02 
rs1131820 
 
154744852 0.17 1.88E-02 -0.10 3.80E-02 
rs7532286 
 
154750816 0.00 9.51E-01 0.15 4.21E-04 
rs1506982 
 
154753697 0.20 1.76E-01 0.03 7.29E-01 
rs4845671 
 
154755126 -0.05 6.01E-01 -0.07 1.21E-01 
rs12135902 
 
154756104 0.01 9.71E-01 -0.19 1.65E-02 
rs11264261 
 
154756443 0.15 4.13E-02 -0.08 8.46E-02 
rs883319 
 
154758422 -0.10 3.25E-01 -0.10 5.32E-02 
rs11584635 
 
154760965 -0.22 9.95E-03 0.10 3.05E-02 
rs17719287 
 
154766495 0.14 3.13E-01 0.09 2.19E-01 
rs1419110 
 
154768689 -0.09 2.26E-01 0.00 9.48E-01 
rs4492614 
 
154769561 0.13 1.54E-01 -0.07 1.90E-01 
rs17719419 
 
154771916 0.04 7.90E-01 -0.23 1.10E-03 
rs6690388 
 
154774447 -0.23 1.44E-02 0.12 1.77E-02 
rs6426944 
 
154776412 -0.19 4.64E-02 0.04 3.55E-01 
rs2256209 
 
154779544 0.20 2.01E-01 -0.10 2.04E-01 
rs2798601 
 
154779685 -0.33 1.69E-03 0.11 5.06E-02 
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SNP Importance Position KCNN3 aerQTL KCNN3 eQTL 
   
Beta p value Beta p value 
rs6688473 
 
154783773 0.15 1.74E-01 -0.12 9.61E-03 
rs2335406 
 
154786686 0.00 9.58E-01 0.00 9.97E-01 
rs1106236 
 
154787136 -0.03 6.95E-01 0.15 4.76E-04 
rs1106235 
 
154787213 -0.06 5.28E-01 0.09 9.18E-02 
rs1218601 
 
154791676 -0.04 6.41E-01 0.11 2.23E-02 
rs951241 
 
154793798 0.03 7.83E-01 -0.14 1.32E-02 
rs12029542 
 
154794897 0.06 5.90E-01 -0.07 1.43E-01 
rs11264268 
 
154796520 0.09 3.55E-01 0.09 7.08E-02 
rs6681725 
 
154797062 -0.08 5.12E-01 -0.12 5.58E-02 
rs1218551 
 
154801173 0.02 8.39E-01 -0.11 1.46E-02 
rs11264270 
 
154802379 -0.02 9.07E-01 0.12 7.13E-02 
rs4845394 
 
154808287 -0.04 6.10E-01 0.03 5.12E-01 
rs1218578 
 
154810030 -0.10 1.90E-01 0.02 6.32E-01 
rs11264274 
 
154811127 0.06 4.78E-01 -0.06 1.86E-01 
rs12128882 
 
154811435 -0.02 8.22E-01 0.00 9.96E-01 
rs1218574 
 
154811677 -0.08 4.51E-01 0.11 7.08E-02 
rs12740456 
 
154814197 0.08 4.62E-01 -0.14 1.82E-02 
rs13376333 AF GWAS 154814353 0.10 2.89E-01 -0.17 2.11E-04 
rs6426987 
 
154815257 0.08 3.85E-01 -0.15 5.32E-04 
rs1218565 
 
154817687 -0.05 5.18E-01 0.10 1.68E-02 
rs4845396 
 
154828409 -0.08 3.66E-01 0.16 9.74E-05 
rs1061122 
 
154832290 0.18 7.04E-02 -0.10 4.04E-02 
rs76110919 
 
154842095 - - - - 
rs2335407 
 
154843347 -0.14 7.80E-02 0.21 3.12E-07 
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Results of association testing at the 1q21 locus. Effects are presented as log effect sizes (Beta) of the minor allele referenced to the major allele. The significance 
threshold after correction for multiple testing at this locus was 7.57e-04. Significant associations are in bold.
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Table A2.2 Associations at chromosome 7q31 in blood 
SNP Importance Position CAV1 aerQTL CAV1 eQTL CAV2 aerQTL 
   
Beta p value Beta p value Beta p value 
rs17138749 
 
116133098 0.10 2.42E-03 -0.07 3.71E-01 -0.43 1.60E-08 
rs8940 CAV2 Transcribed 116146074 0.03 4.39E-01 -0.07 4.21E-01 0.14 1.90E-04 
rs6466578 
 
116150869 0.04 3.17E-01 0.08 3.39E-01 0.12 3.43E-01 
rs3919515 
 
116151784 0.07 8.18E-04 -0.03 6.16E-01 0.11 1.86E-02 
rs17588172 
 
116154015 0.08 2.70E-03 -0.08 1.99E-01 0.06 2.08E-01 
rs4236601 Glaucoma GWAS 116162729 0.00 1.00E+00 -0.05 5.37E-01 0.12 3.14E-03 
rs4730748 
 
116167595 0.03 4.39E-01 -0.09 3.30E-01 0.13 3.13E-04 
rs959173 
 
116182054 0.05 2.06E-01 0.02 7.99E-01 0.12 2.47E-01 
rs3807989 AF GWAS 116186241 0.10 4.15E-05 -0.03 6.03E-01 0.04 1.00E+00 
rs11773845 AF, PR interval GWAS 116191301 0.10 4.15E-05 -0.03 6.42E-01 0.04 1.00E+00 
rs1049314 
 
116199695 0.01 1.00E+00 -0.05 5.60E-01 0.13 2.26E-02 
rs8713 
 
116199797 0.02 5.27E-01 -0.02 7.81E-01 0.11 4.18E-02 
rs9920 
 
116200092 -0.01 1.00E+00 -0.02 8.66E-01 -0.13 1.91E-01 
rs1049334 CAV1 Transcribed 116200380 0.23 7.50E-09 -0.04 6.85E-01 -0.56 1.17E-07 
rs1049337 CAV1 Transcribed 116200587 -0.08 3.73E-06 0.04 5.21E-01 -0.08 3.43E-01 
rs1860588 
 
116206486 0.07 1.21E-01 0.04 6.45E-01 0.12 4.30E-01 
The significance threshold after correction for multiple testing was 3.12E-03. Effects are presented as log effect sizes (Beta) of the minor allele referenced to the 
major allele. The major alleles of the SNPs rs3807989 and rs11773845 are associated with increased AF risk. Significant associations are in bold.
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Table A2.3 Associations at chromosome 9q22 in blood 
SNP Importance Position C9orf3 aerQTL C9orf3 eQTL FANCC aerQTL 
   
Beta p value Beta p value Beta p value 
rs7848139 
 
97495467 -0.04 7.68E-02 -0.04 1.13E-01 0.02 1.87E-01 
rs356122 
 
97565461 0.09 2.94E-03 0.10 6.05E-03 0.03 3.90E-01 
rs4744381 
 
97601089 
      rs1530331 
 
97620602 0.00 9.26E-01 -0.05 3.02E-01 0.08 5.70E-02
rs10993391 
 
97675840 0.24 4.14E-07 0.21 3.57E-06 -0.02 6.90E-01 
rs7853195 
 
97685298 -0.01 5.82E-01 -0.01 6.67E-01 -0.03 5.13E-02 
rs76455830 
 
97695714 
  
-0.04 9.13E-01 
  rs10821415 AF GWAS 97713459 -0.02 5.08E-01 0.00 8.78E-01 -0.03 5.13E-02
rs10993413 
 
97729136 -0.06 1.92E-01 -0.01 8.33E-01 0.05 1.43E-01 
rs3802458 
 
97741274 0.01 8.75E-01 -0.22 1.81E-02 0.03 6.53E-01 
rs3802457 PCOS GWAS 97741336 0.03 5.61E-01 -0.07 3.17E-01 0.02 6.91E-01 
rs7048941 
 
97809674 0.12 5.70E-04 0.08 3.52E-02 0.00 9.87E-01 
rs4744437 
 
97832830 0.00 9.68E-01 -0.01 7.51E-01 0.03 4.69E-01 
rs7033633 
 
97838781 0.00 8.15E-01 -0.02 5.01E-01 -0.02 4.40E-01 
rs17679141 
 
97842479 0.04 1.05E-01 0.07 1.35E-02 -0.05 5.65E-03 
rs4657 C9orf3 Transcribed 97849090 0.00 7.77E-01 -0.04 1.36E-01 -0.01 7.43E-01 
rs4647554 FANCC Transcribed 97862701 -0.04 8.12E-02 -0.02 4.69E-01 0.03 1.80E-02 
The significance threshold after correction for multiple testing was 2.94E-03. Effects are presented as log effect sizes (Beta) of the minor allele referenced to the 
major allele. Significant associations are in bold.
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Table A2.4 Associations at chromosome 14q23in blood 
SNP Importance Position SYNE2 aerQTL SYNE2 eQTL ESR2 aerQTL 
   
Beta p value Beta p value Beta p value 
rs4459477 
 
64346190 0.07 3.20E-02 -0.01 1.06E-01 0.01 5.27E-01 
rs17750888 
 
64355420 -0.01 3.17E-01 0.01 1.17E-01 0.01 1.80E-01 
rs12588807 
 
64363070 0.08 1.57E-03 -0.03 3.62E-01 0.00 1.00E+00 
rs2275018 
 
64375985 -0.04 2.01E-02 0.03 5.87E-01 0.01 2.37E-01 
rs7153036 
 
64377548 -0.03 9.43E-02 0.03 6.49E-01 0.01 1.57E-01 
rs12879919 
 
64382350 0.04 1.07E-01 -0.02 3.50E-01 0.00 1.00E+00 
rs11158521 
 
64401255 -0.03 2.85E-02 0.04 9.64E-01 0.00 6.55E-01 
rs2184292 
 
64408135 -0.04 1.28E-02 0.03 7.07E-01 0.00 1.00E+00 
rs7153680 
 
64474227 0.00 1.00E+00 0.03 6.24E-01 0.00 1.00E+00 
rs4566057 
 
64506541 -0.09 1.26E-03 -0.02 2.68E-01 0.01 5.27E-01 
rs1890908 
 
64519035 -0.02 2.37E-01 0.01 1.02E-01 0.01 4.39E-01 
rs10137972 
 
64557734 -0.01 5.27E-01 0.01 9.09E-02 -0.02 2.06E-01 
rs17101651 
 
64561324 -0.08 3.20E-02 -0.01 9.90E-02 0.00 1.00E+00 
rs8022428 
 
64563613 -0.05 4.55E-02 -0.01 1.01E-01 0.00 1.00E+00 
rs8007972 
 
64564527 0.02 1.00E+00 -0.05 9.24E-01 0.01 5.27E-01 
rs8016917 
 
64569951 -0.12 1.57E-03 0.04 3.38E-01 -0.05 6.52E-03 
rs10142318 
 
64604281 -0.11 1.19E-06 -0.01 1.18E-01 0.00 1.00E+00 
rs7144688 
 
64613473 -0.13 1.39E-12 -0.02 3.54E-01 0.00 1.00E+00 
rs11158533 
 
64622988 -0.09 2.73E-05 0.03 6.20E-01 0.00 6.55E-01 
rs17751454 
 
64625181 -0.08 2.01E-02 0.07 1.60E+00 0.00 1.00E+00 
rs3866743 
 
64633322 -0.18 1.83E-04 0.04 3.80E-01 -0.04 8.33E-02 
rs7161192 SYNE2 Transcribed 64637147 -0.10 1.19E-06 0.04 8.10E-01 0.00 6.55E-01 
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SNP Importance Position SYNE2 aerQTL SYNE2 eQTL ESR2 aerQTL 
   
Beta p value Beta p value Beta p value 
rs2256191 
 
64656855 -0.10 1.45E-11 0.03 6.38E-01 0.01 5.27E-01 
rs1152591 AF GWAS 64680848 -0.11 7.52E-24 0.00 5.72E-02 0.00 1.00E+00 
rs7145919 
 
64687601 -0.10 8.15E-03 -0.09 1.35E+00 -0.01 6.55E-01 
rs8020646 
 
64691320 -0.14 5.13E-05 0.01 7.68E-02 0.02 2.06E-01 
rs12434245 
 
64691853 -0.10 8.15E-03 -0.09 1.35E+00 -0.01 6.55E-01 
rs1048315 
 
64692465 -0.14 1.80E-06 -0.02 2.56E-01 0.02 2.37E-01 
rs1152582  SYNE2 Transcribed 64692630 0.12 6.19E-37 -0.01 1.29E-01 0.01 3.17E-01 
rs7229  64692825 0.12 2.83E-35 -0.01 2.65E-01 0.00 4.39E-01 
rs2772163  64693385 -0.10 2.68E-09 0.05 1.32E+00 0.00 1.00E+00 
rs928554 ESR2 Transcribed 64694195 0.12 3.98E-32 0.00 3.99E-02 0.00 5.27E-01 
rs4986938 ESR2 Transcribed 64699816 -0.12 1.99E-20 0.04 9.85E-01 -0.01 1.38E-01 
rs1256064 
 
64700739 -0.12 4.15E-05 -0.03 2.99E-01 0.02 1.57E-01 
rs1256063 
 
64702217 0.10 4.15E-05 -0.05 5.50E-01 -0.01 6.55E-01 
rs10144225 
 
64704994 -0.14 1.18E-05 0.01 4.90E-02 0.00 1.00E+00 
rs1256049 ESR2 Transcribed 64724051 -0.09 1.57E-01 -0.08 6.22E-01 0.01 5.27E-01 
The significance threshold after correction for multiple testing was 1.35E-03. Effects are presented as log effect sizes (Beta) of the minor allele referenced to the 
major allele. Significant associations are in bold.
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Table A2.5 Associations with expression at chromosome 16q22 in blood 
SNP Importance Position ZFHX3 aerQTL ZFHX3 eQTL ZFHX3a aerQTL ZFHX3a eQTL 
   
Beta p value Beta p value Beta p value Beta p value 
rs117951282 
 
72820328 - - - - - - - - 
rs699444 
 
72827758 0.03 5.22E-02 0.02 7.79E-01 0.15 2.67E-02 0.04 5.54E-01 
rs740178 ZFHX3 Transcribed 72832135 0.03 2.86E-02 -0.01 8.70E-01 0.18 5.49E-03 0.10 1.42E-01 
rs12929452 
 
72838680 -0.04 1.19E-01 -0.01 8.20E-01 -0.16 1.70E-03 -0.01 8.14E-01 
rs2266943 
 
72854307 0.03 2.96E-02 0.00 9.34E-01 0.17 7.39E-03 0.03 6.40E-01 
rs8058014 
 
72857544 0.03 4.67E-02 0.01 8.00E-01 0.19 3.53E-03 0.09 1.65E-01 
rs1476646 
 
72898348 -0.05 8.63E-03 -0.05 2.47E-01 -0.19 1.55E-04 -0.06 2.07E-01 
rs4788668 
 
72901874 0.03 1.06E-01 0.02 6.72E-01 0.14 2.63E-03 0.02 7.70E-01 
rs4788671 
 
72915085 -0.04 6.22E-02 0.01 7.96E-01 -0.18 6.08E-04 -0.04 3.46E-01 
rs6499594 
 
72917601 0.06 1.33E-02 0.10 1.22E-01 0.11 1.06E-01 0.16 2.31E-02 
rs16971366 
 
72919582 -0.02 4.58E-01 0.04 4.71E-01 -0.21 6.49E-05 0.03 6.36E-01 
rs9940310 
 
72925982 0.06 2.42E-02 0.13 7.95E-02 0.20 1.51E-02 0.20 1.88E-02 
rs9925261 
 
72927533 0.03 1.23E-01 0.06 1.45E-01 -0.13 8.54E-03 0.08 1.07E-01 
rs16971384 
 
72931085 0.02 2.58E-01 0.03 5.45E-01 -0.17 2.08E-04 0.05 3.69E-01 
rs4788482 
 
72937079 -0.06 6.34E-02 -0.07 3.22E-01 -0.25 5.08E-08 -0.09 2.33E-01 
rs4788679 
 
72956544 0.01 6.94E-01 -0.01 8.57E-01 -0.19 4.26E-05 0.03 6.64E-01 
rs9936884 
 
72960230 0.02 3.85E-01 -0.05 5.13E-01 -0.07 4.72E-01 0.01 8.89E-01 
rs4788488 
 
72960283 0.01 4.69E-01 -0.02 6.10E-01 -0.21 8.73E-06 0.02 6.62E-01 
rs8055870 
 
72972090 -0.02 3.81E-01 0.06 1.32E-01 0.13 1.95E-02 0.01 8.77E-01 
rs6499600 
 
72979374 0.01 8.13E-01 -0.06 1.55E-01 -0.20 3.94E-05 -0.02 7.40E-01 
rs13336412 
 
72981949 -0.01 6.99E-01 0.01 8.68E-01 0.20 3.10E-04 -0.02 6.61E-01 
rs2228200 
 
72984668 0.03 4.42E-01 0.10 2.42E-01 0.12 4.29E-01 0.07 4.82E-01 
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SNP Importance Position ZFHX3 aerQTL ZFHX3 eQTL ZFHX3a aerQTL ZFHX3a eQTL 
   
Beta p value Beta p value Beta p value Beta p value 
rs2106258 
 
72990553 -0.02 4.80E-01 -0.06 2.02E-01 -0.26 3.61E-12 -0.02 6.96E-01 
rs2157786 
 
72991286 -0.01 6.94E-01 -0.06 1.88E-01 -0.24 2.70E-09 -0.05 3.37E-01 
rs10852515 ZFHX3a Transcribed 72991660 -0.04 1.77E-01 -0.10 1.13E-01 -0.25 7.47E-15 -0.15 3.68E-02 
rs7193297 
 
72993831 0.04 1.27E-01 0.03 4.04E-01 0.21 1.20E-03 -0.01 8.98E-01 
rs7404992 
 
72994419 -0.01 8.49E-01 -0.06 4.77E-01 -0.13 1.84E-01 -0.10 3.06E-01 
rs756717 
 
72996162 -0.02 4.61E-01 0.06 1.56E-01 0.06 2.60E-01 0.11 2.35E-02 
rs4788683 
 
72997747 0.01 4.60E-01 -0.01 9.03E-01 -0.05 3.47E-01 -0.03 4.93E-01 
rs9921395 
 
73001957 -0.04 7.91E-02 -0.03 5.41E-01 -0.09 9.19E-02 -0.07 1.30E-01 
rs12445932 
 
73004432 -0.03 2.31E-01 0.01 8.13E-01 -0.16 1.19E-02 -0.03 6.57E-01 
rs7199343 Kawasaki GWAS 73009024 -0.02 2.71E-01 -0.06 1.54E-01 -0.02 6.91E-01 -0.12 1.40E-02 
rs11075954 
 
73012164 0.02 2.44E-01 0.05 2.66E-01 -0.09 6.86E-02 0.08 1.03E-01 
rs2040508 
 
73012685 -0.01 5.97E-01 -0.08 1.17E-01 -0.02 8.31E-01 -0.07 2.61E-01 
rs16971456 
 
73013036 -0.03 3.67E-01 -0.02 7.54E-01 0.18 3.22E-02 0.03 6.40E-01 
rs9930445 
 
73013482 -0.03 1.71E-01 -0.03 5.20E-01 0.08 1.90E-01 -0.02 6.60E-01 
rs4788684 
 
73013633 0.03 8.34E-02 0.09 2.82E-02 0.02 7.12E-01 0.10 5.11E-02 
rs16971464 
 
73016143 0.05 1.77E-01 0.15 6.07E-02 0.28 1.78E-02 0.17 8.25E-02 
rs16971465 
 
73017061 0.01 7.14E-01 0.05 4.23E-01 0.16 8.41E-02 0.10 2.19E-01 
rs4788489 
 
73017118 0.01 8.13E-01 0.00 9.89E-01 -0.05 3.29E-01 -0.01 8.38E-01 
rs16971474 
 
73019004 -0.02 5.46E-01 -0.03 5.23E-01 0.00 9.49E-01 0.00 9.50E-01 
rs11640106 
 
73020116 -0.02 4.14E-01 -0.02 6.61E-01 0.03 5.69E-01 -0.07 1.93E-01 
rs1858800 
 
73024276 0.02 3.18E-01 0.04 3.12E-01 -0.10 7.52E-02 0.02 6.34E-01 
rs756720 
 
73028921 0.00 9.95E-01 0.07 1.70E-01 0.10 1.39E-01 0.06 3.26E-01 
rs7193343 AF GWAS 73029160 -0.02 4.84E-01 0.02 6.50E-01 -0.05 4.35E-01 0.02 7.64E-01 
rs11075958 
 
73033869 -0.01 6.23E-01 0.05 2.72E-01 0.13 1.25E-01 0.01 8.02E-01 
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SNP Importance Position ZFHX3 aerQTL ZFHX3 eQTL ZFHX3a aerQTL ZFHX3a eQTL 
   
Beta p value Beta p value Beta p value Beta p value 
rs8056528 
 
73036633 -0.01 7.83E-01 -0.05 2.87E-01 0.06 3.91E-01 -0.02 6.67E-01 
rs719353 
 
73042551 0.01 7.48E-01 -0.04 3.06E-01 0.00 9.49E-01 -0.02 6.46E-01 
rs4788689 
 
73049830 -0.03 2.62E-01 -0.10 1.02E-01 -0.03 7.29E-01 -0.11 1.20E-01 
rs2106261 AF GWAS 73051620 -0.01 7.10E-01 -0.02 6.66E-01 0.01 8.85E-01 -0.02 8.04E-01 
rs11863932 
 
73053579 -0.05 2.94E-01 -0.02 8.37E-01 -0.13 8.88E-02 0.04 6.67E-01 
rs1548373 
 
73059861 0.02 3.68E-01 -0.01 7.39E-01 0.09 1.45E-01 0.01 9.20E-01 
rs4788692 
 
73065656 -0.06 7.31E-02 -0.09 2.08E-01 0.05 6.25E-01 -0.14 1.05E-01 
rs12373097 
 
73068515 -0.02 5.79E-01 0.07 1.66E-01 -0.01 8.46E-01 0.07 2.59E-01 
rs8057081 
 
73068977 -0.01 7.74E-01 -0.03 4.90E-01 0.00 9.86E-01 -0.01 8.64E-01 
rs4788696 
 
73070310 0.00 9.45E-01 -0.01 8.99E-01 -0.12 3.41E-02 0.08 2.27E-01 
rs8060701 
 
73073289 0.17 1.29E-04 -0.04 6.15E-01 0.09 3.91E-01 -0.04 6.69E-01 
rs9940321 
 
73073808 0.03 2.87E-01 -0.03 5.27E-01 0.02 7.24E-01 -0.06 2.33E-01 
rs9940520 
 
73074012 0.11 3.63E-03 -0.09 1.50E-01 0.20 2.89E-02 -0.07 3.21E-01 
rs11641701 
 
73079212 0.01 7.58E-01 -0.01 8.30E-01 -0.12 2.17E-02 -0.05 3.18E-01 
rs7204751 
 
73079683 0.05 1.24E-01 0.02 8.05E-01 -0.09 2.49E-01 0.02 7.90E-01 
rs4788697 
 
73087494 -0.02 2.94E-01 -0.05 2.98E-01 -0.10 6.68E-02 -0.09 8.47E-02 
rs8052905 
 
73097663 0.03 5.60E-01 -0.04 6.91E-01 0.14 2.83E-01 -0.17 1.56E-01 
rs739414 
 
73097956 0.00 9.88E-01 -0.01 8.04E-01 -0.10 8.17E-02 0.02 7.80E-01 
rs8051826 
 
73102456 -0.01 6.36E-01 -0.03 6.30E-01 0.11 2.99E-01 -0.12 1.68E-01 
The significance threshold after correction for multiple testing was 7.69E-04. Effects are presented as log effect sizes (Beta) of the minor allele referenced to the 
major allele. Significant associations are in bold.
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Table A2.6 Comparison of aerQTLs between the NE and SA cohorts for ZFHX3a in blood 
SNP Importance Position NE Cohort SA Cohort Combined data set 
   
Beta p value Beta p value Beta p value 
rs117951282 
 
72820328 - - 0.36 2.09E-01 0.36 1.82E-01 
rs699444 
 
72827758 0.15 2.67E-02 0.06 8.06E-01 0.14 4.00E-02 
rs740178 Transcribed 72832135 0.18 5.49E-03 0.00 1.00E+00 0.13 2.50E-02 
rs12929452 
 
72838680 -0.16 1.70E-03 0.22 6.93E-02 -0.09 7.64E-02 
rs2266943 
 
72854307 0.17 7.39E-03 -0.02 8.28E-01 0.09 8.24E-02 
rs8058014 
 
72857544 0.19 3.53E-03 -0.02 8.73E-01 0.13 2.87E-02 
rs1476646 
 
72898348 -0.19 1.55E-04 0.24 2.07E-02 -0.09 6.78E-02 
rs4788668 
 
72901874 0.14 2.63E-03 0.01 9.04E-01 0.09 2.00E-02 
rs4788671 
 
72915085 -0.18 6.08E-04 0.21 2.33E-02 -0.06 1.81E-01 
rs6499594 
 
72917601 0.11 1.06E-01 -0.11 1.39E-01 0.00 9.63E-01 
rs16971366 
 
72919582 -0.21 6.49E-05 -0.03 8.17E-01 -0.17 8.36E-04 
rs9940310 
 
72925982 0.20 1.51E-02 -0.13 1.17E-01 0.02 7.70E-01 
rs9925261 
 
72927533 -0.13 8.54E-03 -0.18 3.84E-02 -0.14 1.00E-03 
rs16971384 
 
72931085 -0.17 2.08E-04 0.01 9.16E-01 -0.11 7.25E-03 
rs4788482 
 
72937079 -0.25 5.08E-08 -0.13 3.96E-01 -0.23 7.26E-07 
rs4788679 
 
72956544 -0.19 4.26E-05 -0.24 5.57E-02 -0.20 1.59E-05 
rs9936884 
 
72960230 -0.07 4.72E-01 0.04 5.51E-01 0.01 9.07E-01 
rs4788488 
 
72960283 -0.21 8.73E-06 0.01 8.43E-01 -0.13 2.04E-03 
rs8055870 
 
72972090 0.13 1.95E-02 0.18 8.18E-02 0.14 4.38E-03 
rs6499600 
 
72979374 -0.20 3.94E-05 -0.16 1.78E-02 -0.18 4.88E-06 
rs13336412 
 
72981949 0.20 3.10E-04 0.08 2.71E-01 0.15 9.51E-04 
rs2228200 
 
72984668 0.12 4.29E-01 0.42 1.35E-01 0.19 1.50E-01 
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SNP Importance Position NE Cohort SA Cohort Combined data set 
   
Beta p value Beta p value Beta p value 
rs2106258 
 
72990553 -0.26 3.61E-12 -0.34 1.36E-11 -0.29 7.09E-22 
rs2157786 
 
72991286 -0.24 2.70E-09 -0.34 1.25E-09 -0.27 5.41E-17 
rs10852515 Transcribed 72991660 -0.25 7.47E-15 -0.34 1.73E-18 -0.29 7.06E-31 
rs7193297 
 
72993831 0.21 1.20E-03 -0.18 1.47E-02 0.02 7.13E-01 
rs7404992 
 
72994419 -0.13 1.84E-01 -0.16 4.24E-02 -0.15 1.30E-02 
rs756717 
 
72996162 0.06 2.60E-01 0.08 3.47E-01 0.07 1.47E-01 
rs4788683 
 
72997747 -0.05 3.47E-01 -0.06 3.98E-01 -0.06 2.06E-01 
rs9921395 
 
73001957 -0.09 9.19E-02 0.19 1.24E-02 0.02 7.05E-01 
rs12445932 
 
73004432 -0.16 1.19E-02 0.13 2.92E-01 -0.08 1.60E-01 
rs7199343 Kawasaki GWAS 73009024 -0.02 6.91E-01 0.34 1.63E-03 0.07 1.89E-01 
rs11075954 
 
73012164 -0.09 6.86E-02 -0.20 1.27E-03 -0.14 3.70E-04 
rs2040508 
 
73012685 -0.02 8.31E-01 -0.10 1.89E-01 -0.06 2.46E-01 
rs16971456 
 
73013036 0.18 3.22E-02 0.13 1.47E-01 0.15 1.21E-02 
rs9930445 
 
73013482 0.08 1.90E-01 0.17 7.62E-03 0.13 3.48E-03 
rs4788684 
 
73013633 0.02 7.12E-01 -0.20 8.60E-04 -0.08 3.68E-02 
rs16971464 
 
73016143 0.28 1.78E-02 -0.21 5.98E-01 0.23 5.43E-02 
rs16971465 
 
73017061 0.16 8.41E-02 0.00 9.91E-01 0.07 2.87E-01 
rs4788489 
 
73017118 -0.05 3.29E-01 -0.19 4.30E-03 -0.11 7.79E-03 
rs16971474 
 
73019004 0.00 9.49E-01 0.17 3.25E-02 0.08 1.16E-01 
rs11640106 
 
73020116 0.03 5.69E-01 0.26 2.84E-03 0.10 2.99E-02 
rs1858800 
 
73024276 -0.10 7.52E-02 -0.17 7.02E-02 -0.12 1.34E-02 
rs756720 
 
73028921 0.10 1.39E-01 0.20 3.97E-02 0.14 1.41E-02 
rs7193343 AF GWAS 73029160 -0.05 4.35E-01 -0.04 6.29E-01 -0.05 3.70E-01 
rs11075958 
 
73033869 0.13 1.25E-01 0.48 2.63E-03 0.21 4.94E-03 
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SNP Importance Position NE Cohort SA Cohort Combined data set 
   
Beta p value Beta p value Beta p value 
rs8056528 
 
73036633 0.06 3.91E-01 0.05 5.19E-01 0.05 2.88E-01 
rs719353 
 
73042551 0.00 9.49E-01 0.01 9.23E-01 0.00 1.00E+00 
rs4788689 
 
73049830 -0.03 7.29E-01 0.14 1.22E-01 0.05 3.72E-01 
rs2106261 AF GWAS 73051620 0.01 8.85E-01 0.15 1.06E-01 0.07 2.31E-01 
rs11863932 
 
73053579 -0.13 8.88E-02 0.11 4.62E-01 -0.07 3.21E-01 
rs1548373 
 
73059861 0.09 1.45E-01 0.00 9.98E-01 0.05 3.00E-01 
rs4788692 
 
73065656 0.05 6.25E-01 -0.10 1.88E-01 -0.05 3.82E-01 
rs12373097 
 
73068515 -0.01 8.46E-01 -0.09 2.39E-01 -0.05 3.16E-01 
rs8057081 
 
73068977 0.00 9.86E-01 0.05 5.25E-01 0.02 6.58E-01 
rs4788696 
 
73070310 -0.12 3.41E-02 -0.25 1.68E-01 -0.13 1.76E-02 
rs8060701 
 
73073289 0.09 3.91E-01 -0.04 6.36E-01 0.00 9.52E-01 
rs9940321 
 
73073808 0.02 7.24E-01 0.04 5.94E-01 0.03 5.22E-01 
rs9940520 
 
73074012 0.20 2.89E-02 0.01 9.44E-01 0.08 1.90E-01 
rs11641701 
 
73079212 -0.12 2.17E-02 0.02 8.08E-01 -0.06 1.43E-01 
rs7204751 
 
73079683 -0.09 2.49E-01 -0.05 5.05E-01 -0.07 2.09E-01 
rs4788697 
 
73087494 -0.10 6.68E-02 -0.01 8.77E-01 -0.06 1.59E-01 
rs8052905 
 
73097663 0.14 2.83E-01 0.08 3.13E-01 0.09 1.51E-01 
rs739414 
 
73097956 -0.10 8.17E-02 -0.15 5.47E-02 -0.12 9.91E-03 
rs8051826 
 
73102456 0.11 2.99E-01 0.24 1.55E-02 0.18 9.97E-03 
Effect sizes and p-values are shown for each of the NE and SA cohorts and for the combined data set. Effects are presented as log effect sizes (Beta) of the minor 
allele referenced to the major allele. The significance threshold after correction for multiple testing was 7.69E-04. Significant associations are in bold.
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Table A2.7 Comparison of aerQTLs between the NE and SA cohorts for KCNN3 in blood 
SNP Importance Position NE Cohort SA Cohort Combined data set 
   
Beta p value Beta p value Beta p value 
rs1995662 
 
154679567 -0.02 8.66E-01 -0.04 7.42E-01 -0.02 7.40E-01 
rs6695232 
 
154681950 0.11 1.78E-01 0.02 7.91E-01 0.07 2.06E-01 
rs10128027 
 
154691445 -0.01 8.65E-01 0.08 3.43E-01 0.02 6.79E-01 
rs4845663 
 
154692088 -0.02 7.55E-01 0.06 4.96E-01 0.01 9.24E-01 
rs7523074 
 
154692269 0.06 6.17E-01 -0.16 1.13E-01 -0.05 5.38E-01 
rs7554577 
 
154692883 -0.03 7.28E-01 -0.13 9.63E-02 -0.07 2.04E-01 
rs11264249 
 
154693181 -0.04 6.46E-01 0.09 2.81E-01 0.01 8.12E-01 
rs11264251 
 
154693538 0.01 9.23E-01 0.07 3.83E-01 0.03 5.55E-01 
rs12087736 
 
154695678 0.09 5.13E-01 -0.12 3.42E-01 0.00 9.67E-01 
rs10494301 
 
154701218 -0.14 1.01E-01 0.03 8.17E-01 -0.09 1.62E-01 
rs12402320 
 
154701406 0.08 3.62E-01 -0.06 5.13E-01 0.02 7.19E-01 
rs884664 
 
154703725 0.07 4.03E-01 0.04 6.69E-01 0.06 3.51E-01 
rs6426905 
 
154706620 -0.02 8.93E-01 -0.27 1.32E-03 -0.19 1.39E-02 
rs960182 
 
154710756 -0.02 7.85E-01 -0.05 5.76E-01 -0.03 5.88E-01 
rs10908429 
 
154710904 0.05 5.41E-01 0.06 5.34E-01 0.05 3.88E-01 
rs6682000 
 
154711226 -0.03 7.50E-01 0.04 6.12E-01 0.00 9.63E-01 
rs12145386 
 
154713499 0.00 9.99E-01 -0.15 9.47E-02 -0.07 3.02E-01 
rs4999127 
 
154714006 -0.01 9.01E-01 0.03 8.18E-01 0.00 9.89E-01 
rs868108 
 
154720289 -0.13 1.65E-01 -0.07 4.44E-01 -0.10 1.17E-01 
rs6698628 
 
154721780 -0.19 4.78E-01 0.26 2.54E-02 0.17 1.52E-01 
rs906276 
 
154724392 -0.09 4.09E-01 -0.10 4.37E-01 -0.10 2.59E-01 
rs4845390 
 
154726374 -0.13 6.99E-02 0.01 9.25E-01 -0.07 1.57E-01 
rs10494300 
 
154726546 0.15 5.98E-02 0.06 5.51E-01 0.12 5.23E-02 
  
 
 
2
4
3
 
SNP Importance Position NE Cohort SA Cohort Combined data set 
   
Beta p value Beta p value Beta p value 
rs6682291 
 
154732776 0.25 4.13E-02 -0.04 7.04E-01 0.11 1.95E-01 
rs4845391 
 
154739104 -0.06 4.54E-01 -0.03 7.07E-01 -0.05 4.10E-01 
rs1051614 
 
154744807 0.13 2.17E-02 0.09 9.61E-02 0.11 4.60E-03 
rs1131820 
 
154744852 0.17 1.88E-02 0.15 2.31E-02 0.16 1.21E-03 
rs7532286 
 
154750816 0.00 9.51E-01 -0.14 6.59E-02 -0.06 2.46E-01 
rs1506982 
 
154753697 0.20 1.76E-01 -0.01 9.48E-01 0.12 2.67E-01 
rs4845671 
 
154755126 -0.05 6.01E-01 -0.03 6.49E-01 -0.04 4.93E-01 
rs12135902 
 
154756104 0.01 9.71E-01 -0.25 4.80E-01 -0.03 8.42E-01 
rs11264261 
 
154756443 0.15 4.13E-02 0.14 6.19E-02 0.15 5.86E-03 
rs883319 
 
154758422 -0.10 3.25E-01 -0.05 6.44E-01 -0.08 2.80E-01 
rs11584635 
 
154760965 -0.22 9.95E-03 -0.29 8.12E-03 -0.24 2.94E-04 
rs17719287 
 
154766495 0.14 3.13E-01 -0.13 5.65E-01 0.08 4.83E-01 
rs1419110 
 
154768689 -0.09 2.26E-01 -0.10 2.87E-01 -0.09 1.07E-01 
rs4492614 
 
154769561 0.13 1.54E-01 0.06 6.32E-01 0.11 1.33E-01 
rs17719419 
 
154771916 0.04 7.90E-01 -0.04 8.77E-01 0.02 8.53E-01 
rs6690388 
 
154774447 -0.23 1.44E-02 -0.10 3.20E-01 -0.18 9.58E-03 
rs6426944 
 
154776412 -0.19 4.64E-02 -0.12 1.36E-01 -0.16 1.39E-02 
rs2256209 
 
154779544 0.20 2.01E-01 -0.06 5.81E-01 0.05 6.13E-01 
rs2798601 
 
154779685 -0.33 1.69E-03 -0.19 5.99E-02 -0.26 2.99E-04 
rs6688473 
 
154783773 0.15 1.74E-01 0.01 8.89E-01 0.08 2.78E-01 
rs2335406 
 
154786686 0.00 9.58E-01 -0.05 6.07E-01 -0.02 7.42E-01 
rs1106236 
 
154787136 -0.03 6.95E-01 -0.04 5.53E-01 -0.04 5.03E-01 
rs1106235 
 
154787213 -0.06 5.28E-01 0.24 3.65E-02 0.04 5.62E-01 
rs1218601 
 
154791676 -0.04 6.41E-01 -0.04 6.86E-01 -0.04 5.37E-01 
rs951241 
 
154793798 0.03 7.83E-01 0.09 2.92E-01 0.06 3.68E-01 
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SNP Importance Position NE Cohort SA Cohort Combined data set 
   
Beta p value Beta p value Beta p value 
rs12029542 
 
154794897 0.06 5.90E-01 0.14 9.25E-02 0.10 1.34E-01 
rs11264268 
 
154796520 0.09 3.55E-01 0.02 8.31E-01 0.06 3.73E-01 
rs6681725 
 
154797062 -0.08 5.12E-01 0.16 4.68E-02 0.07 3.13E-01 
rs1218551 
 
154801173 0.02 8.39E-01 -0.14 2.03E-01 -0.03 6.51E-01 
rs11264270 
 
154802379 -0.02 9.07E-01 -0.13 2.74E-01 -0.07 4.47E-01 
rs4845394 
 
154808287 -0.04 6.10E-01 -0.03 7.43E-01 -0.04 5.38E-01 
rs1218578 
 
154810030 -0.10 1.90E-01 -0.07 3.45E-01 -0.09 1.07E-01 
rs11264274 
 
154811127 0.06 4.78E-01 0.13 2.22E-01 0.08 2.10E-01 
rs12128882 
 
154811435 -0.02 8.22E-01 0.04 6.05E-01 0.01 8.80E-01 
rs1218574 
 
154811677 -0.08 4.51E-01 0.08 3.12E-01 0.01 8.47E-01 
rs12740456 
 
154814197 0.08 4.62E-01 0.07 7.57E-01 0.08 4.06E-01 
rs13376333 
 
154814353 0.10 2.89E-01 -0.04 5.89E-01 0.03 6.40E-01 
rs6426987 
 
154815257 0.08 3.85E-01 -0.01 8.86E-01 0.04 5.64E-01 
rs1218565 
 
154817687 -0.05 5.18E-01 -0.11 2.07E-01 -0.07 2.11E-01 
rs4845396 
 
154828409 -0.08 3.66E-01 -0.13 5.50E-02 -0.11 5.31E-02 
rs1061122 
 
154832290 0.18 7.04E-02 0.08 3.81E-01 0.13 4.91E-02 
rs76110919 
 
154842095 
      rs2335407 
 
154843347 -0.14 7.80E-02 -0.05 5.41E-01 -0.10 7.88E-02
Effect sizes and p-values are shown for each of the NE and SA cohorts and for the combined data set. Effects are presented as log effect sizes (Beta) of the minor 
allele referenced to the major allele. The significance threshold after correction for multiple testing at this locus was 7.57e-04. Significant associations are in bold.
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Table A2.8 Associations between SNPs at 1q21 and 14q23 and CAV1 expression in blood 
SNP Importance Chromosome Position CAV1 eQTL 
  
 
 
Beta p value 
rs1995662 
 
1 154679567 -0.05 5.01E-01 
rs6695232 
 
1 154681950 0.07 1.14E-01 
rs10128027 
 
1 154691445 -0.03 4.80E-01 
rs4845663 
 
1 154692088 0.05 2.77E-01 
rs7523074 
 
1 154692269 -0.03 6.41E-01 
rs7554577 
 
1 154692883 0.00 9.23E-01 
rs11264249 
 
1 154693181 -0.02 6.81E-01 
rs11264251 
 
1 154693538 0.03 5.51E-01 
rs12087736 
 
1 154695678 -0.08 2.59E-01 
rs10494301 
 
1 154701218 0.04 4.39E-01 
rs12402320 
 
1 154701406 -0.04 4.23E-01 
rs884664 
 
1 154703725 -0.05 3.31E-01 
rs6426905 
 
1 154706620 -0.03 7.43E-01 
rs960182 
 
1 154710756 0.00 9.29E-01 
rs10908429 
 
1 154710904 -0.04 4.13E-01 
rs6682000 
 
1 154711226 0.09 4.25E-02 
rs12145386 
 
1 154713499 -0.09 1.43E-01 
rs4999127 
 
1 154714006 -0.08 1.94E-01 
rs868108 
 
1 154720289 0.08 1.02E-01 
rs6698628 
 
1 154721780 -0.07 5.54E-01 
rs906276 
 
1 154724392 -0.06 3.83E-01 
rs4845390 
 
1 154726374 0.03 5.51E-01 
rs10494300 
 
1 154726546 0.03 5.21E-01 
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SNP Importance Chromosome Position CAV1 eQTL 
  
 
 
Beta p value 
rs6682291 
 
1 154732776 0.07 4.00E-01 
rs4845391 
 
1 154739104 -0.04 4.17E-01 
rs1051614 Transcribed 1 154744807 -0.18 1.98E-04 
rs1131820 
 
1 154744852 -0.07 1.93E-01 
rs7532286 
 
1 154750816 0.06 1.67E-01 
rs1506982 
 
1 154753697 0.16 5.28E-02 
rs4845671 
 
1 154755126 0.08 7.61E-02 
rs12135902 
 
1 154756104 0.03 7.45E-01 
rs11264261 
 
1 154756443 -0.12 1.92E-02 
rs883319 
 
1 154758422 0.01 8.72E-01 
rs11584635 
 
1 154760965 0.05 3.12E-01 
rs17719287 
 
1 154766495 -0.07 4.27E-01 
rs1419110 
 
1 154768689 -0.02 6.34E-01 
rs4492614 
 
1 154769561 -0.12 4.62E-02 
rs17719419 
 
1 154771916 -0.02 8.07E-01 
rs6690388 
 
1 154774447 -0.03 5.46E-01 
rs6426944 
 
1 154776412 -0.04 3.64E-01 
rs2256209 
 
1 154779544 -0.08 2.96E-01 
rs2798601 
 
1 154779685 -0.02 7.80E-01 
rs6688473 
 
1 154783773 -0.03 5.68E-01 
rs2335406 
 
1 154786686 0.01 8.16E-01 
rs1106236 
 
1 154787136 -0.01 7.48E-01 
rs1106235 
 
1 154787213 -0.07 2.57E-01 
rs1218601 
 
1 154791676 -0.01 8.94E-01 
rs951241 
 
1 154793798 0.05 4.38E-01 
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SNP Importance Chromosome Position CAV1 eQTL 
  
 
 
Beta p value 
rs12029542 
 
1 154794897 -0.01 8.90E-01 
rs11264268 
 
1 154796520 0.03 5.04E-01 
rs6681725 
 
1 154797062 0.03 6.27E-01 
rs1218551 
 
1 154801173 -0.04 4.44E-01 
rs11264270 
 
1 154802379 0.01 8.70E-01 
rs4845394 
 
1 154808287 -0.01 7.39E-01 
rs1218578 
 
1 154810030 0.04 4.13E-01 
rs11264274 
 
1 154811127 -0.04 3.72E-01 
rs12128882 
 
1 154811435 -0.06 2.16E-01 
rs1218574 
 
1 154811677 -0.08 2.42E-01 
rs12740456 
 
1 154814197 0.03 6.81E-01 
rs13376333 AF GWAS 1 154814353 0.02 7.51E-01 
rs6426987 
 
1 154815257 0.01 8.67E-01 
rs1218565 
 
1 154817687 0.02 6.25E-01 
rs4845396 
 
1 154828409 0.02 7.15E-01 
rs1061122 
 
1 154832290 -0.02 7.28E-01 
rs76110919 
 
1 154842095 NA 
 rs2335407 
 
1 154843347 0.06 1.90E-01
rs4459477 
 
14 64346190 -0.04 6.72E-01 
rs17750888 
 
14 64355420 -0.09 1.50E-01 
rs12588807 
 
14 64363070 -0.01 8.88E-01 
rs2275018 
 
14 64375985 -0.06 3.99E-01 
rs7153036 
 
14 64377548 0.00 9.59E-01 
rs12879919 
 
14 64382350 -0.08 3.59E-01 
rs11158521 
 
14 64401255 -0.12 6.10E-02 
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SNP Importance Chromosome Position CAV1 eQTL 
  
 
 
Beta p value 
rs2184292 
 
14 64408135 -0.09 1.91E-01 
rs7153680 
 
14 64474227 -0.11 9.21E-02 
rs4566057 
 
14 64506541 -0.11 2.57E-01 
rs1890908 
 
14 64519035 0.08 5.22E-01 
rs10137972 
 
14 64557734 -0.08 5.29E-01 
rs17101651 
 
14 64561324 -0.17 1.70E-01 
rs8022428 
 
14 64563613 0.01 8.52E-01 
rs8007972 
 
14 64564527 0.13 1.43E-01 
rs8016917 
 
14 64569951 -0.12 3.41E-01 
rs10142318 
 
14 64604281 -0.13 1.74E-01 
rs7144688 
 
14 64613473 0.02 7.77E-01 
rs11158533 
 
14 64622988 0.22 9.35E-04 
rs17751454 
 
14 64625181 0.14 7.29E-02 
rs3866743 
 
14 64633322 -0.09 4.66E-01 
rs7161192 
 
14 64637147 0.19 4.23E-03 
rs2256191 
 
14 64656855 0.10 1.39E-01 
rs1152591 AF GWAS 14 64680848 0.20 1.26E-03 
rs7145919 
 
14 64687601 0.31 4.89E-03 
rs8020646 
 
14 64691320 -0.15 1.73E-01 
rs12434245 
 
14 64691853 0.31 4.89E-03 
rs1048315 
 
14 64692465 -0.07 4.49E-01 
rs1152582 Transcribed 14 64692630 -0.11 5.27E-02 
rs7229 
 
14 64692825 -0.09 1.20E-01 
rs2772163 
 
14 64693385 0.12 9.24E-02 
rs928554 
 
14 64694195 -0.14 1.75E-02 
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SNP Importance Chromosome Position CAV1 eQTL 
  
 
 
Beta p value 
rs4986938 
 
14 64699816 0.07 3.12E-01 
rs1256064 
 
14 64700739 -0.05 5.96E-01 
rs1256063 
 
14 64702217 0.09 4.23E-01 
rs10144225 
 
14 64704994 -0.15 1.53E-01 
rs1256049 
 
14 64724051 0.16 3.85E-01 
Effects are presented as log effect sizes (Beta) of the minor allele referenced to the major allele. The significance threshold after correction for multiple testing for 
trans-acting associations was 2.48E-04. Significant associations are in bold.  
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Table A2.9  Associations with total expression of KCNN3 in chromosome band 1q21 in tissue 
   RAA eQTL LAA eQTL IMA eQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs1995662  154679567 -0.02 8.07E-01 0.21 2.46E-01 -0.37 2.37E-02 
rs6695232  154681950 -0.02 6.26E-01 -0.10 4.31E-01 0.19 4.97E-02 
rs10128027  154691445 -0.02 6.59E-01 0.11 3.17E-01 0.09 3.58E-01 
rs4845663  154692088 0.03 5.96E-01 -0.08 4.83E-01 0.16 1.04E-01 
rs7554577  154692883 0.02 6.41E-01 -0.07 4.05E-01 0.10 2.95E-01 
rs11264249  154693181 0.04 4.31E-01 -0.07 4.28E-01 0.06 5.29E-01 
rs11264251  154693538 -0.01 8.93E-01 0.01 8.94E-01 0.06 5.67E-01 
rs12087736  154695678 0.11 1.27E-01 -0.04 7.87E-01 -0.05 7.45E-01 
rs10494301  154701218 0.06 2.70E-01 -0.12 4.81E-01 -0.04 7.53E-01 
rs12402320  154701406 -0.05 2.89E-01 0.01 9.66E-01 -0.07 5.14E-01 
rs884664  154703725 -0.01 9.08E-01 -0.09 5.56E-01 0.13 2.13E-01 
rs925042  154704595 0.01 8.75E-01 0.03 7.57E-01 -0.14 1.92E-01 
rs6426905  154706620 0.16 6.23E-02 -0.14 5.65E-01 0.12 4.63E-01 
rs960182  154710756 -0.04 3.87E-01 0.16 7.34E-02 -0.13 2.07E-01 
rs10908429  154710904 -0.06 3.12E-01 -0.10 3.71E-01 0.05 7.25E-01 
rs6682000  154711226 0.03 5.95E-01 0.13 4.24E-01 -0.15 1.51E-01 
rs12145386  154713499 0.04 4.89E-01 0.11 3.37E-01 0.12 3.92E-01 
rs4999127  154714006 0.05 4.47E-01 -0.38 2.04E-02 0.12 3.90E-01 
rs6698628  154721780 -0.18 1.44E-01 0.01 9.65E-01 -0.20 5.55E-01 
rs906276  154724392 -0.01 8.51E-01 0.01 9.36E-01 -0.03 8.45E-01 
rs4845390  154726374 -0.12 8.21E-03 -0.14 2.32E-01 0.00 9.98E-01 
rs10494300  154726546 0.12 1.13E-02 0.09 4.16E-01 -0.09 4.22E-01 
rs10908435  154729394 0.08 1.11E-01 0.01 8.92E-01 -0.06 6.02E-01 
rs6682291  154732776 0.14 1.54E-01 0.09 7.31E-01 0.21 3.44E-01 
  
 
 
2
5
1
 
   RAA eQTL LAA eQTL IMA eQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs4845391  154739104 0.03 5.97E-01 -0.16 2.47E-01 -0.07 5.34E-01 
rs1051614 KCNN3 Transcribed 154744807 0.04 4.25E-01 0.29 2.53E-02 -0.03 7.66E-01 
rs1131820  154744852 0.08 1.70E-01 0.18 1.78E-01 0.04 7.28E-01 
rs7532286  154750816 -0.02 6.05E-01 0.01 9.65E-01 0.11 2.39E-01 
rs1506982  154753697 0.02 8.34E-01 -0.02 9.38E-01 0.01 9.69E-01 
rs4845671  154755126 0.01 8.70E-01 -0.29 2.53E-02 -0.09 3.95E-01 
rs11264261  154756443 0.06 2.65E-01 0.29 2.53E-02 0.00 9.88E-01 
rs883319  154758422 -0.06 2.67E-01 -0.26 8.26E-02 -0.19 1.36E-01 
rs11584635  154760965 -0.08 1.22E-01 -0.17 2.35E-01 -0.04 7.42E-01 
rs17719287  154766495 0.01 9.56E-01 0.09 7.31E-01 0.27 2.63E-01 
rs1419110  154768689 0.02 6.73E-01 -0.17 2.45E-01 -0.06 5.41E-01 
rs4492614  154769561 -0.08 2.62E-01 0.26 5.17E-02 0.02 8.98E-01 
rs17719419  154771916 0.13 2.72E-01 0.09 7.31E-01 0.20 5.02E-01 
rs6690388  154774447 -0.09 1.47E-01 -0.07 5.37E-01 0.05 7.08E-01 
rs6426944  154776412 -0.13 1.49E-02 0.01 9.32E-01 0.19 7.39E-02 
rs2256209  154779544 -0.14 5.81E-02 0.16 2.98E-01 0.19 2.25E-01 
rs2798601  154779685 -0.07 2.82E-01 -0.03 7.65E-01 0.13 2.46E-01 
rs6688473  154783773 -0.05 4.89E-01 0.10 3.67E-01 0.22 1.26E-01 
rs2335406  154786686 0.06 1.58E-01 0.17 1.56E-01 -0.09 3.41E-01 
rs1106236  154787136 -0.03 5.03E-01 -0.09 4.53E-01 -0.03 7.47E-01 
rs1106235  154787213 -0.02 7.06E-01 -0.10 2.11E-01 -0.15 2.06E-01 
rs1218601  154791676 -0.06 2.54E-01 -0.19 5.25E-02 -0.07 5.38E-01 
rs951241  154793798 0.02 7.75E-01 0.11 3.17E-01 0.19 2.21E-01 
rs12029542  154794897 -0.05 4.01E-01 0.20 4.28E-02 0.18 1.45E-01 
rs11264268  154796520 0.05 3.74E-01 -0.02 8.86E-01 -0.09 4.73E-01 
rs6681725  154797062 0.05 4.52E-01 -0.09 5.93E-01 0.04 8.17E-01 
  
 
 
2
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   RAA eQTL LAA eQTL IMA eQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs1218551  154801173 -0.01 7.68E-01 0.13 1.84E-01 0.07 5.18E-01 
rs11264270  154802379 -0.16 7.72E-03 0.21 2.09E-01 0.03 8.56E-01 
rs4845394  154808287 0.03 5.51E-01 -0.07 4.51E-01 0.01 9.05E-01 
rs1218578  154810030 0.04 3.75E-01 -0.08 4.33E-01 0.05 6.26E-01 
rs12128882  154811435 0.04 4.62E-01 0.20 1.89E-01 0.07 5.41E-01 
rs1218574  154811677 -0.04 5.17E-01 0.01 9.66E-01 -0.08 4.89E-01 
rs12740456  154814197 0.06 3.50E-01 -0.10 5.87E-01 -0.26 4.26E-02 
rs13376333 AF GWAS 154814353 0.08 9.43E-02 -0.05 7.38E-01 0.02 8.51E-01 
rs6426987  154815257 0.05 2.74E-01 0.00 9.99E-01 0.05 6.16E-01 
rs1218565  154817687 0.01 8.89E-01 0.00 9.81E-01 0.02 7.88E-01 
rs4845396  154828409 0.08 8.63E-02 -0.12 1.68E-01 -0.05 6.06E-01 
rs1061122  154832290 0.10 6.66E-02 -0.10 3.32E-01 0.07 6.14E-01 
rs76110919  154842095       
rs2335407  154843347 -0.05 3.40E-01 0.12 1.83E-01 -0.12 3.03E-01 
The significance threshold after correction for multiple testing was 7.81E-04. Effects are presented as log effect sizes (Beta) of the minor allele referenced to the 
major allele. Significant associations are in bold. 
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Table A2.10  Associations with allelic expression ratio of KCNN3 in chromosome band 1q21 in tissue 
   
RAA aerQTL LAA aerQTL IMA aerQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs1995662 
 
154679567 -0.10 4.39E-01 -0.32 3.57E-01 -0.43 6.50E-03 
rs6695232 
 
154681950 0.10 1.12E-01 -0.01 9.32E-01 0.05 6.26E-01 
rs10128027 
 
154691445 0.02 7.59E-01 0.05 7.83E-01 -0.16 1.06E-01 
rs4845663 
 
154692088 0.10 1.21E-01 -0.09 6.68E-01 0.02 8.17E-01 
rs7554577 
 
154692883 0.08 2.56E-01 0.07 7.94E-01 0.12 1.85E-01 
rs11264249 
 
154693181 0.12 8.49E-02 0.07 7.94E-01 0.15 1.09E-01 
rs11264251 
 
154693538 -0.04 6.38E-01 0.07 7.33E-01 -0.15 1.35E-01 
rs12087736 
 
154695678 0.11 2.41E-01 0.30 2.05E-01 0.12 3.39E-01 
rs10494301 
 
154701218 0.08 2.29E-01 0.09 5.30E-01 -0.02 8.18E-01 
rs12402320 
 
154701406 -0.12 1.58E-01 -0.03 9.14E-01 0.01 9.19E-01 
rs884664 
 
154703725 0.06 3.89E-01 -0.15 4.04E-01 0.09 4.39E-01 
rs925042 
 
154704595 -0.16 2.52E-02 -0.09 7.29E-01 -0.07 4.89E-01 
rs6426905 
 
154706620 0.33 3.20E-03 -0.36 2.95E-01 0.23 1.57E-01 
rs960182 
 
154710756 -0.04 5.14E-01 -0.07 7.46E-01 -0.04 6.25E-01 
rs10908429 
 
154710904 0.13 9.11E-02 0.19 2.12E-01 0.12 2.42E-01 
rs6682000 
 
154711226 0.09 2.13E-01 0.20 1.88E-01 0.19 6.16E-02 
rs12145386 
 
154713499 -0.24 1.45E-02 0.27 4.49E-01 -0.03 8.06E-01 
rs4999127 
 
154714006 0.24 2.65E-02 
  
0.12 3.82E-01 
rs6698628 
 
154721780 0.08 7.34E-01 
    rs906276 
 
154724392 0.23 9.58E-03 0.33 1.61E-01 0.21 1.54E-01 
rs4845390 
 
154726374 0.25 9.08E-06 0.33 1.10E-02 0.20 1.64E-02 
rs10494300 
 
154726546 -0.16 8.84E-03 -0.31 4.60E-02 -0.16 5.61E-02 
rs10908435 
 
154729394 -0.03 6.52E-01 -0.09 6.68E-01 -0.01 9.11E-01 
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RAA aerQTL LAA aerQTL IMA aerQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs6682291 
 
154732776 -0.31 1.19E-03 -0.46 1.68E-01 -0.44 5.14E-03 
rs4845391 
 
154739104 0.03 6.15E-01 0.03 8.99E-01 0.10 2.54E-01 
rs1051614 KCNN3 Transcribed 154744807 -0.31 8.38E-23 -0.35 7.73E-07 -0.30 9.80E-10 
rs1131820 
 
154744852 -0.30 4.39E-09 -0.35 8.49E-04 -0.31 1.25E-05 
rs7532286 
 
154750816 0.17 3.49E-03 0.22 6.75E-02 0.17 7.33E-02 
rs1506982 
 
154753697 -0.13 5.11E-01 
  
-0.14 4.17E-01 
rs4845671 
 
154755126 0.18 1.15E-02 
  
0.24 1.13E-02 
rs11264261 
 
154756443 -0.27 3.58E-07 -0.19 1.52E-01 -0.25 9.59E-04 
rs883319 
 
154758422 0.11 1.73E-01 -0.27 4.49E-01 0.26 1.43E-02 
rs11584635 
 
154760965 0.33 3.39E-08 0.32 8.35E-02 0.27 1.06E-03 
rs17719287 
 
154766495 -0.31 9.47E-03 -0.46 1.68E-01 -0.37 2.30E-02 
rs1419110 
 
154768689 -0.21 6.08E-04 -0.43 5.42E-02 -0.14 1.41E-01 
rs4492614 
 
154769561 -0.01 9.19E-01 0.11 5.76E-01 -0.08 6.06E-01 
rs17719419 
 
154771916 -0.09 6.19E-01 0.46 1.68E-01 -0.25 2.87E-01 
rs6690388 
 
154774447 0.22 1.25E-02 0.32 1.72E-01 0.25 5.86E-02 
rs6426944 
 
154776412 0.05 5.14E-01 0.00 9.83E-01 -0.02 8.58E-01 
rs2256209 
 
154779544 -0.03 7.52E-01 -0.33 1.61E-01 -0.06 6.38E-01 
rs2798601 
 
154779685 0.13 2.23E-01 0.32 1.72E-01 0.04 8.04E-01 
rs6688473 
 
154783773 -0.06 4.64E-01 -0.07 7.44E-01 -0.18 1.16E-01 
rs2335406 
 
154786686 -0.08 2.09E-01 -0.04 8.23E-01 0.07 4.85E-01 
rs1106236 
 
154787136 0.11 8.43E-02 0.34 2.69E-02 0.00 9.99E-01 
rs1106235 
 
154787213 0.23 1.22E-02 0.32 3.57E-01 0.28 5.69E-02 
rs1218601 
 
154791676 0.15 7.71E-02 0.09 6.58E-01 0.18 8.75E-02 
rs951241 
 
154793798 0.08 4.10E-01 0.46 1.68E-01 -0.08 6.53E-01 
rs12029542 
 
154794897 0.06 4.71E-01 0.13 5.29E-01 -0.03 7.84E-01 
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RAA aerQTL LAA aerQTL IMA aerQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs11264268 
 
154796520 -0.10 1.99E-01 -0.38 3.11E-02 -0.10 3.69E-01 
rs6681725 
 
154797062 -0.10 3.91E-01 0.36 1.18E-01 -0.26 1.18E-01 
rs1218551 
 
154801173 0.05 4.51E-01 0.22 1.86E-01 0.04 6.08E-01 
rs11264270 
 
154802379 -0.09 3.34E-01 -0.33 1.61E-01 -0.33 4.16E-02 
rs4845394 
 
154808287 0.12 5.76E-02 -0.22 1.48E-01 0.06 5.48E-01 
rs1218578 
 
154810030 0.07 3.54E-01 0.21 2.12E-01 0.07 4.56E-01 
rs12128882 
 
154811435 -0.04 5.28E-01 0.36 4.93E-02 0.01 9.62E-01 
rs1218574 
 
154811677 -0.04 6.79E-01 0.32 3.57E-01 -0.11 4.62E-01 
rs12740456 
 
154814197 -0.05 6.01E-01 0.39 9.26E-02 -0.03 8.37E-01 
rs13376333 AF GWAS 154814353 -0.01 9.27E-01 0.38 9.62E-04 0.07 5.16E-01 
rs6426987 
 
154815257 -0.03 6.55E-01 0.37 9.85E-03 0.05 6.72E-01 
rs1218565 
 
154817687 -0.03 6.24E-01 0.36 2.61E-03 0.04 7.17E-01 
rs4845396 
 
154828409 -0.09 1.29E-01 -0.03 8.57E-01 0.00 9.90E-01 
rs1061122 
 
154832290 0.09 2.53E-01 -0.10 5.23E-01 0.07 5.07E-01 
rs76110919 
 
154842095 
      rs2335407   154843347 0.01 8.27E-01 -0.07 6.76E-01 -0.09 3.06E-01 
The significance threshold after correction for multiple testing was 7.81E-04. Effects are presented as log effect sizes (Beta) of the minor allele referenced to the 
major allele. Significant associations are in bold. 
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Table A2.11 Associations with total expression of PRRX1 in chromosome band 1q24 in tissue 
   RAA eQTL LAA eQTL IMA eQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs12021752  170510520 -0.15 4.78E-02 -0.17 5.40E-01 0.15 1.46E-01 
rs16863425  170519884 -0.14 4.30E-02 -0.17 5.40E-01 0.10 2.71E-01 
rs913257 GORAB Transcribed 170521376 -0.08 1.49E-01 -0.29 2.46E-01 0.02 8.07E-01 
rs7552922 GORAB Transcribed 170521650 -0.13 1.47E-01 0.61 9.67E-02 0.14 2.82E-01 
rs12038857  170535636 -0.01 8.65E-01 -0.17 7.09E-01 -0.22 5.13E-02 
rs7535322  170554924 -0.04 6.10E-01 0.06 8.35E-01 -0.04 7.03E-01 
rs12027180  170563205 0.13 4.11E-02 -0.07 8.49E-01 -0.05 6.17E-01 
rs3903239 AF GWAS 170569317 -0.11 7.23E-02 0.43 3.33E-01 -0.09 2.91E-01 
rs619456  170585832 0.12 4.49E-02 -0.50 6.64E-02 -0.09 2.56E-01 
rs12129225  170615833 0.01 8.38E-01 -0.09 7.55E-01 0.11 1.87E-01 
rs12038255  170618461 0.14 9.10E-02 0.11 6.97E-01 -0.12 3.86E-01 
rs659580  170633896 -0.01 8.32E-01 0.55 1.10E-01 -0.06 5.32E-01 
rs502612  170641803 -0.10 1.01E-01 0.43 3.33E-01 -0.05 4.70E-01 
rs591715  170642509 0.13 7.55E-02 -0.07 8.49E-01 -0.02 8.49E-01 
rs12066968  170652434 -0.08 4.75E-01 0.07 8.76E-01 0.21 1.41E-01 
rs513287  170664237 0.01 9.17E-01 0.14 6.00E-01 0.05 5.51E-01 
rs7540713  170674903 0.05 4.77E-01 -0.33 3.52E-01 -0.11 3.08E-01 
rs58473244  170705898 0.00  0.00  0.00  
rs3820416 PRRX1 Transcribed 170707675 -0.08 2.17E-01 0.18 4.12E-01 0.09 3.18E-01 
rs4656799  170709195 -0.02 7.18E-01 0.09 6.67E-01 0.01 8.74E-01 
rs11799764  170714230 0.05 4.94E-01 -0.20 4.65E-01 -0.15 2.07E-01 
rs2421494  170715531 -0.07 3.35E-01 -0.39 3.76E-01 0.07 4.83E-01 
  
 
 
2
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rs11589602  170716202 0.09 2.06E-01 -0.21 4.32E-01 0.00 9.96E-01 
The significance threshold after correction for multiple testing was 2.17E-03. Effects are presented as log effect sizes (Beta) of the minor allele referenced to the 
major allele. Significant associations are in bold. 
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Table A2.12 Associations with allelic expression ratio of PRRX1 in chromosome band 1q24 in tissue 
   
RAA aerQTL LAA aerQTL IMA aerQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs12021752 
 
170510520 -0.14 2.72E-01 
  
-0.14 4.37E-01 
rs16863425 
 
170519884 -0.10 4.42E-01 
  
-0.10 5.96E-01 
rs913257 GORAB Transcribed 170521376 -0.18 1.81E-01 
  
-0.21 2.75E-01 
rs7552922 GORAB Transcribed 170521650 0.08 6.73E-01 
  
-0.07 8.10E-01 
rs12038857 
 
170535636 -0.15 3.52E-01 
  
-0.12 5.56E-01 
rs7535322 
 
170554924 -0.01 9.58E-01 
  
0.04 8.54E-01 
rs12027180 
 
170563205 0.65 8.60E-06 
  
0.68 4.34E-04 
rs3903239 AF GWAS 170569317 -0.37 2.53E-03 
  
-0.47 1.12E-02 
rs619456 
 
170585832 0.52 1.88E-04 
  
0.54 7.66E-03 
rs12129225 
 
170615833 0.02 9.15E-01 
  
-0.09 6.41E-01 
rs12038255 
 
170618461 0.21 1.15E-01 
  
0.37 1.92E-02 
rs659580 
 
170633896 0.01 9.40E-01 
  
-0.12 6.91E-01 
rs502612 
 
170641803 -0.40 1.31E-03 
  
-0.39 3.29E-02 
rs591715 
 
170642509 0.71 1.93E-05 
  
0.69 8.55E-04 
rs12066968 
 
170652434 0.61 9.09E-03 
  
0.69 3.85E-03 
rs513287 
 
170664237 -0.66 1.22E-12 
  
-0.68 2.13E-08 
rs7540713 
 
170674903 0.52 1.37E-03 
  
0.52 1.78E-02 
rs58473244 
 
170705898 
      rs3820416 PRRX1 Transcribed 170707675 -0.68 2.50E-36 
  
-0.69 3.25E-25 
rs4656799 
 
170709195 -0.68 3.25E-20 
  
-0.69 2.90E-11 
rs11799764 
 
170714230 0.69 1.51E-03 
  
0.65 5.12E-02 
rs2421494 
 
170715531 -0.68 1.24E-12 
  
-0.69 5.74E-09 
rs11589602   170716202 0.49 1.42E-02     0.46 1.27E-01 
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The significance threshold after correction for multiple testing was 2.17E-03. Effects are presented as log effect sizes (Beta) of the minor allele referenced to the 
major allele. Significant associations are in bold. 
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Table A2.13 Associations with total expression of GORAB in chromosome band 1q24 in tissue 
   RAA eQTL LAA eQTL IMA eQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs12021752  170510520 -0.08 1.09E-01 0.08 3.82E-01 0.01 8.70E-01 
rs16863425  170519884 -0.06 1.89E-01 0.08 3.82E-01 -0.03 6.72E-01 
rs913257 GORAB Transcribed 170521376 -0.08 6.41E-02 0.04 6.46E-01 0.02 6.83E-01 
rs7552922 GORAB Transcribed 170521650 0.02 7.16E-01 0.03 7.99E-01 -0.09 3.10E-01 
rs12038857  170535636 -0.04 4.20E-01 -0.03 8.35E-01 -0.02 7.77E-01 
rs7535322  170554924 -0.02 6.55E-01 0.06 5.25E-01 0.00 9.58E-01 
rs12027180  170563205 0.11 8.92E-03 0.09 3.05E-01 -0.06 3.03E-01 
rs3903239 AF GWAS 170569317 -0.04 3.36E-01 0.26 3.11E-02 0.13 1.09E-02 
rs619456  170585832 0.09 2.80E-02 -0.14 1.25E-01 -0.06 2.50E-01 
rs12129225  170615833 -0.08 5.72E-02 -0.19 1.30E-02 -0.08 1.48E-01 
rs12038255  170618461 0.24 3.02E-05 0.03 7.30E-01 0.03 7.17E-01 
rs659580  170633896 -0.09 5.17E-02 0.18 1.10E-01 0.11 7.50E-02 
rs502612  170641803 0.01 8.45E-01 0.30 2.32E-02 0.11 1.83E-02 
rs591715  170642509 0.10 4.13E-02 0.19 1.08E-01 -0.07 3.23E-01 
rs12066968  170652434 -0.02 7.69E-01 0.18 2.41E-01 0.01 9.15E-01 
rs513287  170664237 -0.02 6.34E-01 -0.13 1.73E-01 -0.04 4.54E-01 
rs7540713  170674903 0.05 3.06E-01 -0.11 4.02E-01 0.05 5.15E-01 
rs58473244  170705898 0.00  0.00  0.00  
rs3820416 PRRX1 Transcribed 170707675 -0.05 2.50E-01 -0.10 2.98E-01 0.05 4.26E-01 
rs4656799  170709195 0.01 7.49E-01 -0.18 3.63E-03 0.09 9.25E-02 
rs11799764  170714230 0.03 5.43E-01 -0.14 9.84E-02 0.02 8.23E-01 
rs2421494  170715531 -0.01 8.75E-01 0.05 7.68E-01 0.05 4.65E-01 
  
 
 
2
6
1
 
rs11589602  170716202 0.05 3.24E-01 0.02 8.43E-01 -0.11 6.78E-02 
The significance threshold after correction for multiple testing was 2.17E-03. Effects are presented as log effect sizes (Beta) of the minor allele referenced to the 
major allele. Significant associations are in bold. 
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Table A2.14 Associations with total expression of GORAB in chromosome band 1q24 in tissue 
   
RAA aerQTL LAA aerQTL IMA aerQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs12021752 
 
170510520 0.19 3.52E-08 -0.35 8.33E-02 0.23 2.17E-03 
rs16863425 
 
170519884 0.17 9.87E-08 -0.35 8.33E-02 0.19 2.80E-04 
rs913257 GORAB Transcribed 170521376 0.23 8.02E-14 -0.38 3.36E-03 0.31 1.71E-08 
rs7552922 GORAB Transcribed 170521650 -0.09 6.60E-04 0.00 1.00E+00 0.05 2.06E-01 
rs12038857 
 
170535636 0.15 1.40E-03 -0.19 1.38E-01 0.09 2.37E-01 
rs7535322 
 
170554924 0.08 2.01E-02 -0.24 2.01E-02 0.12 4.04E-02 
rs12027180 
 
170563205 -0.12 1.57E-03 0.40 1.21E-01 -0.06 3.71E-01 
rs3903239 AF GWAS 170569317 0.06 8.33E-02 -0.17 2.17E-03 0.04 4.39E-01 
rs619456 
 
170585832 -0.11 2.70E-03 0.40 1.21E-01 -0.11 9.43E-02 
rs12129225 
 
170615833 0.06 1.80E-01 0.16 5.84E-03 -0.01 1.00E+00 
rs12038255 
 
170618461 -0.06 1.60E-02 0.24 2.85E-02 -0.05 2.37E-01 
rs659580 
 
170633896 0.01 1.00E+00 -0.17 2.17E-03 0.03 5.27E-01 
rs502612 
 
170641803 0.07 2.85E-02 -0.14 4.29E-04 0.07 2.06E-01 
rs591715 
 
170642509 -0.15 1.83E-04 0.18 1.80E-01 -0.08 1.80E-01 
rs12066968 
 
170652434 0.10 7.36E-02 -0.19 1.38E-01 -0.02 1.00E+00 
rs513287 
 
170664237 -0.02 5.27E-01 0.12 1.80E-01 0.01 6.55E-01 
rs7540713 
 
170674903 -0.12 1.13E-03 0.19 1.21E-01 -0.05 4.39E-01 
rs58473244 
 
170705898 
      rs3820416 PRRX1 Transcribed 170707675 0.03 3.71E-01 -0.25 5.27E-01 0.03 5.27E-01 
rs4656799 
 
170709195 -0.02 6.55E-01 0.10 4.39E-01 0.08 1.80E-01 
rs11799764 
 
170714230 -0.07 1.21E-01 0.12 3.71E-01 -0.01 1.00E+00 
rs2421494 
 
170715531 0.08 6.52E-02 
  
0.01 1.00E+00 
rs11589602   170716202 -0.06 3.17E-01 -0.15 2.37E-01 -0.03 6.55E-01 
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The significance threshold after correction for multiple testing was 2.17E-03. Effects are presented as log effect sizes (Beta) of the minor allele referenced to the 
major allele. Significant associations are in bold. 
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Table A2.15 Associations with total expression of PITX2a/b in chromosome band 4q25 in tissue 
   RAA eQTL LAA eQTL IMA eQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs75911264  111538810       
rs6533526  111538827       
rs2595110  111545323 -0.09 5.63E-01 -0.09 6.76E-01 0.26 3.43E-01 
rs976568  111550721 0.16 3.42E-01 0.23 2.53E-01 -0.40 2.72E-01 
rs2739200 PITX2 Transcribed 111558411 0.12 4.67E-01 0.31 1.87E-01 -0.48 1.84E-01 
rs12498374  111584419 0.17 3.54E-01 0.05 8.29E-01 -0.71 6.19E-02 
rs2723296  111604483 0.16 3.30E-01 0.31 1.87E-01 -0.50 1.68E-01 
rs1448799  111622782 0.42 1.79E-02 0.09 6.89E-01 0.19 5.73E-01 
rs16997168  111629039 0.66 8.96E-04 0.16 4.77E-01 -0.87 6.17E-02 
rs10222783  111634826 0.08 7.35E-01 -0.42 2.45E-01 0.05 9.14E-01 
rs4307025  111657503 0.44 1.13E-02 0.23 3.13E-01 0.11 7.28E-01 
rs2723333  111699091 0.04 8.57E-01 0.47 1.78E-01 0.41 2.49E-01 
rs17042171 AF GWAS 111708287 0.70 6.48E-04 0.21 3.30E-01 -0.31 4.85E-01 
rs2200733 AF GWAS 111710169 0.68 1.42E-03 0.14 2.80E-01 -0.44 3.71E-01 
rs13126975  111717525 -0.18 4.39E-01 -0.04 9.43E-01 0.15 6.44E-01 
rs6843082 AF GWAS 111718067 0.58 1.35E-03 0.23 2.73E-01 0.04 9.19E-01 
rs10033464 AF GWAS 111720761 0.09 7.64E-01 0.13 7.90E-01 0.38 4.04E-01 
rs6533531  111731965 0.32 3.88E-02 0.19 4.93E-01 0.23 4.83E-01 
rs3853444  111734136 0.17 2.88E-01 -0.48 7.22E-02 0.59 2.18E-02 
rs17570669  111736882 -0.66 8.02E-02   0.24 7.62E-01 
rs7674295  111741438 -0.46 2.47E-02 0.13 6.85E-01 -0.37 3.45E-01 
rs11938968  111742752 -0.24 1.15E-01 0.24 1.84E-01 -0.04 8.67E-01 
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   RAA eQTL LAA eQTL IMA eQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs3866836  111745640 0.15 3.89E-01 -0.16 4.88E-01 -0.29 3.82E-01 
rs4032971  111751723 0.26 1.70E-01 -0.23 2.79E-01 -0.18 6.43E-01 
rs3853445  111761487 -0.14 4.55E-01 -0.15 6.10E-01 0.45 1.74E-01 
rs17571707  111765413 -0.31 3.10E-01 0.19 6.02E-01 -0.50 3.26E-01 
rs6838973  111765495 -0.38 1.12E-02 -0.09 6.87E-01 0.26 3.98E-01 
rs3866823  111782436 -0.02 8.87E-01 -0.26 1.71E-01 -0.07 8.08E-01 
rs4033102  111784205 -0.15 7.41E-01   -0.01 9.88E-01 
rs542331  111798258 -0.16 4.26E-01 -0.19 5.58E-01 0.41 3.13E-01 
rs6817202  111799254 0.13 4.85E-01 -0.23 2.79E-01 -0.45 1.82E-01 
rs7679158  111812327 -0.26 1.04E-01 -0.15 6.13E-01 0.16 6.22E-01 
rs11947581  111812531 0.08 6.53E-01 -0.12 5.79E-01 -0.52 8.33E-02 
rs570881  111816849       
rs561873  111829967 -0.23 4.78E-01 -0.23 5.37E-01 -0.28 6.58E-01 
rs581241  111836832 -0.44 6.45E-02 0.00 9.96E-01 0.80 6.87E-02 
rs441624  111844449 0.49 1.66E-01 1.01 1.39E-02 0.29 6.54E-01 
rs374582  111849422 0.16 2.76E-01 0.19 3.67E-01 0.08 7.43E-01 
rs11943026  111872144 -0.30 1.30E-01 0.00 9.96E-01 0.50 2.64E-01 
rs17513835  111894848 0.18 5.16E-01 -0.21 3.62E-01 0.05 9.27E-01 
The significance threshold after correction for multiple testing was 1.35E-03. Effects are presented as log effect sizes (Beta) of the minor allele referenced to the 
major allele. Significant associations are in bold. 
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Table A2.16 Associations with total expression of PITX2c in chromosome band 4q25 in tissue 
   RAA eQTL LAA eQTL IMA eQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs75911264  111538810       
rs6533526  111538827       
rs2595110  111545323   -0.09 4.96E-01 -0.41 3.58E-01 
rs976568  111550721   -0.03 8.47E-01 -0.36 4.54E-01 
rs2739200 PITX2 Transcribed 111558411   0.02 8.76E-01 -0.36 4.54E-01 
rs12498374  111584419   0.05 7.23E-01 -0.91 4.37E-02 
rs2723296  111604483   0.01 9.17E-01 -0.40 4.00E-01 
rs1448799  111622782   0.13 3.76E-01 0.58 2.12E-01 
rs16997168  111629039   -0.01 9.24E-01 -0.43 4.04E-01 
rs10222783  111634826   0.03 8.94E-01 0.59 3.68E-01 
rs4307025  111657503   -0.10 4.75E-01 0.57 1.17E-01 
rs2723333  111699091   -0.15 5.09E-01 0.28 5.87E-01 
rs17042171 AF GWAS 111708287   -0.09 5.25E-01 0.09 8.70E-01 
rs2200733 AF GWAS 111710169   -0.12 3.27E-01 -0.02 9.76E-01 
rs13126975  111717525   0.11 7.12E-01 -0.82 1.31E-01 
rs6843082 AF GWAS 111718067   -0.09 4.84E-01 0.09 8.70E-01 
rs10033464 AF GWAS 111720761   -0.05 8.67E-01 0.00  
rs6533531  111731965   -0.09 5.68E-01 0.79 7.86E-02 
rs3853444  111734136   0.12 4.89E-01 0.30 3.38E-01 
rs17570669  111736882   -0.02 9.44E-01 0.00  
rs7674295  111741438   -0.24 2.07E-01 0.17 8.01E-01 
rs11938968  111742752   -0.12 2.42E-01 0.44 1.60E-01 
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   RAA eQTL LAA eQTL IMA eQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs3866836  111745640   0.32 7.71E-03 -0.50 1.72E-01 
rs4032971  111751723   0.31 5.29E-03 -0.41 4.04E-01 
rs3853445  111761487   -0.06 7.46E-01 0.48 3.05E-01 
rs17571707  111765413   -0.39 6.65E-02 0.16 8.61E-01 
rs6838973  111765495   -0.01 9.23E-01 0.09 8.57E-01 
rs3866823  111782436   0.27 9.87E-03 -0.44 2.07E-01 
rs4033102  111784205   -0.02 9.44E-01 0.00  
rs542331  111798258   0.04 8.60E-01 0.05 9.14E-01 
rs6817202  111799254   0.31 5.29E-03 -0.51 1.57E-01 
rs7679158  111812327   -0.04 8.33E-01 0.04 9.11E-01 
rs11947581  111812531   0.17 2.02E-01 -0.51 1.57E-01 
rs570881  111816849   0.00  0.00  
rs561873  111829967   -0.02 9.43E-01 -0.72 2.65E-01 
rs581241  111836832   -0.03 8.62E-01 0.42 4.14E-01 
rs441624  111844449   -0.14 6.54E-01 0.33 7.17E-01 
rs374582  111849422   -0.11 3.50E-01 0.33 2.79E-01 
rs11943026  111872144   -0.03 8.62E-01 0.65 2.43E-01 
rs17513835  111894848   0.00 9.91E-01 0.05 9.28E-01 
The significance threshold after correction for multiple testing was 1.35E-03. Effects are presented as log effect sizes (Beta) of the minor allele referenced to the 
major allele. Significant associations are in bold. 
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Table A2.17 Associations with allelic expression ratio of PITX2 in chromosome band 4q25 in tissue 
   
RAA aerQTL LAA aerQTL IMA aerQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs75911264 
 
111538810 
      rs6533526 
 
111538827 
      rs2595110 
 
111545323 -0.08 6.37E-01 -0.25 3.12E-01 0.35 2.60E-01 
rs976568 
 
111550721 -0.04 7.70E-01 -0.01 9.65E-01 -0.23 3.05E-01 
rs2739200 PITX2 Transcribed 111558411 0.00 9.80E-01 -0.01 9.65E-01 -0.26 2.11E-01 
rs12498374 
 
111584419 0.04 7.95E-01 -0.12 6.51E-01 -0.32 1.31E-01 
rs2723296 
 
111604483 0.00 9.80E-01 -0.20 4.36E-01 -0.26 2.11E-01 
rs1448799 
 
111622782 0.08 6.85E-01 0.44 4.59E-03 0.05 8.60E-01 
rs16997168 
 
111629039 0.06 7.93E-01 0.44 4.59E-03 0.05 8.60E-01 
rs10222783 
 
111634826 0.25 6.23E-01 
    rs4307025 
 
111657503 0.03 8.92E-01 0.32 1.48E-01 0.06 8.48E-01 
rs2723333 
 
111699091 -0.47 4.70E-02 -0.52 7.78E-02 0.27 6.77E-01 
rs17042171 AF GWAS 111708287 -0.02 9.39E-01 0.52 7.78E-02 0.06 8.48E-01 
rs2200733 AF GWAS 111710169 0.23 5.20E-01 0.52 7.78E-02 0.06 8.48E-01 
rs13126975 
 
111717525 0.22 5.31E-01 
  
0.23 6.04E-01 
rs6843082 AF GWAS 111718067 0.10 6.41E-01 0.52 7.78E-02 0.06 8.48E-01 
rs10033464 AF GWAS 111720761 0.30 4.03E-01 
    rs6533531 
 
111731965 0.13 5.30E-01 0.32 1.48E-01 0.06 8.48E-01 
rs3853444 
 
111734136 0.14 5.02E-01 
  
0.48 1.73E-01 
rs17570669 
 
111736882 -0.06 9.11E-01 0.36 2.87E-01 
  rs7674295 
 
111741438 -0.21 3.46E-01 0.13 7.28E-01 0.36 3.18E-01 
rs11938968 
 
111742752 -0.21 2.97E-01 0.13 7.28E-01 0.56 5.77E-02 
rs3866836 
 
111745640 0.03 9.06E-01 
  
-0.36 4.26E-01 
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RAA aerQTL LAA aerQTL IMA aerQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs4032971 
 
111751723 0.03 9.06E-01 
  
-0.25 5.00E-01 
rs3853445 
 
111761487 0.12 5.93E-01 0.36 2.87E-01 -0.75 7.08E-02 
rs17571707 
 
111765413 0.06 9.11E-01 0.13 7.28E-01 
  rs6838973 
 
111765495 -0.13 4.44E-01 
  
-0.15 7.39E-01 
rs3866823 
 
111782436 -0.03 8.71E-01 0.36 2.87E-01 -0.56 5.77E-02 
rs4033102 
 
111784205 
  
0.36 2.87E-01 
  rs542331 
 
111798258 -0.08 6.77E-01 
  
-0.75 7.08E-02 
rs6817202 
 
111799254 0.06 7.75E-01 
  
-0.36 4.26E-01 
rs7679158 
 
111812327 -0.17 3.59E-01 -0.36 2.87E-01 0.06 8.89E-01 
rs11947581 
 
111812531 0.02 9.57E-01 0.13 7.28E-01 -0.50 4.29E-01 
rs570881 
 
111816849 
      rs561873 
 
111829967 -0.56 4.09E-02 
  
-0.94 1.19E-01 
rs581241 
 
111836832 0.15 5.63E-01 -0.36 2.87E-01 0.82 4.59E-02 
rs441624 
 
111844449 -0.01 9.57E-01 -0.52 7.78E-02 0.60 1.62E-01 
rs374582 
 
111849422 0.18 3.35E-01 -0.13 7.28E-01 0.33 2.94E-01 
rs11943026 
 
111872144 0.11 6.41E-01 -0.36 2.87E-01 0.82 4.59E-02 
rs17513835   111894848 -0.56 4.09E-02     -0.94 1.19E-01 
  
 
 
2
7
0
 
Table A2.18  Associations with total expression of CAV1 in chromosome band 7q31 in tissue 
   RAA eQTL LAA eQTL IMA eQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
 CAV2 Transcribed        
rs6466578  116150869 -0.03 5.95E-01 -0.15 4.31E-02 0.13 8.19E-02 
rs3919515  116151784 0.08 4.87E-02 -0.07 3.80E-01 0.08 2.29E-01 
rs959173  116182054 0.02 7.15E-01 -0.11 2.11E-01 0.12 9.80E-02 
rs3807989 AF GWAS 116186241 0.11 1.33E-02 0.09 2.34E-01 0.07 3.38E-01 
rs11773845 AF, PR interval GWAS 116191301 0.11 7.73E-03 0.06 3.56E-01 0.09 2.03E-01 
rs8713  116199797 -0.07 1.08E-01 0.09 1.48E-01 -0.03 7.25E-01 
rs9920 CAV1 Transcribed 116200092 0.20 4.04E-03 0.02 8.24E-01 0.07 4.29E-01 
rs1049334 CAV1 Transcribed 116200380 0.06 4.66E-01 0.10 1.80E-01 -0.11 3.15E-01 
rs1049337 CAV1 Transcribed 116200587 -0.09 3.32E-02 -0.01 8.85E-01 0.06 3.73E-01 
rs1860588  116206486 -0.03 7.07E-01 -0.11 2.11E-01 0.12 1.61E-01 
The significance threshold after correction for multiple testing was 4.55E-03. Effects are presented as log effect sizes (Beta) of the minor allele referenced to the 
major allele. Significant associations are in bold. 
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Table A2.19 Associations with total expression of CAV2 in chromosome band 7q31 in tissue 
   RAA eQTL LAA eQTL IMA eQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
 CAV2 Transcribed        
rs6466578  116150869 0.00 9.70E-01 -0.18 5.64E-02 0.17 3.79E-02 
rs3919515  116151784 0.08 1.20E-02 -0.09 5.59E-01 0.13 7.40E-02 
rs959173  116182054 0.04 3.78E-01 -0.18 6.43E-02 0.17 2.99E-02 
rs3807989 AF GWAS 116186241 0.10 6.17E-03 -0.04 6.50E-01 0.09 2.34E-01 
rs11773845 AF, PR interval GWAS 116191301 0.10 3.66E-03 -0.07 5.71E-01 0.10 1.58E-01 
rs8713  116199797 -0.02 5.18E-01 -0.01 9.14E-01 0.00 9.66E-01 
rs9920 CAV1 Transcribed 116200092 0.19 7.29E-04 0.06 7.62E-01 0.09 3.33E-01 
rs1049334 CAV1 Transcribed 116200380 -0.03 6.75E-01 0.02 8.65E-01 -0.21 8.05E-02 
rs1049337 CAV1 Transcribed 116200587 -0.07 3.71E-02 0.07 6.03E-01 0.03 7.08E-01 
rs1860588  116206486 0.01 8.97E-01 -0.18 6.43E-02 0.17 5.95E-02 
The significance threshold after correction for multiple testing was 4.55E-03. Effects are presented as log effect sizes (Beta) of the minor allele referenced to the 
major allele. Significant associations are in bold. 
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Table A2.20  Associations with allelic expression ratio of CAV1 in chromosome band 7q31 in tissue 
   
RAA aerQTL LAA aerQTL IMA aerQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs8940 CAV2 Transcribed 116146074 0.05 3.71E-01 0.42 1.57E-01 0.18 4.04E-02 
rs6466578 
 
116150869 0.05 1.00E+00 -0.01 1.00E+00 0.37 1.28E-02 
rs3919515 
 
116151784 0.17 3.79E-07 0.06 1.80E-01 0.34 3.47E-04 
rs959173 
 
116182054 0.09 1.57E-01 -0.01 1.00E+00 0.34 1.14E-02 
rs3807989 AF GWAS 116186241 0.15 5.89E-08 0.06 1.80E-01 0.06 3.59E-02 
rs11773845 AF, PR interval GWAS 116191301 0.15 5.89E-08 0.06 1.80E-01 0.06 3.59E-02 
rs8713 
 
116199797 -0.03 2.73E-01 0.12 7.29E-03 0.01 1.00E+00 
rs9920 CAV1 Transcribed 116200092 -0.06 5.22E-03 
  
-0.11 1.80E-01 
rs1049334 CAV1 Transcribed 116200380 0.14 2.29E-10 0.04 2.73E-01 0.04 1.21E-01 
rs1049337 CAV1 Transcribed 116200587 -0.29 5.07E-19 -0.03 6.55E-01 -0.34 1.49E-07 
rs1860588   116206486 0.08 2.37E-01 -0.01 1.00E+00 0.30 4.55E-02 
The significance threshold after correction for multiple testing was 4.55E-03. Effects are presented as log effect sizes (Beta) of the minor allele referenced to the 
major allele. Significant associations are in bold. 
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Table A2.21  Associations with allelic expression ratio of CAV2 in chromosome band 7q31 in tissue 
   
RAA aerQTL LAA aerQTL IMA aerQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs8940 CAV2 Transcribed 116146074 -0.11 2.52E-08 
  
-0.11 2.91E-04 
rs6466578 
 
116150869 0.11 1.50E-01 
  
0.04 6.05E-01 
rs3919515 
 
116151784 -0.11 2.56E-04 
  
-0.09 2.65E-02 
rs959173 
 
116182054 0.11 1.50E-01 
  
0.05 4.56E-01 
rs3807989 AF GWAS 116186241 -0.05 2.97E-01 
  
-0.04 4.51E-01 
rs11773845 AF, PR interval GWAS 116191301 -0.05 2.97E-01 
  
-0.04 4.51E-01 
rs8713 
 
116199797 -0.10 1.61E-03 
  
-0.05 2.37E-01 
rs9920 CAV1 Transcribed 116200092 0.07 1.00E+00 
  
0.19 6.01E-02 
rs1049334 CAV1 Transcribed 116200380 0.15 2.44E-01 
    rs1049337 CAV1 Transcribed 116200587 0.09 2.26E-02 
  
0.07 1.28E-01 
rs1860588   116206486 0.08 4.66E-01     0.03 6.93E-01 
The significance threshold after correction for multiple testing was 4.55E-03. Effects are presented as log effect sizes (Beta) of the minor allele referenced to the 
major allele. Significant associations are in bold. 
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Table A2.22 Associations with total expression of C9orf3 in chromosome band 9q22 in tissue 
   RAA eQTL  LAA eQTL  IMA eQTL  
SNP Importance Position Beta p value Beta p value Beta p value 
rs356122  97565461 -0.02 6.79E-01 0.23 2.76E-01 -0.13 1.01E-01 
rs4744381  97601089 0.00  0.00  0.00  
rs1530331  97620602 -0.01 8.66E-01 0.00  -0.07 4.72E-01 
rs10993391  97675840 0.16 8.41E-02 0.23 5.73E-01 -0.07 5.25E-01 
rs7853195  97685298 0.00 9.26E-01 -0.18 2.18E-01 -0.09 1.87E-01 
rs10821415 AF GWAS 97713459 0.01 9.09E-01 -0.19 3.12E-01 -0.09 2.13E-01 
rs10993413  97729136 0.02 7.78E-01 -0.01 9.83E-01 0.12 2.33E-01 
rs3802458  97741274 0.07 7.57E-01 0.00  0.78 1.39E-02 
rs3802457 PCOS GWAS 97741336 -0.07 6.47E-01 -0.14 6.92E-01 0.29 2.21E-01 
rs7048941  97809674 0.05 4.70E-01 0.20 5.60E-01 0.06 5.50E-01 
rs4744437  97832830 0.06 5.12E-01 0.00  0.02 8.22E-01 
rs7033633  97838781 -0.10 9.13E-02 -0.26 1.81E-01 -0.03 6.94E-01 
rs17679141  97842479 0.06 2.10E-01 0.00 9.83E-01 -0.09 1.87E-01 
rs4657 C9orf3 Transcribed 97849090 -0.05 3.05E-01 -0.11 5.07E-01 0.01 9.35E-01 
rs4647554 FANCC Transcribed 97862701 -0.03 5.80E-01 0.14 6.07E-01 0.09 1.83E-01 
The significance threshold after correction for multiple testing was 3.33E-03. Effects are presented as log effect sizes (Beta) of the minor allele referenced to the 
major allele. Significant associations are in bold. 
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Table A2.23 Associations with total expression of FANCC in chromosome band 9q22 in tissue 
   RAA eQTL LAA eQTL IMA eQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs356122  97565461 0.00 9.38E-01 -0.13 2.80E-01 0.09 5.46E-01 
rs4744381  97601089 0.00  0.00  0.00  
rs1530331  97620602 0.01 8.58E-01 0.00  -0.02 9.11E-01 
rs10993391  97675840 0.11 1.35E-01 0.03 8.70E-01 -0.21 3.08E-01 
rs7853195  97685298 0.04 3.18E-01 0.05 6.75E-01 0.21 6.56E-02 
rs10821415 AF GWAS 97713459 0.05 1.98E-01 0.06 5.65E-01 0.26 2.60E-02 
rs10993413  97729136 0.10 1.74E-01 -0.43 2.59E-02 0.13 4.06E-01 
rs3802458  97741274 0.08 7.07E-01 0.00  1.00 6.87E-02 
rs3802457 PCOS GWAS 97741336 -0.01 9.44E-01 0.02 9.38E-01 0.59 1.36E-01 
rs7048941  97809674 0.08 2.00E-01 0.09 7.09E-01 -0.01 9.43E-01 
rs4744437  97832830 0.08 3.18E-01 0.00  0.02 9.24E-01 
rs7033633  97838781 -0.11 2.94E-02 0.10 4.66E-01 0.19 1.27E-01 
rs17679141  97842479 0.09 3.27E-02 0.01 9.38E-01 0.03 7.89E-01 
rs4657 C9orf3 Transcribed 97849090 -0.06 1.33E-01 0.12 2.65E-01 0.09 3.91E-01 
rs4647554 FANCC Transcribed 97862701 -0.05 2.58E-01 0.04 8.41E-01 -0.16 1.43E-01 
The significance threshold after correction for multiple testing was 3.33E-03. Effects are presented as log effect sizes (Beta) of the minor allele referenced to the 
major allele. Significant associations are in bold. 
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Table A2.14 Associations with allelic expression ratio of C9orf3 in chromosome band 9q22 in tissue 
   
RAA aerQTL LAA aerQTL IMA aerQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs356122 
 
97565461 -0.05 1.71E-01 -0.07 4.18E-01 0.01 8.64E-01 
rs4744381 
 
97601089 
      rs1530331 
 
97620602 -0.05 2.80E-01 
  
-0.05 6.47E-01 
rs10993391 
 
97675840 0.18 1.02E-02 
  
0.08 2.03E-01 
rs7853195 
 
97685298 -0.10 1.51E-05 -0.09 4.39E-02 0.01 7.51E-01 
rs10821415 AF GWAS 97713459 -0.10 1.51E-05 -0.09 4.39E-02 0.01 7.51E-01 
rs10993413 
 
97729136 0.10 2.55E-02 
  
0.04 6.89E-01 
rs3802458 
 
97741274 
      rs3802457 PCOS GWAS 97741336 0.11 2.08E-01 
  
0.13 2.34E-01 
rs7048941 
 
97809674 -0.01 8.62E-01 
  
0.10 2.12E-01 
rs4744437 
 
97832830 -0.11 3.30E-03 
  
-0.07 3.48E-01 
rs7033633 
 
97838781 -0.09 5.07E-08 -0.09 6.45E-03 0.00 9.89E-01 
rs17679141 
 
97842479 0.07 1.88E-02 0.10 2.67E-01 -0.02 6.15E-01 
rs4657 C9orf3 Transcribed 97849090 -0.10 7.69E-12 -0.09 1.62E-05 -0.01 7.42E-01 
rs4647554 FANCC Transcribed 97862701 0.11 4.67E-09 0.09 6.45E-03 0.03 3.80E-01 
The significance threshold after correction for multiple testing was 3.33E-03. Effects are presented as log effect sizes (Beta) of the minor allele referenced to the 
major allele. Significant associations are in bold. 
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Table A2.25 Associations with allelic expression ratio of FANCC in chromosome band 9q22 in tissue 
   
RAA aerQTL LAA aerQTL IMA aerQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs356122 
 
97565461 -0.02 3.64E-01 -0.09 1.09E-01 -0.01 7.17E-01 
rs4744381 
 
97601089 
      rs1530331 
 
97620602 0.04 1.72E-01 
  
-0.05 1.30E-01 
rs10993391 
 
97675840 -0.05 1.58E-01 -0.06 4.84E-01 0.02 3.94E-01 
rs7853195 
 
97685298 -0.05 4.14E-07 -0.05 7.35E-02 -0.03 5.83E-03 
rs10821415 AF GWAS 97713459 -0.06 8.92E-08 -0.05 7.35E-02 -0.04 1.88E-03 
rs10993413 
 
97729136 0.06 1.32E-02 
  
-0.04 7.42E-02 
rs3802458 
 
97741274 
      rs3802457 PCOS GWAS 97741336 0.05 5.61E-01 
    rs7048941 
 
97809674 -0.01 7.46E-01 -0.06 4.84E-01 0.04 1.93E-01 
rs4744437 
 
97832830 0.05 9.42E-02 
  
-0.09 3.93E-02 
rs7033633 
 
97838781 -0.03 3.53E-02 -0.08 9.33E-03 -0.01 7.31E-01 
rs17679141 
 
97842479 -0.06 1.06E-06 0.00 9.57E-01 -0.04 8.88E-03 
rs4657 C9orf3 Transcribed 97849090 -0.01 2.91E-01 -0.09 8.12E-03 -0.01 4.47E-01 
rs4647554 FANCC Transcribed 97862701 0.04 7.65E-05 0.07 2.97E-03 0.03 8.69E-03 
The significance threshold after correction for multiple testing was 3.33E-03. Effects are presented as log effect sizes (Beta) of the minor allele referenced to the 
major allele. Significant associations are in bold. 
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Table A2.26 Associations with total expression of MYOZ1 in chromosome band 10q22 in tissue 
   
RAA eQTL LAA eQTL IMA eQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs7080456 
 
75391217 -1.08 2.38E-03 
  
0.31 1.13E-01 
rs41280400 MYOZ Transcribed 75391823 -0.80 5.09E-02 
  
0.34 4.49E-01 
rs4745718 
 
75402788 -0.62 5.54E-03 -2.12 2.46E-02 -0.01 9.31E-01 
rs34163229 SYNPO2L Transcribed 75406912 -1.36 9.49E-15 -2.85 8.35E-04 0.13 3.45E-01 
rs3812629 SYNPO2L Transcribed 75407290 -1.37 4.68E-15 -2.85 8.35E-04 0.13 3.38E-01 
rs4746139 SYNPO2L Transcribed 75407649 -1.37 8.56E-15 -2.85 8.35E-04 0.12 4.02E-01 
rs12247028 
 
75410052 -0.78 1.38E-08 -1.47 4.93E-02 0.16 1.37E-01 
rs60632610  SYNPO2L Transcribed 75415677 -1.37 1.12E-14 -2.85 8.35E-04 0.11 4.24E-01 
rs10824026 AF GWAS 75421208 -1.37 5.52E-15 -2.85 8.35E-04 0.11 4.17E-01 
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Table A2.27 Associations with total expression of SYNPO2L in chromosome band 10q22 in tissue 
   
RAA eQTL LAA eQTL IMA eQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs7080456 
 
75391217 -0.06 6.90E-01 
  
1.51 2.22E-02 
rs41280400 MYOZ Transcribed 75391823 0.02 9.27E-01 
  
0.05 9.72E-01 
rs4745718 
 
75402788 0.03 7.59E-01 -0.49 1.12E-01 0.80 1.59E-01 
rs34163229 SYNPO2L Transcribed 75406912 0.06 5.10E-01 -0.43 2.13E-01 0.82 1.17E-01 
rs3812629 SYNPO2L Transcribed 75407290 0.06 5.21E-01 -0.43 2.13E-01 0.83 1.02E-01 
rs4746139 SYNPO2L Transcribed 75407649 0.06 5.08E-01 -0.43 2.13E-01 0.66 1.94E-01 
rs12247028 
 
75410052 -0.01 8.38E-01 -0.12 6.56E-01 0.82 6.45E-02 
rs60632610  SYNPO2L Transcribed 75415677 0.06 5.16E-01 -0.43 2.13E-01 0.82 1.17E-01 
rs10824026 AF GWAS 75421208 0.05 5.28E-01 -0.43 2.13E-01 0.83 1.02E-01 
The significance threshold after correction for multiple testing was 5.56E-03. Effects are presented as log effect sizes (Beta) of the minor allele referenced to the 
major allele. Significant associations are in bold. 
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Table A2.28 Associations with allelic expression ratio of MYOZ1 in chromosome band 10q22 in tissue 
   
RAA aerQTL LAA aerQTL IMA aerQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs7080456 
 
75391217 1.09 5.24E-04 
    rs41280400 MYOZ Transcribed 75391823 1.09 5.24E-04 
    rs4745718 
 
75402788 1.72 1.00E+00 
    rs34163229 SYNPO2L Transcribed 75406912 1.34 5.66E-06 
    rs3812629 SYNPO2L Transcribed 75407290 1.34 5.66E-06 
    rs4746139 SYNPO2L Transcribed 75407649 1.34 5.66E-06 
    rs12247028 
 
75410052 1.35 1.61E-02 
    rs60632610  SYNPO2L Transcribed 75415677 1.34 5.66E-06 
    rs10824026 AF GWAS 75421208 1.34 5.66E-06         
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Table A2.29 Associations with allelic expression ratio of SYNPO2L in chromosome band 10q22 in tissue 
   
RAA aerQTL LAA aerQTL IMA aerQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs7080456 
 
75391217 -0.04 4.39E-01 -0.09 6.55E-01 0.13 1.38E-01 
rs41280400 MYOZ Transcribed 75391823 -0.02 1.00E+00 -0.10 1.00E+00 0.25 1.38E-01 
rs4745718 
 
75402788 -0.13 3.03E-05 -0.09 3.17E-01 0.08 1.00E+00 
rs34163229 SYNPO2L Transcribed 75406912 -0.14 6.53E-08 
  
0.10 2.01E-02 
rs3812629 SYNPO2L Transcribed 75407290 -0.14 6.53E-08 
  
0.10 2.01E-02 
rs4746139 SYNPO2L Transcribed 75407649 -0.14 6.53E-08 
  
0.10 2.01E-02 
rs12247028 
 
75410052 -0.11 4.68E-03 -0.11 5.13E-02 0.14 9.12E-03 
rs60632610  SYNPO2L Transcribed 75415677 0.16 9.43E-02 
  
0.10 2.85E-02 
rs10824026 AF GWAS 75421208 0.16 9.43E-02     0.10 2.85E-02 
The significance threshold after correction for multiple testing was 5.56E-03. Effects are presented as log effect sizes (Beta) of the minor allele referenced to the 
major allele. Significant associations are in bold. 
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Table A2.30 Associations with total expression of SYNE2 in chromosome band 14q23 in tissue 
   
RAA eQTL LAA eQTL IMA eQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs4459477 
 
64346190 0.04 6.06E-01 
  
-0.15 3.35E-01 
rs17750888 
 
64355420 0.00 9.70E-01 -0.12 6.48E-01 -0.12 1.19E-01 
rs12588807 
 
64363070 0.03 7.96E-01 
  
-0.06 7.24E-01 
rs2275018 
 
64375985 -0.01 9.06E-01 -0.01 9.60E-01 -0.16 5.43E-02 
rs7153036 
 
64377548 0.06 2.83E-01 -0.07 7.26E-01 -0.09 2.96E-01 
rs12879919 
 
64382350 -0.04 5.69E-01 -0.12 7.82E-01 0.09 4.04E-01 
rs11158521 
 
64401255 0.02 6.59E-01 0.10 7.47E-01 -0.08 2.69E-01 
rs2184292 
 
64408135 0.04 4.41E-01 0.44 1.19E-01 -0.14 1.08E-01 
rs7153680 
 
64474227 0.03 4.96E-01 0.47 5.97E-02 -0.11 1.37E-01 
rs4566057 
 
64506541 -0.03 6.71E-01 -0.42 1.98E-01 0.10 4.02E-01 
rs1890908 
 
64519035 0.00 9.72E-01 0.00 
 
0.16 3.37E-01 
rs10137972 
 
64557734 0.05 6.68E-01 0.13 7.65E-01 -0.02 9.24E-01 
rs17101651 
 
64561324 -0.08 4.35E-01 -0.12 7.82E-01 -0.07 6.88E-01 
rs8022428 
 
64563613 0.03 5.92E-01 -0.30 3.26E-01 -0.01 8.76E-01 
rs8007972 
 
64564527 0.02 7.58E-01 
  
0.00 9.67E-01 
rs8016917 
 
64569951 -0.16 2.81E-01 
  
0.07 7.25E-01 
rs10142318 
 
64604281 0.00 9.57E-01 -0.38 2.31E-01 0.07 4.64E-01 
rs7144688 
 
64613473 -0.08 2.05E-01 -0.52 1.66E-02 0.13 1.41E-01 
rs11158533 
 
64622988 0.01 8.45E-01 0.40 2.03E-01 -0.06 4.11E-01 
rs17751454 
 
64625181 0.08 1.79E-01 0.42 1.07E-01 -0.10 2.55E-01 
rs3866743 
 
64633322 -0.02 9.20E-01 
  
0.09 6.89E-01 
rs7161192 SYNE2 Transcribed 64637147 0.02 7.13E-01 0.23 6.24E-01 -0.10 1.84E-01 
rs2256191 
 
64656855 0.09 1.05E-01 0.34 6.59E-02 -0.08 3.06E-01 
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RAA eQTL LAA eQTL IMA eQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs1152591 AF GWAS 64680848 -0.10 6.05E-02 -0.16 4.77E-01 0.01 9.21E-01 
rs7145919 
 
64687601 -0.02 8.25E-01 -0.21 5.34E-01 0.00 9.69E-01 
rs12434245 
 
64691853 -0.01 8.79E-01 -0.21 5.34E-01 0.01 9.12E-01 
rs1152582 SYNE2 Transcribed 64692630 -0.08 1.35E-01 -0.20 4.31E-01 0.08 2.81E-01 
rs928554 ESR2 Transcribed 64694195 -0.06 2.39E-01 -0.23 2.42E-01 0.05 4.70E-01 
rs4986938 ESR2 Transcribed 64699816 0.11 3.91E-02 0.47 1.39E-03 -0.13 8.49E-02 
rs1256064 
 
64700739 -0.07 3.46E-01 -0.35 2.09E-01 0.07 5.17E-01 
rs1256063 
 
64702217 -0.31 2.35E-03 
  
-0.18 4.34E-01 
rs10144225 
 
64704994 0.10 1.94E-01 -0.45 1.62E-01 0.01 9.21E-01 
rs1256049  ESR2 Transcribed 64724051 -0.43 6.57E-03 -0.17 7.07E-01 -0.08 7.26E-01 
The significance threshold after correction for multiple testing was 1.52E-03. Effects are presented as log effect sizes (Beta) of the minor allele referenced to the 
major allele. Significant associations are in bold. 
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Table A2.31 Associations with total expression of ESR2 in chromosome band 14q23 in tissue 
   
RAA eQTL LAA eQTL IMA eQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs4459477 
 
64346190 -0.06 6.37E-01 
  
-0.55 3.19E-01 
rs17750888 
 
64355420 0.08 3.09E-01 -0.14 6.64E-01 -0.31 2.72E-01 
rs12588807 
 
64363070 -0.08 6.16E-01 
  
-0.62 3.08E-01 
rs2275018 
 
64375985 0.11 2.02E-01 -0.12 6.67E-01 -0.17 5.38E-01 
rs7153036 
 
64377548 0.05 5.90E-01 0.31 1.97E-01 0.00 9.90E-01 
rs12879919 
 
64382350 -0.14 2.00E-01 -0.11 7.95E-01 -0.48 2.14E-01 
rs11158521 
 
64401255 0.02 8.39E-01 -0.28 3.19E-01 -0.09 7.38E-01 
rs2184292 
 
64408135 0.09 3.19E-01 0.18 5.84E-01 0.06 8.35E-01 
rs7153680 
 
64474227 0.02 8.12E-01 0.13 6.16E-01 -0.15 5.53E-01 
rs4566057 
 
64506541 -0.01 9.08E-01 -0.78 8.65E-02 -0.41 3.44E-01 
rs1890908 
 
64519035 0.03 8.27E-01 
  
-0.56 3.84E-01 
rs10137972 
 
64557734 -0.03 8.61E-01 0.30 6.03E-01 0.14 8.04E-01 
rs17101651 
 
64561324 0.09 5.83E-01 -0.03 9.55E-01 -0.23 6.73E-01 
rs8022428 
 
64563613 -0.01 8.88E-01 -0.47 2.67E-01 -0.16 6.43E-01 
rs8007972 
 
64564527 0.05 6.75E-01 -0.17 7.70E-01 -0.41 3.13E-01 
rs8016917 
 
64569951 -0.02 9.28E-01 
  
0.08 9.12E-01 
rs10142318 
 
64604281 0.09 4.27E-01 -0.46 2.73E-01 0.05 8.98E-01 
rs7144688 
 
64613473 -0.08 4.44E-01 -0.31 3.78E-01 0.67 6.20E-02 
rs11158533 
 
64622988 -0.04 5.81E-01 -0.15 6.20E-01 0.05 8.58E-01 
rs17751454 
 
64625181 -0.02 8.60E-01 0.16 6.24E-01 0.04 8.89E-01 
rs3866743 
 
64633322 0.20 4.76E-01 
  
0.81 3.57E-01 
rs7161192 SYNE2 Transcribed 64637147 -0.06 4.33E-01 -0.45 4.90E-01 0.24 3.68E-01 
rs2256191 
 
64656855 0.07 4.38E-01 -0.26 2.98E-01 0.23 3.53E-01 
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rs1152591 AF GWAS 64680848 0.00 9.69E-01 0.31 2.56E-01 -0.61 2.23E-02 
rs7145919 
 
64687601 -0.14 3.32E-01 -0.54 1.87E-01 0.75 8.05E-02 
rs12434245 
 
64691853 -0.13 3.54E-01 -0.54 1.87E-01 0.78 6.56E-02 
rs1152582 SYNE2 Transcribed 64692630 0.02 7.90E-01 0.51 6.89E-02 -0.60 2.93E-02 
rs928554 ESR2 Transcribed 64694195 0.00 9.75E-01 0.43 5.94E-02 -0.54 3.72E-02 
rs4986938 ESR2 Transcribed 64699816 -0.04 6.16E-01 -0.09 7.26E-01 0.32 2.18E-01 
rs1256064 
 
64700739 0.12 2.92E-01 -0.36 3.27E-01 -0.18 6.58E-01 
rs1256063 
 
64702217 -0.10 5.32E-01 -0.09 7.84E-01 -0.78 2.96E-01 
rs10144225 
 
64704994 0.25 2.98E-02 -0.49 3.10E-01 -0.05 8.96E-01 
rs1256049  ESR2 Transcribed 64724051 -0.25 3.23E-01 -0.04 9.49E-01 -1.03 2.49E-01 
The significance threshold after correction for multiple testing was 1.52E-03. Effects are presented as log effect sizes (Beta) of the minor allele referenced to the 
major allele. Significant associations are in bold. 
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Table A2.32 Associations with allelic expression ratio of SYNE2 in chromosome band 14q23 in tissue 
   
RAA aerQTL LAA aerQTL IMA aerQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs4459477 
 
64346190 -0.03 3.17E-01 
  
0.03 6.55E-01 
rs17750888 
 
64355420 -0.02 3.71E-01 0.05 2.37E-01 -0.02 6.55E-01 
rs12588807 
 
64363070 0.00 1.00E+00 
  
0.07 3.17E-01 
rs2275018 
 
64375985 0.02 3.17E-01 0.06 2.06E-01 0.01 6.55E-01 
rs7153036 
 
64377548 0.03 3.17E-01 0.07 2.06E-01 -0.03 5.27E-01 
rs12879919 
 
64382350 -0.03 1.80E-01 -0.06 5.27E-01 -0.02 6.55E-01 
rs11158521 
 
64401255 -0.01 6.55E-01 0.03 5.27E-01 -0.06 1.57E-01 
rs2184292 
 
64408135 0.03 1.80E-01 0.09 3.59E-02 -0.02 6.55E-01 
rs7153680 
 
64474227 0.03 2.06E-01 0.09 3.59E-02 0.01 6.55E-01 
rs4566057 
 
64506541 -0.12 2.42E-03 0.04 6.55E-01 -0.19 7.29E-03 
rs1890908 
 
64519035 -0.09 6.52E-03 
  
-0.19 3.36E-03 
rs10137972 
 
64557734 0.01 6.55E-01 0.15 4.04E-02 -0.08 4.39E-01 
rs17101651 
 
64561324 0.01 1.00E+00 0.05 6.55E-01 -0.02 6.55E-01 
rs8022428 
 
64563613 -0.05 1.07E-01 0.09 8.33E-02 -0.10 3.59E-02 
rs8007972 
 
64564527 -0.06 2.26E-02 -0.21 5.27E-01 -0.05 3.71E-01 
rs8016917 
 
64569951 0.12 5.13E-02 
  
-0.16 1.38E-01 
rs10142318 
 
64604281 -0.08 5.22E-03 0.03 1.00E+00 -0.15 1.26E-03 
rs7144688 
 
64613473 -0.08 3.74E-05 0.08 8.33E-02 -0.10 3.01E-03 
rs11158533 
 
64622988 0.00 1.00E+00 0.10 1.43E-02 0.01 1.00E+00 
rs17751454 
 
64625181 0.04 1.07E-01 0.10 1.21E-01 0.04 5.27E-01 
rs3866743 
 
64633322 0.11 3.17E-01 
  
-0.18 2.73E-01 
rs7161192 SYNE2 Transcribed 64637147 0.00 1.00E+00 0.10 1.43E-02 0.03 6.55E-01 
rs2256191 
 
64656855 -0.02 2.73E-01 0.06 2.37E-01 -0.07 4.55E-02 
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RAA aerQTL LAA aerQTL IMA aerQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs1152591 AF GWAS 64680848 0.03 5.13E-02 -0.09 6.52E-03 0.09 1.95E-03 
rs7145919 
 
64687601 -0.05 1.57E-01 0.14 4.55E-02 -0.06 3.17E-01 
rs12434245 
 
64691853 -0.05 1.57E-01 0.14 4.55E-02 -0.06 3.17E-01 
rs1152582 SYNE2 Transcribed 64692630 0.05 5.13E-05 -0.08 8.15E-03 0.12 1.07E-06 
rs928554 ESR2 Transcribed 64694195 0.05 3.86E-04 -0.08 8.15E-03 0.11 2.45E-05 
rs4986938 ESR2 Transcribed 64699816 -0.02 3.17E-01 0.08 1.38E-01 -0.10 9.12E-03 
rs1256064 
 
64700739 -0.11 8.60E-06 0.04 5.27E-01 -0.10 2.85E-02 
rs1256063 
 
64702217 -0.01 6.55E-01 
  
0.10 2.06E-01 
rs10144225 
 
64704994 -0.10 1.48E-04 0.03 1.00E+00 -0.11 2.53E-02 
rs1256049  ESR2 Transcribed 64724051 -0.11 1.21E-01 0.05 6.55E-01 0.04 6.55E-01 
The significance threshold after correction for multiple testing was 1.52E-03. Effects are presented as log effect sizes (Beta) of the minor allele referenced to the 
major allele. Significant associations are in bold. 
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Table A2.33 Associations with allelic expression ratio of ESR2 in chromosome band 14q23 in tissue 
   
RAA aerQTL LAA aerQTL IMA aerQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs4459477 
 
64346190 0.00 1.00E+00 
  
0.04 5.27E-01 
rs17750888 
 
64355420 0.01 5.27E-01 0.05 1.07E-01 0.01 1.00E+00 
rs12588807 
 
64363070 0.03 4.39E-01 
  
0.01 1.00E+00 
rs2275018 
 
64375985 -0.01 6.55E-01 0.05 1.07E-01 -0.02 6.55E-01 
rs7153036 
 
64377548 -0.01 6.55E-01 0.02 1.00E+00 0.01 1.00E+00 
rs12879919 
 
64382350 0.04 1.21E-01 -0.04 6.55E-01 0.05 4.39E-01 
rs11158521 
 
64401255 0.03 2.37E-01 0.04 3.17E-01 0.01 1.00E+00 
rs2184292 
 
64408135 0.00 1.00E+00 0.08 4.68E-03 0.00 1.00E+00 
rs7153680 
 
64474227 0.01 6.55E-01 0.08 4.68E-03 0.01 1.00E+00 
rs4566057 
 
64506541 -0.03 5.27E-01 0.04 6.55E-01 0.10 2.06E-01 
rs1890908 
 
64519035 0.06 8.33E-02 
  
0.04 6.55E-01 
rs10137972 
 
64557734 -0.09 3.20E-02 0.02 1.00E+00 0.09 5.27E-01 
rs17101651 
 
64561324 -0.12 1.33E-04 0.04 6.55E-01 0.07 4.39E-01 
rs8022428 
 
64563613 -0.07 2.01E-02 0.03 6.55E-01 0.05 3.71E-01 
rs8007972 
 
64564527 0.02 5.27E-01 
  
0.02 6.55E-01 
rs8016917 
 
64569951 0.07 1.80E-01 
  
-0.06 5.27E-01 
rs10142318 
 
64604281 0.05 6.52E-02 0.01 1.00E+00 -0.04 4.39E-01 
rs7144688 
 
64613473 0.00 1.00E+00 0.02 6.55E-01 -0.03 4.39E-01 
rs11158533 
 
64622988 -0.01 6.55E-01 0.07 4.68E-03 -0.02 5.27E-01 
rs17751454 
 
64625181 0.04 8.33E-02 0.09 1.02E-03 0.02 6.55E-01 
rs3866743 
 
64633322 0.09 1.80E-01 
  
-0.06 5.27E-01 
rs7161192 SYNE2 Transcribed 64637147 -0.01 6.55E-01 0.07 4.68E-03 -0.02 6.55E-01 
rs2256191 
 
64656855 0.03 8.33E-02 0.06 1.21E-01 0.03 5.27E-01 
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RAA aerQTL LAA aerQTL IMA aerQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs1152591 AF GWAS 64680848 -0.01 5.27E-01 -0.07 7.29E-03 0.00 1.00E+00 
rs7145919 
 
64687601 -0.08 4.04E-02 0.02 1.00E+00 -0.07 2.06E-01 
rs12434245 
 
64691853 -0.08 4.04E-02 0.02 1.00E+00 -0.07 2.06E-01 
rs1152582 SYNE2 Transcribed 64692630 -0.02 1.57E-01 -0.05 3.59E-02 0.01 6.55E-01 
rs928554 ESR2 Transcribed 64694195 -0.02 1.21E-01 -0.05 3.59E-02 0.02 5.27E-01 
rs4986938 ESR2 Transcribed 64699816 0.04 2.26E-02 0.08 1.43E-02 0.03 3.71E-01 
rs1256064 
 
64700739 0.03 2.37E-01 0.02 1.00E+00 -0.05 3.71E-01 
rs1256063 
 
64702217 -0.03 3.71E-01 
  
-0.11 2.06E-01 
rs10144225 
 
64704994 0.06 2.01E-02 0.01 1.00E+00 -0.04 5.27E-01 
rs1256049  ESR2 Transcribed 64724051 -0.09 4.55E-02 0.04 6.55E-01 0.00 1.00E+00 
The significance threshold after correction for multiple testing was 1.52E-03. Effects are presented as log effect sizes (Beta) of the minor allele referenced to the 
major allele. Significant associations are in bold. 
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Table A2.34 Associations with total expression of HCN4 in chromosome band 15q24. 
   
RAA eQTL LAA eQTL IMA eQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs8040516 
 
73598548 0.03 7.36E-01 -0.58 5.23E-01   
rs3743496 HCN4 Transcribed 73614408 0.04 6.12E-01 -0.41 3.29E-01   
rs35177144 HCN4 Transcribed 73614704 0.04 6.22E-01 -0.41 3.29E-01   
rs529004 HCN4 Transcribed 73614834 0.20 2.61E-01 0.42 5.49E-01   
rs488156 
 
73625895 0.08 2.85E-01 0.51 8.28E-02   
rs2623998 
 
73628086 -0.05 5.88E-01 0.40 4.75E-01   
rs12905211 
 
73628168 -0.02 8.36E-01 -0.58 1.21E-01   
rs8030574 
 
73628214 0.08 3.67E-01 0.55 2.95E-01   
rs2623997 
 
73628714 0.06 4.13E-01 0.38 5.00E-01   
rs478438 
 
73630686 -0.27 1.33E-02 -0.86 7.42E-02   
rs3784807 
 
73631830 0.10 2.60E-01 0.37 4.25E-01   
rs11857639 
 
73637772 -0.12 3.91E-01 0.39 6.46E-01   
rs3826046 
 
73650824 0.47 4.24E-04 0.40 4.75E-01   
rs7164883 AF GWAS 73652174 -0.10 2.88E-01 -0.58 1.20E-01   
rs12440104 
 
73653009 0.11 1.84E-01 0.25 5.33E-01   
rs2680344 
 
73653485 -0.09 2.85E-01 -0.40 3.36E-01   
rs11638230   73656261 0.10 4.41E-01 -0.74 3.73E-01   
The significance threshold after correction for multiple testing was 2.94E-03. Effects are presented as log effect sizes (Beta) of the minor allele referenced to the 
major allele. Significant associations are in bold. 
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Table A2.35 Associations with allelic expression ratio of HCN4 in chromosome band 15q24. 
   
RAA aerQTL LAA aerQTL IMA aerQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs8040516 
 
73598548 -0.08 1.83E-04 -0.03 1.64E-04 
  rs3743496 HCN4 Transcribed 73614408 -0.08 1.62E-06 -0.03 1.48E-04 
  rs35177144 HCN4 Transcribed 73614704 -0.08 1.62E-06 -0.03 1.48E-04 
  rs529004 HCN4 Transcribed 73614834 0.11 5.22E-03 0.27 1.00E+00 
  rs488156 
 
73625895 0.11 2.26E-07 0.03 2.06E-01 
  rs2623998 
 
73628086 0.08 1.13E-03 0.03 5.27E-01 
  rs12905211 
 
73628168 0.09 1.83E-04 0.03 5.78E-02 
  rs8030574 
 
73628214 0.08 2.26E-02 0.03 6.55E-01 
  rs2623997 
 
73628714 -0.07 9.11E-04 -0.03 1.48E-04 
  rs478438 
 
73630686 0.04 3.17E-01 0.03 1.60E-02 
  rs3784807 
 
73631830 -0.06 9.12E-03 -0.03 4.55E-02 
  rs11857639 
 
73637772 0.09 2.26E-02 
    rs3826046 
 
73650824 -0.03 5.27E-01 -0.03 4.39E-01 
  rs7164883 AF GWAS 73652174 0.02 6.55E-01 0.04 3.71E-01 
  rs12440104 
 
73653009 -0.06 2.26E-02 -0.03 1.21E-01 
  rs2680344 
 
73653485 -0.01 1.00E+00 0.02 1.00E+00 
  rs11638230   73656261 -0.03 6.55E-01 -0.03 4.39E-01     
The significance threshold after correction for multiple testing was 2.94E-03. Effects are presented as log effect sizes (Beta) of the minor allele referenced to the 
major allele. Significant associations are in bold. 
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Table A2.36 Associations with total expression of ZFHX3 in chromosome band 16q22 in tissue 
   
RAA eQTL LAA eQTL IMA eQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs117951282 
 
72820328 -0.32 2.25E-01 
    rs699444 
 
72827758 0.04 4.11E-01 -0.06 8.22E-01 0.05 4.68E-01 
rs740178 ZFHX3 Transcribed 72832135 0.02 6.77E-01 0.05 6.50E-01 0.15 3.15E-02 
rs12929452 
 
72838680 -0.05 1.41E-01 0.05 6.12E-01 -0.22 1.80E-04 
rs2266943 
 
72854307 0.02 5.84E-01 0.14 4.21E-01 0.16 2.02E-02 
rs8058014 
 
72857544 0.02 6.23E-01 0.05 6.50E-01 0.15 3.57E-02 
rs1476646 
 
72898348 -0.02 5.34E-01 0.01 9.09E-01 -0.10 7.20E-02 
rs4788668 
 
72901874 -0.02 5.72E-01 0.08 4.34E-01 0.10 9.82E-02 
rs4788671 
 
72915085 -0.01 7.14E-01 -0.06 5.61E-01 -0.08 2.02E-01 
rs6499594 
 
72917601 0.04 4.58E-01 -0.48 4.31E-02 0.05 6.13E-01 
rs16971366 
 
72919582 -0.04 3.16E-01 0.07 4.14E-01 -0.08 2.10E-01 
rs9940310 
 
72925982 0.02 7.46E-01 -0.48 4.31E-02 0.05 6.88E-01 
rs9925261 
 
72927533 -0.03 4.34E-01 0.03 7.78E-01 -0.04 5.70E-01 
rs16971384 
 
72931085 -0.04 2.67E-01 0.07 3.89E-01 -0.08 2.19E-01 
rs4788482 
 
72937079 -0.01 8.79E-01 -0.06 7.85E-01 -0.14 2.07E-01 
rs4788679 
 
72956544 -0.01 8.74E-01 -0.02 8.19E-01 -0.08 3.25E-01 
rs9936884 
 
72960230 -0.01 8.26E-01 -0.06 8.22E-01 0.20 5.61E-02 
rs4788488 
 
72960283 -0.01 7.61E-01 -0.03 7.61E-01 0.01 8.57E-01 
rs8055870 
 
72972090 0.03 4.47E-01 0.00 9.97E-01 0.02 6.95E-01 
rs6499600 
 
72979374 0.01 7.49E-01 -0.01 9.05E-01 -0.04 4.37E-01 
rs13336412 
 
72981949 0.01 7.30E-01 0.20 2.26E-02 0.02 6.92E-01 
rs2228200 
 
72984668 0.08 5.18E-01 
  
0.14 5.69E-01 
rs2106258 
 
72990553 0.00 9.16E-01 -0.09 3.73E-01 -0.15 4.63E-02 
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RAA eQTL LAA eQTL IMA eQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs2157786 
 
72991286 -0.03 3.79E-01 -0.07 4.58E-01 -0.02 8.13E-01 
rs10852515 ZFHX3a Transcribed 72991660 -0.02 6.40E-01 -0.02 9.17E-01 -0.13 1.50E-01 
rs7193297 
 
72993831 0.02 5.38E-01 0.15 6.60E-02 0.03 6.26E-01 
rs7404992 
 
72994419 -0.05 4.53E-01 
  
0.10 3.70E-01 
rs4788683 
 
72997747 0.08 2.76E-02 0.04 6.59E-01 0.03 5.72E-01 
rs9921395 
 
73001957 -0.02 5.44E-01 0.11 2.82E-01 0.01 9.14E-01 
rs12445932 
 
73004432 0.05 1.60E-01 0.02 7.98E-01 0.05 4.19E-01 
rs7199343 Kawasaki GWAS 73009024 -0.07 5.80E-02 0.10 2.52E-01 0.06 3.37E-01 
rs11075954 
 
73012164 0.05 1.17E-01 -0.12 2.93E-01 -0.02 7.33E-01 
rs2040508 
 
73012685 -0.06 1.06E-01 0.00 9.93E-01 0.04 5.67E-01 
rs16971456 
 
73013036 0.02 7.75E-01 0.02 9.29E-01 -0.04 6.37E-01 
rs9930445 
 
73013482 -0.03 3.30E-01 0.06 4.48E-01 -0.01 8.61E-01 
rs4788684 
 
73013633 -0.03 4.43E-01 -0.04 7.25E-01 -0.02 7.95E-01 
rs16971464 
 
73016143 0.07 2.72E-01 -0.16 2.80E-01 -0.01 9.50E-01 
rs16971465 
 
73017061 -0.01 8.01E-01 0.02 9.09E-01 0.02 8.39E-01 
rs4788489 
 
73017118 -0.02 5.01E-01 -0.06 5.43E-01 0.02 7.60E-01 
rs16971474 
 
73019004 0.07 1.24E-01 -0.03 8.75E-01 -0.08 2.67E-01 
rs11640106 
 
73020116 -0.07 3.72E-02 0.12 3.03E-01 0.04 4.35E-01 
rs1858800 
 
73024276 0.06 9.26E-02 -0.18 2.38E-01 0.00 9.87E-01 
rs756720 
 
73028921 0.00 9.85E-01 0.00 9.99E-01 0.00 9.41E-01 
rs7193343 AF GWAS 73029160 0.03 5.39E-01 0.02 9.29E-01 -0.01 8.60E-01 
rs11075958 
 
73033869 -0.01 8.76E-01 0.01 8.78E-01 -0.04 5.41E-01 
rs8056528 
 
73036633 0.00 9.92E-01 -0.02 8.29E-01 0.03 6.84E-01 
rs719353 
 
73042551 0.00 9.58E-01 -0.02 8.51E-01 0.01 9.09E-01 
rs4788689 
 
73049830 -0.02 7.55E-01 0.06 7.61E-01 -0.01 9.39E-01 
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RAA eQTL LAA eQTL IMA eQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs2106261 AF GWAS 73051620 0.03 5.44E-01 0.02 9.29E-01 0.02 8.20E-01 
rs11863932 
 
73053579 0.11 2.17E-01 
  
-0.09 5.06E-01 
rs1548373 
 
73059861 0.01 7.83E-01 -0.05 6.93E-01 0.05 3.97E-01 
rs4788692 
 
73065656 -0.10 1.78E-01 0.06 7.61E-01 -0.01 9.20E-01 
rs12373097 
 
73068515 -0.01 7.91E-01 -0.18 2.87E-01 0.08 2.97E-01 
rs8057081 
 
73068977 0.02 6.99E-01 0.02 9.29E-01 -0.04 6.37E-01 
rs4788696 
 
73070310 0.02 6.12E-01 -0.05 6.64E-01 0.01 9.28E-01 
rs8060701 
 
73073289 -0.01 9.15E-01 
  
-0.08 4.66E-01 
rs9940321 
 
73073808 0.06 1.28E-01 -0.20 2.28E-01 0.03 6.45E-01 
rs9940520 
 
73074012 -0.07 1.62E-01 0.06 8.22E-01 -0.04 5.93E-01 
rs11641701 
 
73079212 0.08 1.93E-02 -0.07 6.49E-01 0.02 6.94E-01 
rs4788697 
 
73087494 0.08 3.44E-02 -0.18 2.28E-01 -0.07 2.92E-01 
rs8052905 
 
73097663 -0.12 8.74E-02 0.06 8.22E-01 0.00 9.80E-01 
rs739414 
 
73097956 0.02 6.32E-01 0.20 2.41E-02 0.04 5.06E-01 
rs8051826   73102456 -0.02 8.20E-01 0.07 6.82E-01 0.05 5.94E-01 
The significance threshold after correction for multiple testing was 7.90E-04. Effects are presented as log effect sizes (Beta) of the minor allele referenced to the 
major allele. Significant associations are in bold. 
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Table A2.37 Associations with total expression of ZFHX3a in chromosome band 16q22 in tissue 
   
RAA eQTL LAA eQTL IMA eQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs117951282 
 
72820328 -0.12 7.37E-01 
    rs699444 
 
72827758 0.05 3.67E-01 -0.16 6.92E-01 0.24 1.86E-02 
rs740178 ZFHX3 Transcribed 72832135 0.05 3.45E-01 0.14 4.37E-01 0.26 9.11E-03 
rs12929452 
 
72838680 -0.03 5.51E-01 0.04 7.71E-01 -0.24 5.15E-03 
rs2266943 
 
72854307 0.06 2.82E-01 0.28 2.64E-01 0.27 5.39E-03 
rs8058014 
 
72857544 0.05 3.21E-01 0.14 4.37E-01 0.26 7.69E-03 
rs1476646 
 
72898348 0.01 8.88E-01 -0.02 8.88E-01 -0.16 3.49E-02 
rs4788668 
 
72901874 -0.04 4.13E-01 0.15 3.36E-01 0.16 6.93E-02 
rs4788671 
 
72915085 0.02 5.83E-01 -0.10 5.18E-01 -0.17 4.79E-02 
rs6499594 
 
72917601 0.11 1.67E-01 -0.47 2.19E-01 0.04 8.10E-01 
rs16971366 
 
72919582 -0.02 6.39E-01 0.17 1.62E-01 -0.05 5.95E-01 
rs9940310 
 
72925982 0.09 2.58E-01 -0.47 2.19E-01 0.00 9.83E-01 
rs9925261 
 
72927533 0.02 7.46E-01 0.14 2.89E-01 0.05 5.61E-01 
rs16971384 
 
72931085 -0.02 6.54E-01 0.17 1.52E-01 0.03 7.41E-01 
rs4788482 
 
72937079 0.09 2.46E-01 0.14 6.66E-01 -0.01 9.59E-01 
rs4788679 
 
72956544 0.04 4.61E-01 0.07 5.63E-01 0.08 4.97E-01 
rs9936884 
 
72960230 -0.06 4.90E-01 -0.16 6.92E-01 0.19 1.92E-01 
rs4788488 
 
72960283 0.03 5.89E-01 0.06 6.51E-01 0.11 2.46E-01 
rs8055870 
 
72972090 0.03 5.25E-01 -0.10 4.06E-01 -0.08 3.36E-01 
rs6499600 
 
72979374 0.03 4.94E-01 0.15 3.43E-01 0.03 6.87E-01 
rs13336412 
 
72981949 0.02 6.31E-01 0.25 6.84E-02 -0.03 7.17E-01 
rs2228200 
 
72984668 0.01 9.44E-01 
  
0.26 4.54E-01 
rs2106258 
 
72990553 0.07 1.69E-01 -0.01 9.26E-01 0.03 7.73E-01 
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RAA eQTL LAA eQTL IMA eQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs2157786 
 
72991286 -0.02 7.09E-01 0.02 9.07E-01 0.13 1.69E-01 
rs10852515 ZFHX3a Transcribed 72991660 0.03 5.91E-01 0.19 5.22E-01 0.08 5.33E-01 
rs7193297 
 
72993831 0.02 5.76E-01 0.22 8.63E-02 -0.02 8.22E-01 
rs7404992 
 
72994419 0.03 7.77E-01 
  
0.15 3.31E-01 
rs4788683 
 
72997747 0.13 3.16E-03 0.08 5.13E-01 0.06 5.09E-01 
rs9921395 
 
73001957 -0.07 1.15E-01 0.19 1.83E-01 0.03 6.88E-01 
rs12445932 
 
73004432 0.03 5.77E-01 0.01 9.26E-01 -0.05 6.23E-01 
rs7199343 Kawasaki GWAS 73009024 -0.05 2.62E-01 0.15 2.39E-01 0.07 4.15E-01 
rs11075954 
 
73012164 0.06 1.52E-01 -0.17 3.23E-01 -0.01 9.31E-01 
rs2040508 
 
73012685 -0.08 1.09E-01 0.05 7.74E-01 0.14 1.45E-01 
rs16971456 
 
73013036 0.03 6.35E-01 -0.10 8.02E-01 -0.07 5.87E-01 
rs9930445 
 
73013482 0.02 6.27E-01 0.06 6.09E-01 -0.04 6.34E-01 
rs4788684 
 
73013633 -0.05 2.31E-01 0.00 9.90E-01 -0.01 9.36E-01 
rs16971464 
 
73016143 -0.12 1.86E-01 -0.13 6.07E-01 -0.04 7.96E-01 
rs16971465 
 
73017061 -0.10 1.71E-01 0.22 4.45E-01 -0.04 7.89E-01 
rs4788489 
 
73017118 -0.03 4.81E-01 -0.10 4.79E-01 0.04 5.84E-01 
rs16971474 
 
73019004 0.12 4.66E-02 0.00 9.98E-01 -0.03 8.04E-01 
rs11640106 
 
73020116 -0.10 2.62E-02 0.20 2.57E-01 0.04 5.68E-01 
rs1858800 
 
73024276 0.09 6.30E-02 -0.32 1.50E-01 -0.03 6.83E-01 
rs756720 
 
73028921 0.05 2.49E-01 0.01 9.34E-01 0.01 8.92E-01 
rs7193343 AF GWAS 73029160 0.02 7.99E-01 -0.10 8.02E-01 -0.02 8.41E-01 
rs11075958 
 
73033869 0.06 2.77E-01 0.01 9.55E-01 -0.09 3.82E-01 
rs8056528 
 
73036633 -0.05 2.86E-01 0.03 8.28E-01 0.07 4.20E-01 
rs719353 
 
73042551 -0.04 4.07E-01 0.02 8.98E-01 0.05 5.65E-01 
rs4788689 
 
73049830 0.04 5.22E-01 0.13 6.72E-01 0.14 2.80E-01 
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RAA eQTL LAA eQTL IMA eQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs2106261 AF GWAS 73051620 0.02 7.74E-01 -0.10 8.02E-01 0.01 9.47E-01 
rs11863932 
 
73053579 0.15 1.71E-01 
  
0.00 9.90E-01 
rs1548373 
 
73059861 -0.07 1.33E-01 -0.02 9.19E-01 0.02 8.47E-01 
rs4788692 
 
73065656 -0.08 3.81E-01 0.13 6.72E-01 0.21 3.12E-01 
rs12373097 
 
73068515 -0.02 6.94E-01 -0.42 7.58E-02 0.06 5.63E-01 
rs8057081 
 
73068977 0.03 5.76E-01 -0.10 8.02E-01 -0.02 8.81E-01 
rs4788696 
 
73070310 -0.05 3.39E-01 0.00 9.94E-01 0.10 3.63E-01 
rs8060701 
 
73073289 0.06 5.20E-01 
  
0.02 9.07E-01 
rs9940321 
 
73073808 0.06 2.15E-01 -0.09 7.24E-01 -0.09 3.47E-01 
rs9940520 
 
73074012 -0.06 3.35E-01 0.24 5.48E-01 -0.10 3.60E-01 
rs11641701 
 
73079212 0.06 1.48E-01 -0.18 4.26E-01 0.09 2.70E-01 
rs4788697 
 
73087494 0.12 1.47E-02 -0.07 7.51E-01 -0.13 2.06E-01 
rs8052905 
 
73097663 -0.23 9.67E-03 0.24 5.48E-01 -0.17 2.23E-01 
rs739414 
 
73097956 0.05 3.30E-01 0.16 2.77E-01 0.17 3.39E-02 
rs8051826   73102456 0.07 4.56E-01 0.19 4.47E-01 0.06 6.51E-01 
The significance threshold after correction for multiple testing was 7.90E-04. Effects are presented as log effect sizes (Beta) of the minor allele referenced to the 
major allele. Significant associations are in bold. 
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Table A2.38 Associations with allelic expression ratio of ZFHX3 in chromosome band 16q22 in tissue 
   
RAA aerQTL LAA aerQTL IMA aerQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs117951282 
 
72820328 NA 1.00E+00 
  
NA 1.00E+00 
rs699444 
 
72827758 0.02 2.10E-01 
  
-0.04 4.01E-03 
rs740178 ZFHX3 Transcribed 72832135 0.01 3.85E-01 
  
-0.03 1.28E-02 
rs12929452 
 
72838680 -0.01 7.56E-01 
  
0.03 1.47E-01 
rs2266943 
 
72854307 0.01 6.56E-01 
  
-0.03 1.15E-02 
rs8058014 
 
72857544 0.01 5.77E-01 
  
-0.03 1.15E-02 
rs1476646 
 
72898348 -0.02 3.21E-01 
  
0.02 4.05E-01 
rs4788668 
 
72901874 0.01 6.27E-01 
  
-0.03 6.80E-02 
rs4788671 
 
72915085 -0.03 1.44E-01 
  
0.01 5.84E-01 
rs6499594 
 
72917601 -0.03 2.05E-01 
  
0.01 7.37E-01 
rs16971366 
 
72919582 -0.02 1.96E-01 
  
-0.03 8.63E-02 
rs9940310 
 
72925982 -0.03 2.74E-01 
  
0.00 9.27E-01 
rs9925261 
 
72927533 -0.02 3.14E-01 
  
-0.01 4.09E-01 
rs16971384 
 
72931085 -0.01 5.02E-01 
  
-0.02 2.22E-01 
rs4788482 
 
72937079 -0.05 3.18E-02 
  
0.00 9.75E-01 
rs4788679 
 
72956544 -0.03 1.26E-01 
  
0.02 3.76E-01 
rs9936884 
 
72960230 0.05 1.64E-01 
  
-0.06 5.78E-02 
rs4788488 
 
72960283 -0.01 4.16E-01 
  
-0.02 3.45E-01 
rs8055870 
 
72972090 0.01 6.75E-01 
  
0.00 9.11E-01 
rs6499600 
 
72979374 -0.01 5.29E-01 
  
0.02 4.61E-01 
rs13336412 
 
72981949 0.02 3.31E-01 
  
-0.02 3.35E-01 
rs2228200 
 
72984668 -0.06 4.06E-01 
    rs2106258 
 
72990553 -0.04 3.15E-02 
  
0.00 9.00E-01 
  
 
 
2
9
9
 
   
RAA aerQTL LAA aerQTL IMA aerQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs2157786 
 
72991286 -0.03 1.05E-01 
  
-0.01 7.67E-01 
rs10852515 ZFHX3a Transcribed 72991660 -0.05 2.62E-02 
  
0.01 7.86E-01 
rs7193297 
 
72993831 0.02 2.39E-01 
  
-0.05 3.84E-02 
rs7404992 
 
72994419 0.03 4.06E-01 
  
-0.06 5.78E-02 
rs4788683 
 
72997747 0.00 9.98E-01 
  
-0.04 1.39E-02 
rs9921395 
 
73001957 -0.02 2.42E-01 
  
0.00 9.66E-01 
rs12445932 
 
73004432 -0.02 2.47E-01 
  
-0.02 1.91E-01 
rs7199343 Kawasaki GWAS 73009024 -0.01 7.06E-01 
  
-0.01 5.21E-01 
rs11075954 
 
73012164 0.03 1.01E-01 
  
0.00 9.97E-01 
rs2040508 
 
73012685 -0.01 6.41E-01 
  
0.00 9.57E-01 
rs16971456 
 
73013036 -0.02 5.21E-01 
  
0.01 6.20E-01 
rs9930445 
 
73013482 -0.01 4.97E-01 
  
-0.03 1.78E-01 
rs4788684 
 
73013633 0.03 1.01E-01 
  
0.00 9.88E-01 
rs16971464 
 
73016143 -0.05 5.38E-01 
  
0.03 5.13E-01 
rs16971465 
 
73017061 -0.05 2.79E-01 
  
-0.03 4.42E-01 
rs4788489 
 
73017118 0.02 3.89E-01 
  
0.03 3.87E-01 
rs16971474 
 
73019004 -0.03 3.49E-01 
  
0.03 2.34E-01 
rs11640106 
 
73020116 -0.01 5.89E-01 
  
0.00 9.21E-01 
rs1858800 
 
73024276 0.02 4.10E-01 
  
0.03 1.24E-01 
rs756720 
 
73028921 0.02 4.15E-01 
  
-0.04 7.67E-02 
rs7193343 AF GWAS 73029160 -0.03 6.78E-02 
  
0.02 3.72E-01 
rs11075958 
 
73033869 0.00 8.66E-01 
  
-0.05 7.47E-02 
rs8056528 
 
73036633 0.00 9.41E-01 
  
0.00 9.09E-01 
rs719353 
 
73042551 -0.03 1.17E-01 
  
0.01 4.06E-01 
rs4788689 
 
73049830 -0.01 8.35E-01 
  
0.03 3.84E-01 
  
 
 
3
0
0
 
   
RAA aerQTL LAA aerQTL IMA aerQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs2106261 AF GWAS 73051620 -0.04 3.84E-02 
  
0.01 5.09E-01 
rs11863932 
 
73053579 -0.07 2.05E-01 
  
-0.01 8.68E-01 
rs1548373 
 
73059861 -0.03 6.00E-02 
  
0.01 7.85E-01 
rs4788692 
 
73065656 0.01 8.42E-01 
  
0.05 2.89E-01 
rs12373097 
 
73068515 0.04 8.94E-02 
  
0.02 4.48E-01 
rs8057081 
 
73068977 -0.03 1.19E-01 
  
0.00 9.95E-01 
rs4788696 
 
73070310 -0.02 3.56E-01 
  
0.02 4.95E-01 
rs8060701 
 
73073289 0.04 3.15E-01 
  
-0.05 1.61E-01 
rs9940321 
 
73073808 -0.02 3.48E-01 
  
-0.02 2.62E-01 
rs9940520 
 
73074012 0.03 3.28E-01 
  
-0.04 1.83E-01 
rs11641701 
 
73079212 -0.01 5.96E-01 
  
0.01 4.44E-01 
rs4788697 
 
73087494 -0.02 3.64E-01 
  
0.00 8.46E-01 
rs8052905 
 
73097663 0.01 8.58E-01 
  
0.02 5.75E-01 
rs739414 
 
73097956 0.00 8.65E-01 
  
0.00 9.55E-01 
rs8051826   73102456 0.01 8.45E-01     -0.06 1.36E-01 
The significance threshold after correction for multiple testing was 7.90E-04. Effects are presented as log effect sizes (Beta) of the minor allele referenced to the 
major allele. Significant associations are in bold. 
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Table A2.39 Associations with allelic expression ratio of ZFHX3a in chromosome band 16q22 in tissue 
   
RAA aerQTL LAA aerQTL IMA aerQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs117951282 
 
72820328 NA 1.00E+00 
  
NA 1.00E+00 
rs699444 
 
72827758 0.08 2.25E-01 
  
0.01 8.83E-01 
rs740178 ZFHX3 Transcribed 72832135 0.10 7.29E-02 
  
0.01 8.35E-01 
rs12929452 
 
72838680 0.03 5.05E-01 
  
0.02 7.53E-01 
rs2266943 
 
72854307 0.12 4.24E-02 
  
0.01 8.35E-01 
rs8058014 
 
72857544 0.10 7.29E-02 
  
0.01 8.53E-01 
rs1476646 
 
72898348 -0.02 7.10E-01 
  
-0.06 3.91E-01 
rs4788668 
 
72901874 0.04 3.38E-01 
  
0.09 2.00E-01 
rs4788671 
 
72915085 -0.01 7.43E-01 
  
-0.08 2.65E-01 
rs6499594 
 
72917601 -0.01 8.64E-01 
  
-0.16 2.07E-01 
rs16971366 
 
72919582 0.13 3.30E-03 
  
0.09 7.59E-02 
rs9940310 
 
72925982 -0.05 6.08E-01 
  
-0.24 1.85E-01 
rs9925261 
 
72927533 0.06 1.30E-01 
  
0.08 1.46E-01 
rs16971384 
 
72931085 0.08 6.12E-02 
  
0.10 7.68E-02 
rs4788482 
 
72937079 0.09 1.03E-02 
  
0.12 1.37E-02 
rs4788679 
 
72956544 0.08 5.17E-02 
  
0.12 1.53E-02 
rs9936884 
 
72960230 -0.18 8.38E-03 
  
-0.03 7.44E-01 
rs4788488 
 
72960283 0.03 4.93E-01 
  
0.12 1.88E-02 
rs8055870 
 
72972090 -0.06 2.80E-01 
  
-0.15 5.97E-02 
rs6499600 
 
72979374 0.05 3.14E-01 
  
0.12 6.34E-02 
rs13336412 
 
72981949 -0.12 1.48E-02 
  
-0.06 4.14E-01 
rs2228200 
 
72984668 
      rs2106258 
 
72990553 0.06 8.99E-02 
  
0.11 8.33E-03 
  
 
 
3
0
2
 
   
RAA aerQTL LAA aerQTL IMA aerQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs2157786 
 
72991286 0.04 2.37E-01 
  
0.14 2.91E-03 
rs10852515 ZFHX3a Transcribed 72991660 0.07 4.02E-02 
  
0.11 1.16E-02 
rs7193297 
 
72993831 -0.15 1.41E-02 
  
-0.11 3.06E-01 
rs7404992 
 
72994419 -0.13 8.89E-02 
  
-0.03 7.44E-01 
rs4788683 
 
72997747 0.04 3.78E-01 
  
0.07 1.75E-01 
rs9921395 
 
73001957 0.03 5.26E-01 
  
0.11 4.45E-02 
rs12445932 
 
73004432 0.06 2.27E-01 
  
0.10 7.65E-02 
rs7199343 Kawasaki GWAS 73009024 -0.04 4.90E-01 
  
0.00 9.72E-01 
rs11075954 
 
73012164 0.04 3.99E-01 
  
0.02 7.22E-01 
rs2040508 
 
73012685 0.00 9.98E-01 
  
0.00 9.79E-01 
rs16971456 
 
73013036 -0.05 5.50E-01 
  
-0.06 6.02E-01 
rs9930445 
 
73013482 -0.02 6.82E-01 
  
-0.10 2.61E-01 
rs4788684 
 
73013633 0.07 1.10E-01 
  
-0.07 2.63E-01 
rs16971464 
 
73016143 0.04 7.22E-01 
    rs16971465 
 
73017061 0.02 8.34E-01 
    rs4788489 
 
73017118 0.04 3.56E-01 
  
-0.05 5.78E-01 
rs16971474 
 
73019004 -0.06 4.04E-01 
  
0.10 2.70E-01 
rs11640106 
 
73020116 -0.04 3.68E-01 
  
0.00 9.91E-01 
rs1858800 
 
73024276 0.05 3.83E-01 
  
-0.03 7.53E-01 
rs756720 
 
73028921 0.04 5.02E-01 
  
-0.06 3.31E-01 
rs7193343 AF GWAS 73029160 0.00 9.97E-01 
  
-0.01 9.07E-01 
rs11075958 
 
73033869 -0.05 4.29E-01 
  
-0.08 3.21E-01 
rs8056528 
 
73036633 0.03 6.05E-01 
  
0.00 9.72E-01 
rs719353 
 
73042551 0.02 6.96E-01 
  
0.00 9.54E-01 
rs4788689 
 
73049830 0.02 7.79E-01 
  
0.02 8.08E-01 
  
 
 
3
0
3
 
   
RAA aerQTL LAA aerQTL IMA aerQTL 
SNP Importance Position Beta p value Beta p value Beta p value 
rs2106261 AF GWAS 73051620 0.03 6.38E-01 
  
-0.01 9.07E-01 
rs11863932 
 
73053579 -0.01 8.93E-01 
  
0.15 6.07E-02 
rs1548373 
 
73059861 0.04 4.97E-01 
  
-0.02 7.67E-01 
rs4788692 
 
73065656 -0.13 7.28E-02 
  
-0.01 9.09E-01 
rs12373097 
 
73068515 0.03 6.36E-01 
  
-0.15 1.51E-01 
rs8057081 
 
73068977 0.08 1.49E-01 
  
-0.02 7.27E-01 
rs4788696 
 
73070310 -0.01 8.01E-01 
  
0.12 5.97E-02 
rs8060701 
 
73073289 -0.03 7.43E-01 
  
0.08 3.11E-01 
rs9940321 
 
73073808 0.00 9.85E-01 
  
0.07 1.88E-01 
rs9940520 
 
73074012 -0.03 7.43E-01 
  
0.08 3.11E-01 
rs11641701 
 
73079212 -0.04 3.82E-01 
  
0.07 2.49E-01 
rs4788697 
 
73087494 0.05 2.82E-01 
  
0.01 9.23E-01 
rs8052905 
 
73097663 -0.12 3.56E-01 
  
0.09 4.71E-01 
rs739414 
 
73097956 -0.05 4.60E-01 
  
-0.02 8.15E-01 
rs8051826   73102456 -0.05 4.55E-01     0.01 8.94E-01 
The significance threshold after correction for multiple testing was 7.90E-04. Effects are presented as log effect sizes (Beta) of the minor allele referenced to the 
major allele. Significant associations are in bold.
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